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for the degree.

Preparation of this dissertation, for instance, required more

than four years, most of which was devoted to the literature review. Chapter II
was prepared during 1979, Chapter ITI 1979-1980, Chapter IV 1980-1981, and
Chapter V 1981-1982.
Certain recent,

dramati~<

developments in the field of insulin research,

therefore, were not included in this review.

Most important are the findings

that the insulin receptor consists of two 125,000 M. W. a subunits and two
90,000 M. W. B subunits (M. Czech, Amer. J. Med. 70: 142, 1981). The a subunit
presumably binds insulin, while the B subunit, which is highly susceptible to
proteolytic cleavage, possesses kinase activity and phosphorylates itself at a
tyrosine residue in response to binding of the hormone (M. Kasuga et al.,
Science 215: 185, 1982; Roth and Cassell, Science 219: 299, 1983). Binding of
insulin activates a membrane protease which cleaves a glycopeptide mediator
from the receptor. This mediator stimulates glycogen synthetase and inhibits
glycogen phosphorylase by activating glycogen synthetase phosphatase and
inactivating glycogen synthetase kinase (phosphorylase b kinase kinase, cAMPdependent protein kinase), stimulates mitochondrial pyruvate dehydrogenase by
activating the phosphatase that dephosphorylates the inactive dehydrogenase's
iii

a subunit, inhibits the (Ca ++ + Mg ++ )-ATPase of adipocyte plasma meJ?brane
by decreasing enzyme phosphorylation, and activates the endo-plasmic reticulum phosphodiesterase (Czech, 1981; Chan and McDonald, J. Bioi. Chern. 257:
7443, 1982; J. Larner et al., Rec. Prog. Horm. Res. 38: 511, 1982).
Insertion of the human insulin gene into the genome of the bacterium
Escherichia coli, resulting in microbial production of human insulin on an
industrial scale, also was not reviewed. This achievement represents the first
commercial health care product derived from recombinant DNA technology (I.
S. Johnson, Science 219:

632, 1983). I believe, however, that these develop-

ments do not appreciably affect justification of the research described or
evaluation of the results reported:·in this dissertation.

M.E.K.

April1983
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ACD

acid-citrate-dextrose

ACTH

adrenocorticotrophic hormone, corticotropin

ADH

alloxan-diabetic, hypophysectomized

ADHA

alloxan-diabetic, hypophysectomized, adrenalectomized

AI

atypical insulin

AlB

a -aminoisobutyric acid

AIS

anti-insulin serum

ala

alanine

AMP

adenosine monophosphate

app.

apparent

arg

arginine

asn

asparagine

asp

aspartic acid

ATE

adipose tissue extract

ATP

adenosine triphosphate

B

bound

b

slope

Bo

percent tracer bound to antibody in absence of unlabeled
antigen

BHK

baby hamster kidney

BI

''bound insulin n

bioi. act.

biological activity
xviii

BME

Eagle's Basal Medium with Earle's salts

BSA

bovine serum albumin

~AMP

cyclic AMP, adenosine 3',5'-monophosphate

CD

circular dichroism

cGMP

cyclic GMP, Guanosine 3',5'-monophosphate

Ci

Curie (3.7 x 1010 disintigrations per second)

circul.

circulating

CM

complete medium (with FBS)

CM-

carboxymethyl-

CNBr

cyanogen bromide

Co A

coenzyme A

CPB

carboxypeptidase B

CPD

citra te-phospha te~extrose

C-peptide

proinsulin connecting peptide

CPM

counts per minute

c.v.

coefficient of variation= (x/SD) x 100

cys

cysteine

0 2o,w

diffusion coefficient at 20°C in water

DAA

desalanine~esasparagine

DEAE-

diethylaminoethyl-

DNA

deoxyribonucleic acid

DNP

dinitrophenyl

DOP

desoctapeptide

dpm

disintigrations per minute

EDTA

ethylenediaminetetraacetate
xix

EGF

epidermal growth factor

ELISA

enzyme-linked immunosorbent assay

BOP

efficiency of plating

F

free

FBS

fetal bovine serum

FDNB

1,2,4-fiuorodinitrobenzene

FGF

fibroblast growth factor

FITC

fluorescein isothiocyanate

GIT

glutathione-insulin transhydrogenase

gln

glutamine

glu

glutamic acid

gly

glycine

GMP

guanosine monophosphate

GR

glutathione reductase

GSH

glutathione

HGH

human growth hormone, somatotropin
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CHAPTER I

INTRODUCTION

ST ATE~ENT OF THE PROBLEM

When Frederick Sanger completed the elucidation of the primary
structure of bovine insulin in 1955, all appeared right with the world of insulin.
The hormone had been purified to a high degree, making possible the effective
treatment of diabetes mellitus. The physiologic effects of insulin were well
understood and its site of biosynthesis and secretion was lmown. Many of the
hormone's physicochemical properties, including its minimum molecular weight
and aggregative behavior, were lmown. Sanger's accomplishment had verified
several fundamental tenets of protein chemistry and opened new areas of
investigation. Insulin had been crystallized in several different forms and the
zinc atoms coordinately bonded in the hexamer were easily replaced by heavy
metal atoms, promising another seminal accomplishment of protein chemistry:
the elucidation of a protein's tertiary structure by x-ray diffraction. In vivo
bioassays of increased sensitivity and a new in vitro rat diaphragm bioassy made
possible the measurement of insulin in blood for the first time.

A thorough

understanding of the cause of diabetes as well as a possible cure for the disease
appeared imminent. Yet, within five years, the question of circulating insulin
and its relation to normal and diabetic physiology was characterized by a state
of utter confusion.
1
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--

With the introduction of in vitro bioassays for insulin, which measure what
was termed insulin-like activity (ILA), a plethora of substances that mimic
insulin effects measured by the assays (e.g_., stimulation of glucose uptake,
glycogen synthesis or carbon dioxide production), but do not exhibit certain
physicochemical properties of the hormone, were discovered in human serum and
plasma. In 1958, an in vitro bioassay for insulin using rat epididymal fat pads
was introduced (Martin et al., 1958; Ref. 393). Although this assay was at least
ten times more sensitive than the diaphragm assay, it was immediately noted
that serum insulin levels measured with the fat pad assay were 5-20 times higher
than those found using the latter assay.
Antoniades et al. (1965; Ref. 511, 512) then found that Dowex cation

--

~·

exchange resin used to prepare human blood plasma, when eluted with strong
acid or alkali, yielded significant quantities of ILA detectable by the fat pad
assay, but not by the diaphragm assay. When this cationic serum protein fraction
was treated with acid, alkali, acid-ethanol or an aqueous extract of adipose
tissue, the ILA was detectable by the diaphragm assay, was found to reside in a
soluble, anionic fraction, and was neutralized by anti-insulin serum.

This

treatment also generated an insoluble, cationic protein fraction, suggesting a
serum insulin-binding protein dissociated from the hormone by a factor produced
by adipose tissue (Antoniades, 1961; Antoniades and Gundersen, 1961; Ref. 509,
514).
The existence of an insulin-binding protein in normal human serum was
further supported by the work of Shaw and Shuey (1963; Ref. 390), who
demonstrated that adipose tissue extract causes a 12-fold increase of normal
fasting human serum ILA measured by the diaphragm assay and that anti-insulin
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serum prevents this ILA increment. Gundersen and Lin (1965; Ref.

39~)

then

found that heparin also increases diaphragm-assayable ILA in cationic serum
protein fractions and in normal human sera to levels found with the fat pad assay
and that this ILA increment is neutralized by anti-insulin serum. The existence
of a human serum insulin-binding protein appeared virtually assured with the
appearance of several reports of the electrophoretic migration of radioactivity
with a-globulins after incubation of exogenous radiolabeled insulin with normal
human serum (Clausen et al., 1963; Mitchell, 1960; Ref. 520, 521).
Berson and Yalow, however, disputed the concept of ''bound insulin" on
several grounds, contending that the only physiologically significant insulinbinding proteins are the anti-insulin antibodies found in the blood of insulintreated diabetics.

They observed no increase in insulin measured by

radioimmunoassay (RIA) after treatment of human sera with adipose tissue
extract (1961, Ref. 523) and they demonstrated that apparent association of
radiolabeled insulin with normal serum proteins represents irreversible binding of
damaged tracer by these proteins (1965, Ref. 515). They also pointed out that
the behavior of ''bound insulin" is inconsistent with established physiologic insulin
response, since total plasma insulin levels ("bound" plus "free") reported by
Antoniades decrease after intravenous glucose administration (1965,Ref.515).
Berson and Yalow also refuted the concept of "bound insulin" on
theoretical grounds. They argued that rapid insulin kinetics in vivo, resulting in
quick onset of diabetic symptoms after pancreatectomy, are inconsistent with
the slow kinetics of hormones such as thyroxine that are lmown to be bound to
serum carrier proteins. They pointed out that symptoms of thyroid hormone
deficiency appears only weeks after thyroidectomy and that in cases of proven
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insulin binding by serum proteins-formation of insulin-antibody
insulin-resistant

diabetics-insulin-dependent

carbohydrate

compl~xes

homeostasis

in
is

frankly deranged (1965,Ref.528).
The concept of "bound insulin" is also inconsistent with the observations
of Froesch et al., who found that about 90% of human serum ILA measured by
the rat fat pad assay is not suppressible by anti-insulin serum (nonsuppressible
insulin-like activity, NSILA), that levels of

antiserum~uppressible

ILA are very

similar to those found with RIA, and that only about 10% of serum NSILA is
extractable with acid-ethanol (designated NSILA-8) (Froesch et al., 1963;
Labhart et al., 1972; Jakob et al., 1968; Ref. 527, 546, 547). Furthermore, the
remaining serum NSILA (NSILA-P}was found to be a protein of molecular weight
100,000-150,000 daltons that is not dissociable by acid or urea (Ref. 546, 547).
Subsequently, NSILA-8 was found to be structurally similar to insulin, but
to exhibit the function of a growth factor in vivo (Rinderknecht and Humbel,
1976; Zapf et al., 1975; Ref. 549, 550, 557), while the ILA exhibited by
supraphysiologic concentrations of NSILA-8 was demonstrated to be due to a 2%
cross-reactivity of the factor with insulin receptors (Gavin et al., 1973; Ref.
565). In addition, other plasma growth factors (i.e., somatomedins A and C and
multiplication stimulating activity) were also found to exhibit ILA at
supraphysiologic concentrations, suggesting a family of insulin-like growth
factors (IGFs) that, with insulin, derive from a common ancestral gene and
diverged functionally (Shields, 1977; Ref. 728). The arguments of Berson and
Yalow and characterization of the IGFs therefore caused the concept of "bound
insulin" to fall into disfavor.
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Two developments, however, have again made the question of "bound
insulin" a worthwhile object of study. 1) Guenther (1974, Ref. 387) reported that
heparin treatment of cationic serum protein fractions causes an increase of
insulin measured by the RIA and implicated biotin as the ILA-potentiating factor
in adipose tissue extract.

2) IGFs have been found to have serum binding

proteins (Zapf et al., 1975; Van Wyk et al., 1974; Ref. 557, 598), making an
insulin-binding protein a plausible expectation.

SPECIFIC OBJECTIVES

Zapf et al. (1975, Ref. 5&7) elucidated the serum carrier protein for
'

NSILA-8 by gel chromatography and charcoal adsorption analysis of radiolabeled
NSILA-8 incubated with human serum.

They found that about 40% of 125 1-

NSILA-S radioactivity added to normal human serum eluted from Sephadex G200 at positions corresponding to proteins of significantly higher molecular
weights than free NSILA-8 {apprx. 7,000 daltons). Addition of excess unlabeled
NSILA-8 to serum-tracer mixtures resulted in nearly complete abolition of two
upfield peaks of radioactivity with a concomitant increase of free NSILA-8 peak
activity. Acid treatment of serum, followed by dialysis and gel chromatography
yielded fractions that exhibited reversible binding of NSILA-8.
This kind of study, however, has not been applied to the question of serum
insulin-binding protein.

Benson and Yalow utilized electrophoretic and

ultracentrifugation techniques, but no gel chromatography, in their experiments,
nor did they investigate the effect of heparin on serum immunoreactive insulin
{IRI).

Therefore, I endeavored to investigate both the question of a normal
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human serum insulin-binding protein using the approach of Zapf et al. and the
contribution of serum growth factors to ILA using a cultured cell bioassay
capable of discriminating between specific insulin-like activity and the effects
of growth factors.
Purified 125 1-insulin will be incubated with normal human serum and
plasma, followed by Sephadex G-200 gel chromatography in order to determine
whether radioactivity becomes associated with high molecular weight fractions.
Reversibility of association will be tested by gel chromatography of plasmatracer mixtures and upfield peak material incubated with excess unlabeled
insulin and by dextran-coated charcoal analysis of upfield peak material in the
presence of excess unlabeled insulin and 8 M urea. Initially, the verifiability of
heparin-induced IRI in cationic serum protein fractions will be tested in order to
determine whether heparin can also be used as a potential dissociative agent.
The possibility of irreversible binding of damaged tracer to albumin will be
examined by affinity chromatography using anti-albumin antibodies coupled to
Sepharose 4B, followed by ultrafiltration of radioactivity retained by the
immunoadsorbent.
The appropriateness of both diploid and malignant human cell lines for use
in an insulin bioassay will be tested based on three criteria: 1) demonstration of
cell-surface insulin receptors by peroxidase-antiperoxidase immunocytochemical
staining and specific adsorption of 12 51-insulin by cells; 2) demonstration of a
significant insulin-induced, dose-dependent increment in the rate of glucose
uptake by cells, using replicate multiwell cultures and measurement of glucose
concentration in the supernatant medium; and

3) prolonged stasis of cell

proliferation without cell death in serum-free media (with and without insulin),
with resumption of log-phase growth after addition of serum.
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An insulin bioassay capable of discriminating the effects of specific ILA
and growth factors will thus be developed to generate the following parameters
relative to control cultures: cell number (representing stimulation of cell
proliferation by growth factors), total glucose uptake {representing ILA
irrespective of cell number), and rate of glucose uptake {representing specific
ILA). This assay will be used to examine serum fractions generated by molecular
size separations (ultrafiltration and gel chromatography) in order to determine
the relationship of proliferative effects and specific ILA to total ILA.
The relationship of immunoreactive insulin to specific ILA will be
determined by radioimmunoassay of all fractions and the role of biotin and
heparin in stimulating ILA will be ascertained by also carrying out the bioassay
'

of all fractions in the presence of these agents.
The range of subjects involved in this research is broad. Examination of
insulin structure is important to considerations of aggregation, immunochemistry
and biologic activity. Knowledge of cellular insulin receptor properties is basic
to evaluation of differential hormone effects relative to hormone concentration
and to choice of cells appropriate for an insulin bioassay. Evidence pertaining to
mechanisms of insulin action bear upon interpretation of observations that
contradict previous reports.

A survey of insulin assays, requiring an

understanding of the hormone's physiologic and metabolic effects, is necessary
for an appreciation of ILA in its proper historical perspective and for evaluation
of assays employed in this work.

A discussion of atypical ILA must include

insulin precursors and, of course, serum growth factors. I review all these topics
in what I hope is sufficient depth to enable the reader to evaluate the
observations reported and to judge the appropriateness of the conclusions drawn
from them.

CHAPTER II
INSULIN: THE ANABOLIC HORMONE
INSULIN-OR LACK OF IT (DIABETES)-IN ANTIQUITY
At least oblique reference to the most striking symptoms of diabetes-excessive thirst (polydipsia) and urination (polyuria)-may be found among the
oldest human documents.

The Ebers papyrus, the 16th century B.C. Egyptian

medical treatise, contains the phrase, "A medicine to drive away the passing
of too much urine" (1).
Unequivocal discussions cpncerning diabetes mellitus appear in Hindu
medical texts dating back to the first century B.C. The writers of these texts
anticipated use of the term mellitus, a Latin word meaning "honey sweet," by
nearly two millenia, when they referred to the disease as Iksumeha or Madhumea
(sugar or honey urine).

This designation probably derived, however, from the

resemblance of the diabetic's almost colorless urine to the juices of the sugar
cane or from the particular attraction it had for insects, rather than from its
taste, since no mention is made of tasting the urine (2). The writers recognized
that the diabetic "gradually loses strength, flesh, and healthy glow of complexion." The symptoms of thirst, fatigue, diminution of sexual capacity, confusion,
abscesses and carbuncles are also listed.
The first century Roman medical writer Aulus Cornelius Celsus rendered
a concise description of the disease he declined to name when he stated, "But
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when the urine exceeds the fluid taken • • • it gives rise to wasting and
danger"(3).

Although the perceived fluid imbalance was in error, appreciation

of the impressive polyuria is clear.

During the following century, the Greek

physician Aretaeus of Cappadocia rendered the best ancient clinical account
of the disease, which not only contained the first mention of the term diabetes,
a Greek word meaning "siphon" ("because the fluid does not remain in the
body, but uses the man's body as a ladder, whereby to leave it."), but also is
the first concise and accurate contribution to the knowledge of diabetes in
the medical literature of the western world. He described in great detail this
wasting disease as a "melting of the flesh," enumerating such symptoms as
thirst and loss of body constitueqts via the urine (4).
In analyzing two cases of diabetes, Aretaeus' renowned contemporary

colleague and compl:ltriot, Galen, demonstrates the Greek gift for intuitive
reasoning when he postulates a failure of the assimilatory functions and
considers the discoloration of the urine as the result of a lack of "coction"
(analogous to the modern concept of metabolism), which Galen describes as
an alteration of nutrients in the body (5).
The classic tradition of astute diagnosis was ably continued in medieval
times by the great 12th century Jewish Aristotelian scholar, philosopher, and
physician, Moses Maimonides, who noted twenty cases of diabetes in Egypt,
but only two in Spain and northwest Africa (6).

Thus, diabetes mellitus was

considered a rare disease until the 17th century, when the British physician
Thomas Willis diagnosed a considerable number of cases.

Although ancient

physicians are widely credited with knowledge of diabetic glycosuria because
of references to honey or sugar urine in their accounts of the disease, Willis
rendered the first true documentation of the sweet taste of the diabetic's
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urine (5). He did not demonstrate the actual presence of sugar in the urine,
however, but believed-like the 16th century physician and alchemist Paracelsus-that the focus of the body's derangement is salts.
Willis did recognize that diabetes mellitus is a metabolic disease and
in fact was the first to implicate the blood's role in the malady, stating "the
serum and the blood are in fault, because they lend too hastily their contents."
It was the experiments of the British physician Matthew Dobson a century

later that indicated excessive "saccharine matter" in both the urine and serum
of diabetics, leading him to conclude that the glycosuria results from hyperglycemia (7).

In 1815, the French chemist Michel-Eugene Chevreul showed that

this saccharine matter is

glucos~

(5).

The foundation thus was laid for the

general acceptance of William Cullen's earlier delineation of diabetes mellitus
and diabetes insipidus (8).
Several developments during the 19th century formed the real basis for
the discovery of insulin. First, the renowned French physiologist Claude Bernard
established the concept of homeostasis based on the effects of internal secretions (9). Second, Paul Langerhans, a pupil of the German father of pathology,
Rudolph Virchow, described in 1869 a group of cells in the pancreas that were
different from the enzyme-secreting acinar cells (10). Third-and most important-was the work of

~the

physiologists Oskar Minkowski and Baron Joseph von

Mering.
In 1884, Minkowski had implicated 8-hydroxybutyric acid as a major

cause of diabetic acidosis, demonstrated a decrease of blood carbon dioxide
during diabetic coma, and introduced alkali therapy to counteract the condition
(11).

Five years later, at the University of Strassburg, Minkowski and Mering

attempted to disrupt fat digestion in dogs by removing the pancreas, known
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to secrete lipases.

They found that the dogs greatly increased their urine

output and died in ten to thirty days. The presence of large amounts of sugar
in the urine confirmed the diagnosis of classic diabetes mellitus. Furthermore,
replacement of the pancreas under the skin ameliorated the symptoms. Thus,
these facts and the influence of Bernard's milieu interieur concept enabled
Minkowski to postulate the secretion by the pancreas of a substance responsible
for the maintenance of systemic carbohydrate homeostasis (12).
When in 1901 the U.S. pathologist Eugene L. Opie described degenerative
changes in the Islets of Langerhans associated with diabetes (13,14), leading
such physiologists as Sir Edward Sharpey-Schafer to conclude that Islet cells
are the source of the postulated l)ypoglycemic substance (15), the fundamental
'
mechanism of diabetes mellitus was clear. The challenge that remained for
a series of investigators during the next twenty years was the extraction of
this pancreatic principle in a form capable of reversing diabetic hyperglycemia
and its deadly consequences.
Georg Ludwig Zuelzer of Germany in 1907-1909 (16), Israel Kleiner of
the United States in 1915-1919 (17), and Nicholas Paulesco of Romania in 1921
(18) were able to reverse the acute symptoms of ,diabetes with relatively crude
pancreatic extracts, but frequent febrile responses to these extracts precluded
their usefulness as therapeutic agents.
Zuelzer extracted calf pancreas and, after observing the extract's
hypoglycemic effects in animals, attempted to use it to treat human diabetics.
He was able to show that the extract reversed diabetic glycosuria, ketonuria,
and ketonemia, but consistent hyperpyrexia forced him to abandon these efforts.
Zuelzer was also hampered by an inability to monitor blood glucose levels in
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humans, since micromethods for determination of the sugar ware not de:veloped
until 1913 (5).
Kleiner injected aqueous filtrates prepared from canine pancreases into
depancreatized dogs and observed almost immediate hypoglycemic effects,
consisting of decreases in blood glucose as great as 200 mg/100 ml.

This

hypoglycemic effect lasted about two hours and was accompanied by decreased
glycosuria.

Kleiner also demonstrated that extracts from organs other than

the pancreas fail to have this effect.

He was disturbed, however, not only

by febrile reactions, but also by "tremor of the head and hind legs" (probably
Furthermore, the necessity of injecting 100-150

symptoms of hypoglycemia).

rnl of his weak extract to obtain the observed effects presented an obstacle
to its use in human subjects.
In a well-controlled, thorough study, Paulesco repeated Kleiner's observations on pancreatectomized dogs and also noted a specific pancreatic extractinduced decrease of blood and urine urea and acetone. He demonstrated doseresponse behavior of the extract-induced decrease in blood glucose and urea
concentrations, not only in diabetic, but also in normal animals.
Because they isolated it in a form sufficiently pure to be consistently
effective in the treatment of human diabetes without serious side effects, the
physiologists Frederick Grant Banting and Charles Herbert Best are generally
credited with the discovery of the hormone they named insulin, an obvious
reference to its origin in the islets of Langerhans.

A struggling Canadian

orthopedic surgeon, Banting accepted a lectureship at the University of Western
Ontario, London, in 1920.

It was there, while preparing a lecture, that he

carne across a paper by Moses Barron, detailing destruction of the acinar
pancreas in dogs after ligation of the pancreatic duct (19).

At that point,
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Banting was struck by the possibility that the proteolytic enzymes secreted
by the acinar pancreas could have precluded the preparation of a hormone
extract sufficiently potent to treat diabetes and that the ligation described
by Barron might provide a solution to the problem. Destruction of the acinar
pancreas was later found to be unnecessary for the isolation of biologically
active insulin, but the inspiration proved fateful.
Banting obtained permission from John Macleod, director of the physiology laboratories at the University of Toronto, to use one of the laboratories
at that institution and there entered into a fortuitous collaboration with Best,
a student of biochemistry.

The two worked incessantly through the summer

of 1921, attempting to induce

at~phy

of the canine acinar pancreas. Finally,

they succeeded in obtaining a potent aqueous extract that had a hypoglycemic
effect in pancreatectomized dogs, then obtained a preparation s1.1itable for
treatment of human diabetics using an improved acid-ethanol extraction procedure (20).

Immediately, Macleod put Best and J. B. Collip to work on the

development of a large-scale bovine pancreatic insulin purification procedure
for the Connaught Laboratories in Canada and the Eli Lilly Company in the
United States (21,22). A grateful scientific community and public were reflected
in the award of the 1923 Nobel Prize for physiology or medicine to Banting
and Macleod.
Thus, one era ended and another began.

The horrifying spectacle of

the "melting of the flesh" gave way to the first consistent reports of diabetic
neuropathy and angiopathy in those now able to live long enough-60 or more
years past their former life expectancy-to manifest these pathologies.

The

history of diabetes as Aretaeus' "wonderful" and hopeless disease ended; the
history of insulin as an illustrious influence on the development of endocrinology,
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protein chemistry, and clinical chemistry began.

As will be seen, although

not the first proven instance of hormone action, insulin was the first protein
whose primary structure was elucidated, the first complete protein to be
synthesized in the laboratory, the object of the first radioimmunoassay, and
the first hormone for which a prohormone was found. Insulin research continues
more vigorously than ever, yet the ultimate cause and eradication of diabetes
mellitus remain as elusive as ever. Perhaps insulin will be the focus of another
discovery that will not only open a new field of endeavour, but will finally
eradicate one of the oldest and mo.:;t perplexing diseases to plague the human
species.
'•'

PHYSiOLOGIC EFFECTS

Islet tissue containing insulin-secreting 8-cells is found in all vertebrates,
from cyclostomes to man (23). Insulin-producing cells have also been reported
among vertebrate precursors, in the entodermal epithelium of certain starfishes
and tunicates (24).

Glucagon-secreting a-cells are found in vertebrates only

beyond the cyclostomes, with the appearance of the organized proximity of
exocrine and endocrine pancreatic tissues (25,26).
In mammals, the islets are scattered throughout the acinar pancreas and
consist of cords of intermingled

a-cells,

B -cells, and D (at)-cells, which

probably secrete gastrin (27) and/or somatostatin (28).

It is in this class of

vertebrates that insulin appears to have its greatest integrative influence on
systemic anabolism, governing biosynthetic processes involving carbohydrates,
proteins, fats, and electrolytes in liver, muscle, adipose tissue, connective
tissue, leukocytes, endothelium, and epithelium. Insulin has not been found to
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have an effect on nervous tissue or erythrocytes, nor does it promote intestinal
absorption or renal tubule reabsorption of glucose.
In mammalian studies, concerning especially rats, dogs, and humans,
insulin has been found to increase the uptake of glucose by muscle and adipose
tissue (29-32).

Although glucose uptake by liver is insulin-independent (33),

insulin stimulates glucose utilization in that organ, as it does in muscle and
adipose tissue, promoting glycogenesis in liver and muscle (34,35) and glucose
oxidation in target tissues (36).

At the same time, the hormone inhibits

glycogenolysis in liver and muscle and gluconeogenesis in liver (34).

The

systemic result of insulin effects on target tissue carbohydrate metabolism
makes it the most potent hypoglycemic agent of mammalian physiology.
Insulin promotes amino acid uptake and protein synthesis by muscle and
liver (37-44), while decreasing tissue proteolysis (45,46).
creates a positive nitrogen balance.

Thus, the hormone

Only recently has the profound impact

of insulin on lipid metabolism in adipose tissue and liver been appreciated.
The hormone induces the synthesis and esterification of fatty acids while
inhibiting the hydrolysis of triglycerides in adipocytes and liver, serving as a
potent antagonist of such fatty acid mobilizing hormones as epinephrine,
thyrotropin, adrenocorticotropin, glucagon, somatotropin, and glucocorticoids
(47-52).

This anti-lipolytic effect prevents the formation and appearance in

blood of the "ketone bodies," acetoacetate,

s -hydroxybutyrate,

and acetone.

Insulin-induced uptake of K+ also occurs in the absence of glucose (53) and,
therefore, insulin is a hypokalemic, as well as a hypophosphoremic, agent (54).
The enormous impact of insulin on mammalian metabolism is profoundly
appreciated by observing the course of "brittle" diabetes mellitus, whether
induced by total pancreatectomy or selective destruction of the

s -cells

by
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such agents as alloxan and streptozotocin, or appearing spontaneously, usually
in the immature animal (juvenile onset).
Immediately after complete termination of s-cell function, the unopposed
stimulation of liver gluconeogenesis by glucocorticoids and glucagon (if loss of
islet function is subtotal), liver and muscle glycogenolysis by epinephrine and
glucagon, and suppression of tissue glucose uptake by somatotropin, as well as
a marked reduction of insulin-dependent glucose uptake and glycogenesis, results
in general glucose mobilization and a hyperglycemic state (55,56).

Within

hours, the concentration of plasma glucose exceeds 300 mg/100 ml, twice the
maximum attained in normal individuals (57).
The renal tubules normally
cannot reabsorb glucose in excess of 160
.•
mg/100 ml plasma (58) and, as this renal threshold is passed, the sugar "spills
over" into the urine, creating glycosuria. Water is lost with the excess glucose,
leading to polyuria.

The need to replace this water causes polydipsia and, if

replacement is insufficient, dehydration ensues.
Thyroid hormone-induced glucose oxidation and the energy requirements
of tissues dependent on insulin for glucose uptake quickly result in exhaustion
of these tissues' carbohydrate reserves. Epinephrine stimulation of proteolysis
results in muscle wasting and mobilization of amino acids, which feed gluconeogenesis in the liver, exacerbating the hyperglycemia.

Requisite deamination

of these metabolized amino acids drives the plasma urea concentration to
excessively high levels (55).
The virtual shutdown of carbohydrate utilization and the potent free
fatty acid mobilizing, lipolytic, and anti-lipogenic effects of epinephrine,
glucagon, somatotropin, corticotropin (ACTH), and glucocorticoids (48,49,51,59)
force the diabetic individual to switch to the products of fatty acid catabol-
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ism-the oxybutyrates-as his primary energy currency.

Thus, the plasma

concentration of free fatty acids as well as of acetoacetate, its reduction
product B-hydroxybutyrate, and its spontaneous decarboxylation product acetone-the ketone bodies-rises precipitously, producing a striking lipemia, ketonemia, and a consequent ketonuria.

Because two of the three ketone bodies

are acids, a dangerous acidosis ensues, leaching K+ from tissues and causing
a further deterioration in the insulin-dependent electrolyte balance.
Acidosis and electrolyte imbalance have a disastrous effect on the central
nervous system, leading to coma and death, despite the individual's attempts
to alleviate the acidosis by conserving carbon dioxide through a deep Kussmaul
respiration (60).

Even with insufin control and non-ketogenic maturity-onset

diabetes, the induction of normally minor pathways of carbohydrate metabolism
by frequent hyperglycemia eventually results in thickening of vascular basement
membranes with deposited mucopolysaccharides and abnormal intracellular
osmolality in Schwann cells due to high concentrations of sorbitol.

These

derangements are major factors in diabetic angiopathy (including retinopathy)
and neuropathy (61-64).
Because of the potent insulin antagonism of such pituitary hormones as
corticotropin, somatotropin, and thyrotropin, such hormones of the adrenal
medulla as epinephrine, and such hormones of the adrenal cortex as glucocorticoids as well as the pancreatic hormone glucagon, total pancreatectomy accompanied by hypophysectomy (Moussay animals) and/or adrenalectomy greatly
alleviates the consequences of insulin loss, preventing or greatly delaying the
onset of ketogenic diabetes by throwing the animal into a precarious balance
between hyperglycemia and hypoglycemia (65).
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METABOLIC EFFECTS

Most of the observed physiologic effects of insulin are necessarily based
on some impact on the quantity or function of the enzymes governing intermediary metabolism.

In this respect, the broad anabolic influence that insulin

exerts on mammalian physiology can be seen to derive from the various ways
in which the hormone affects "key" enzymes* of the major metabolic pathways.
Insulin has been found to influence intermediary metabolism in at least
three ways: 1) a delayed influence on enzyme biosynthesis, requiring several
hours to several days; 2) an immediate effect on preformed enzyme activity
within minutes by affecting

the;~

intracellular concentration of one or more

"messengers" (see Chapter III); and 3) an indirect feedback inhibition-based
modulation of enzyme activity through changes in the concentration of insulinaffected key enzyme reaction products.
Insulin has been found to induce the key glycolytic enzymes glucokinase,
phosphofructokinase, and pyruvate kinase (67-69) while suppressing the biosynthesis of the key gluconeogenic enzymes phosphoenolypyruvate carboxykinase,
pyruvate carboxylase, fructose diphosphatase, and glucose-6-phosphatase (70-72).
Weber found that in liver the activities and quantities of the key glycolytic enzymes decrease and of the key gluconeogenic enzymes increase after
induction of alloxan diabetes in rats (73-74).

These trends, including a

precipitous rise in the ratio of key gluconeogenic enzymes to key glycolytic

*The use of the term ''key enzyme" here is that of George Weber (66) in that
it signifies an enzyme catalyzing an essentially irreversible reaction, which
thus is not utilized in an opposing metabolic pathway; ~ glycogen synthetase
for glycogenesis and glycogen phosphorylase for glycogenolysis.
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enzymes, continue over a period of several days (66).

After insulin is

administered to these diabetic rats, the trends reverse themselves and return
to normal levels within two days.
The insulin-induced increase in key glycolytic enzyme activities is blocked
by such inhibitors of protein synthesis as actinomycin, puromycin, and ethionine
(73), while a glucocorticoid (triamcinolone)-induced increase of key gluconeogenic enzyme activities is prevented or reversed by inhibitors of protein
synthesis and insulin (75). The same reciprocal relationship of the key hepatic
enzymes was seen in starved rats that were subsequently re-fed. Increases of
glycolytic enzyme activities and decreases of gluconeogenic enzyme activities
upon re-feeding were blocked by

~dministration

that this phenomenon is insulin-dependent.

of anti-insulin serum, indicating
Hexokinase activity, however,

remained unchanged during starvation and re-feeding, indicating insulin independence, although Krahl's group have reported insulin restoral of diabetes- and
fasting-diminished hexokinase activity in rats (76-77).
Insulin promotes glucose oxidation while providing NADPH for fatty acid
synthesis by inducing the key enzymes of the pentose phosphate pathway,
glucose-6-phosphate dehydrogenase and 6-phosphogluconate dehydrogenase (7880), and malic enzyme (NADP-malate dehydrogenase) (66, 71), providing a critical
link in the conversion of glucose to fatty acids.

The hormone also induces

key enzymes of lipid synthesis.
Like the key glycolytic enzymes, an insulin-induced increase of starvation- and diabetes-depleted citrate cleavage enzyme and fatty acid synthetase
was seen in rat liver (81).

Evidence for an insulin-induced increase in liver

microsomal fatty acid desaturase and glycerol kinase, leading to ·triglyceride
formation, has also been found (82-83).

Meanwhile, insulin suppresses the
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synthesis of hydroxymethyl glutaryl CoA synthetase, the key enzyme of. acetoacetate formation in liver (84).
Insulin helps conserve a pool of amino acids for protein synthesis, thus
promoting a positive nitrogen balance, by suppressing the biosynthesis of
transaminases and other enzymes of amino acid degradation, as well as the
key urea cycle enzymes, ornithine carbamyl transferase (ornithine transcarbamyIase), arginine synthetase, and arginosuccinase in liver (85-88). Insulin suppression of urea cycle enzymes not only accounts for the marked increase of urea
excretion by diabetics, but also increases the quantity of aspartate available
for protein biosynthesis by decreasing urea cycle conversion of the amino acid
to fumarate, a substrate for glt;tconeogenesis in liver cell cytoplasm.

The

ammonium ion normally converted to urea may be utilized in the glutamine
synthetase-catalyzed conversion of glutamate to glutamine, increasing the
availability of the latter amino acid for protein synthesis.
Increased glutamine and the carbon dioxide otherwise converted to urea
may also serve as substrate for cytoplasmic formation of carbamyl phosphate,
which can then be utilized, with aspartate (also a substrate of purine synthesis),
in pyrimidine biosynthesis, leading to speculation that insulin causes a substratedriven increase of nucleic acid synthesis (89).

Insulin has also been found,

however, to induce rat liver thymidine phosphorylase, the first enzyme in the
degradative pathway for the nucleotide (66).
A more direct basis for insulin enhancement of nucleic acid synthesis
may be found in evidence that the hormone induces RNA polymerase in rat
liver (90), increases DNA polymerase activity in rat liver and mammary
epithelium (91,92), and causes cell proliferation in severely diabetic rat liver
(91).
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The best example of a rapid effect of insulin on enzyme activity is
found in hepatic glycogen metabolism, consisting of a simultaneous activation
of glycogen synthetase and inactivation of glycogen phosphorylase within a few
minutes {93). The hormone also causes an immediate inactivation of triglyceride
lipase in adipose tissue {94).

Evidence basing these effects on a reversal of

the Sutherland cyclic AMP-mediated mechanism for ephinephrine and glucagon
action is reviewed in Chapter III.
The most profound immediate effect of insulin on target tissues other
than liver-an increase in glucose transport across the cell membrane, followed
by a rise in the intracellular concentration of glucose-6-phosphate-remains an
enigma. Neither the mechanism !'nor the structures responsible for this facilitated sugar transport has yet been elucidated, and there exists no clear evidence
that insulin has any effect on hexokinase biosynthesis.

However, several

investigators have reported an insulin-dependent association of type II hexokinase with mitochondria in rat muscle, adipose tissue, and mammary epithelium
{95-97), suggesting a rapid enhancement by the hormone of anabolic processes
in these tissues through an increase of cellular energy charge, resulting from
an accelerated rate of oxidative phosphorylation.
Weber {98) has proposed a system of insulin integration of hepatic
intermediary metabolism, resulting from immediate insulin effects and occurring
before insulin-induced influence on enzyme biosynthesis. This integrative effect
is based on immediate insulin effects on the concentration of metabolites that

inhibit key enzymes of pathways involved in their biosynthesis.
Free fatty acids, their oxidation product, acetyl CoA, and the substrates
of gluconeogenesis-all decreased by insulin-have been found to inhibit the key
enzymes of glycolysis. In addition, free fatty acids, which in high concentrations
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nonspecifically inhibit many enzymes, are particularly inhibitory in high physiologic concentrations toward the key enzymes of glycolysis, the pentose phosphate pathway and the tricarboxylic acid cycle.
Insulin decreases liver uptake of L-alanine (99), an inhibitor of pyruvate
kinase, and decreases the availability of ATP (by increasing its utilization in
glucose-6-phosphate formation and lipid biosynthesis, while decreasing liver
adenylate kinase activity (100)), an inhibitor of phosphofructokinase and pyruvate
kinase, free fatty acids (by inactivating lipases), and acetyl CoA (by increasing
its utilization in fatty acid synthesis).
Insulin's immediate effects in adipose tissue-facilitation of glucose uptake, resulting in a substrate (glucose-6-phosphate)-induced increase in a'

glycerophosphate-causes a rapid fall in plasma free fatty acids, which in turn
alleviates the free fatty acid feedback inhibition of key enzymes of glycolysis,
the pentose phosphate pathway, and the tricarboxylic acid cycle.

These

pathways and, consequently, lipid biosynthesis are facilitated before insulin
effects on enzyme biosynthesis become apparent.
Even a cursory examination of insulin's effects on mammalian intermediary metabolism thus reveals impressive evidence that it is indeed the master
hormone of anabolism in this class of animals, providing all materials-enzymes,
substrates, high-energy phosphate anhydrides, and electron donors-necessary
for biosynthesis of complex carbohydrates, fats, proteins, and nucleic

acids~

in

liver, muscle, adipose and connective tissue, lymphoid cells, epithelium, and
endothelium.

The fact that insulin triggers an orchestrated chain of such

events, commencing immediately after ingestion of a meal and continuing at
different levels of metabolic regulation for several days thereafter, also argues
for insulin's proposed pivotal role as the "feast or famine" hormone in animal
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evolution, enabling an animal to make the most efficient use of ingested
nutrients for further utilization in times of starvation that often require
vigorous exercise in pursuit of another meal.
One may thus speculate that man-made prosperity has created an
evolutionary trap, evidenced by the apparent correlation of maturity-onset
diabetes with consumption of fats in industrialized western nations (101).

CHAPTER III

INSULIN ACTIVITY ON THE MOLECULAR LEVEL

THE INSULIN MOLECULE

Extraction and Purification

The first insulin used to treat a human diabetic (January 11, 1922) was
extracted from bovine pancreases obtained from commercial sources by Banting
and Best.

They extracted the pancreatic tissue with cold acidified saline,

followed by ethanol to a final

con~entration

of 60%. The filtrate was evaporated

to dryness in a stream of warm air, the residue was washed with toluene and
then was dissolved in saline.

This material possessed an insulin activity of

slightly more than one international unit per ml (102).
During the previous year, Banting and Best had also found this method
to be the most effective in producing potent insulin extracts from canine and
fetal calf pancreas, the latter being the source of a preparation possessing
ten times the potency of the adult bovine extract, probably because fetal calf
pancreas of under five months' development does not contain pancreatic
enzymes, while producing a large quantity of insulin.
Soon after commenoement of large-scale commercial production of
insulin in 1922, acetone wrls substituted for ethanol and the wind tunnel was
replaced by a vacuum still. After the U.S. chemist John Jacob Abel first crys-
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tallized insulin around 1925 {103), it was found that crystallization of the
hormone requires zinc or another divalent metal cation, such as cobalt, nickel
or cadmium {104).

Due in large part to D.A. Scott's delineation of the role

of zinc in the crystallization of insulin {105), protamine zinc insulin was
introduced in 1936 as a long-acting agent that abrogated the diabetic's requirement for frequent injections of the hormone (106).
As the requirement for pure insulin from a variety of animal species
for physicochemical studies of the hormone became felt, ever more sophisticated
biochemical separation techniques were brought to bear on the problem of
insulin isolation and purification. Techniques used include fractional precipitation with ethanol or salt,

isoelectr~c

precipitation, ion exchange chromatography,

gel filtration, and partition chromatography using paper and adsorbent columns
(104).
For example, rat insulin has been isolated from frozen pancreas extracted
in 8096 ethanol adjusted to pH 3 with phosphoric acid, followed by addition of
ammonium hydroxide to pH 8.

After clarification of the solution, insulin is

precipitated first by adding ethanol and ether and again with picric acid. The
I

picrate is dissolved in acid acetone, precipitated with excess acetone, washed
with ether and dried {104).

Bovine insulin has been purified from pancreatic

extracts by gel filtration on Sephadex G-50 equilibrated with 0.2 M ammonium
bicarbonate, pH 7.8, at 4 °C, followed by crystallization from zinc acetate, pH
5.9 (107). Sephadex G-50 has also been used to purify feline (108) and human
(109) insulins, using 1 M acetic acid for elution.

After crystallization from

citrate buffer, the human insulin was found to be relatively free of glucagon.
Cellulose acetate electrophoresis has also proven to be an effective means of
separating the two hormones (110).

The proinsulin (as much as 296)
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contaminating commercial preparations of insulin may also be removed by
sephadex G-50 chromatography with 1 M acetic acid (111).
Insulin has been extracted from human plasma with ethanol, normal
butanol and toluene acidified with hydrochloric acid, resulting in recovery of
80-9096 exogenous (35g) insulin and a forty-fold increase of endogenous insulin
activity (112).

Physical Properties
The zinc-complexed insulin first crystallized by Abel was in the rhombohedral form, consisting of insulin hexamers each containing 2 or 4 zinc atoms
(113).

Later, the zinc-insulin he}Camer was crystallized in monoclinic form in

the presence of phenol and a zinc-free orthorhombic form has been crystallized
at acid pH (104).
It was the prevalence of the zinc-containing insulin hexamer (M.W.

35,000-36,000) in preparations subjected to physical studies before 1948 that
led early investigators to believe that the molecular weight of the hormone
lay somewhere between 36,000 and 48,000. In 1948, Gutfreund concluded that

.

these species were aggregates of a molecular weight 12,000 subunit (114).
Finally, in 1952, Harfenist and Craig showed that the ultimate insulin subunit,
or monomer, was a molecule of approximately 6,000 daltons molecular weight
(115), quickly confirmed by elucidation of the hormone's primary structure,
which assigned to bovine insulin a molecular weight of 5, 734 daltons.

Based

on its amino acid composition, the molecular weight of human insulin is 5,808
daltons.
The insulin dimer of molecular weight 10,000-12,000 has been shown to
have a sedimentation coefficient (S 2o,w> of 1.85 x 10-13 sec., a diffusion
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coefficient (D2o,w> of 13.5 x to-7 cm2/sec., and a frictional ratio (f/fo) of
1.1,

while

the

monomer

of

6,000-7,500

molecular

weight

shows

s2o,w

= 1.2 x to-13 sec., D2o,w = 16 x 1o-7 cm2/sec. and f/fo=1.12 (104),

indicating that the molecule is nearly spherical in shape.
Both bovine pancreatic insulin and human plasma insulin derived from
portal vein blood have been found to have an electrophoretic mobility between
albumin and at-globulins (116), but a substantial portion of human endogenous
plasma insulin of the peripheral circulation has been shown to migrate with

a -globulins

(see Chapter IV).

Primary Structure
The complete elucidation of the primary structure of bovine pancreatic
insulin, an outstanding tour de force achieved by the biochemist Frederick
Sanger and co-workers at Oxford University, reported in 1955 (117), was a
watershed of protein chemistry, not only because it represented the first amino
acid sequence determination of a protein, but also because it conclusively
demonstrated the uniqueness

and~

consistency of protein structure (be., the

amino acid sequence of every molecule of a given protein is identical, but
different from every other protein) and proved the veracity of the peptide
bond hypothesis advanced by Hofmeister and Fischer in 1906 (118).
The chain of events leading to the elucidation of the amino acid sequence
of bovine insulin, shown in figure 1, began in 1945 when Sanger introduced
1,2,4-fluorodinitrobenzene (FDNB, since called the Sanger reagent) for dinitrophenyl (DNP) labelling of amino-terminal amino acids according to the following
reaction:
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FIGURE 1. AMINO ACID SEQUENCES OF INSULINS AND CUMULATIVE
AMINO ACID REPLACEMENTS AT POSITIONS WHERE VARIATIONS OCCUR.
B chain insulin:
[a]

pig, dog, cattle, sheep, goat, horse; sperm, fin and sei whales

[b)

human, African elephant

[c)

rabbit

[d), [e)

rat, mouse

[f)

chicken

[g)

guinea pig

[h)

coypu

(i]

bonito*

[j]

cod fish

(k]

angler fish

*
t

Either B 24 or B 25 phe deleted.
Deletion.

* Single component

from mixture of bonito, tuna and swordfish insulins.

(Reproduced with permission from the American Diabetes Association, Inc.,
from Ref. 128. Copyright 1972 by the American Diabetes Association, Inc.)
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(119)

The labelled protein was then subjected to acid hydrolysis as follows:
~ Q I
NHCHC-R

c$JNO,
N0 2

6N HCl
+ amino acids.

18 hrs.

The bright yellow DNP-N-terminal amino acid was separated from other
amino acids by extraction with ether and identified by partition chromatography
with reference to standard DNP-amino acids. Thus, FDNB labelling of insulin
followed by acid hydrolysis yielded the expected

e:-DNP derivative of lysine

and cx-DNP derivatives of phenylalanine and glycine. Based on the molecular
weight of 12,000 assigned to insulin at that time, Sanger deduced that the
hormone consists of four amino acid chains, two with N-terminal phenylalanine
and two with N-terminal glycine (120).
By 194 7, Sanger was able to obtain the separated chains of insulin intact
by oxidation of the hormone with performic acid, yielding the cysteic acid
derivatives (121).

Because an accurate amino acid analysis of insulin was

available to Sanger from the beginning of his endeavour, he knew that complications resulting from oxidation of tryptophan and methionine would be avoided
since these amino acids are not present in bovine insulin. He found two kinds
of polypeptide chains: one, designated A-chain, was acidic and had a simpler
\

amino acid composition than the complete insulin molecule, lacking lysine,
arginine, histidine, phenylalanine, threonine, and proline; the other, designated
B-chain, was basic, containing all the basic amino acids of the insulin molecule.

..
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The A-chain, with N-terminal glycine, was found to consist of 21 residues,
four of which were cysteic acid, while the B-chain, with N-terminal phenylalanine, possessed 30 residues, two of which were cysteic acid.
The B-chain, having a more distinctive composition than the A-chain,
proved easier to study, and was sequenced first.

Mild acid hydrolysis yielded

about 45 peptides of varying size, which were separated and recovered by
electrophoresis, ion-exchange chromatography, and adsorption on charcoal, followed by two-dimensional paper chromatography. Such treatment of the DNP
derivatives of the separated chains enabled the first four N-terminal amino
acids of the B-chain and the first five N-terminal amino acids of the A-chain
to be deduced. Preliminary

sequ~ncing

and amino acid analysis of the separated

chains demonstrated that insulin consists of only two kinds of polypeptide
chains.

Thus, it was concluded that insulin either consists of two identical

halves or is a molecule of molecular weight 6,000. The latter alternative was
later found to be the case.
Peptide fragments enabled all but four B-chain amino acids to be assigned
their proper sequence. The complete B-chain amino acid sequence was determined in 1950 after additional, longer peptides were obtained by proteolytic
cleavage with pepsin, trypsin, and chymotrypsin (122), which also enabled
assignments of positions for glutamine and asparagine (123), otherwise converted
to their corresponding acids by acid hydrolysis.
The major problem encountered in sequencing the A-chain arose from
the juxtaposition of two cysteine residues at positions 6 and 7, resulting in
the formation of peptides that could not be separated adequately by paper
chromatography. This problem was solved by paper electrophoresis at pH 2. 75,
at which point carboxylic acids are uncharged, cysteic acid is negatively
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charged, and amines are positively charged. Thus, the sequence of the A-chain
was known by 1953 (124,125).
At this time, a molecular weight of approximately 6,000 daltons hsd
already been assigned to insulin. Thus, the hormone had to consist of one copy
of each of the two polypeptide chains, A and B, linked by cystine disulfide
bonds.

The disparity between the number of cysteines found in the A and B

chains indicated that they were linked by two interchain disulfide bonds and
that the remaining two cysteines in the A-chain formed an intrachain disulfide
bond. Because of rearrangement of disulfide bonds that occurs in acid solution,
however, it wasn't until 1955 that the correct linkages could be determined
after it was learned that enzymic proteolysis at neutral pH and acid hydrolysis
in the presence of sulfhydryl compounds such as thioglycollic acid proceeds
without disulfide rearrangement (126).

Implications of Variations in Primary Structure
More than twenty distinct amino acid sequences for insulin from the
various species studied, the majority of which are depicted in figure 1, are
now known (127). It may be seen that the insulin molecule consists of certain
amino acids that are invariant among the different species: all the cysteines,
A1, A2, A16, A19, B6, BS, Bll, B12, B15, B16, B18, B23, B24, and B26
hydrophobic residues, and AS and A21 amides; other amino acids that are
conservatively variant: A3, B1, and B2 apolar residues, A18 polar residue, and
A4, B5, and B13 charged residues; and the remaining amino acids, that are
freely variant, especially at positions AS, A9, A10, B20, B21, B22, B29, and
B30. In addition, coypu (or nutria, Myocastor coypus, a large South American
rodent) insulin A-chain has been found to have an additional amino acid, a
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c-terminal aspartate, and B-chain one less residue at position 25, while certain
fish insulin B-chains have an additional amino acid at the N-terminus, but are
lacking an amino acid at the C-terminus.

Because even guinea pig, coypu,

and fish insulins exhibiting differences of 19 to 22 residues compared to bovine
insulin have been shown to have biological activity among different species
(128), one may conclude that the invariant residues are important to the
biological activity of the hormone, either by insuring a molecular conformation
that preserves the shape of the active site or by functioning in the active
site itself.
The results of chemical modification of the insulin molecule, summarized
in Table I, tend to confirm that invariant amino acids play a critical role in
the hormone's biological activity.' Specifically, oxidative or reductive cleavage
of the disulfide bonds and removal of the Al glycine, A2 isoleucine, A21
asparagine, and the last eight amino acids of the B-chain, which include B23
glycine, B24 phenylalanine, and B26 tyrosine, result in serious losses of activity.
On the other hand, removal or modification of the variable Bl, B29, and B30
residues causes no significant reduction of insulin activity. Further confirmation of the modification studies is provided by proinsulin, which possesses 1796
insulin bioactivity (141) and 0.06-2896 insulin immunoreactivity (136).

The

proinsulin connecting peptide, which joins the amino terminus of the A-chain
to the carboxy terminus of the B-chain, not only obscures the A-chain amino
terminal residues, but also is known to cover the A14 and A19 tyrosines (143),
which appear to be important to insulin immunoreactivity.

TABLE I.

EFFECTS OF CHEMICAL MODIFICATIONS ON INSULIN BIOLOGICAL
ACTIVITY AND IMMUNOREACTIVITY

Altered Residues

Type of Residue*

Free amine-bearing

1 I, 1 C, 1

Free carboxy-bearing

1 I, 2

Cystine S2

A7, B7 cystine

A6, All cystine
Tyrosine-0 H
A1 glycine

c,

3

I

I

I
3 I, 1
I

v

v
v

Method of
Alteration

96 Biol. Act.
of Native
Insulin

acetylation

78-98a

129

<0.5g

130

reduction

45-63a

131

oxidation

oa,f

132

s-car boxymethylation

40-1ooa,f

133

s-sulfonation

15a

133

S-thionylation

1f

acetylation

<3a

esterification

96 Immunoreactivity of
Native Insulin

t

Ref.

134
129

2-1of,h

20-30j

133

15h

40j

133

arginine addition

59-ssa,h

40j

133

lys-arg addition

20h

34j

133

40-1oof,h
35-4oh

47j

133
135

removal
amine removal

acetylation

<;.:»
~

TABLE I

(CONTINUED)

Altered Residues
A1 glycine

A14 tyrosine

A14, A19 tyrosines
A21 asparagine
A-chain
B1 phenylalanine

Type of Residue*
I

v
V, I
I
10 I, 3 C, 8

c

v

Method of
Alteration

B30 alanine

v

activity of
Native Insulin

Ref.

17h

135

2-dimethyl-3-formylD-thiazolidine-4carbonyl conjugation

13h

135

nitration

60-70a,c

6-38j,k

136

iodination

1ooi

93j

137

iodination

7oa,c

4-59j,k

136

removal

0-2g

138

removal

oa,b

139

removal

9of

103j

133

60-7oh

85j

133

4oa

24-56j

136

75-1oof,h

85j

133

fluorescein isothiocyanate conjugation
(FITC)

v

% Immunore-

of Native
Insulin

t-butoxycarbonylation

_E-iodination

B29 lysine

% Biol. Act.

E:

-acetylation

removal

98-lOOa,g

138,140
<:.)

arg2 addition

61a

141

<:.11

TABLE I

(CONTINUED)

Altered Residues

Type of Residue*

Method of
Alteration

B1 phe/B29 lys

c, v

gly subst./ E -acetylat ion

B1 phe,B29 lys

c, v

acetylation

B1-B6
B23-B30

1 I, 3

c,

2

v

3 I, 5 V

% Biol. Act.

% Immunore-

of Native
Insulin

activity of
Native Insulin

Ref.

35a

25j

133

85-1oof,h

3oj

133

removal

>44a

142

removal

15d,g

138

<0.2

143

oa

B-chain
A1 gly, B1 phe

12 I, 4 C, 14
I, C

v

o.o8-2.oj,k

136

<4a,g

148,149

removal

0a,b

139

removal

1.6-7f,h

15j

133

FITC

4a

3-32j

136

oa

0-4j

136

A1 gly, B1 phe, B29 lys

I, C, V

FITC

A1-A2, B1-B2

2 I, 2 C

removal

0.2h

2j

133

I, V

removal

ta

0.17-3.5j,k

136

A21 asn, B30 ala

FOOTNOTES TO TABLE I.

a.
b.
c.
d.
e.
f.
g.
h.
i.

Mouse convulsion assay
Mouse hemidiaphragm assay
Mouse blood sugar assay
Rat hemidiaphragm assay
Rat epididymal fat pad assay
Rat blood sugar assay
Rabbit blood sugar assay
Fat cell assay (incorporation of 3-3H glucose into adipocyte lipids; 144,145)
Fat cell assay (glucose oxidation)
j. Radioimmunoassay
k. Immunohemolysis

*

I = invariant
C = conservatively variant
V = variant

38

-

secondarY Structure
Calculations based on low ultraviolet optical rotatory dispersion (ORD)

and ci:-cular dichroism (CD) spectra have led investigators to conclude that 30
to 4096 of insulin residues are confined to tight right-handed

a -helical

conformations (146,147). This figure is in good agreement with the 35% a-helix
found in x-ray diffraction studies, which also indicate that nearly 5096 of the
insulin residues contribute to right-handed helices and none to left-handed
helices (104,143).

All the

a-helical residues are found in two stretches of

a -helix, one in the A-chain, between A2 isoleucine and AS alanine, and the
other in the B-chain, between B9 serine and B19 cystine.
non-a-helix lies between A13

leu~ine

A stretch of

and A21 asparagine. In addition, hydrogen

bonds are formed between the A19 carbonyl oxygen and the B25

cx-amido

hydrogen, the A21 a-carboxy oxygen and the B22 arginine guanidinium amino
hydrogen, and the A4 glutamate carboxy oxygen and the B29 cr-amido hydrogen,
while the C-terminal residues of the B-chain, from B21 glutamate to the B30
terminus, form half of an antiparallel

e -pleated

sheet important in insulin

dimer formation (143) (See Chapter IV, "Insulin Aggregates").

Tertiary Structure
The elucidation of insulin's tertiary structure began in 1935, when the
British chemist and crystallographer Dorothy Hodgkin crystallized insulin in
the rhombohedral form, as Abel had done, and performed single-crystal x-ray
analysis on the preparation (150). She found that the protein molecular weight
of the unit cell of these crystals was about 36,000, the same value Svedberg
had deduced from sedimentation velocity studies of insulin in solution (151),
and that the crystals had trigonal symmetry. This finding meant that the unit
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could be divided into three equivalent parts, each with a molecular weight of
12,000, suggesting that the predominant insulin species being studied· at the
time consisted of at least three equal subunits.

It is now known that this

species is actually the insulin hexamer.
It was not until 1960 that Barbara Low, using the acid orthorhombic
crystal form of insulin, demonstrated that each asymmetric unit contained two
molecules related by a twofold (!Y-) axis perpendicular to the vertical threefold
crystal (!-) axis (152).

After Schlichtkrull's discovery that a minimum of two

zinc ions per hexamer are necessary for crystallization of insulin in the
rhombohedral form (153), it was concluded that these ions must lie along the
threefold axis, equally spaced above and below the local twofold axes.

After

isomorphous replacements of these zinc atoms with heavy metal atoms were
made, x-ray diffraction patterns were obtained that enabled the construction
0

of electron density maps at 2.8 A resolution.

Based on the known primary

structure of porcine insulin, a three-dimensional model of the porcine insulin
0

0

monomer, with a diameter of 50 A and a height of 35 A (pictured in figure
2), was constructed (154,155).
Examination of the tertiary structure of the insulin monomer, based on
x-ray diffraction studies, reveals that the B-chain termini emerge from the
central stretch of

a-helix, through sharp turns at BS glycine and the

tetrapeptide from B20 glycine to B23 glycine, in a fully extended conformation.
The A-chain sits compactly between these arms, on the B-chain a-helix. The
A2-A8

<>-helix runs across the top of the molecule and the A13-A21 helix

folds across the face of the molecule to bring the C-terminal residues of the
A-chain back beneath those of the A-chain N-terminus. Eight of 14 invariant
hydrophobic residues-B6, Bll, B15 and A16 leucines, A2 isoleucine, B18 valine,
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FIGURE 2. REPRESENTATION OF THE TERTIARY STRUCTURE OF THE
INSULIN MONOMER, VIEWED PERPENDICULAR TO THE THREEFOLD AXIS
(Reproduced with permiSSion from the American Diabetes Association, Inc.,
from Ref. 143. Copyright 1972 by the American Diabetes Association, Inc.)
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B24 phenylalanine, and B26 tyrosine-form the molecule's apolar core, while
many other nonpolar residues are located on the surface with their side chains
directed inward toward the interior of the molecule.

Thus, the invariant

hydrophobic residues appear to be critically important to the maintenance of
the molecule's tertiary structure, which is requisite for insulin's biological
activity, as evidenced by the fact that desoctapeptide (B23-B30 deletion) insulin,
which has not been found to possess more than 15% insulin activity, has been
shown by CD studies to undergo extensive conformational changes compared
to native insulin (156).
The B-chain a -helix is flanked by the two interchain disulfide bonds,
the B7-A 7 cystine, which lies on ;the surface of the molecule, and the B19-A20
cystine, which is partially concealed.

The intrachain A6-A11 cystine is

completely buried in the hydrophobic core. A number of invariant residues at
the surface of the monomer, including several apolar amino acids with their
side chains directed outward, appear to be important to the biological activity
and aggregative properties of insulin. A1 glycine, AS glutamine, A19 tyrosine,
A21 asparagine, and B25 phenylalanine are especially likely to be involved in
the active site (135), with an important contact being made between the A19
tyrosine phenolic hydroxy group and the A2 isoleucine side chain.

Removal

of A21 asparagine, which nearly abolishes biologic activity, has also been found
to cause extensive conformational alterations and to reduce greatly the ability
of the radiolabeled (1251) insulin derivative to bind to adipocyte receptors (135).
The remainder of the insulin monomer surface consists. of two hydrophobic
faces, one consisting of B12 valine, B16 tyrosine, and B30 alanine and the
other of B1 phenylalanine, B14 alanine, B17 leucine, B18 valine, A13 leucine,
and A14 tyrosine, which are involved in formation of the insulin dimer and
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hexamer. The quaternary structure of insulin is dealt with further in .Chapter
IV, where insulin aggregates are discussed.

§_ynthesis
During the 1960s, insulin was the object of yet another landmark in
protein chemistry, the first laboratory synthesis of a complete protein, carried
out by Katsoyannis and co-workers. The synthesis involved initial amino acid
conjugation, peptide elongation, and joining of peptide fragments after reactive
side chains and amino and carboxy termini had been masked with blocking
groups easily removed under mild conditions with a minimum of racemization
to yield a crystalline product readily separated from other reaction components.
The A- and B-chains were synthesized separately as sulfocysteinyl derivatives
and, after reduction of the A-chain to the cysteinyl form, they were combined
in the presence of air, resulting in a 12-16% yield of biologically active,
completely synthetic sheep insulin (157-158).

Synthesis of insulin derivations

has proven to be a valuable means of studying the effects on biological activity
of the otherwise unattainable modification of specific amino acids.
THE INSUUN RECEPTOR
It is now widely recognized that the first event of cellular hormone

action is the binding of the hormone to a cell "receptor."

Indeed, one may

apply equally well to any hormone receptor Pedro Cuatrecasas' operational
definition of the insulin receptor (159), which "signifies those molecules of the
cell which are uniquely capable of recognizing and interacting with insulin with
a high degree of selectivity and affinity and which, in addition, possess the
capability of conveying the occurrence of the interaction to biochemical
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processes resulting in metabolicelly significant events. Thus, the receptor has
at least two functions: 1) to specifically recognize insulin and 2) to somehow
convey to other molecules the fact that insulin has been recognized."
In relation to the first function, it is pertinent to examine where in
the cell recognition of insulin takes place, the specificity and affinity of the
insulin-receptor association, the nature of the insulin receptor, the fate of
both the hormone and receptor, and the means by which the cell modulates
its insulin response at the receptor level; regarding the second function, the
question obviously remains how the signal generated by insulin-receptor association is conveyed to the cell's metabolic machinery.

Location
Unlike steroid and thyroid hormones, which enter the cell before encountering specific receptors, protein hormones are now generally believed to trigger
their effects at the cell surface by binding to receptors integrally associated
with the plasma membrane.

Several lines of evidence strongly suggest that

insulin receptors are situated exclusively at the surface of the cell:
1.

Specific binding of insulin to fat cell homogenate fractions is almost

exclusively limited to particulate, or plasma membrane, fractions, which exhibit
an insulin binding capacity comparable to that of intact adipocytes.

Little

binding of insulin to nuclear or mitochondrial fractions was found and the
soluble cellular fraction did not compete effectively with insulin binding to
membranes (160,161).
2.

Trypsin treatment of intact adipocytes and isolated adipocyte plasma

membranes abolishes the ability of these preparations to bind insulin (161).
The same abolition of insulin binding to adipocytes was found after the cells
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were exposed to trypsin covalently bound to agarose beads larger than the
cells themselves, indicating that the insulin receptors are limited to the cell
surface (162).
3. Insulin covalently coupled to dextran-40 (average molecular weight = 40,000)
stimulates glycogen synthesis and sugar transport by intact rat diaphragm (163)
and stimulates glucose metabolism in adipose tissue (164).
coupled to dextran-2000 (average molecular weight

Insulin covalently

= 2,000,000)

has been found

to stimulate glucose metabolism in adipocytes (165).
4. Cuatrecasas attached insulin to agarose beads 60 to 300

1J

m in diameter

via the B1 a -NH2 or the B29 lysine £-NH2 group (159,166). As little as 1 to 3
lJ

U of this preparation per ml i!'"mediately stimulated glucose utilization and

inhibited hormone-stimulated lipolysis in adipocytes 50 to 100

1J

m in diameter,

increased RNA synthesis and a -aminoisobutyrate accumulation in isolated
mammary cells, and activated glycogen synthetase in tadpole liver slices
(159,166-169). The increased glucose utilization by adipocytes could be completely reversed by addition of anti-insulin serum, even after prolonged incubation with insulin-Sepharose (166).
Extensive washing of the beads with 8M urea and 6M guanidine did not
result in liberation of free insulin (166), but Oka and Topper (170) have found
that an insulin-like material can be extracted from insulin-Sepharose in the
presence of 2.5% bovine serum albumin.

This material elicits "super-insulin"

responses from virgin and pregnant mouse mammary epithelial cells, consisting
of greater than standard insulin stimulation of

a -aminoisobutyrate uptake,

DNA synthesis, and glucose-6-phosphate dehydrogenase and phosphogluconate
dehydrogenase activities. The increment in a-aminoisobutyrate uptake, greater
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than 5 times that obtained with insulin, is completely abolished by anti-insulin
serum.
5. Inverted, or "inside-out," adipocyte plasma membrane vesicles, or "ghosts,"
don't bind insulin.

If such inside-out ghosts are formed in the presence of

insulin, the vesicle-bound insulin exchanges with the medium much more slowly
than when "right-side out" vesicles are used, but no discrepancy is seen after
the inverted vesicles are broken {171).

The observations indicate that insulin

receptors are located on the outside of the plasma membrane.
Although there appears to be widespread concurrence that insulin receptors are confined to the plasma membrane, controversy, which is a common
feature in many areas of insulin :'research, has arisen around this issue also.
Goldfine and co-workers are foremost among those who postulate that
intracellular penetration and bind;ng of insulin to receptors on organelle surfaces
is the underlying mechanism of many insulin effects.

They have reported a

reversible, saturable binding of 125J-insulin to rat liver nuclei which they
determined to be free of plasma membranes by electron microscopy and the
absence of Na--K+ ATPase activity, a plasma membrane marker {172).

The

binding, which amounts to about 1096 of that found with plasma membranes,
is abolished by trypsin treatment and inhibited by insulin analogues in proportion
to their biologic activity and ability to inhibit binding of radiolabelled insulin
to plasma membrane receptors.
These investigators obtained similar results with cultured human lymphocytes, finding 796 of total insulin bound to cells associated

~ith

purified nuclei

{173). Using radioautographic analysis, they observed 5496 of grains over the
Plasma membrane, 1996 over the cytosol and 2196 over the nucleus 5 minutes
after addition of 125J-insulin to lymphocytes at 37°C.

After 120 minutes,
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38 % of grains were observed over the plasma membrane, 27% over the cytosol,
and 28% over the nucleus. Goldfine's group have also demonstrated intrac·enular
uptake of insulin by cultured lymphocytes using radioautographic electron
microscopy (17 4). They noted increasing concentrations of grains over the cell
interior, localized mainly over the cytoplasm and nucleus, from 30 seconds to
30 minutes after addition of 1251-insulin at 37°C.
Several other investigators have used radioautography as a basis for
claims of intracellular penetration of insulin. Carpentier and co-workers found
a penetration of 1251-insulin into cultured lymphocytes of 0.9
into rat hepatocytes of 1.6

\.l

m at 37°C (176).

\.lm

(175) and

In the latter case, it was

found that 1-125 activity became increasingly associated with lysosomes, possibly
indicating a mechanism of insulin' degradation following pinocytosis. Apparent
support for this contention may be found in the results of Bergeron et al.
(177), who found that in rat livers removed 3 minutes after injection of 68.2
\.l

Ci (426 ng) 1251-insulin into the portal vein, radioautographic grains were

confined to the plasmalemma, but that in livers removed 10 to 20 minutes
after injection, a high proportion of grains were located over lysosomes, Golgi
apparatus and other organelles.

Properties
The necessity of strong insulin binding to cells prior to the onset of
the hormone's biological effects was first postulated by W.c. Stadie and coworkers in 1949 (178) after they observed that the action of insulin on glycogen
synthesis in diaphragm muscle, initiated during a short exposure to insulin,
persisted after the tissue was rinsed with and transferred to insulin-free medium.
Subsequently they found that 131J- and 35s-labeled insulin was bound by muscle
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in proportion to the hormone's effect on glycogen synthesis (179).

Narahara

(180) also found that an immediate binding of insulin to frog sartorius muscle
precedes the insulin-dependent acceleration of glucose transport, with an appreciable interval observed between binding and the commencement of transport
acceleration.

Numerous investigators have demonstrated that the specific

binding of insulin from various animal species, proinsulin, and several insulin
analogues to isolated cells and cell membranes is directly proportional to the
biologic activity of the insulin or insulin analogue, as determined by such
criteria as glucose oxidation in adipocytes.

Receptor preparations employed

include rat liver membrane (181,182), isolated rat adipocytes (159), cultured
human lymphocytes (183), and cultured human fibroblasts (184) .
.'

Although, generally, procedures that result in alterations of the insulinbinding properties of cell receptors also cause quantitatively similar impairments
of insulin-induced metabolic responses in these cells (159), the insulin-receptor
interaction and the hormone's physiologic effects can be uncoupled.

Insulin

binds to frog muscle at 0°C, but does not cause the increase of glucose
transport seen at higher temperatures (180). Treatment of cells with neuraminidase, which removes terminal sialic acid residues from cell-surface glycoproteins, abolishes insulin-induced glucose uptake and inhibition of lipolysis, but
doesn't alter insulin binding to the cells (159,171,183,185-187).

Starvation of

rats or prior treatment with prednisone or streptozotocin reduces the metabolic
response of fat cells to insulin, but does not
the receptors for the hormone (188).

affec~

the quantity or affinity of

Furthermore, the binding of insulin to

fat cells obtained from hamsters, rabbits, mice and guinea pigs is similar to
that of rat adipocytes, but cells from the former group of rodents are
significantly less responsive to insulin than are rat cells (188).

It has also
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been reported that the insulin insensitivity of large fat cells is not due to a
reduced insulin binding (189).
The properties of insulin-receptor interactions have been studied in a
great variety of tissues, mainly from humans and rats.

It may be seen from

Table II that insulin receptors fall roughly into two categories: high affinity
(Kassoc.

z

109-1010 M-1)/low concentration (40-11,000 receptors per cell) and

low affinity (Kassoc.

z

107-1o9 M-1)/high concentration (1,300-250,000 recep-

tors per cell). These categories of insulin receptors, represented by curvilinear
Scatchard plots (201), have been found in cells isolated from animal tissues,
circulating leukocytes, cultured cells, plasma membrane preparations and solubilized membrane proteins.

Good; correspondence of affinities for insulin of

different preparations from the same tissue

(~.g.,

rat adipocytes) have been

reported.
Association of insulin with human erythrocytes, which are insensitive to
the hormone, is of a decidedly lower order than the other tissues studied and
may be due to nonspecific protein binding (202).

Crofford et al. observed no

significant binding of 1251-insulin to erythrocyte plasma membranes (203).
Likewise, no specific binding of insulin to circulating human lymphocytes
purified on a nylon-fiber column was found by Krug et al. (195), contrary to
reports of insulin binding to normal circulating lymphocytes by others (196,204).
Subsequently, it was demonstrated that the specific insulin binding observed
using preparations of normal human mononuclear leukocytes was due to monocytes, not lymphocytes (205).

Lymphocytes induced to undergo blastogenesis

in short-term culture by mitogens such as concanavalin A (195), immune

stimulated lymphocytes (206), and malignantly transformed lymphocytes in
continual culture, obtained from hosts suffering from lymphoproliferative dis-

'·"'""!!!"'t''~

TABLE II A.
Species
Human

SOME PROPERTIES OF INSULIN RECEPTORS

Tissue
Adipose

Temp.

Preparation
Isolated
cells

pH
optimum

Kassoc.
M-1

1.

6.7

X

108

Kdissoc.
M
1.5 X 1o-9

2.

1.3

X

108

8.0

X

10-9

X

oc

Fibroblasts

Cultured
cells

3. 15

4.9

109

2.0

X

1o-1o

Placenta

Plasma
membranes

5. 30

5.(f, X 107

2.0

X

10-8

Particulate
receptors

6.

4

2.8

X

109

3.6

X

1o-1o

7.

4

2.5

X

107

4.0

X

10-8

8. 24

2.0

X

108

5.0

X

1o-9

9. 24

4.7

X

107

2.1 x 1o-8

1.0

X

109

1.0

Soluble
receptors

1o-9

10.

4

11.

4

3.1

X

108

3.2 x 1o-9

12. 24

3.0

X

109

3.3

X

1o-1o

13. 24

1.5

X

108

6.7

X

1o-9

7.8

X

k1*
M-1sec.-1

k_1t
sec.-1

1.7

X

105

3.4 x 1o-5

6.6

X

103

6.6 x 1o-6

3.8

X

104

1.3 'X 10-5
CJ1

0

'1

TABLE II A.
Species
Human

(CONTINUED)

Tissue
Placenta

Preparation

Temp.

pH
optimum

4.8

X

109

Kdissoc.
M
2.1 X lo-lo

9.8

X

108

1.0

X

10-9

6.0

X

109

1.7

X

lo-10

2.0

X

107

5.0

X

lo-8

1.2

X

lolO

8.3

X

19. 15

1.1

X

109

9.1

20. 30

1.5

X

109

2.1

X

22. 15

5.8

Isolated
cells

23.

Membranes
Soluble
receptors

Cultured
cells

oc

Circul.
cells

Erythrocytes

Rat

Liver

Circul.
cells

k_lt
sec.-1

X

106

1.0 x lo-3

7.4

X

106

1.2 x lo-3

lo-ll

1.0

X

106

8.3

X

lo-5

X

lo-10

9.2

X

105

8.3

X

lo-4

6.7

X

lo-10

1.2

X

106

8.1

X

lo-4

106

4.8

X

10-7

3.7

X

102

1.8

X

10-4

X

102

1.7

X

10-3

1.4

X

lolo

7.1

X

lo-11

24. 24

1.5

X

1o1o

6.7

X

1o-11

3.5

X

106

2.7

X

10-4

25. 24

7.7

X

109

1.3

X

lo-lo

7.6

16. 22

8.0

17. 22
Lymphocytes Cultured
cells

kl*
M-lsec.-1
4.8

14. 15
15. 15

Granulocytes

Kassoc.
M-1

18. 15

21. 15

7.8

8.0

U1
.....

TABLE II A.

(CONTINUED)

Species

Tissue

Preparation

Rat

Adipose

Isolated
cells

•. Membranes

Soluble
receptors

*Association rate constant
tnissociation rate constant

Temp.

pH
optimum

Kassoc.
M-1

26. 24

1.3

X

lolO

Kdissoc.
M
8.0 X lo-u

27. 24

2.0

X

109

5.0

X

10-10

28. 24

3.3

X

108

3.0

X

lo-9

29. 37

3.3

X

108

3.0

X

1.3

·x 1010

7.5

oc

30. 24

7.5

kl*
M-lsec.-1

k_lt
sec.-1

1.5

X

107

7.4 x lo-4

lo-9

4.2

X

105

1.2

X

10-3

X

lo-ll

8.5

X

106

4.2

X

lo-4

31. 24

2.0

X

109

5.0

X

lo-lo

32. 24

3.3

X

108

3.0

X

lo-9

33. 24

7.7

X

109

1.3

X

10-10

TABLE

n B. SOME PROPERTIES OF INSULIN RECEPTORS
Sites/Cell

Sites/~ m2

pmole/mg

Degradation
fmole/106 cells or mg·hr.
40
15°
24°

Ref.
37°

1.

50,000

2.3

190

2.

250,000

11.5

190

3.

3,300

4.

87,600

184

0

184

5.

0.9

191

6.

0.45

192

18.1

192

1.4

192

9.

4.6

192

10.

4.2

11.

6.9

192

12.

0.6

192

13.

6.3

192

7.
8.

-

14.

480

15.

50,000

0.4
36

2.1

0

0

15

0.36

192

193
193

CJl

w

TABLE

n

B.

(CONTINUED)

Sites/Cell

Sites/ ~m2

16.

40

17.

1,300

18.

350

19.

12,500

4.4

20.

12,000

4.2

21.

10,500

22.

2.79 x 106

pmole/mg

Degradation
fmole/106 cells or mg·hr.
40
15°
24°

0.07

O.Olt

Ref.
37°
1.4

2.3

194

0.12

183,195
183

0
X

0.5**

0

74
2.0

194

0

o**

196

0

o**

197

104

197
160

23.
24.

181

0

25.

0.3

198
159

26.

11,000

27.

3,000

199

28.

30,000

199

29.

50,000

30

0

16
0.2

0

144
200

CTI

oj::o.

TABLE II B.

(CONTINUED)

Sites/Cell

Sites/ JJffi2

pmole/mg

Degradation
fmole/105 cells or mg·hr.
4°

15°

24°

Ref.
37°

31.

199

32.

199

33.

0.63

198

56
orders (195,196), however, do po3sess specific insulin receptors and are widely
used in studies of receptor properties and development of radioreceptor ·assays
for insulin.
Based on the expectation that the steady-state concentration of free
insulin maintained in the tissues is approximately equal to the concentration
of insulin in the peripheral circulation, the dissociation constant (K o) exhibited
by a given set of insulin receptors will be that concentration of circulating
insulin at which the receptors are half saturated. Thus, comparison of insulin
concentrations necessary for half maximal stimulation of insulin-dependent
processes with dissociation constants observed for insulin-receptor interactions
suggests the existence of several p_opulations of receptors responsible for initiat'
ing various insulin-dependent functions. Insulin concentrations of 5-7 x lo-ll
M (7-10

~.a

U/ml), in the range of dissociation constants for the highest affinity

insulin receptors, have been found to produce half-maximal stimulation of
glucose oxidation (160,207) and lipogenesis (144), indicating that one or more
rate-limiting steps of these processes are affected by high affinity insulin
receptors at fasting insulin levels.
On the other hand, much higher insulin concentrations have been necessary to affect glucose transport in cells.

For instance, Guidotti

~

al. (208)

found a significant increase in glucose uptake by 10-day-old chick embryo
hearts only at 10 mU insulin/ml (7 x to-8 M).

As will be seen, large doses

of insulin have also been required to stimulate cell proliferation (Chapter 4).
Gammeltoft and Gliemann (144) postulated that about 2% of rat adipocyte
receptors, for which they determined the Ko to be 3 x l·o-9 M, were bound
to insulin when lipogenesis was half-maximally stimulated in these cells at an
insulin concentration of 7 x to-ll M.

Kono and Barham (207) found that
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approximately 2.4% (corresponding to 4,000) rat adipocyte receptors of .K 0

=7

x 1o-9 M were bound to insulin when glucose oxidation was maximally stimulated
at an insulin concentration of 40

lJ

U/ml (2.8 x lo-10 M) and that 1,200

receptors were bound at half-maximal stimulation (4.4 x lo-ll M insulin).
Crofford et al. (209) estimated that both glucose and amino acid metabolism
in rat adipocytes are stimulated maximally when approximately 3,000 insulin
molecules are taken up by each cell.

At about the same time that the above

studies were published, Cuatrecasas reported the discovery of high affinity rat
adipocyte insulin receptors with Ko = 8 x lo-ll M (159,160,200).
Thus, it may be seen from Table III that 50% of the high affinity
receptors will be bound to insulin when the low affinity receptors are less
than 10% saturated. In fact, 78% of the high affinity receptors (Kassoc.
x 1010 M-1; Ko
(40

=8 x

=1.25

lo-ll M) will be bound in the presence of 2.8 x lo-10 M

lJU/ml) insulin. At 22 \JU insulin/ml (1.6 x lo-10 M), the point at which

maximal stimulation of glucose oxidation in adipocytes is just attained, 2.2%
receptors of Ko = 7 x lo-9 M (Kassoc. = 1.4 x 108 M-1) are bound to insulin
while the high affinity receptors would be two-thirds saturated.

Based on

160,000 low affinity receptors per cell reported by Kono and Barham and 400

high affinity receptors per cell, 3,600 low affinity receptors and 270 high
affinity receptors would be filled at this point.

At 6 lJ U insulin/ml (4.4 x

1o-l1 M), where half-maximal stimulation of glucose oxidation is attained,
0.6%, or 980, low affinity receptors and one-third, or about 140, high affinity

receptors would be bound to insulin.
Until 1973, the non-linearity of the Scatchard plots describing insulinreceptor interactions (in contrast to linear plots obtained for other hormones,
such as somatotropin binding to cells) was routinely ascribed to receptor hetero-

INSULIN-RECEPTOR BINDING AT PHYSIOLOGIC INSULIN CONCENTRATIONS

TABLE III.
Kassoc.

No receptors/cell

M-1
1.25

5.0

X

[insulin]
nM

1010

300

x 109

3,000

1.0 x 109

50,000

*

[free insulin]

= [total

t

Based on

11

*

% receptors boundt

U/ml

1.4
14
70
140
1.4
14
70
140
1.4
14
70
140

0.01
0.1
0.5
1.0
0.01
0.1
0.5
1.0
0.01
0.1
0.5
1.0

33
168
258
279
150
990
2,130
2,490
500
4,500
16,500
25,000

11

56
86
93
5
33
71

83
1
9
33
50

··T.-,

insulin] in physiologic steady state.

[bound receptor] = Kassoc. x [insulin];
[free receptor]
% receptors bound = {1 -{+ [boun/ reeel!tor

~

No. receptors bound/cell

[free receptor]

)1J

1

I

X

100.
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geneity.

At that time, however, De Meyts et al. (210) suggested that the

curvilinear Scatchard plots characteristic of insulin-receptor interactions could
be the result of site-site interactions among insulin receptors, or . negative
cooperativity; that is, that binding of insulin at one site causes a decrease in
affinity for insulin of other receptors.

Indeed, Hill plots (211) for insulin-

receptor interactions yield Hill coefficients, n = 0.53 - 0. 73 (193,194,212),
indicative of negative cooperativity (n = 1 indicates no cooperativity and n>1
indicates positive cooperativity).
be contradictory.

However, the results of Hill plots appear to

Although Podskalny et al. (193) report an average Hill

coefficient of 0. 73 for insulin binding to cultured placental cells, the first
three points of their plot,

coverin~

fall on a line of slope, n

= 1,

the physiologic insulin range (0-100 IJU/ml),

while points above 10-8 M insulin tend toward a

Hill coefficient less than 0. 73.

On the

oth~r

hand, Fussganger et al. (194)

have demonstrated a Hill coefficient of 0. 7 for insulin binding to human
granulocytes throughout the physiologic range with a sudden shift to n

=1

at

insulin concentrations greater than 1o-7 M.
The most compelling evidence for negative cooperativity among insulin
receptors was introduced by DeMeyts et al. in 1973 (210): radiolabeled insulin
is released from cells at a significantly higher rate when the cells are diluted
with a large excess of unlabeled insulin-containing medium compared to dilution
with insulin-free medium, indicating that the decrease in the apparent affinity
of insulin receptors characteristic of negative cooperativity is due to an increase
in the rate of dissociation.

The insulin-induced increment in dissociation is

unaffected by varying the dilution factor or by adding cells, and the effect is
specific for insulin, since substitution of other hormones for unlabeled insulin
does not accelerate dissociation.

A number of insulin analogs also accelerate
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dissociation of labeled insulin in proportion to their ability to inhibit binding
of radiolabeled insulin to the receptors. Using this method, investigators have
demonstrated cooperative effects among insulin receptors on cultured human
lymphocytes {210), cultured human placental cells (193), circulating human
granulocytes (194), cultured human fibroblasts (184), circulating human monocytes (213), mouse, rat, guinea pig and chicken liver membranes (214,215), and
turkey, frog and trout erythrocytes (215).
Receptor binding and cooperativity can apparently also be uncoupled.
Greatly decreased or no cooperative effect is seen with desalanine-desasparagine
(DAA) and desoctapeptide (DOP) insulins (184,193,210), high concentrations of
insulin (::~..lo-4 M; 210), insulin dim~rs (possibly accounting for loss of cooperativity at high insulin concentrations; 210), the plant lectin concanavalin A
(212), urea and acid pH (216).

Recently, DeMeyts et al. (217) have implicated

a surface region of the insulin molecule as responsible for the negative
cooperativity of insulin-receptor interactions, based on the ability of insulin
analogues to accelerate insulin-receptor dissociation.

This "cooperative" site

is situated on the hydrophobic face that includes the putative receptor-binding
region, borders those structures necessary for insulin dimerization, and comprises the B23 glycine, B24-25 phenylalanines, B26 tyrosine, and A21 asparagine.
The finding of curvilinear Scatchard plots for and insulin-augmented
dissociation of the hormone from solubilized insulin receptors (192,218) has
called into question the concept of negative cooperativity as site-site interactions among membrane-bound receptors.

The observations of Ginsberg et al.

(218), however, may provide a basis for negative cooperativity as a modulation

of the insulin-receptor association at the receptor itself, initiated by insulin
binding and resulting in an alteration of the quaternary structure of the
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receptor. They found that incubation of solubilized avian erythrocyte .receptors
with 25 ng insulin/ml (625
low affinity state.

lJ U/ml)

produced a shift of 35% receptors to the

Gel chromatography revealed that about 25% of the

receptors had shifted from molecular weight 300,000 to 75,000 daltons,
consistent with a tetramer to monomer conversion.

The fact that no more

than one-third of the receptors are affected considerably above the physiologic
range of insulin concentration may mean that the cooperative effect is
physiologically unimportant and points to the need for caution in interpreting
evidence for negative cooperativity.

For example, the possibility that this

evidence may also be produced by a receptor-associated insulinase has not
been eliminated.

Resolution.:· of the debate regarding insulin receptor

heterogeneity versus negative cooperativity awaits definitive demonstration of
the existence or non-existence of discrete subpopulations of cell insulin
receptors.
Binding of insulin to cell receptors is a specific, reversible, and saturable
process that is dependent on time and temperature.

Harrison

~

al. (192)

found that insulin association with soluble placental receptors attained an
apparent steady state within one hour at 37°C and 24°C, by 3 hours at 15°C
and by 12 hours at 4°C. Gavin et al. {183) determined that maximum binding
of insulin to cultured lymphocytes occurs at 15°C, at which temperature a
steady state is reached by 60 minutes and is maintained for at least one hour.
The inverse relationship between apparent association constant and temperature
is probably due to the marked temperature-sensitivity of insulin-receptor
dissociation, the rate of which increases with temperature to a half-life of
about 7-10 minutes for adipocytes at 37°C {144,219).
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The kinetics of insulin-receptor association are second-order, or bimolecular, while dissociation obeys first-order kinetics (159,181).

Cuatrecasas (200)

has determined that the free energy of association ( llG) of insulin and adipocyte
membranes of -14 kcal/mole, based on an equilibrium constant of 2 x 1010
M-1 at 24°C, is due to a very large decrease in enthalpy ( llH = -28 kcal/mole)
partially offset by a large decrease in entropy ( ll S = -45 cal mole-1 deg. -1 ).
Insulin-receptor association is also dependent on pH, but the role of
divalent cations in the interaction is questionable.

Maximum binding has been

observed at pH 7.8 for lymphocytes (183), placental cell membranes and
solubilized placental receptors (192), pH 7.6 for cultured placental cells (193),
pH 7.5 for adipocyte membranes
(194).

~200),

and pH 8.0 for circulating granulocytes

Binding is totally absent below pH 5.0 (183,192).

Gavin et al. (183)

found that ca++, Mg++, and ethylenediaminetetraacetate (EDTA) had no effect
on 125J-insulin binding to cultured lymphocytes at concentrations of 1 to 10
mM.

Likewise, Harrison et al. (192) reported that 5 mM ca++, Mg++, and

EDTA were without effect on insulin binding to soluble placental receptors.
However, Podskalny et al. (193) noted a 25% inhibition of 125J-insulin binding
to cultured placental cells in the presence of 1 to 5 mM CaCl2.
The insulin receptor apparently is a highly asymmetric glycoprotein of
molecular weight 300,000 (218,220,221), which sediments with a coefficient of

• (220,222).
11 S and behaves like a particle with a Stokes radius of about 70 A
The protein nature of the receptor is indicated by the fact that proteolytic
digestion of cells or receptor preparations with such enzymes as trypsin,
chymotrypsin and papain impairs or abolishes insulin binding and (in the case
of cells) insulin-induced metabolic effects, while pretreatment with insulin
protects the receptor from proteolytic agents (181).

Cuatrecasas (162) has
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found that exposure of fat cells to 10

JJ

g trypsin per ml at 37°C for 15

minutes causes a 10-fold fall in receptor affinity for insulin, while affecting
only slightly insulin-stimulated adipocyte glucose oxidation and the cell's insulin
binding capacity. All these functions were completely abolished in the presence
of higher trypsin concentrations.

Very similar results were obtained with

chymotrypsin and papain. Gavin et al. (183) found that treatment of cultured
lymphocytes with more than 100

g trypsin/ml for 15 minutes at 37°C resulted

in significant decreases in insulin binding. Indication that the insulin receptor
is an integral membrane glycoprotein, largely immersed in membrane phospholipids, is afforded by the fact that low concentrations of trypsin even somewhat
mimic the metabolic effects of

i~sulin

on adipocytes (223), that pretreatment

of cells and membranes with phospholipases enable complete abolition of insulin
binding at low protease concentrations that otherwise would have no significant
effect on these preparations' ability to bind insulin (159), and that only 2

lJ g

trypsin/ml (15 min., 37°C) is sufficient to abolish completely the ability of
solubilized placental receptors to bind insulin (192).

However, Cuatrecasas

(220) has provided evidence that the insulin receptor is not a lipoprotein. The
lack of functionally important nucleic acid in the insulin receptor is indicated
by the fact that digestion of cultured human lymphocytes with ribonuclease
and deoxyribonuclease has no ef!ect on binding of 125J-insulin to the cells (183).
As mentioned above, neuraminidase digestion of cells indicates that sialic
acid is unimportant to the insulin recognition function of the receptor, but is
critical to the transmission of the insulin-binding signal from the recognition
site to the glucose transport site.

Mild

a-galactosidase digestion affects

neither cellular insulin binding nor response, but a-galactosidase treatment
subsequent to neuraminidase digestion, which itself abolishes. insulin response,
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results in complete abolition of cell insulin binding (222), suggesting that
penultimate

B-linked D-galactose, normally masked by terminal sialic acid (or

terminal galactose occluded by proximal sialic acid termini), is important to
insulin recognition.

Further, Cuatrecasas (171,224) has found that the plant

Iectins concanavalin A, which is specific for terminal a -D-mannopyranosyl or
a -D-glucopyranosyl and internal 2-0-linked-D-mannopyranosyl residues

226),

and

wheat-germ

N-acetylglucosamine

or

agglutinin,
its

dimer

which

is

specific

(di-N-acetylchitobiose;

for
227),

(225,

terminal
in

low

concentrations produce insulin-like effects on fat cells, while at higher
concentrations they inhibit insulin binding to the cells.
Early claims of inhibition

o~

reversal of tissue insulin effects and binding

in the presence of sulfhydryl-blocking or disulfide disruptive agents, respectively, led to postulation of a covalent bond between insulin and its receptors
involving disulfide bonds (228-231).

This notion has been discarded, however,

due to the realization that insulin-independent metabolic effects are brought
about by these agents, more recent studies showing no effect of disulfide
inhibitors such as N-ethylmaleimide, iodoacetamide, iodoacetate, arsenite, dithiothreitol, and parachloromercuribenzoate on specific insulin-receptor association, demonstration that insulin dissociated from receptors retains full binding,
biological and physical properties, and the non-covalent association kinetics of
insulin-receptor interaction (192,198,200,219,232).
reported

that

the

water-soluble

Cuatrecasas (200) has also

carbodiimide

reagent,

1-ethyl-3-(3-

dimethylaminopropyl) carbodiimide, which forms peptide bonds via conjugation
with free carboxy functions, does not modify insulin binding after reaction
with adipocyte membranes in the absence or presence of the amino ligand
glycine-0-methyl ester.

Neither is insulin binding affected by treatment of
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the membranes with the tryptophan-modifying agents 2-hydroxy-5-nitrobenzyl
bromide

and

2-methoxy-5-nitrobenzyl

bromide.

However, treatment of

membranes with tetranitromethane, which reacts with tyrosyl as well as
sulfhydryl and tryptophanyl residues, results in a dramatic reduction of insulin
binding.

Diazonium-1-H tetrazole, which reacts primarily with histidyl and

tyrosyl and to a lesser extent with tryptophanyl residues, totally abolishes the
ability of the membrane to bind insulin.

Thus, tyrosyl and possibly histidyl,

but not sulfhydryl, free carboxyl, or tryptophanyl groups are involved in the
specific recognition of insulin.
As can be seen from Table II, the quantity and density of insulin receptors
varies widely, from 40 per cell fpr granulocytes (194) to 250,000 per cell for
human adipocytes (190), from less than 0.1 per
per

~m2 for granulocytes to 36

~ m2 for cultured placental cells (193), and from

0.2 pmole per mg

membrane protein for adipocytes to more than 18 pmole per mg membrane
protein for placental cells (192). An enigmatic, but consistent observation has
been the presence in membranes of "occult" insulin receptors unmasked at high
ionic strength or by treatment with phopholipases. A two- to sixfold increase
in insulin binding capacity was seen following treatment of adipocyte membranes
(200), hepatocyte membranes (181), and cultured lymphocytes (195) with 5-100
'llg phospholipase C/ml. A lesser increase in membrane insulin binding capacity
can be brought about by treatment with phospholipase A in the presence of
ca++ (181), but not with phopholipase D (222), and the phospholipase-induced
unmasking of occult insulin receptors can be partially reversed by addition of
exogenous phospholipid (171).

Although the occult receptors (approximately

65,000 per adipocyte; 162) are very similar to the normally exposed receptors
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in their E..ffinity for insulin, association-dissociation kinetics and sensitiyity to
trypsin, they are unable to trigger a biological response to the hormone.
A very similar increase in the insulin-binding capacity of adipocyte (200)
and hepatocyte (181) membranes was found in the presence of hypertonic salt
solutions, attaining a maximum in 2 M NaCl and also (for adipocytes) in 2 M
KCl or 0.5 M LiCl.

The salt-induced increment in binding capacity was

observed to be much lower after treatment of adipocyte membranes with
phospholipase C, indicating that occult insulin receptors are also exposed at
high ionic strength. Harrison et al. (192) also found an increase in the insulin
binding capacity-apart from an increase in affinity-of particulate placental
membranes at low temperature. ;'

Regulation
As was mentioned at the beginning of this section, it is now generally
believed that protein hormones elicit their effects at the cell surface via
membrane-bound receptors.

Therefore, the cell must possess the means by

which to adjust, or regulate, the magnitude of its metabolic response to a
given external concentration of the hormone effector.

Cellular regulation of

hormone response can be envisioned to involve at least three critical aspects
of cell function: 1) hormone recognition, at the level of the receptor; 2)
amplitude of the signal generated by hormone-receptor association, at the level
of one or more intracellular mediators; and 3) the magnitude of metabolic
response to a given signal amplitude, at the level of key components of
metabolic processes.

The last two aspects will be discussed later in this

section, under consideration of mechanism; the first aspect, that of regulation
at the receptor level, will be dealt with here.
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Any discussion of cellular regulation of hormone response must endeavor
to explain how the response is initiated (cell sensitivity to the hormone), how
the response is maintained (time-dependent magnitude of response at a given
hormone concentration), and how the response is terminated.

As was made

evident in the foregoing discussion of receptor binding properties, similar
hormone response at the receptor level (assuming constant signal amplitude
and metabolic response per receptor bound) is dependent upon both the affinity
of the receptor for the hormone and the number of receptors per cell. Thus,
for a constant number of receptors per cell, the fraction bound, and therefore
magnitude of response, is directly proportional to the affinity of the receptor
for hormone; for a receptor

popu~ation

of given affinity, the absolute number

bound, and therefore magnitude of response, is directly proportional to the
number of receptors per cell. Both the sensitivity of a cell to a hormone and
the magnitude of the cell's response to a given concentration of hormone may
be modulated at the receptor level by varying receptor affinity for hormone

and/or number of receptors per cell.
A built-in decay of response, and therefore a constant duration of signal
maximum dependent upon the magnitude of pancreatic insulin release, is
provided by the concept of negative cooperativity, in which the affinity of
receptor for hormone is inversely proportional to hormone concentration. It is
to be expected that such a system would require connection of each receptor
to mediators for all insulin-affected cell functions, with different signal amplitudes and/or response/signal characteristics for different sets of functions,
resulting in characteristic insulin sensitivities and insulin concentration-response
profiles for each function. The same kind of variation of hormone sensitivity
and response can be provided by discrete receptor subpopulations, each with
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a characteristic affinity for hormone and each connected to mediators for a
specific set of cell functions.

This receptor heterogeneity model, however,

does not provide by itself for decay of hormone response, which would have to
be effected by other means.

In fact, evidence does exist for such a separate

mechanism of response decay via cell modulation of receptor concentration.
The fact that cells can increase the number of surface insulin receptors
is indicated, not only by discovery of occult receptors, but also by the emergence
of approximately 350 insulin receptors per cell when normal circulating lymphocytes, which exhibit no significant insulin-binding capacity, undergo blast
transformation in the presence of concanavalin A, phytohemagglutinin, or
periodate (195,233).

The number, of receptors increases sharply to reach a

maximum between 24 and 46 hours after exposure of the cells to mitogen,
coinciding with an increase in thymidine incorporation into nuclear DNA, but
preceding the appearance of enlarged, morphologically transformed cells.

A

similar density of insulin receptors was found on giant, polynucleated cells
resulting from transformation of circulating lymphocytes with cytochalasin B
and on circulating leukemic lymphoblasts obtained from patients suffering from
acute lymphoblastic leukemia, but not on chronic lymphocytic leukemia cells.
More important to cellular regulation of the physiologic insulin response
is evidence for a decrease in the number of cell surface insulin receptors in
response to extracellular conditions, known as "down-regulation."

A 25%

decrease in insulin-binding capacity was observed . after cultured lymphocytes
were preincubated with 4 ng (100

~

U) insulin/ml for 1 hour or 16 hours at

37°C, but 10 ~ g insulin/ml (3 hours, 37°C preincubation) was required to
produce the same decrease in insulin-binding capacity of. adipocytes (234).

A

maximum decrease in binding capacity of 75% was seen after preincubating
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lymphocytes 16 hours with 100 ng insulin/mi. A significant decrease in insulinbinding capacity was also found for rat hepatocytes obtained from 72 hourfasted animals, parallel to a decrease in liver membrane phospholipids and
despite a 3-fold increase in membrane protein (235).
Although it is tempting to postulate an internalization of the insulinreceptor complex followed by lysosomal degradation of both insulin and receptor,
which would neatly explain evidence of intracellular insulin receptors, certain
observations argue against receptor internalization prior to degradation.

The

down-regulation noted by Huang and Cuatrecasas (234) was not affected by
· the metabolic poisons sodium fluoride and dinitrophenol, inhibitors of RNA and
protein synthesis, or agents that interfere with phagocytosis _and microtubule
and microfilament function. The insulin-dependent reduction of insulin binding
also occurs with insulin analogs, such as reduced and carboxymethylated and
synthetic B-chain, which possess no biologic activity, suggesting the triggering
of a receptor-degrading system separate from the insulin recognition function.
Using a radioimmunoassay for the human insulin receptor, Harrison et al. (236)
have been able to study the fate of the receptor during down-regulation of
cultured human lymphocytes. They found that cellular insulin binding decreased
8896 during maximum down-regulation with 1o-6 M insulin. When the receptors
were solubilized with 196 Triton X-100, the decrement in insulin binding was
reduced to 6296, suggesting dilution by intracellular binding sites. The decrease
in immunoassayable solubilized receptors was almost identical, indicating that
down-regulation of insulin binding is due to a decrease in the number of
receptor molecules.

Establishment of the phenomenon of down-regulation as

a physiologic mechanism for response decay is problematic, however, since
maximum down-regulation has been seen only with pharmacologic insulin
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concentrations, where the possibility of artifactual observations due to
contaminating proteases is most likely.
A separate mechanism is also required to account for termination of
insulin response in both the negative cooperativity and receptor heterogeneity
models. This mechanism is provided by the well-documented process of systemic
and localized insulin degradation.

Insulin Degradation
The critical role of the liver in removal of insulin from systemic
circulation was appreciated as early as 1927, when Kepinow and Dutaillis
demonstrated that the hypoglyceJ?1iC activity of the peripheral blood of a dog
injected intravenously with 12 units of insulin was not detectable 3 to 20
minutes afterwards, but that hypoglycemic activity persisted beyond this time
interval if the portal vein was anastomosed to the renal vein, bypassing the
liver (237). Later, it was found that 8 passages through isolated bullfrog liver
were necessary for complete removal of insulin activity (238), but that approximately half the insulin entering rat and human liver is removed in a single
passage (239,240).

The importance of hepatic uptake, or capture, of insulin

in systemic clearance of the hormone was indicated by a rapid decrease of
trichloroacetic acid (TCA)-precipitable 1-131 activity compared to a slow
increase of TCA-soluble radioactivity during cyclic perfusion of 131J-insulin
through isolated rat liver (239,241). Normally the half-life of crystalline insulin
in human circulation is approximately 5 minutes (242). An increase in hepatic
clearance rate of the hormone has been observed in fasted and diabetic animals
(238,243-245).
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By 1939, it was known that insulin degradation proceeded by two
mechanisms: a reductive cleavage of disulfide bridges mediated by sulfhydryl
compounds such as glutathione and cysteine and an enzymic proteolysis.

The

previous year Lehmann and Schlossmann (246} had reported a two-component
system for reductive degradation of insulin in a cell-free muscle extract,
consisting of a heat-stable, diffusible compound capable of catalyzing the
reduction by a non-enzymatic mechanism and a heat-labile enzyme. The former
component is now known to be glutathione (GSH) and the latter has been
termed glutathione-insulin transhydrogenase (GIT), or protein-disulfide reductase
(glutathione) (EC 1.8.4.2), in deference to the wide range of substrates it has
been found to act upon.

In liver, the enzyme is coupled to the oxidation of

NADPH via glutathione reductase (GR) as follows:
insulin A (S-S}2x:4 GSHX 2 NADP+
GIT
A (SH)2

2 GS-SG

GR
2 NADPH+2 H+

+
(247).
Glutathione-insulin transhydrogenase is a glycoprotein of molecular
weight 53,000-62,000 daltons and possesses amino terminal lysine, leucine, and
valine, suggesting three polypeptide chains or subunits (248,249}.

The pH

optimum for GIT is between 7.5 and 8.5 (250}. Understandably, GIT is inhibited
by thiol reagents (251). The enzyme is also inhibited competitively by insulin
analogs, oxytocin and vasopressin, noncompetitively by glucagon, and both
competitively and noncompetitively by somatotropin (252).

The activity of

GIT is enhanced by ethylenediaminetetraacetate (EDTA) (253).
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In the rat, relative tissue concentrations of GIT have been found to be
as follows: pancreas>liver>intestine>spleen>kidney

= testis = thymus = fat

=

lung>brain>heart>diaphragm = skeletal muscle (254). The kinetics of the GITcatalyzed separation of insulin A and B chains is second order (255), exhibiting
a Km of approximately 50

).l

M insulin (256).

insulin degradation at 37°C using 8.4

).l

The velocity of GIT-catalyzed

M insulin and 3 mg rat liver homogenate

protein/ml was found to be 8.4 nmole per hour per mg wet weight homogenate
and 5.8 pmole/hr./mg for 0.8 nM insulin and 0.5 mg liver homogenate protein
(255,257).
In 1949, Mirsky and Broh-Kahn (258) described a specific enzymic
proteolysis of insulin by liver,

kidn~y,

and muscle tissue preparations and termed

the enzyme responsible insulinase. Later, Brush and Kitabchi (259) demonstrated
the presence in both soluble and particulate fractions of rat diaphragm muscle
homogenates of an insulin-specific protease that degrades the hormone to
oligopeptides and amino acids and is inhibited by N-ethylmaleimide. The soluble
fraction had a Km (app.) for 1311-insulin of 2 x 1o-7 M, while the particulate
fraction had a Km apparently 15 to 20 times higher (249).
Probably the most physiologically significant insulinases described thus
far are the A and B chain-degrading neutral peptidases, which are inhibited
by EDTA, indicating a divalent metal cation requirement (255,260). Proteolytic
A-chain degradation, which obeys first-order kinetics, also requires the presence
of sulfhydryl compounds (255). The concentration of enzyme activity has been
found to be greatest in kidney, followed by skeletal muscle, liver and heart
(261).

The velocity of A-chain degradation is 1.7 x 10-10 mole/hr./mg wet

weight homogenate using 8.4

).l

M insulin and 3 mg rat liver homogenate protein
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(255) and 2.0 x 1o-13 mole/hr./mg homogenate with 0.8 nM insulin and 0.5 mg
homogenate protein (257).
In contrast, the B chain-degrading enzyme recently described by Phelps
et al. (260) is inhibited by dithiothreitol as well as potassium phosphate salts,
-but not by trypsin inhibitors, Trasylol, or phenylmethylsulfonyl fluoride (PMSF).
Relative tissue concentrations of the enzyme in the rat were found to be as
follows:
muscle

kidney»intestine>pancreas
==

diaphragm>lung

==

==

spleen>fat.

testis>liver>thymus>heart

==

skeletal

The B-chain degrading activity of

intestine and pancreas was observed to be partly inhibitable by trypsin inhibitors,
Trasylol and PMSF, suggesting contamination with pancreatic proteases.
Optimum activity of B-chain degrading neutral peptidase was observed at pH
6.5-7 .0.

An insulin-reversible depression of the enzyme in the kidney, liver

and adipose tissue of streptozotocin diabetic rats was also noted.
Varandani has presented much evidence indicating that GIT and the
neutral peptidases constitute a stepwise mode of insulin degradation, not only
in liver and kidney, but also generally in insulin target tissues, representing
the primary means by which the hormone is degraded-first by reduction of
interchain disulfide bonds and then by proteolysis-both systemically and locally
(253,255,257 ,260,261). Although the ability of insulin analogs to inhibit insulin

binding to and degradation by target cells is closely parallel (262), the insulin
degradative function of cells, also a time- and temperature-dependent process
(263), is distinct from receptor binding of the hormone (192,264).

Both GIT

and neutral peptidase activities have been found to reside in cell microsomal
and plasma membrane fractions, near insulin receptors (265,266).
Insulin degradation rates found for placental, granulocyte and adipocyte
cell and membrane preparations (Table D) at 37°C range from 3.6 x 10-16
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mole/106 cells/hr. to 1.6 x 1o-14 mole/106 cells (mg)/hr., more than an order
of magnitude lower than degradation rates observed for hepatic tissue. PMSFinhibition of granulocyte insulin degradation (194) may indicate the nonspecific
action of lysosomal proteases.

Mechanism of Insulin Action
While much detailed information has been obtained concerning the insulin
receptor and the hormone's effect on its ultimate targets, such as key enzymes
of intermediary metabolism, the means by which the two are connected remains
elusive. Both the nature of the signal generated by insulin-receptor association
and the mechanism by which the signal is propagated, modulated and interfaced
'

with well-characterized molecular effectors of the cell's biological response
have been particularly subject to the speculation and faddism to which insulin
research is prone.
During the 1940s, when the pathways of intermediary metabolism were
being elucidated, attempts were made to explain insulin's effects based on a
putative modulation of the activity of critical enzymes involved in carbohydrate
metabolism, most notably Carl and Gerty Cori's hexokinase theory (267).
According to this view, insulin counteracts inhibition of hexokinase by pituitary,
adrenal and other substances. The hexokinase theory was abandoned with the
accumulation of evidence that insulin exerts no effect on the enzyme, that
insulin's impact on carbohydrate metabolism actually is enhanced in hypophysectomized, adrenalectomized animals, and that the hormone profoundly influences
metabolic events independent of glucose phosphorylation (see Chapter I).
The efforts of physiologists during the following decade resulted in
considerably greater understanding of sugar transport across plasma membranes
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and insulin's effect on this process. Insulin's profound enhancement of glucose
uptake by non-hepatic target tissues, independent of other metabolic events,
is the hormone's signature, so to speak.

At that time, therefore, the belief

that all metabolic effects on the hormone were consequential to increased
cellular glucose uptake became prominent. Although glucose transport continues
to be recognized as a unique and fundamental target of insulin action and
itself has served as a basis for abandoning otherwise universal theories of
insulin action

(~.g.,

cyclic AMP, below) several aspects of cellular metabolism

profoundly affected by insulin, such as amino acid and electrolyte transport,
are known to be independent of glucose uptake.
Perhaps the most significant development in endocrinology research
during the 1960s was the elucidation of the role of adenosine 3',5'-monophosphate, or cyclic AMP, as an intracellular mediator of hormone action.

After

a somewhat complete picture had been obtained regarding the intracellular
events commencing with binding of epinephrine or glucagon to plasma membrane
receptors, resulting in an increase in the intracellular concentration of cyclic
AMP, and culminating in a concomitant activation of glycogen phosphorylase
b and inactivation of glycogen synthetase in muscle, it was logical to suppose
that insulin, which exerts an influence on the cell largely antithetical to these
two hormones, causes a decrease in the intracellular concentration of cyclic
AMP.

This hypothesis was largely discredited, however, by an inability to

demonstrate a consistent insulin-induced decrement in intracellular cyclic AMP.
There was a brief flurry of excitement early in the 1970s following
PUblication of evidence indicating a complementary antagonism between cyclic
AMP and cyclic GMP due to their me~:Hation of opposing cellular processes,
With subsequent reports of insulin-induced increments in intracellular cyclic
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GMP concentrations. Unfortunately, the results of cyclic GMP research have
proven somewhat ephemeral, being plagued by poor reproducibility. Currently,
the most promising hypothesis attributes a pivotal role to calcium, probably
acting in concert with cyclic nucleotides, as an intracellular mediator of insulin
action.
The major concepts involved in postulated mechanisms of insulin action,
.!:~·'

membrane sugar carriers, cyclic nucleotides, and calcium, will now be

examined in more detail.

1. Sugar transport.

Transport of monosaccharides across cell plasma

membranes is temperature-dependent, selective, and bidirectional.

The rate

of D-glucose accumulation inside adipocyte ghosts at 25°C was found to be
five times greater than at 4°C (268).

Both hexoses and pentoses enter cells,

but sorbitol, the alcohol analog of glucose, is excluded (269). Although many
of the transported sugars, such as L-arabinose and 3-Q-methylglucose (30MG),
are not metabolized by the cell, they inhibit the uptake of other, including
metabolizable, sugars, indicating a common site of sugar entry (269).

The

affinity of this site for sugars has been found to be: glucose=30MG>
galactose>xylose>L-arabinose (270).
Transport of sugars across the cell membrane is also stereospecific. In
erythrocytes, D-galactose enters the cell while L-galactose is excluded (271);
rat epididymal adipose tissue is slightly permeable to L-glucose, but far more
so to D-glucose (32); and the transport of 0-glucose across rat fat cell
membranes has been found to be ten times that of L-glucose (268).

The

cellular sugar transport mechanism also favors 0-glucose in the chair conformation, with the greatest number of hydroxyl groups in the equatorial position
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(272). That this mechanism is also capable of transporting sugars out of the
cell is evidenced by the finding that after equilibration of cells with the
nonmetabolizable sugars 30MG and L-arabinose, addition to the medium of Dglucose, which is rapidly phosphorylated inside the cell, causes an efflux of
the nonmetabolizable sugar, even against a concentration gradient (32,268270,273). This phenomenon, known as countertransport, provides strong support
for the concept that sugar transport across the cell membrane does not proceed
by simple symmetrical diffusion, but is facilitated by a mobile membrane
carrier.

Facilitated diffusion obeys Michaelis-Menten kinetics, which are

reflected in the equation for the steady-state ratio of internal ([Si]) to external
([S 0 1) nonmetabolized sugar conceT)trations during countertransport in the presence of glucose ([ G]):
[Sil

1 + [Gil/Kg
=

1 + [G 0 1/Kg

where Kg is the Michaelis constant for glucose.

(270),
Thus, countertransport has

been very useful in determining the kinetic parameters of glucose transport
across cell membranes.
Although the glucose uptake of most tissues, like that of working rat
heart depicted in figure 3, obeys Michaelis-Menten kinetics and does not require
energy expenditure by cells, some cells accumulate the sugar by mechanisms
of active transport (273). The passage of molecules from- the capillary, through
the extracellular spaces, to the cell surface generally takes place by a process
of simple diffusion, resulting in a rapid equilibration of the extracellular space
with the peripheral circulation. For instance, 80% of the equilibrium distribution
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GURE 3. EFFECT OF GLUCOSE CONCENTRATION IN PERFUSATE AND
:JsULIN ON GLUCOSE UPTAKE AND INTRACELLULAR GLUCOSE LEVELS
IN THE PERFUSED RAT HEART.

aesults are expressed per gram of dry heart. Insert in upper panel is a
Lineweaver-Burk plot of the glucose uptake of control hearts.

s
v

sugar concentration (mM)
rate of glucose uptake (

\.l

moles/g·hr.)

(Reproduced with permission, from Ref. 185, p. 79. Copyright 1975 by Futura
Publishing Co., Inc.)
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of sorbitol in the extracellular volume of the perfused rat heart is attained
within 30 seconds after the compound is added to the perfusate (269}. In such
insulin target tissues as muscle, however, simple diffusion plays no significant
role in sugar transport into the cell (270}. The expression for glucose transport
into the cell is
Tin ward

=

T max

(

Go

)

Go+ Kt
where Tmax is the maximal transport rate, G0 is the glucose concentration
outside the cell and Kt is the concentration of glucose at which the transport
rate is half maximal. This expression is completely analogous to the MichaelisMenten equation for the enzyme-catalyzed reaction velocity,

v

=

where Vmax is the maxim urn velocity, S0 is the initial substrate concentration,
and Km is the Michaelis constant, the initial substrate concentration required
for half maximal velocity.

For bidirectional transport,
(269}.

The contention that glucose enters the cell by facilitated transport is further
supported by the observation that the first five minutes of efflux of the sugar
from adipocyte ghosts during countertransport conforms to zero-order kinetics
and that glucose is not transported against a concentration gradient (268}. As
early as 1937 it was noted that glucose uptake by canine extra-hepatic tissues
is dependent upon blood sugar concentration, to the poiht where large
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extracellular glucose concentrations could compensate for the lack of insulin
in diabetes (27 4).
The apparent Michaelis constant, Km (app.), or the glucose transport
constant, Kt, reported for muscle and erythrocytes falls into a narrow range of
4 to 11 mM (269,270,273,275). The reported Vmax' or Tmax' for perfused rat
heart varies between 100 and 487

l1 mole

glucose/g dry tissue/hr. (269,275).

On the other hand, kinetic parameters of glucose transport in adipose tissue
have been found to vary widely (Km

= 0.2-140

mM; Vmax

=100-833 l1 mole/g•hr.)

(32,268).
In heart muscle, glucose transport is inhibited by free fatty acids (leading
to preferential utilization of free :fatty acids by myocardium), serum hypoosmolality, and high potassium concentrations, and is stimulated by ouabain (which
inhibits Na+ /K+ ATPase), serum hyperosmolality, increased muscle work, and
metabolic poisons such as dinitrophenol and salicylate (269,276). In both muscle
and adipose tissue, the process is inhibited by the polyphenol compound phloretin
and its glycoside phlorhizin, and nonmetabolizable sugars such as 30MG (Ki

=

16.3 mM for fat cell membranes) and is stimulated by anoxia (27% increase in
rat heart muscle) (268-270,272,276).
Intact transport of glucose into adipocyte ghosts (268) and intracellular
accumulation of the sugar in the presence of inhibitors of glucose metabolism
(277) indicate that sugar transport is not coupled to glucose metabolism.
Furthermore, transport has been found to be the rate-limiting step in glucose
utilization at physiologic plasma concentrations (<20 mM in adipose tissue and
<11 mM in both normal and anoxic rat heart; 132,269) of the sugar. Consequently, intracellular glucose concentrations are normally low and glucose efflux
from cells into which its transport is facilitated is negligible (269).
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At greater than physiologic plasma· concentrations of glucose, when sugar
transport approaches maximum velocity, hexokinase-catalyzed glucose phosphorylation, which also obeys Michaelis-Menten kinetics, becomes limiting for
cellular glucose utilization (269). In normal rat heart, glucose phosphorylation
has been found to have a Km of 0.6 mM and a Vmax of 81

J.J

mole/g·hr. Anoxia

is also stimulatory for glucose phosphorylation, decreasing the Km and increasing
the Vmax (269).
Since Levine et al. (278) outlined the transfer theory of insulin action
in 1949, there have emerged five major lines of evidence for a discrete mobile
membrane carrier mechanism for sugar transport: 1) the specificity and 2)
kinetics of transport; 3) inhibition of transport by specific reactive compounds;
4) competitive inhibition of glucose transport by certain other sugars, suggesting
a common transport site; and 5) countertransport (273).

In addition, the rate

of glucose uptake by adipocyte ghosts has been found to be directly proportional
to the concentration of membrane protein in the preparation (268).
With general acceptance of the Singer-Nicholson fluid mosaic model of
membrane structure (279), there has emerged a popular concept of the sugar
carrier (pictured in figure 4) as an intrinsic membrane protein containing an
interior hydrophilic channel through which sugar transport is facilitated and
subject to allosteric regulation. Certain investigators, however, have advanced
alternate theories of facilitated sugar transport, exemplified by Stein's dimerization concept (280), in which he considers evidence derived from erythrocyte
studies suggesting a specific catalytic component of the membrane, termed a
dimerizer, which could bring sugar molecules together in pairs and so orient
them as to induce dimer formation.

Since the dimers have fewer free

hydrophilic groups they could cross the cell membrane more easily.
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FIGURE 4.
ACTIVE OR FACILITATED TRANSPORT OF MOLECULE
THROUGH MEMBRANE PROTEIN CHANNEL VISUALIZED TWO-DIMENSIONALLY.

Molecule impinges (top) on active site (shaded) of protein, following which
some energy-yielding enzyme reaction triggers shift in subunit configuration
(bottom) that "squeezes" the molecule through the membrane.
(Reproduced, with permission, from Ref. 281. Copyright 1975 by HP Publishing
co., Inc. Illustration by Bunji Tagawa.)

84
'' .-~

-~'>-------'-·.-~~-[ }~\;

. ;·.;;. -:~~..,.-~-~

..;_.~ ....

---..

..:.

~

,··
~

..r: . . . .:

.

·':--~

.•

:.

~~

.-

~,~~;..

-··

85
Whatever the precise mechanism of membrane carrier facHitation of
sugar transport may be, the fact that the process is inhibited noncompetitively
by parachloromercuribenzoate, gold and mercury indicates that one or more
sulfhydryl groups is critically involved (272). An enhancement of cellular sugar
transport consequent to inhibition of generation of high-energy phosphate
compounds by anoxia, 2,4-dinitrophenol and salicylate also suggests the conversion of an inactive phosphorylated carrier to an active, dephosphorylated form
(282).
'Much evidence exists that insulin simply enhances the cell's normal sugar
transport mechanism. The hormone accelerates sugar transport both into and
out of adipocyte ghosts (268)

an~,

heart muscle cells (269), increases the rate

of transport of nonmetabolizable sugars such as D-galactose and L-arabinose
(29,271), but does not induce L-glucose uptake by either muscle (270) cells or
adipocyte ghosts (268). Crofford and Renold (32), however, reported a significant insulin stimulation of L-glucose uptake by rat epididymal adipose tissue.
Furthermore, countertransport also occurs in the presence of insulin (32).

A

nearly maximal (fourfold) stimulation of L-arabinose countertransport in rat
heart muscle has been observed in the presence of 100

l.J

U insulin per ml (269).

The Michaelis-Menten kinetics of glucose transport are preserved during
insulin stimulation of the process (269). In heart muscle, the hormone causes
a great increase in both the Km (from 9 to 28 mM) and Vmax (from 100 to
500

l.J

moles/g·hr.) of glucose transport (269).

On the other hand, insulin

stimulation of glucose uptake by adipose tissue involves a 3- to 13-fold decrease
in Km while Vmax remains unaffected (32). Consequently, in insulin-stimulated
muscle tissue, glucose phosphorylation (which is unaffected by the hormone)
becomes rate-limiting for cellular uptake of the sugar through the physiologic
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range of plasma glucose concentrations (>50 mg/100 ml, or 2.8 mM), where
insulin exerts its maximum effect (269,275).

Under these conditions, the

intracellular glucose concentration can increase to as much as 30% of that
outside the cell, resulting in a significant efflux of the sugar from the cell
(270).

Since glucose phosphorylation in muscle is already rate-limiting at

plasma glucose concentrations greater than 200 mg/100 ml (11.1 mM, attained
in diabetes), insulin effects on cellular glucose uptake are minimal under these
circumstances (269,275).
Insulin enhancement of glucose uptake by muscle is independent of
monovalent cation concentrations, but prior chelation of divalent cations with
ethylenediaminetetraacetate

rend~rs

the phenomenon insensitive to the hor-

mone. Addition of ca++ or Mg++ to the medium restores transport sensitivity
to insulin, indicating that the presence of these cations is necessary for insulin
potentiation of glucose transport in muscle (283,284).

The role of sulfhydryl

functions is indicated again, this time in insulin potentiation of transport, by
the fact that N-ethylmaleimide (NEM) blocks insulin stimulation of 30MG
transport into brown fat cells without affecting basal transport rates or binding
of the hormone to cell receptors (285).
cells with 50

J..l

A 10-minute preincubation of the

U insulin/ml or agents such as hydrogen peroxide that stimulate

glucose transport without binding to insulin receptors prevent NEM inhibition
of insulin stimulation of transport.

The mechanism of insulin stimulation of

glucose transport appears to be unique, however, since the hormone can exert
a striking effect on transport in muscle under anaerobic conditions (286), under
which the Km is decreased and the Ymax is increased (269), in contrast to
the insulin-induced increase in both Km and Vmax in this tissue.
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Both the potential role of insulin as an effector of protein carrier
dephosphorylation and the independence of insulin stimulation of glucose transport from the hormone's other effects, as facilitated glucose transport is
independent of glucose metabolism, is underscored by the observation that a
5-minute preincubation of rat epididymal fat cells with lo-4 M ATP at 24 °C
leads to a 2.5-fold inhibition of augmented glucose transport in the presence
of 100

1-1U insulin/ml without affecting insulin binding to receptors, basal

glucose oxidation, insulin inhibition of lipolysis or basal glucose transport (222).
The effect of ATP, which consists of a blocking of the insulin-induced decrease
of transport Km, accompanied by phosphorylation of a specific membrane
protein, cannot be overcome by tt"le addition of large amounts of insulin. The
S, y -methylene derivative of ATP, which cannot donate the terminal phosphate,
not only can't suppress insulin-stimulated transport, but also inhibits both the
ATP effect and membrane phosphorylation by ATP.

Further, demonstration

that insulin stimulation of glucose transport is dissociated from its effects on
glycogen synthesis (287) and that high extracellular glucose concentrations do
not reproduc-e insulin effects on cells (288) indicate that while an increase of
glucose transport into cells is the primary effect of insulin on muscle and
adipose tissue, it alone by no means leads to other effects of the hormone.
Another clue to the nature of the insulin-sensitive transport mechanism
may be supplied by the work of Guidotti (208), who postulated the existence
of an additional, insulin-sensitive membrane based on his studies of chick
embryo hearts.

He and his co-workers found that after the 7th day of

development, when

t3 -granules first appear in the endocrine pancreas, the

heart exhibits normal, transport-limited kinetics and are sensitive to insulin.
Prior to that time, however, glucose uptake by heart cells is insulin insensitive
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and proceeds at a maximal (insulin-stimulated) glucose phosphorylation-limited
rate, suggesting the formation of an insulin-sensitive structure of facilitated
sugar transport coincident with the development of the insulin secretory
apparatus.

2. Cyclic AMP. In 1957, Sutherland and Rall began studying the means
by which glucagon and epinephrine exert their effects on liver, specifically
the activation of glycogen phosphorylase, the enzyme catalyzing degradation
of glycogen to its constituent glucose molecules.

They found that exposure

of liver slices to the hormones resulted in the rapid appearance of a watersoluble heat-stable factor identified as adenosine 3' ,5 '-monophosphate (cyclic
AMP; cAMP) via stimulation at the cell surface of a membrane-bound enzyme,
adenylate cyclase (289-291).

During the ensuing years, Sutherland and his

associates and others succeeded in elucidating what is now considered the
classic mechanism of cell response triggered by binding of catabolic hormones
to cell-surface receptors, illustrated in figure 5.
Briefly, hormone binding to a cell-surface receptor activates a proximal
adenylate cyclase and/or inhibits the phosphodiesterase that degrades cyclic
AMP, resulting in a transient increase in intracellular cyclic AMP concentrations

(lo-s

to

lo-6

M).

Cyclic AMP binds to the regulatory subunit of a cyclic

AMP-dependent protein kinase (also termed phosphorylase b kinase kinase,
PbKK), causing its dissociation from the now active kinase. This kinase causes
the phosphorylation of phosphorylase b kinase (PbK), activating it. The active
PbK then causes phosphorylation of glycogen phosphorylase b, converting it to
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FIGURE 5.

SUMMARY OF GLYCOGEN SYNTHESIS AND DEGRADATION
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the active a-form, which causes removal of terminal glycogen residues as
glucose-1-phosphate molecules. Meanwhile, the cAMP-dependent protein kinase
also catalyzes phosphorylation of glycogen synthetase and glycogen phosphorylase a phosphatase, inactivating both enzymes and generally promoting glycogen
breakdown (292-296). The same kind of cAMP-mediated activation of adipocyte
lipase has been demonstrated to explain the stimulatory effect of epinephrine
on lipolysis (295,296).
One of the most striking features of this mechanism is its amplification
potential. The action of this hormone initiates a "cascade" in which the effect
of the original hormonal stimulus is amplified at least 100 times at each of
the four enzymatic steps in the ;process, for a total amplification of 1o8 or
more; thus a single molecule of glucagon or epinephrine can theoretically
trigger the release of about 100 million glucose molecules (296).

In addition

to glucagon and catecholamines, increases in intracellular cyclic AMP concentrations have been found to accompany the mediation of adrenocorticotropin,
luteinizing hormone, vasopressin, thyrotropin, parathyroid hormone, melanocytestimulating hormone, histamine, thyrotropin-releasing hormone and certain prostaglandins effects (293).
From this work evolved four criteria for establishing a cyclic nucleotide's
role as a mediator of hormone action: 1) elevation of intracellular cyclic
nucleotide levels by the hormone; 2) activation of the nucleotidyl cyclase by
the hormone in broken cell preparations; 3) recapitulation of the hormone's
effects by addition of the cyclic nucleotide or its derivatives to a target cell
Preparation; and 4) potentiation of the hormone's effects in the presence of
an inhibitor of the phosphodiesterase catalyzing that cyclic nucleotide's degradation (296).

The fact that insulin antagonizes many cyclic AMP-mediated
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hormone effects on its target tissues has led several investigators to

po~tulate

that the effects of this hormone are mediated by a decrease in the intracellular
concentration of the cyclic nucleotide (297).
A number of reports, in fact, seem to support this supposition. Insulin
antagonizes the increase in cyclic AMP levels and output of glucose brought
about by low concentrations of glucagon or catecholamines and the action of
added cyclic AMP itself in perfused livers (297-300).

Butcher et al. (301)

showed that insulin lowers intracellular cyclic AMP levels in adipocytes. This
effect was especially pronounced when cAMP levels had first been elevated
by pretreatment of the tissue with epinephrine and caffeine.

Also, cA'\1P-

induced K+ release from perfused ~at liver was found to be significantly reduced
in the presence of 25 mU insulin/ml to a cAMP concentration of about 5 x
lo-5 M (297).

In vivo administration of anti-insulin serum to rats causes a

progressive increase in hepatic cAMP levels, accompanied by an activation of
glycogenolysis (302), and a diabetes-induced, insulin-reversible increase in rat
liver cAMP concentrations has been observed (297).
Insulin has been reported to alter adenylate cyclase activity in adipose
tissue (303).

Numerous investigators have described insulin inhibition of basal

and hormone-stimulated adenylate cyclase in adipocytes (304), hepatocytes
(304),

cultured

fibroblasts

(305),

and

cell

membrane

preparations

(195,222,304,306). In addition, insulin has been found to stimulate membranebound cAMP phosphodiesterase, either directly (307) or after treatment of cells
With the hormone (308,309).
The results of experiments designed to demonstrate an effect of insulin
on intracellular cyclic AMP levels are contradictory, however.

Goldberg and

Larner in 1967 found that in both muscle and liver cells one could obtain full
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expression of insulin action either without any lowering of cAMP levels or
before any lowering was detectable (296). Numerous reports demonstrating an
inability of insulin to affect basal cAMP levels in liver, muscle and fat cells
have appeared (219,297).

Insulin does not inhibit the activation of glucose

output in perfused liver by dibutyryl cAMP (normally a potent cAMP analog)
(298-300) and the hormone can activate glycogen synthetase without causing
any change in the activity of glycogen phosphorylase or a decrease in the
concentration of cAMP (310,311), contrary to expectations for a process
mediated by a decrease in cAMP levels. Insulin has also been found to inhibit
cellular K+ release without affecting glycogenolysis (298,300).
Evidently, cAMP-mediated ;mechanisms are not involved in other insulin
effects, namely stimulation of glucose transport (312) and protein synthesis
(313), and inhibition of urea production (298,300) and lipolysis (313,314).

The

inability to satisfy the important third and fourth criteria of cyclic nucleotide
mediation of insulin action is exemplified by the fact that such agents as
prostaglandins E1 and adenosine, which cause decreases in intracellular cAMP
concentrations, do not mimic insulin's effects on glucose transport and lipolysis
(219,315). Finally, in a number of studies using cultured cells (including human
fibroblasts), no correlation was found between insulin binding to cells and the
activation or inhibition of of any component of the adenylate cyclase system,
although binding does correlate with stimulating effects on thymidine incorporation into DNA and amino acid transport (316).

3. Cyclic GMP. Although guanosine 3',5'-monophosphate (cyclic GMP;
CGMP) had been found in biological fluids previously, it wasn't until 1969 that
the compound was detected in animal tissues, almost simultaneously with the
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discovery of guanylate cyclase (317-319), because the concentration of cGMP
in cells is as much as 100-fold less than that of cAMP (296).

Development

of highly sensitive radioimmtinoassays for the compound, however, enabled a
spate of cGMP measurements using a wide variety of species, tissues, and
effectors. From these studies emerged guanylate cyclase, cGMP phosphodiesterase and a cG MP-dependent protein kinase as predominant components of the
cG1\1P system.

The cyclase has been found in both soluble and particulate

cell fractions (320), while the phosphodiesterase is predominantly soluble (321).
Substrates for the kinase include histones (322), nuclear acidic proteins (323)
and membrane proteins (324,325).
What has also emerged from cGMP research is a tendency for cellular
processes in opposition to those mediated by cA!\1P to be accompanied by
increased levels of cGMP. These include uterine contraction, venoconstriction,
platelet aggregation, polymorphonuclear leukocyte motility, lymphocytotoxicity,
intestinal contraction, gallbladder contraction, release of lysosomal enzymes,
ductus deferens contraction, and inhibition of lipolysis and heart contraction
(296).

One of the most important ideas resulting from these observations is

the possibility that insulin is a cGMP agonist.
Insulin has been found to increase intracellular cGMP concentrations in
adipose tissue (326-328), liver (326) and intestinal mucosa (329).

In the first

case, physiologic insulin concentrations cause a marked but transient rise in
the cellular level of cGMP and a stimulation of membrane-bound guanylate
cyclase (222). Much information has also been gained from studies of cultured
fibroblasts. In such cells of mouse and hamster origin insulin causes a transient
increase in cGMP with a concomitant decrease in cAMP concentrations (330335), and mitogenesis induced in mouse fibroblasts by high concentrations of
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the hormone is accompanied by

li

ten- to fortyfold increase in intracellular

cGMP concentrations (332). In these cells, cAMP-induced decreases in leucine
and hexose uptake are antagonized by addition to the medium of cGMP (336).
Unfortunately, cGMP mediation of hormone effects is not so clear-cut
as has been found for cAMP. Direct stimulation of guanylate cyclase by any
cGMP agonist has not yet been observed (321,337) and dissociation of cGMPdependent protein kinase into catalytic and regulatory subunits by cGMP has
proven difficult to demonstrate (321).

Studies designed to establish cGMP

mediation of insulin action are no less prone to inconsistencies than those
involving cAMP.

For instance, atropine, a potent cGMP antagonist, does not

affect the insulin-induced

increas~

in intracellular cGMP concentrations in fat

cells (326). Furthermore, the presence of ca++ is required, not only for cellular
processes associated with increased cG MP levels, but also for the rise in
intracellular concentrations of the cyclic nucleotide itself (296).

Indeed, this

fact may provide a key to the elucidation of a plausible mechanism for insulin
action.

4. Calcium. The critical role of calcium in nerve and muscle function
has long been known. During the past ten years, however, evidence has emerged
implicating the ion of this metal, ca++, as a ubiquitous and pivotal mediator
of many metabolic processes in a great variety of cells.
While certain investigators have found it necessary to postulate an
unsubstantiated intracellular compartmentalization of cyclic nucleotides to
explain observed inconsistencies in the behavior of these compounds during
manipulation of cellular processes putatively mediated by them (297), such
compartmentalization is well documented

for

ca++.

The cytoplasmic
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concentration of ca++ in the typical mammaiian cell is very low (apprx. to-7
M) compared to the extracellular (lo-3 M) and mitochondrial concentrations
of the ion. The mitochondrion is the cell's primary repository of ca++ (except
in muscle cells, which employ the sarcoplasmic reticulum for this purpose), in
which the total ca++ concentration is to-2 M. Because of the high intramitochondrial phosphate concentration, 99% of the ca++ in this organelle is stored
as insoluble calcium phosphate, leaving to-4 M soluble ca++, which is still
1,000-fold greater than that of the cytoplasm.

These large differences in

ca++ concentrations are maintained by ion pumps that require cellular energy
expenditure-membrane-localized ca++ -dependent ATPases, enabling precisely
regulated, rapid changes in cytpplasmic ca++ concentrations (337).

This

situation is particularly significant in view of the interrelation of intracellular
ca++ and cyclic nucleotide metabolism, exemplified by the ca++ dependence
of cGMP metabolism already mentioned.
The effects of ca++ on cellular metabolism-especially where related
to cyclic nucleotides-is tissue specific, another condition necessarily imposed
on cyclic nucleotide mediation of extracellular effectors. While ca++ antagonizes cAMP-mediated processes in adipose tissue, where the ion facilitates the
conversion of the glucose-6-phosphate-dependent form of glycogen synthetase
to the independent form (338), it stimulates the activation of glycogenolysis
by phosphorylase b kinase in muscle (339), where an increase in free calcium
concentrations from to-8 M to lo-4 M produces a four- to eightfold rise in
pyruvate dehydrogenase phosphatase activity (340), leading to activation of the
dehydrogenase and promoting glucose oxidation.
A now-classic example of cyclic nucleotide-ca++ co-mediation of hormone action is provided by the salivary gland of the blowfly, the cells of
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which secrete isotonic potassium chloride in response to hormonal stimulation
by serotonin at the cell surface.

At first it was thought that this system

represented a typical case of cAMP-mediated hormone effects, since it satisfied
the experimental criteria previously iterated.

The effect of serotonin on

intracellular cAlVIP and on KCl secretion could be uncoupled, however, if the
extracellular medium were ca++ -depleted. It has been found subsequently that
binding of serotonin to cell membrane receptors not only activates adenylate
cyclase, but also increases plasma membrane permeability to ca++.

In turn,

cAMP increases mitochondrial membrane permeability to ca++. Consequently,
intracellular ca++ concentrations rise significantly.

In the blowfly salivary

gland, increased intracellular cAMP activates a K+ pump that transports the
cation £!!!_ of the cell, against a concentration gradient, into the lumen.
Meanwhile,

ca++

mediates

increased

membrane

permeability

to

Cl-.

Furthermore, ca++ inactivates adenylate cyclase, providing a feedback loop
which is conspicuously lacking in classic cyclic nucleotide mediation mechanisms
(337).

A different kind of interrelationship between ca++ and cAMP exists in
mammalian longitudinal intestinal smooth muscle. In this tissue, acetylcholine
causes muscle contraction by increasing intracellular ca++ concentrations while
epinephrine causes muscle relaxation by decreasing intracellular ca++ levels.
Both effectors cause increases in intracellular cAMP levels, however.

This

apparent discrepancy was resolved when the actual mechanisms of effector
action were elucidated. Acetylcholine directly causes contraction by promoting
entrance into the cell of extracellular ca++ and release of the ion from
sarcoplasmic reticulum. Increased ca++ concentrations inhibit cAMP phosphodiesterase, leading to an increase of the cyclic nucleotide, which promotes uptake
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of ca++ by sarcoplasmic reticulum.

As cytoplasmic ca++ levels

f~ll,

the

phosphodiesterase is again activated and cAMP returns to basal levels. Thus,
termination of both contraction and the termination signal is provided for by
a dual messenger mechanism. Epinephrine, on the other hand, causes relaxation
of smooth muscle by decreasing cytoplasmic ca++ concentrations through an
immediate increase in cAMP levels due to stimulation of adenylate cyclase by
the hormone.

The signal is terminated by degradation of cAMP by an

increasingly more active phosphodiesterase (337).

The blowfly salivary gland

and the mammalian longitudinal intestinal smooth muscle are only examples
of many well-documented cases of the diverse regulatory systems provided by
a ca++-cyclic nucleotide synergjsm that enables the exquisite tailoring of
biologic response to external stimuli underlying the integration and subordination
of the functions of specific cell types to the requirements of the whole organism.
Particularly significant is the apparent role of ca++ in cellular responses
to insulin, especially those effects that have not been associated with other
postulated mediators. Insulin antagonizes epinephrine-induced extrusion of ca++
from adipocyte ghosts by ca++-dependent ATPase (341). An insulin-dependent
material that stimulates ca++ uptake by isolated mitochondria has been extracted from liver cytoplasm (342).

However, McDonald et al. have found that

insulin treatment of adipocytes does not alter total mitochondrial calcium, but
causes an increase in the labile form of the cation and a decrease in the
stable form (343). Procaine, lanthanum and the ca++ ionophore A23187, which
an increase intracellular ca++ concentrations, mimic insulin's metabolic effects
in liver and adipose tissue (344-346), satisfying an important criterion of
hormone mediation lacking in cyclic nucleotide models of insulin action.

It

has been found that plasma membrane permeability to glucose and amino acids
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is a function of membrane-bound ca++ (347), and that the presence

o~

ca++

is required for insulin-induced protein synthesis (348). Furthermore, the activity
of several enzymes involved in mediating the intracellular action of insulin is
calcium-dependent (340,347 ,349).

Seals, McDonald and Jarett (350-352), have

demonstrated that insulin causes the activation of what may be a plasma
membrane-associated ca++ -dependent phosphatase (M. W. 120,000) that dephosphorylates the alpha subunit (M. W. 42,000) of pyruvate dehydrogenase, leading
to activation of the latter enzyme in cell-free preparations of rat adipose
tissue.

Recently, Jarett and Seals (342) reported that insulin-treated muscle

extracts contain a factor that directly stimulates pyruvate dehydrogenase
activity in isolated adipocyte mitochondria in the presence of ca++.
A prime contender for the role of an insulin-mediating factor is one of
a family of enzymically active ca++-binding proteins exemplified by calmodulin,
found in a great variety of tissues, and troponin C in skeletal muscle (353).
Although these proteins tend to serve as kinases after binding ca++, the great
variability of their specific functions in different cell types makes it possible
that they may also act as phosphatases, an enzymic role frequently associated
with insulin responses.
Based on evidence available at this time, it is probable that insulin
effects are mediated by a complex network of messengers, primarily ca++,
ca++-binding proteins, cAMP and cGMP.

ca++-mediated effects may include

direct activation of ca++-dependent enzymes (including nucleotidyl cyclases
and phosphodiesterases), dephosphorylation of membrane proteins affecting
sugar, ion and amino acid transport, and phosphorylation and dephosphorylation
of chromosomal proteins, ribosomal proteins and cyclic nucleotide-dependent
Protein kinases affecting enzyme induction and suppression, DNA, RNA and

100
protein synthesis, and phosphorylation-dependent enzyme activity; cyclic nucleotide-mediated effects may include cell proliferation, antagonism of catabolic
hormone effects, and termination of the calcium signal.

Thus, by increasing

the intracellular ca++ concentration (perhaps through a ca++_binding protein
cascade commencing with one in direct proximity to the insulin receptor),
insulin may trigger an incredibly complex train of events appropriate to a
hormone of unequaled profundity in regard to mammalian metabolism.

CHAPTER IV
INSULIN ASSAYS
An assay for insulin is herein defined as a procedure carried out for
the specific purpose of measuring the amount of insulin present in a given
sample.

Although a great deal of research has been conducted to determine

the physiologic and metabolic effects and physico- and immunochemical properties of insulin and the molecular mechanisms of insulin action, only the use
of such work in the development of reproducible, reliable, quantitative assays
for the hormone will be reviewed in this chapter.
Ideally, any assay should

~

1) convenient, enabling a maximum number

of determinations with a minimum of manipulation; 2) reproducible, exhibiting
an interassay variation of less than ten percent; 3) sensitive, being able to
detect basal levels of the measured substance in the flui'ds being studied; 4)
accurate, reflecting the true quantities of the substance and its actual fluctuations in experimental or physiologic processes; 5) precise, with an intraassay
variation of less than five percent; and 6) specific, measuring only what it is
supposed to measure, relative to an appropriate standard.

In the case of

insulin, this standard is usually pure crystalline monomeric pancreatic insulin.
Of course, few assays fully satisfy the above iterated criteria and assays
for insulin are not among them. However, the history of insulin assays is one
of steady progression toward this goal, hampered by certain complications, the
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most conspicuous of which are the ignorance concerning the form of insulin
existing in the peripheral circulation and the multiplicity of hormone properties
that may be measured.

One may assay insulin's physicochemical properties,

immunoreactivity, or biological activity, which in most cases includes the
integrity of the molecule's receptor-binding site.

In the following account,

the properties recognized by a given assay and the appropriate applications
for that assay will be considered.

Each assay will be evaluated in terms of

the above criteria, with special attention devoted to the assay's sensitivity,
precision and range of human serum insulin concentrations in normal individuals.
IN VIVO BIOASSAYS
The First Insulin Assays
Even before the isolation of insulin was accomplished, Paulesco and
Banting and Best utilized the decrease in blood sugar of dogs as an assay for
the potency of hormone extracts. Of course, an appropriate assay is necessary
to the isolation and characterization of any biological effector.

However, the

use of dogs proved too costly to be used on a routine basis once insulin was
being isolated on an industrial scale.

Rabbit Hypoglycemia Assay
Once Banting et al. (354) found that insulin-induced convulsions in rabbits
were usually associated with a blood glucose concentration of 45 mg/dl, this
method was adopted for routine assay of preparative hormone potency.

The

amount of insulin that produces this concentration in 2-4 hours was first used
as a unit of activity, but soon the unit was formally defined as one-third the
amount required to produce this effect in a rabbit starved for 24 hours (355).

lOS

The First International Standard for Insulin, adopted in 1925 and based on the
"rabbit unit," was said to have a specific activity of 8 units per mg, and
subsequently all preparations of insulin have been assayed directly or indirectly
in terms of it.
By 1935, the unit was defined as 1/22 mg (356) and presently the bovine
insulin standard of the International Union of Pure and Applied Chemistry is
stated to have an activity of 25.0 international units (IU) per mg dry weight
and to contain 0.439% of zinc and 14.9% nitrogen (357). With the expectation
that the maximum specific activity of insulin has been attained, the unit is
now based on the absolute weight of a highly purified composite preparation
(358).
Because considerable variation in the sensitivity of rabbits to insulin
made these first rabbit assays unsatisfactory, Marks recommended the comparison of one preparation in terms of another in two similar groups of rabbits
(359).

One group received the preparation of known activity, the second the

preparation of unknown activity. On another day, the procedure was reversed
to complete a "cross-over" test.

By averaging the hypoglycemic responses to

each preparation over both days, the influence of the variation in sensitivity
between rabbits was considerably reduced and an estimation using the variable
"rabbit unit" of activity was avoided. In a later modification, two such crossover tests were performed, using two dose levels of both the standard and
unknown preparations to provide an additional check on potency (360).
method is presently recommended by the

u.s.

This

Pharmacopeia (361), which

requires a maximum assay deviation from the stated U.S.P. standard value of
7.5 percent.
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All subsequent investigations of the rabbit hypoglycemia assay have
employed cross-over designs. The reduction in blood sugar, the final concentration, the reduction or final concentration as percentages of the initial value,
either at a given time after insulin or averaged over a period of time, have
been used to determine insulin activity.

Lacey (362) demonstrated a linear

relationship bet ween the log of the insulin dose and the percent reduction in
blood sugar down to 0.4 U insulin, which brought about a 22% reduction in
blood sugar, while Young and Romans (363) succeeded in reducing the time
between insulin injection and determination of blood sugar to 50 minutes with
results as precise as those obtained using longer times (364). Using three dose
levels each of standard and test preparation and twelve rabbits in a protocol
requiring three weeks to carry out, Bliss and Marks (365) obtained data (percent
fall in blood sugar over 5 hours) for which coefficients of variation (C.V., the
ratio of the standard deviation to the mean, expressed as a percent) may be
calculated as follows: intraassay variation (bet ween rabbits), 33. 7%; interassay
variation (bet ween days), 19 .9%.
The rabbit hypoglycemia assay has proven satisfactory as a means of
assessing the biologic potency of preparative quantities of insulin, but obviously
is far too insensitive to measure concentrations of the hormone in blood.

In

addition, the assay is costly, cumbersome, extremely time-consuming, and
relatively imprecise.

Mouse Convulsion Assay
Milliunit quantities of insulin injected into mice produce convulsions
(366), and the percentage of mice responding or a mathematical function of
the percent response, known as the normal equivalent deviation, was found to
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increase linearly with the log of the insulin dose (355,367).

Weighting coeffi-

cients were applied, the highest being given to 50% response; responses at the
extreme ends of the dose-response curve were given the lowest values because
of the greater range in doses producing them (368).

A sensitivity of 2 mU

insulin was attained when mice fed on bread and milk and starved overnight
were each injected subcutaneously with 50

lJ

g promethazine hydrochloride 30

minutes before insulin administration (369). Hemmingsen obtained an interassay
variation of 7-10% in a series of cross-over tests using 160 mice (370).
Typically, the numbers of mice that die, exhibit frank convulsions, or
lie still for more than 2-3 seconds when placed on their backs are recorded
(369). In an effort to overcome possible observer error in determining positive
responses, mice, after injection with insulin, were placed on a wire-mesh screen
inclined at an angle of 600 (371,372) or placed within a rotating cylinder
similarly inclined (373).

Mice exhibiting convulsive symptoms are unable to

retain their foothold and fall from the screen or cylinder and are counted as
positive responders. This "mouse-drop" assay, however, offered no increase in
precision compared to the more conventional method employing continuous
observation (369).
In a comparison of the rabbit hypoglycemia and mouse convulsion assays,
Smith (374) found no significant difference between values for insulin standards
obtained by the two methods.

In addition, the mouse assay offers greater

sensitivity (although still not sufficient to measure insulin in blood), while being
more economical (four mice have an efficiency equivalent to one rabbit) and
requiring far less time to obtain a result.

Nevertheless, the rabbit assay is

the one presently employed to determine the biologic potency of insulin prepared
for therapeutic use (375).
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~sulin-Sensitive

Animal Assays

Removal of the hypophysis and adrenal glands renders an animal hypersensitive to insulin.

Using rats prepared in this way, Gellhorn et al. (376)

obtained a linear relationship between the blood sugar concentration and insulin
dose from 0.3 to 1.0 mU insulin/100 g body weight. When diabetes is induced
in these animals with alloxan, variations in response to injected insulin, caused
by the presence of endogenous insulin, may be reduced.

Employing rats from

which the adrenal medullae had been removed, injected with alloxan and then
hypophysectomized, Anderson et al. (377) increased the sensitivity of the assay
to 125

ll U

insulin/rat (approximately 200 g).

The first direct measurements of human plasma insulin concentrations
in normal individuals were made by Bornstein, who carried out total adrenalectomy in the hypophysectomized rat with diabetes induced by alloxan (ADHA
rat). He obtained a linear regression of blood sugar depression vs. insulin dose
from 50

ll U

to 500

as low as 100

ll

ll

U insulin. Since 0.5 ml was injected, insulin concentrations

U/ml could be measured (378).

Using this method (8 rats),

Bornstein determined the normal fasting human plasma insulin level to be about
100

ll

U/ml (<100-130

ll

U/ml) in three individuals (379). After ingestion of 50

g glucose, plasma insulin levels were found to have risen to about 200
(<100-400 lJU/ml) at 1 hour and 340 lJU/ml (180-700
then to have fallen to 220

ll U/ml

(100-500

ll

ll U/ml)

ll

U/ml

at 2.5 hours, and

U/ml) at 3.5 hours, describing

a pattern subsequently seen consistently in normal oral glucose tolerance tests.
Intraassay variation ranged from about 1896 (C.V.) at 340 lJ U/ml to 5296 at
100

lJU/ml.

The sensitivity of the ADHA rat to insulin is not affected by

exogenous cortisone, somatotropin or corticotropin (380).
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Although mice are usually more sensitive than rats to insulin, r:to less
than 250

lJ

U insulin per mouse could be measured with the hypophysectomized

alloxan-diabetic mouse (381), mainly because of an extreme lack of precision

(c.v.

= 300-400%).

Since saline alone produces a fall in blood sugar, use of

control animals is especially important in this assay.
Insulin assays using hormone-sensitive animals proved not to be of lasting
significance because they were most useful where they were needed least.
They were far less precise than the traditional rabbit and mouse assays that
are suitable for ascertaining the biological activity of preparative quantities
of insulin and they were not sufficiently sensitive to measure accurately plasma
insulin concentrations in normal individuals. These assays have been superseded
by the more sensitive and precise tissue and cell bioassays, immunoassays and
receptor assays.
IN VITRO BIOASSA YS
Isolated Tissue Assays
1.

Diaphragm assays.

In 1952, Groen et al. (382) described an assay

for insulin based on the net uptake of glucose from the medium by hemidiaphragms removed from starved rats.

A dose-response relationship of glucose

decrement (from a 200 mg/dl initial concentration) above control preparations
with increasing insulin concentration after a 90 minute incubation at 37°C was
obtained between 100 1JU and 1.0 U insulin per ml.

Valiance-owen and Hur-

lock (383) managed to improve the sensitivity of the assay to 10

U/ml. Plas-

ma from normal subjects mimics the effect of insulin in increasing glucose
Uptake by the rat diaphragm, while plasma from depancreatized dogs has
no such effect. Sulfhydryl agents known to inhibit the activity of crystalline
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insulin also abolish plasma insulin-like activity in this assay (382) and inr.ulin
antisera block the effect of plasma insulin-like activity on the diaphragm (384).
However, the rat hemidiaphragm assay for insulin employing the metameter
of glucose uptake has been plagued by imprecision.

For an initial glucose

concentration of 300 mg/dl, a tenfold increase in insulin concentration from 10
to 100 f.IU/ml produces a decrement of only 2% or 4% in glucose concentration
superimposed on a decrement of 6. 7% in the absence of insulin (385).

Thus,

in this physiologic insulin range, the insulin concentration must be increased
about 225% to produce a 1% change in glucose concentration and in the range
100-1,000

f.IU/ml the insulin concentration must increase by about 115% to

produce a 1% change in glucose concentration. Consequently, any experimental
error exercises an inordinate influence on the results of the assay.
The precision of the hemidiaphragm assay was greatly improved by
making glycogen synthesis the criterion of insulin activity.

Incorporation of

C-14 activity into muscle glycogen from a tracer quantity of glucose 1-[14c]
added to the medium is determined after extraction of glycogen from hemidiaphragms with 30% KOH in boiling water and precipitation with 66% ethanol.
Using this method, Moody and Felber attained a sensitivity of 10

f.l

U insulin/ml

for mouse diaphragm (386); Guenther (387) obtained a linear relationship between
CPM C-14 activity incorporated per gram rat diaphragm glycogen and insulin
dose from 50 to 250

f.l U

insulin/ml, with a correlation coefficient (r) of 0.961,

highly significantly different from zero (P<0.001), and a coefficient of variation
for scatter about the line (C.V. (Sy.x» of less than 6%.
An in vivo variation of this method has also been developed (388,389).
Rats are injected intraperitoneally with a mixture consisting of a glucose
solution, a tracer quantity of 14c-glucose, and an insulin standard or unknown.
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Two hours later, the rats are sacrificed, diaphragms removed, glycogen extracted and incorporation of C-14 activity determined as in the in

~

assay.

Using this technique, Guenther (387) obtained a linear relationship bet ween
CPM/g and insulin dose up to 1 mU insulin/ml (r

= 1396) with a sensitivity of about 75

).l

= 0.993,

U insulin/ml.

P«0.001; C.V. (Sy.x)

Obviously, this method

represents a considerable improvement, both in sensitivity and precision, over
previous in vivo insulin bioassays.
A range of 0 to 120

).JU insulin per ml human serum has been found

for normal fasting subjects (390,391), with a threefold increase seen in normal
postprandial subjects (391), using the in vitro rat diaphragm assay.
2. Fat pad assays. Insulin enhances glucose uptake, oxidation of glucose
to C02 and incorporation of glucose carbon into ether-soluble lipid in the rat
epididymal fat pad maintained in Krebs-Henseleit buffer (392). In 1958, Martin
et al. reported development of the first rat epididymal fat pad assay for insulin
based on the second of these effects, insulin induction of glucose oxidation to
C02 in adipose tissue preferentially via the pentose phosphate pathway with
concomitant production of NADPH and ribulose-5-phosphate (393).
The fat pad of each fed male rat is cut into three or six equal parts
and each piece is placed in a separate metabolism flask in buffer containing
1-14c-glucose and insulin standard or unknown.

After two hours incubation

at 37°C in an atmosphere of 95.96 02/596 C02, with shaking, the medium is
acidified to liberate 14co2 remaining in solution; upon contact with the Ba(OH)2
or NaOH in the cup suspended over the reaction mixture, 14co2 is converted
to 14co3 =.

The solution in the cup is assayed for C-14 activity and the

square root or log of CPM per gram adipose tissue is a linear function of
insulin concentration.
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Using this method, Martin et al. (393) attained a sensitivity of 10

~

u

insulin/ml and Guenther (387) obtained a linear relationship between log
CPM/gram tissue and insulin dose up to 500

~U/ml

(r

= 0.999,

P«0.001; C.V.

(Sy.x> = 3.1 %) with an interassay variation of 14.3%. Other metameters used
in the fat pad assay are glucose uptake (394) and total gas exchange (395).
A source of puzzlement for more than two decades has been the degree
of discrepancy between the insulin values found in the sera of normal fasting
individuals using the diaphragm and fat pad assays, the latter yielding values
ranging from 33 to 940

~

U/ml with levels 2-5.5 times as high after the

administration of glucose (396).

Although there can be little question that

the fat pad is very sensitive to the action of plasma insulin, the assay utilizing
this tissue is notoriously lacking in specificity.

Human serum insulin-like

activity (ILA), as determined using the fat pad assay, is not extractable by
acid ethanol (397), is not neutralized by anti-insulin serum (397), and to some
extent persists after treatment of plasma with reduced glutathione (396).
Fasting levels of ILA persist unchanged after pancreatectomy (396-398) and
plasma ILA of

p~ncreatectomized

dogs actually increases after glucose adminis-

tration (398). Although introduction of isolated tissue bioassays enabled routine
measurement of plasma -insulin concentrations for the first time, they also
opened the bewildering and not yet resolved issue of insulin-like activity, or
"atypical insulin," the nature of which is discussed in Chapter

v.

Another disadvantage of isolated tissue bioassays is their particular
sensitivity to the effects of insulin antagonists, especially catecholamines and
free fatty acids. The addition of 0.01

~

g epinephrine/ml significantly reduces

the effect of 0.5 mU insulin/ml on glucose uptake by rat diaphragm (399).
Appreciable degradation of insulin may also occur due to the general action
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of proteases and the specific action of the insulinase system when enzymes
are liberated from cut diaphragm preparations (400). Furthermore, the potent
insulin antagonism of diabetic serum has proven to be due to anti-insulin
antibodies, the study of which led to the development of the radioimmunoassay
(385).
The dilution of such insulin antagonists has been considered the cause of
a disproportionate increase in the amount of ILA (as much as 24-fold) measured
by the diaphragm assay with dilution of human sera (up to 8-fold) (391).
However, quantitative recovery of insulin added to serum implies that the
effect of antagonists is negligible (383,401,402).

Cell Cultures
The use of ·cultured cells for the assay of insulin is best exemplified by
the free fat cell bioassay of Moody et al. (145). Short-term cultures of cells
isolated from rat epididymal fat pads are incubated with 0.1-0.5

~Ci

2- or

3-3H-glucose and insulin standard or unknown for 2 hours at 37°C. Total lipids
are then simply extracted with a toluene-based scintillation fluid and betaradiation assayed in a liquid scintillation spectrophotometer. Thus, one determines the conversion of glucose to lipid, which is greatly accentuated in the
presence of insulin (125-405 times the basal value, which amounts to no more
than 0.05% total counts).
Sensitivity of the assay for insulin is 2.5

~U/ml

between CPM/weight lipid and insulin dose from 4
an intraassay variation of less than 10%.

~

with a linear relationship
U/ml to 15

~

U/ml and

Both the well-recognized insulin

dependence of lipid biosynthesis and the favorable comparison of biologic
activities exhibited by insulin analogs as determined by this method and by in
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vivo bioassays (see Table I) would lead one to expect a high degree of insulin

----specificity for this technique.

Therefore, cultured cell assays for insulin can

afford a degree of sensitivity, convenience and specificity decidedly superior
to and a measure of precision comparable to the best of the bioassays. The
compelling advantage of delineation of insulin and other effects provided by
cultured cells will be examined in Chapter V.
CHEMICAL ASSAYS
Before development of immunoassays, attempts were made to devise
specific tests for insulin based on the physicochemical properties of the hormone
that would possess the precision: characteristic of chemical assays.

Two of

the most promising were based on fibril formation and paper chromatography.

Fibril Assay
Waugh et al. (403} developed an insulin assay based on the fact that
the precipitate formed when a solution of insulin in dilute acid is heated is
composed of radially oriented fibrils (404}.

In this method, an acid solution

of insulin is repeatedly heated and frozen until intense flow birefringence
occurs.

The fibrils so formed are broken by expulsion through a hypodermic

needle and used to seed the standard and test solutions of insulin.

These

solutions are stirred continuously overnight at 48oc and the precipitate formed
is collected, washed, dried and weighed.

The weight of fibrils obtained was

found to be proportional to the amount of insulin present in the seeded solution.
The method could not be applied to samples containing less than 11 units
insulin/mg and the ability of the assay to reflect losses of biologic activity is
questionable (369).

113
Chromatographic Assay

-

In 1952, Robinson and Fehr (405) assayed the insulin content of protamine

zinc insulin by paper chromatography. A solution of insulin was streaked across
a paper and the chromatogram was developed with n-butanol/glacial acetic
acid/water (3:1:4). The insulin spots were stained with bromocresol green, the
color was intensified in ammonia vapor and the stained material was eluted
with borate buffer.

A linear relation was found between light absorption by

the resultant solution and insulin concentration, from 0.25 to 1.5%.
Fenton (406) separated insulin from associated impurities by ascending
paper chromatography with 2-butanol/1% acetic acid (1:1). Insulin was stained
with bromocresol green, the color intensified in ammonia and eluted with 0.1
N NaOH/95% ethanol (1:1). The absorbance of eluate was shown to be linearly
related to weight of insulin applied up to 110
0.5 unit.

~

g, with a sensitivity of about

Good agreement of this method with the mouse convulsion assay

was found.
These two chemical assays are capable only of measuring preparative
quantities of insulin and are less specific and less indicative of the hormone's
biologic activity than in vivo bioassays.

The fibril method using gravimetric

procedures requires a large volume of solution containing at least 1 unit
insulin/mi. Grodsky (407) found that the insulin B-chain, esterified insulin and
carboxypeptidase-inactivated insulin also form fibrils.

The chromatographic

methods estimate between 0.5 unit and 150 units insulin, and impurities
associated with low-grade insulin may interfere.
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Moreover, these methods are more precise and less costly than bioassays.
Fenton (406) calculated that a single determination of insulin potency by paper
chromatography was equal in precision to that obtained with 960 mice.
IM!VIUNOASSAYS
Radioimmunoassay (RIA)
After obtaining her Ph.D. in physics at the University of lllinois, Rosalyn
Yalow accepted a position as physicist in the radioisotope service of the Bronx
Veterans Administration Hospital, where in the early 1950s she began what
was to be a profoundly fruitful association with the physician Solomon Berson.
In order to test I.A. Mirsky's hypothesis that maturity-onset diabetes might
not be due to a deficiency of inshlin secretion, but rather to abnormally rapid
degradation of insulin by hepatic insulinase (408), they studied the metabolism
of 131J-labeled insulin following intravenous administration to nondiabetic and
diabetic subjects (409).

Berson and Yalow observed that radioactive insulin

disappeared more slowly from the plasma of patients who had received insulin,
either for the treatment of diabetics or as shock therapy for schizophrenia,
than from the plasma of subjects never treated with insulin. Suspecting that
the retarded rate of insulin disappearance was due to binding of labeled insulin
to antibodies that had developed in response to administration of exogenous
insulin and presuming that these antibodies were likely to be present in such
low concentrations that classic immunologic techniques would be inadequate
to measure them, the two investigators introduced radioisotopic methods of
high sensitivity for detection of soluble antigen-antibody complexes. Studying
electrophoresis patterns of plasma samples after addition of 1311-labeled insulin,
they found that in plasma from insulin-treated patients the labeled insulin is
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bound to and migrates with an inter

f3- Y globulin, while in control plasmas

the radioactivity remains near the origin, as does free insulin (409,410).
When Berson and Yalow first attempted to publish this observation as
evidence that humans produce insulin-specific antibodies in response to insulin
treatment, their manuscript was rejected with a request for more rigorous
proof that the insulin-binding plasma component is an antibody (411), probably
because of widespread scepticism among immunologists at that time regarding
the ability of any substance below 10,000 daltons molecular weight to serve as
an immunogen (412). Previously, many of the immunological reactions observed
in diabetic patients were attributed to impurities in the insulin preparations
then in use (413), but much eviden?e suggesting the existence of insulin-specific
antibodies in humans and other animals had been reported prior to the work
of Berson and Yalow (414).

This evidence includes development of insulin

resistance by insulin-treated humans; the ability of sera from these individuals
to prevent or reduce insulin-induced convulsions and other hypoglycemic effects
in mice and to abolish the effect of the hormone on glycogen deposition in
isolated rat diaphragm; demonstration that the insulin-neutralizing component
of these sera is associated with the globulins or
precipitation and

starch-block

electrophoresis,

Y-globulins by fractional
is

non-dialyzable

and

is

thermostable; induction of insulin-resistance in rabbits, guinea pigs and other
animals by means of repeated subcutaneous injections of insulin in Freund's
adjuvant; and demonstration that the sera of these animals display the same
properties as sera from insulin-resistant humans outlined above.

Recently it

has been shown that injections into rabbits of USP insulin and high molecular
weight contaminants (including insulin aggregates and proinsulin) found in it
produces insulin-binding antibodies, while highly purified (monocomponent)
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insulin does not, but that even monocomponent insulin is significantly
immunogenic in humans (415,416).
Subsequent to Berson and Yalow's work, it was shown that erythrocytes
coupled to insulin are agglutinated by sera from insulin-treated rabbits and
humans (417-419) and that Y-globulin-bound labeled insulin can be precipitated
with rabbit anti-human

Y-globulin (420,421).

In addition, it has been shown

that generally the serum of insulin-treated animals fails to precipitate the
hormone (417 ,422), confirming Berson and Yalow's suspicions.
the criticism

of the

reviewers,

Berson and

In response to

Yalow demonstrated

that

ultracentrifugation of serum to which labeled insulin has been added also shows
that the hormone moves with the

Y-globulins in the case of insulin-treated

patients, but with the albumin fraction of serum from untreated patients, and
that the addition of increasing amounts of unlabeled insulin to a mixture of
insulin antibody and labeled insulin results in displacement of the labeled insulin
(409).

This latter observation led directly to development of the first

radioimmunoassay (RIA).
The principle of RIA, as pictured in Figure 6, is based on competitive
protein binding rather than simple isotope dilution.

A tracer quantity of a

radiolabeled form of the antigen to be measured (usually 1-125 or 1-131 bound
to the tyrosyl phenolic ring in the case of proteins and H-3 or C-14 substituents
in the case of other antigens), an aliquot of highly diluted xenogeneic antiserum
specific for the antigen (usually prepared by hyperimmunization of rabbits or
guinea pigs with the antigen in the presence of Freund's adjuvant), and a
standard or sample containing unlabeled antigen are mixed in quantities
appropriate to produce approximately 5096 net binding (bound/free antigen,
B/F =1) of labeled antigen by antibody at equilibrium in the absence of unlabeled
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FIGURE 6.
COMPETING
RADIOIMMUNOASSAY.

REACTIONS

THAT

FORM

THE

BASIS

OF

(Reproduced, with permission, from Ref. 411. Copyright 1978 by the American
Association for the Advancement of Science.)
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antigen.

To attain this result, exceedingly small quantities, in the picogram

to nanogram range, of antibody and antigen are required (411).

Net fraction

antigen bound, B/T, is determined as [total CPM (counts per minute) associated
with antibody - nonspecifically bound (NSB) CPM)/[total CPM - NSB CPM) and
net percent antigen bound, %B=B/T x 100.

Nonspecifically bound antigen is

the radioactivity found in the antibody fraction in the absence of specific
antibody or in the presence of a large excess of unlabeled antigen.
When unlabeled antigen is added to the mixture, this species competes
with labeled antigen for antibody binding sites and a significant reduction in
the amount of radioactivity specifically associated with antibody protein is
seen. As the concentration of added unlabeled antigen is increased, antibodybound radioactivity decreases proportionately, resulting in a dose-response
relation between fraction radiolabeled antigen bound to antibody (B/T) and
concentration of unlabeled antigen, exemplified by the standard curve for
insulin reproduced in Figure 7.

The antigen concentration of an unknown

sample may then be determined from the standard curve simply as that antigen
dose corresponding to the proportion of net antibody-bound radioactivity
obtained for the sample.
Unlike isotope dilution techniques, RIA does not require that labeled
and unlabeled antigen exhibit identical behavior in the assay system, but only
that antigen in unknown samples be immunochemically identical to the antigen
standard (411). Even the competitive aspects of antigen-antibody interactions
and attainment of equilibrium need not be strictly observed since successful
RIAs have been developed based on principles of antigen displacement from
antibody and approach to equilibrium, utilizing preincubation of unlabeled
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FIGURE 7. DOSE-RESPONSE CURVE FOR INSULIN RIA, IN WHICH THE
BOUND TO FREE RATIO OF RADIOLABELED INSULIN IS PLOTTED AGAINST
THE ADDED COLD INSULIN.

(Reproduced, with permission, from Ref. 423. Copyright 1965 by the Endocrine
society.)
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antigen and antibody before addition of labeled antigen (424) and shortened
incubation times (423), respectively.
Obviously, the "trick" of RIA is the complete and efficient separation
of antibody-bound from free antigen. The first RIA, that developed by Berson
and Yalow for assay of insulin in human plasma (425), utilized paper
electrophoresis for the separation.

Another separation method based on a

difference in the physical properties of immunoglobulins and measured antigens,
used in early RIAs, is gel chromatography (426). These methods are laborious
and time-consuming, however, and proved unsuitable for routine clinical use.
More rapid and convenient separation methods based on physicochemical
properties of antibody and antigen include nonspecific

precipitation

of

immunoglobulins with ammonium 'sulfate (427), alcohol (428) and polyethylene
glycol (429), and nonspecific adsorption of antigen with talc (430) and charcoal
coated with plasma proteins (431), albumin (432) or dextran (423).

Although

these techniques have found widespread use in clinical RIAs, one may question
their use for more precise applications since anomalous values are likely to
be found for fluids differing significantly in protein composition from normal
serum (433) and precipitation methods tend to disturb the equilibrium of the
antigen-antibody interaction (433,434). Furthermore, relatively high values for
nonspecific binding of labeled antigen to antibody are likely to be found,
including spurious contributions from nonspecific trapping of free antigen in
precipitates and inability of charcoal to adsorb "damaged" tracer which may
nonetheless retain immunoreactivity (433).
Immunoprecipitation of antibody with a second antibody specific for
serum components, gamma globulins or IgG of the species in which the first
antibody was prepared (double antibody method; 435) is well-suited to research
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applications.

Although more time-consuming, the double antibody method

exhibits far less interference due to nonspecifically bound radioactivity and
variation in fluid composition than nonspecific precipitation methods (433).
Because antigen- and second antibody-binding sites are distinct (433), equilibrium
distribution of bound and free antigen is relatively unaffected.

A solid-phase

variation of the double antibody method involves coprecipitation of first and
second antibodies prior to addition of other components, which then require
constant mixing with the insoluble antibody (433).
Solid-phase antibody systems offer a potentially popular means of RIA
separation because they are extremely convenient and easily adapted to
automated protocols, especially the coated tube method (436).

Antibody is

adsorbed onto polystyrene or polyethylene tubes, which may then be stored in
dry form.

After appropriate incubation with labeled and unlabeled antigen,

bound antigen is separated from the free form simply by decantation or aspiration.

Because the composition of the antibody phase is difficult to control,

however, the sensitivity and precision of this method tend to be poorer than
that of soluble antibody RIAs (433).

With the development of more efficient

means of immobilizing immunoglobulins via covalent coupling to insoluble
matrixes, a wide variety of solid-phase RIAs have been attempted, among the
most successful of which employs antibodies coupled to Sephadex (437 ,438).
Although this last method exhibits a high degree of precision and accuracy
(433,439), solid-phase RIAs tend to be costly and wasteful of antiserum (433).
Competitive protein binding assays, including RIA, provide dose response
curves that exhibit severe nonlinearity.

Thus, numerous attempts have been

made to linearize the relation between labeled antigen bound to antibody and
unlabeled antigen added in order to render data reduction compatible with
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automated, relatively simple, low-cost computer systems. The most successful
early attempt was that of Hales and Randle (424), in which Co/Cit where c 0
is the radioactivity of the antigen-antibody complex in the absence of unlabeled
antigen and Ci is the radioactivity of this complex at a given concentration
of unlabeled antigen, is plotted against concentration of unlabeled antigen. An
example of a Hales-Randle plot, obtained by Guenther (387), is shown in Figure
8.

Using a coprecipitated double antibody complex and a microfiltration

technique for separation of bound from free insulin, Guenther obtained a linear
relation between C 0 /Ci and insulin dose up to 200

~

U/ml with a correlation

coefficient of 0.979 (P«0.001, C.V. (Sy•x)=13%). The sensitivity of this assay,
however, was no better than 10

~

U insulin/mi.

A partial linearization of the dose response has been achieved using a
semi-log plot of bound/total radioactivity (B/T) or percent total radioactivity
bound (%B) vs. log unlabeled antigen added, resulting in a sigmoidal curve
(Figure 9).

Several attempts have been made to linearize this plot utilizing

sigmoidal transformations, the most successful of which is the logit transform,
logit Y = ln

Y
= 2.303 log -:-=::-y---:::100 - y
100 - y

where Y=(%B/%B in the absence of unlabeled antigen) x 100=%B 0 (440). When
logit (%B 0 ) is plotted against log antigen dose a linear relationship between
10% and 90% (logit=-2.2 - +2.2) is obtained (Figure 10). It should be emphasized
that the linear relation obtained results from mathematical manipulation of a
non-linear function and does not necessarily reflect any intrinsic property of
the RIA system (440).
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FIGURE 8.
DOSE-RESPONSE CURVE FOR INSULIN RIA,
ACCORDING TO THE METHOD OF HALES AND RANDLE.

Each point is the mean of 10 determinations.
(From Ref. 387)
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FIGURE 9. DOSE-RESPONSE CURVE FOR HUMAN LUTEINIZING HORMONE
RIA: SEMI-LOGARITHMIC PLOT.

Bars indicate the range of 10 replicates.
(Reproduced, with permission, from Ref. 440. Copyright 1968 by the Endocrine
society.)
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FIGURE 10. DOSE-RESPONSE CURVE FOR HUMAN LUTEINIZING HORMONE
RIA: LOGIT-LOG PLOT.
.

Data of Figure 9.
(Reproduced, with permission, from Ref. 440. Copyright 1968 by the Endocrine
society.)
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Although it is technically feasible to apply linear regression analysis to
Iogit-log plots and thereby determine the residual variance (scatter) about the
regression line, the results of such analysis would be invalid and severely biased
due to intensification of heteroscedasticity, or non-uniformity of the residual
variance, by the logit transformation (440).

Thus, a quality control approach

has been found to be the most practical, expedient means of judging the
suitability of established RIAs (440). The four most informative quality control
parameters are B0 , the percent antigen bound in the absence of unlabeled
antigen; the antigen dose at which 96B 0 =5096 (logit Y=O); the intraassay
variation, the coefficient of variation for sample replicates assayed at the
same time; and the interassay variation, the C.V. for samples assayed
repetitively at different times.
lntraassay variation, a measure of assay precision, and interassay
variation, a measure of assay stability and reproducibility, found for RIAs are
typically less than 1096 and 1596, respectively (440-443).

Although the 9096

B0 x-intercept in a logit-log plot is frequently considered the sensitivity of
an RIA, the 5096 intercept is a more suitable reflection of sensitivity for use as
a quality control parameter, since it is situated at the center of the curve
and thus is relatively unaffected by minor fluctuations of slope (440).
little as 1-3

~U

As

insulin/ml is commonly detected by RIA (438,443,444), with

a sensitivity of 0.3

~

U/ml having been reported (445).

Before a given RIA can be considered a useful technique to which quality
control tests may be applied, the validity of the assay must first be proven
by certain established procedures.

Assay specificity is generally verified by

assaying dilutions of samples containing high concentrations of antigen; if the
relation between sample dilution and 96B parallels that of the standard so that
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assignment of an antigen concentration to the sample based on the standard
results in the superimposibility of the sample and standard dose-response· curves,
then one may conclude that antigen in the sample is identical to antigen in
the standard and that the assay measures only that particular antigen in sample
nuid (433,441-443).

When an RIA is meant to measure one of a group of

closely related antigens, such as the gonadotropins (luteinizing hormone, folliclestimulating hormone and chorionic gonadotropin), somatotropin and prolactin,
insulin and proinsulin, and the steroid hormones, assay specificity is often
determined by assaying dilutions of the possibly cross-reacting substances in
the RIA (433,441,443).

The extent of cross-reactivity may be quantitated by

comparing the doses at which 50% B0 is attained.
Accuracy of an RIA may be ascertained by demonstrating "recovery" of
exogenous unlabeled antigen from sample fluid.

Antigen standard is diluted

in sample fluid which is then assayed with the RIA. If the difference between
results obtained for this preparation and that of untreated fluid closely
approximates the antigen concentration of the added standard, the assay is
considered capable of measuring accurately the quantity of immunoreactive
antigen in that fluid (441-443).

If RIAs for a particular antigen have already

been developed, one may also compare the results of a newly-developed RIA
for antigen concentrations in fluids from normal individuals and those suffering
from

well-characterized

pathologic

conditions

reported using previously developed RIAs.

with

corresponding

Insulin levels in human sera from

normal fasting individuals, determined by RIA, range from 1.0 to 20
(443), with a mean of 8.44 0.35
(444).

values

lJU/ml

lJU/ml (S.E.M., n=75) having been reported

Serum insulin concentrations rise four- to tenfold after ingestion of

100 grams oral glucose (oral glucose tolerance test, OGTT), attain their
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maximum values at 30 to 60 minutes, and thereafter gradually fall to the
tasting level or below at two to four hours (443).
so precise and reproducible are RIAs for insulin that it has been possible
to discriminate among normal, pre-diabetic, maturity onset diabetic and juvenile
onset diabetic conditions from the pattern of serum immunoreactive insulin
(IRI) levels during OGTTs (446,447), which have also been used to assess the
probability of diabetic angiopathy, neuropathy and renal disease in maturity
onset diabetics (448).

Furthermore, the use of insulin RIAs for determination

of serum IRI levels after administration of glucose, tolbutamide, leucine or
glucagon

has

made

possible

the

diagnosis

of

insulin-secreting

tumors

(insulinomas) with a high degree of reliability (446).
Radioimmunoassay is uns'urpassed in its sensitivity, reproducibility,
precision and specificity for!! given antigenic species. Thus, the major drawback
regarding RIA is the broader issue of accuracy.

An antigen may lose its

biologic activity, but retain its immunoreactivity, while a closely related or
altered antigen may be capable of exerting a potent biologic effect, but have
a much reduced affinity for antibody utilized in the RIA.

Nowhere does this

question have more important implications than in the fields of insulin and
diabetes research, since there remains the possibility that insulin aggregates
or protein-bound insulin constitute a physiologically important hormone reservoir
that is largely undetected by RIA (see Chapter V).
Radioimmunoassay is also extremely convenient, provided one possesses
the appropriate equipment for carrying it out. Not every laboratory can afford
an automated gamma ray or liquid scintillation spectrophotometer, large
centrifuges, and even a desk computer necessary for large-scale RIAs.

For

those possessing such equipment, antigen determinations can be made on several
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hundred samples in a single assay (411). Of special importance to clinical and
research applications alike is the ability of RIA to measure antigen levels in
very small sample volumes (0.1 ml or less).

Furthermore, the potential

applications of RIA to biomedical research and diagnosis appear virtually
unlimited because of recent advances in techniques for production of haptens
(non-immunogenic compounds rendered capable of eliciting specific antibody
production in animals after conjugation of the compounds to immunogenic
proteins such as albumin) and radioisotopic labeling of organic compounds.
Thus, it is not surprising that during the past twenty years RIAs have
been developed to measure a myriad of substances, including peptide and protein
hormones, thyroid hormones, steroids, prostaglandins, neurotransmitters, nonhormonal serum proteins, drugs,' vitamins, cyclic nucleotides, enzymes, viruses
and tumor antigens (411). Plainly, RIA has had a major impact on those areas
of study that could benefit from a striking increase in the ability to measure
exceedingly small quantities of a given substance, and has even enabled the
monitoring of fluctuations in intracellular concentrations of compounds reliably.
This impact has been especially profound on the fields of endocrinology, cell
physiology, oncology, and immunochemistry.

Regarding this last application,

RIA has been particularly useful in the immunochemical characterization of
insulin.
In their ability to inhibit binding of radiolabeled insulin to anti-insulin
antibodies, insulins derived from various vertebrate species have the dual
advantage of being extensively, but not completely, cross-reacting. Although
the degree of inhibition per unit concentration of unlabeled insulin and thus
the antigen-antibody affinity may differ among various insulins with a given
antiserum, Berson and Yalow (449) found that bovine, porcine, ovine, equine
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and human insulins were all capable of saturating antibody binding sites in
human anti-insulin sera (inhibition curves shown in Figure 11).

These

investigators found that the kinetics of the association indicate that insulin is
probably univalent and that there are at least two distinct orders of antibodycombining sites.

Association constants for high affinity sites ranged from 3

x 108 M-1 (horse insulin) to 1.4 x 109 M-1 (beef insulin) and for low affinity
sites from 3.4 x 106 M-1 to 3.2 x 107 !\1:-1 utilizing serum obtained from an
individual treated with a combination of bovine and porcine insulins.
affinities

of

iodinated,

nitrated,

desalanine-desasparagine

(DAA),

Lower
and

desoctapeptide (DOP) insulins and proinsulin for guinea pig anti-insulin antibodies
compared to native insulin in the RIA, represented by lesser slopes in HalesRandle plots, have also been observed (136).
Apparently, the ability to discriminate among insulin from different
species is dependent mainly upon the source of the insulin used for immunization
and for radiolabeling. Serum from humans treated with porcine insulin cannot
discriminate

among bovine,

porcine,

human and DOP insulins, whether

radiolabeled porcine or bovine insulin is used (450).

When these subjects are

further treated with bovine insulin, however, their antibodies exhibit a lower
affinity for DOP insulin compared to the animal insulins studied if an
1311-porcine insulin tracer is used and can discriminate between bovine and
porcine vs. human and DOP insulins if an 131J-bovine insulin tracer is used
(450). At appropriate dilutions, sera from two of three individuals treated with
a combination of bovine and porcine insulins can discriminate between bovine
and porcine insulins, with bovine insulin exhibiting the greater affinity, provided
a radiolabeled bovine or ovine insulin tracer is used (449).
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FIGURE 11. DOSE-RESPONSE CURVES FOR INSULIN RIA USING HUMAN
ANTI-INSULIN SERUM H.L.

Reproduced from The Journal of Clinical Investigation, 1959, vol. 38, pp. 20172025 (Ref. 449) by copyright permission of The American Society for Clinical
Investigation.
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The results of these experiments suggest that the AB-10 apolar amino
acids, which are the only ones that differ among bovine, porcine, ovine and
equine insulins, are a site of antigenic determinacy (449).

The antigenicity of

the B30 residue, however, may be dependent upon the conformation of the
insulin molecule, since sera from individuals treated with porcine insulin cannot
discriminate between human and porcine insulins, which differ from each other
only in the B30 residue (alanine in the pig, threonine in man), while anti-bovine
insulin sera do discriminate between the two insulins, suggesting that the B30
alanine is presented in a more favorable way immunogenically by bovine insulin
than by porcine insulin. This supposition is supported by the fact that antibodies
to porcine insulin react well with desalanine porcine insulin and cannot
discriminate between DOP bovine and intact insulins, while anti-bovine insulin
sera readily distinguish DOP beef insulin from intact bovine and porcine insulins,
but not necessarily from human insulin (450).

Antisera from rabbits (whose

insulin differs from human and porcine insulins only in containing B30 serine)
immunized with porcine insulin also react with DOP bovine insulin (450).
That the conformation of the insulin molecule differs among species and
that conformational differences affect the antigenicity of the hormone are
supported by the finding that certain human anti-porcine, bovine insulin sera
discriminate sharply between porcine and sperm whale insulins, which possess
identical primary structures (450,451).

Several years before the discovery of

proinsulin, Berson and Yalow interpreted this observation to mean that the
overall protein structure may not be determined by amino acid sequence alone
(451).

The concept that protein conformation is ultimately determined by

primary structure was vindicated, however, when the insulin portion of the
Proinsulin molecule was shown to be in the same conformation as the free

139
insulin molecule (452). Thus, insulin conformation is dependent upon the tertiary
structure of proinsulin, to which the primary structure of the connecting peptide
(c-peptide, see Chapter V, ''Insulin Precursors") would be expected to make a
major contribution and, indeed, comparison of the amino acid sequences of
human, porcine and bovine proinsulins reveal a high degree of variance within
the respective C-peptide segments {453).

This postulate is supported by the

fact that oxidation of reduced A and B chains of sheep insulin yielded only
12-16% biologically active insulin {157 ,158), indicating that insulin is not in its
thermodynamically most stable conformation, while reoxidation of fully reduced
beef and rat proinsulins results in a high proportion of the native configuration,
which could be converted to biologically active insulin by trypsinization {454),
suggesting that the conformation of insulin is dictated by the thermodynamically
most stable conformation of proinsulin.
It may be seen from Table I that the A14 and A19 tyrosines are important
to insulin immunoreactivity.

Unfortunately, RIA is a relatively insensitive

means of investigating the effects of changes at these positions, since they
are prime sites of radioiodination.

Monoiodoinsulin is labeled equally at A14

tyr and A19 tyr (136), leaving half the labeled insulin intact at each site and
able to· bind antibodies specific for these epitopes.

The partial competence

of labeled insulin at these sites is indicated by findings of 37.7 and 58.4%
immunoreactivity for mononitro- and monoiodoinsulin, respectively, by RIA and
corresponding values of 6.7 and 3.9% by immune hemolysis inhibition {136).
Table I also indicates that A1 glycine and A21 asparagine may be important
immunodeterminants, while B1 phenylalanine and B29 lysine are relatively
unimportant.

Alteration of both B1 and B29 residues, however, leads to

significant reductions of immunoreactivity.

Arquilla has suggested that a

140
significant proportion of the antibodies involved with the insulin RIA may
combine with determinants that include B10 histidine (136).
Previously iterated evidence for the immunogenicity of insulin, namely
insulin resistance in animals treated with the hormone and the ability of these
animals' sera to block insulin's biologic effects in both in vivo and in vitro
systems, also provides a basis for the assertion that insulin immunodeterminants
lie in or near the hormone's active site. This contention is also supported by
the induction of experimental diabetes in animals via injection of hyperimmune
anti-insulin sera (414).

Thus, it is especially significant that the A1 glycine,

A19 tyrosine and A21 asparagine-all associated with the insulin active site
(135)-have ·also been implicated as insulin immunodeterminants.

Although

insulin aggregates are important to the immunogenicity of the hormone,
immunodeterminant

residues

have

been

implicated

in

the

hydrophobic

aggregation regions of the monomer: B30 alanine in the dimer face and A14
tyrosine in the hexamer face. This contention is supported by the observation
that compromised immunoreactivity of FITC-insulin derivatives parallels the
progressive inability of these derivatives to form aggregates (136), leading one
to

expect

that

immunoreactivity.

large

insulin

aggregates

should

exhibit

decreased

The immunogenicity of insulin aggregates may be related

to an increased molecular size in excess of that required for processing by
macrophages (455), which may then "read" dissociated monomer determinants.

Enzyme Immunoassays
Because RIA may involve exposure to potentially dangerous radioactivity,
requiring special handling of materials and the use of expensive equipment,
immunoassays utilizing enzyme-labeled antigen have been developed.

Among
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those procedures collectively known as enzyme-linked immunosorbent assays
(ELISA), this technique is based upon the same principles as RIA, but deter.mines
quantity of labeled antigen bound to antibody by measuring enzyme activity
in the presence of a large excess of substrate. Typically, the product of the
enzyme reaction exhibits a characteristic color and may be quantitated in a
simple colorimeter, giving ELISA a potentially great advantage over RIA in
its applicability to small laboratories and fieldwork.

The frequent use of

specific antibody adsorbed to plastic test tubes or multiwell microtiter plates
in ELISA increases the potential convenience of this assay (456,457).
Miedema et al. developed a solid phase ELISA for insulin utilizing antiinsulin serum adsorbed to polystyrene test tubes, insulin coupled to alkaline
phosphatase with glutaraldehyde, and Q:-nitrophenylphosphate as substrate, the
reaction product of which was monitored by measuring absorbance of 405
nanometer wavelength light (A4o5) (458).

The sensitivity of this assay was

found to be no better than 75 · JJU insulin/ml, however, with a mean serum
insulin concentration of 63

JJU/ml (below the sensitivity) for normal fasting

individuals and a normal range of 20 to 106

JJU/ml, indicating that the

sensitivity and precision of ELISA is far inferior to that of RIA for assay of
insulin.

Enzyme Immunoelectrode
Mattiasson and Nilsson (459) described covering an oxygen electrode with
a nylon net to which are coupled guinea pig anti-porcine insulin antibodies for
the immunoassay of insulin. Insulin in a sample competes with glucose oxidaselabeled insulin for antibody sites on the nylon net.

After a three-minute

incubation, substrate (glucose) is added and the signal from the electrode,
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reflecting the change in oxygen concentration because of the enzyme-catalyzed
reaction, is recorded on a strip chart. After the assay, antigen is dissociated
from antibody by washing with a pH 2.2 glycine buffer, and in about three
minutes the electrode is ready for use again. Analysis of each sample requires
about ten minutes.

The sensitivity of the assay (about 10

JJ

g/ml) is many

times poorer than that of RIA techniques and it is not yet applicable to routine
testing (456).
RADIO RECEPTOR ASSAYS
It became apparent soon after systematic studies of insulin-receptor
interactions were begun that a competitive protein-binding assay for insulin
could be developed based on the same principles as RIA, but utilizing specific
cell receptors for the hormone instead of antibodies.

Such as assay may

possess the sensitivity and precision of RIA while measuring the biologic activity
of the hormone.

This promise has been realized through the development of

insulin radioreceptor assays (RRA) utilizing both particulate (membrane) and
solubilized receptor preparations.
Using a crude guinea pig kidney membrane fraction and 125I-porcine
insulin with separation of membrane-bound from free insulin effected by
Millipore membrane filtration, Suzuki et al. obtained a sensitivity of 10

JJ

U

insulin/ml with an intraassay variation of 8% (CV) and an interassay variation
of 13% (460).

Displacement of tracer from receptors by porcine proinsulin

was 28% that of porcine insulin, while guinea pig insulin exhibited less than
1% of the potency of the porcine hormone in the RRA. Human serum insulin
levels during OGTTs were found to increase from a mean of 19
in fasting subjects to a maximum of 90

JJ

U/ml (n=3)

'llU/ml (n=6) at 60 min., after which
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theY declined to 38 'IJ U/ml at 180 min.

Excellent correlation between RIA

and RRA for serum insulin was found (r=0.952) with a correspondence of
y::0.905x+1.24, where y=serum insulin measured by RIA ( 'IJU/ml) and x=serum
insulin measured by RRA ( 'IJ U/ml).
Ozaki and Kalant developed RRAs for insulin utilizing a membrane
fraction derived from fresh normal human placentas and membrane receptors
solubilized with Triton X-100 detergent (461).

Receptor-bound insulin was

separated from free hormone by centrifugation in the case of the membrane
assay and by adsorption of free insulin to dextran-coated charcoal in the case
of the soluble receptor assay. With the latter assay, these investigators were
able to attain a sensitivity of 0.5 'IJ U insulin/ml, which is understandable since
the affinity of the receptor for i~sulin (K=1.8 x 1010 M-1) is similar to that
of the antibody-hormone interaction using hyperimmune xenogeneic sera. The
intraassay variation was 1.3% and the interassay variation was 10.9%, with an
RIA correspondence of y=0.85x+2.7 (r=0.944), where the parameters are the
same as iterated above. In this assay, proinsulin exhibits 4-5% cross-reactivity
with the soluble receptor; thus, the reactivity of the prohormone in the RRA
approximates its biologic activity.
The RRA may well prove to be the ultimate assay for insulin, combining
the best features of RIA and bioassay, but it is unlikely that it will be adopted
for routine clinical use for the following reasons: 1) The lifetime of a receptor
preparation is several months, compared to several years for an antiserum;
thus, it would be necessary to prepare new receptor fairly often. Even if such
a preparation were made available commercially, each lot may exhibit
significantly different binding properties and require recharacterization of the
assay.

2) Characteristic levels and fluctuations of immunoreactive insulin in
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health and disease have already been determined and have proven more than
adequate for clinical purposes.

3) Serum insulin concentrations determined by

RRA are nearly identical to those found by RIA.
Neither RIA nor RRA can be expected to exert much impact on the
state of ignorance concerning the nature of circulating insulin, however, since
there remains the possibility that the hormone may be bound to a carrier
protein or itself (aggregates), masking both antibody- and receptor-binding
structures. Investigation of serum insulin-like activity, including this possibility,
requires a bioassay with a

sensitivity within the

physiologic

range

of

immunoreactive insulin and the ability to discriminate bet ween "typical" insulin
and other serum factors that mimic the effects of the hormone in the traditional
bioassays.

The use of cells in culture may provide such an assay.

CHAPTER V

INSULIN-LIKE ACTIVITY (ILA)

serum insulin-like activity or "atypical" insulin is distinguished from true
. ,monomeric or "typical" insulin by the fact that, while the former mimics the
latter in one or more assay systems, the two differ in their physicochemical,
: tmmunochemical, and/or particular biological properties.

The properties of

, typical and atypical insulin species discussed in the following sections are
summarized in Table V, at the end of this chapter, to facilitate comparisons that
may enable one to formulate conclusions regarding the nature of serum ILA.

TYPICAL INSULIN

Obviously, before the subject of atypical insulin may be broached, it is
firSt necessary to define what is meant by typical insulin, which is the hormone
possessing the physical, chemical and biologic properties described in previous
ehapters. Reiterating some of the more important of these properties, typical
insulin is the monomeric species of the hormone, exhibiting a molecular weight
between 5,500 and 6,000 daltons and consisting of two polypeptide chains
eovalently joined by two disulfide bonds. It exhibits a sedimentation coefficient
(S2o,w> of 1.2 S, a diffusion coefficient (D 2o,w> of 1.6 x 108 cm 2/sec., and a
frictional ratio (f/fo) of 1.12, indicative of a. nearly spherical molecule. This
llpecies also has an electrophoretic mobility between that of albumin and a 1-
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globulins, is soluble in acid ethanol, forms radially oriented fibrils when heated in
dilute acid solution and rhombohedral crystals in the presence of zinc.
Theoretically, one mole of anti-insulin IgG antibodies will bind two moles
of typical insulin.

Thus, typical insulin will bind 13 times its weight in anti-

insulin IgG. Binding capacity of sera from insulin-resistant humans has been
found to range from about 2 to 200 ).Jg typical insulin/ml (366), corresponding to
25).Jg-2.5 mg anti-insulin IgG/ml, and association constants found for anti-insulin
antibodies and typical insulin range from 10 6 to 1011 M-1 (428,440). Association
of antibodies specific for determinants present on a given antigen and that
antigen will be inhibited most efficiently by compounds structurally most similar
to the antigen.

Therefore, IRI concentrations determined by RIA (using an

antiserum raised against pure typical insulin) relative to a typical insulin
standard will be maximal for typical insulin.
Binding capacity of cellular insulin receptors is 40 to 250,000 molecules
typical insulin (TI) per cell, 0.2 to 18 pmole TI per mg membrane protein, and 0.3
to 7 pmole TI per mg soluble receptor protein. Association constants found for
receptor-TI interactions range from 10 7 to 10 10 M-1• Because this interaction is
dependent upon the integrity of the hormone's receptor-binding site, insulin concentrations determined by radioreceptor assays are directly proportional to
specific biologic activity relative to typical insulin.
Intravenous injection of 125 ).J g typical insulin into a 2 kg rabbit starved
for 24 hours will cause an approximately 50% reduction in blood glucose over a
period of 2-4 hours.

Intravenous injection of 40 ng TI into a 25 g alloxan

diabetic, hypophysectomized mouse will cause a reduction in blood glucose
concentration of about 40 mg/dl after 20 minutes (362). Addition of 100 ).JU (4
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ng) Tl/ml to the medium results in a 50% increase in glycogen synthesis by
isolated rat diaphragm, while a concentration of 5 vg Tl/ml causes a 2-fold
increase (relative to insulin-free medium) in C0 2 production by rat epididymal
fat pads (368). Addition of 10 llU (0.4 ng) Tl/ml medium causes a 4-fold increase
in conversion of glucose to total cell lipids by isolated rat fat cells (145).

INSULIN AGGREGATES

Insulin monomers associate non-covalently in solution to form stable
dimers (2 monomers, M2), which associate to form tetramers (M 4), which may
combine with monomers to produce hexamers (M 6), which may themselves
associate to form larger aggregates (M 6n> (462-465).
Chapter

As previously stated in

m, insulin crystals consist of hexamers.

Insulin aggregation is dependent upon insulin concentration, pH, ionic
strength and (for M ~ 6 ) divalent cation concentration. The change in weight
fraction of various aggregates with increasing insulin concentration at pH 2.0,
25° C and ionic strength 0.1 is depicted in Figure 12. Under these conditions,
disaggregation occurs below 0.1% insulin (<1 mg/ml) and the fraction of dimer
attains a maximum between 0.1% and 0.25% insulin, declining thereafter
concomitantly with a steady increase in the fractions of tetramer and hexamer.
At neutral pH the average weight of zinc-free insulin ranges from the dimer to
well above that of the hexamer in the concentration range 0.1-1.0% (466-468).
Holladay et al. (469) found that, for zinc-free insulin at pH 7.4, 20° C and ionic
strength 0.368, the proportion of insulin molecules that exist as dimers follows
the pattern of Fig. 12, attaining a maximum of 32% between 0.05 and 0.8 mg
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FIGURE 12.
INSULIN

APPARENT WEIGHT-AVERAGE MOLECULAR WEIGHT OF
AS

A

FUNCTION

OF

CONCENTRATION; pH 2, IONIC

STRENGTH 0.1. EACH SET OF SYMBOLS REFERS TO A PARTICULAR
EXPERIMENT.

THE SOLID LINE IS

CALCULATED FROM THE

EQUILffiRIUM CONSTANTS ASSUMING NO CHARGE EFFECTS AND
IDEALITY; THE DASHED LINE IS CALCULATED ACCOUNTING FOR
CHARGE EFFECTS. TOP: T

=15°C; BOTTOM: T =25°C.

(Reproduced, with permission, from Ref. 462. Copyright 1966 by the American
Chemical Society.)
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insulin/mi.
Insulin exists in the dim eric form below pH 3 at a concentration of 1% in

o.l M sodium

chloride, while the hormone is dissociated to monomers below pH 3

at a concentration of 0.25% in 0.1 N sodium monophosphate (NaH 2P0 4);
dissociation of the dimer also occurs in sodium chloride at pH 2.0-2.7 below 0.1%
insulin concentration (464). Moderately dilute solutions (0.1-o.25%) of zinc-free
insulin dissociate
(466,467 ,470).

to the

monomers upon increasing the pH to 9.1-9.5

The role of increasing ionic strength promoting aggregation

appears to lie in its effect on the net charge per monomer (number of protons
bound less the number of counterions bound)(470).

For a given degree of

association of insulin molecules, the net proton charge (Z) has been found to
remain the same (e.g_. 2.5/monomer at 20,000 daltons) regardless of pH between
2.7 and 4.0, suggesting that the molecular weight of insulin in acidic media is a
simple function of net charge and, indeed, the average molecular weight has
been found to be a linear function of net charge over the range 7,000 daltons (Z

=

4.1/monomer) to 25,000 daltons (Z = 1.8/monomer)(470). The anion-dependence
of insulin association in acidic media (CNS- > I -

> N0

3- > Br- > Cl- > H2PO 41

therefore reflects the ability of these species to serve as counterions in acidic
media; ~·.K· the dissociation of the dimer in the presence of H2Po 4- at pH 2 can
be attributed to the poor ability of H2PO 4- to act as a counterion at this pH,

where the charge on the monomer approaches 5 proton units (471). A similar
inverse relation between net monomer charge and insulin aggregation has also
been found in alkaline media (470), implying repulsion of similarly charged
molecules. Thus, the proportion of dimers increases with decreasing pH, insulin
concentration and ionic strength.
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The effect of divalent cations in promoting aggregation of insulin beyond
the tetramer stage is striking, as illustrated in Figure 13. Zinc is the only metal

found in crystalline insulin prepared in the absence of external metal sources,
but rhombohedral crystals also form in the presence of Cd++ , Co++ , or Ni++ ,
with 3 atoms of metal found per hexamer (464). Cu++ , Mn++ and Fe++ can also
facilitate formation of rhombohedral insulin crystals, which requires a minimum
of 2 metal atoms per hexamer (153, 473), while metal-free insulin crystallizes in
orthorhombic form (474). The first 2 zinc atoms taken up in the formation of the
hexamer appear tightly bound, but insulin-both in solution and in crystalline
form-is capable of binding more loosely at least an additional 7 zinc atoms per
hexamer (464).
Insulin does not bind zinc (or other metals) below pH 3.5 (464) and the low
incidence of hexamer in acid solution is about the same as for metal-free insulin
in neutral solution (compare Figs. 12 and 13). Insulin binds zinc continuously
with increasing pH above 4.5 to at least an additional 7 atoms per hexamer at pH
8.0 (466,475). At neutral and moderately alkaline pH, the proportion of hexamers increases with increasing zinc content from a few hundredths of a percent
of zinc to about 0.35%, or 2 atoms per hexamer, where the population of
hexamers is predominant when the insulin concentration is greater than 0.1
mg/ml (466, 470, 472, 473). Above 2 atoms zinc per hexamer, a 72,000 dalton
unit occurs and with further increases above 6 atoms per hexamer, a polydisperse
distribution in the range of 200,000-300,000 daltons predominates.

With

increases of pH above 8.0 dissociation again becomes predominant even in the
presence of high zinc content (3-6 atoms per hexamer); under these conditions a
minimum molecular weight of 36,000 is again obtained in the pH range 9-10
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FIGURE 13. A COMPARISON OF THE WEIGHT-FRA<;:TIONS OF MONOMER (a)
AND HEXAMER (b) AS A FUNCfiON OF TOTAL WEIGHT
CONCENTRATION FOR THE ZINC-FREE INSULIN (
) AND
ZINC-INSULIN (- - - - - -) SYSTE!\1S IN TRIS-HCI!NaCI BUFFER AT pH
7 .0, IONIC STRENGTH 0.2 AND 25°C.

=

(Reproduced, with permission, from Ref. 472.
Biomedical Press.)
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(470).
Although the degree of insulin aggregation in blood is unknown, study of
the

hormone's self-association behavior under various conditions strongly

suggests a marked predominance of the monomer at physiologic insulin
concentrations (0.1-3 ng/ml)(476).

Calculations of insulin aggregate con-

centrations at pH 8.0, 25°C, ionic strength 0.1 and an insulin concentration of
10-8M, in the presence of mammalian serum concentrations of Zn++ (1.5-3.7 x
10-SM), based on known insulin association constants, yield values no greater
than

to-26 M for the 2-Zn++ hexamer, to-13 M for the 2-Zn++ tetramer and 2.1 x

10-llM for the dimer (464).
The

physicochemical

properties

of

insulin

aggregates,

including

association constants and molecular weight, are summarized in Tables IV and V.
The considerable enhancement of tetramer and hexamer formation in the
presence of zinc is due to the affinity of sites on the insulin molecule for
divalent metal ions. Two orders of affinities for the first 2 zinc ions bound and
additional zinc binding are confirmed by equilibrium dialysis experiments at pH
8.0, at which maximum zinc binding occurs. This method yields an association
constant of 2 x 105M-1-s x 106M-1 for each of the first 2 zn++ bound and K =7 x
10 3M-1-3.5 x 10 4 M-1 for each subsequent Zn ++ bound, with 10-12 insulin binding
sites per hexamer available for the weaker associations (464, 477).
The fact that agents known to disrupt hydrophobic interactions, such as
guanidine hydrochloride, urea, detergents, dimethylformamide, trifiuoroacetic
acid/ether, pyridine, dioxane, and butanol/dichloroacetic acid, induce dissociation of insulin aggregates (464) indicates that such interactions play an
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TABLE IV. SELF-ASSOCIATION OF INSULIN
Species
Formed

Process

pH

Kassoc.

Dimer

2M

~D

2.0

8x10 3M-1
1.02x10 4

- t. G
(kcal/
mole)

Comments

Ref.

462
5.2

f.!

= 0.1

463

M-1
7.0
7.4

1.1x10 5 M-1
2x10 5 M-1
2.2x10 4 M-1

Zinc-Free
Tetra mer

Zinc
Tetra mer

476
478
5.8

469

8.0

2x10 5 M-1

2.0
7.0

7.8x10 2 M-1
l.7x10 4 M-1

7.4

1o29M-s

D+T :!H

2.0

6.7x10 2 M-1

3D :!H

2.0
7.4

5.3x10 9 M-2
8.6x10 9 M-2

8.0

2.0x10 9 M-2

6M+2Zn++
:!HZn2

7.4

1o32M-7

464

2H :!H 2

7.0

5x10 3 M-1

476

M
D
T
H

monomer
dimer
tetra mer
hexamer
ionic strength
net charge

2D .tT

4M+2 Zn++

479
f.!

= 0.1

463
476
464

:!TZn 2
Zinc-Free
Hexamer

Zinc
Hexamer
Polyhexamer
Abbreviations:

ll

z

= 0.1

463

z = +5.0

464

f.!

13.3

469

z = -3.2

464
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important role in the hormone's self-association. This supposition is verified by
study of the molecule's tertiary structure based on x-ray diffraction analysis of
the insulin crystal, which several lines of evidence indicate is essentially the
same as the insulin dimer and zinc hexamer in solution (464).

This x-ray

diffraction analysis reveals that regions of contacts among insulin molecules are
largely composed of nonpolar residues. As mentioned in Chapter III, the insulin
monomer exhibits two faces-one involved in dimer formation and the other in
dimer-dimer associations-each containing a number of surface apolar residues
with their side-chains contacting solvent in the dissociated state.
In the dimer, about 36 of 111 short atomic separations between the

monomeric association faces involve the side chains of 10 nonpolar residues, the
B12 valine, B16 and B26 tyrosines, and B24 and B25 phenylalanines of each
molecule. In addition, Bll leucine, although not involved in short intermolecular
separations, also forms part of the nonpolar core of the dimer (464). A twofold
relationship between the molecules of the dimer means that the C-terminal
residues of the B-chains run anti-parallel to each other, making possible the
formation of an anti-parallel a-pleated sheet structure involving the B21-B30
residues and containing 4 hydrogen bonds between the monomers.

These

hydrogen bonds, between the backbone amido and carbonyl functions of the B24
and B25 phenylalanines and B26 tyrosine of each molecule, serve to stabilize the
dimer in aqueous solution after formation due to hydrophobic interactions. In
fact, all monomer-monomer contacts involve B-chain residues that contribute
to a-helical and S-pleated sheet structures (143). The dimer constructed from
0

x-ray diffraction analysis has an oval appearance and is about 40 A from end to

• across (143).
end and 25 A
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Of the 99 short intermolecular separations between dimers, about 39
involve the nonpolar side chains of B1 phenylalanine, B14 valine, A 14 tyrosine
and the A13, B6 and B17 leucines (464); B18 valine may also be involved in
hydrophobic interactions as well as the other a-helical residues, B14 and B17
(143). Dimer-dimer interactions are also stabilized by hydrogen bonds, between
the B1 a-amino and A17 glutamate )'"'Carboxy functions and between the A14
tyrosyl phenolic hydroxyl groups across the surface of the molecules (143,464).
0

The 2 tightly bound zinc ions in the hexamer lie on the threefold axis, about 18 A
apart, each coordinated to the N3 imidazole nitrogens of 3 B10 histidines. The
coordination of each Zn++ is completed by water molecules and is apparently
intermediate between octahedral and trigonal prismatic (143). The 7 remaining,
weaker metal-binding sites probably involve the B13 and A17 glutamyl
carboxy and the B1 a-amino functions (464).

y -

Recently, Sudmeier et al. (480)

offered evidence from Cd-113 nuclear magnetic resonance studies that the 6 B13
glutamyl y-carboxy functions normally form a specific Ca++ -binding site in the
center of the 2-Zn++ hexamer. The threefold axis, consisting of B9 serine, B10
histidine and B13 glutamate residues connected by an elaborate water structure,
constitutes a hydrophilic core in the center of the hexamer, which has the shape
0

0

of a flattened disc about 50 A across and 35 A high with prominent channels
lined with solvent molecules running between the dimers from the central zinc
ions to the edge of the molecule (143).
Conclusions regarding roles played by specific residues in dimer-dimer
interactions based on x-ray diffraction analysis tend to be supported by study of
the aggregative properties of rat insulins. Rat insulins I and D both differ from
porcine insulin in substitutions at A4 {glu

~

asp) and B3

(asn~

lys), while rat
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insulin I contains a further substitution at B9 (ser -+pro) and rat insulin n ~t B29
(lys -+met).

Yet rat insulin I forms hexamers less easily than rat insulin

n,

reflecting the importance to hexamer formation of the B9-B19 a-helix and BlO
histidine conformation,

which would

be affected by a nonconservative

substitution at B9 (481).
The equatorial surface of the hexamer is smooth, but the top and bottom
surfaces are broken by projections from residues of the AS-All loop regions on
each surface.

Between these projections large pockets about 10 •A across

result. In the crystal these are partially filled by the A-chain loop regions from
molecules above and below the hexamer in the direction of the 3-fold axis. The
segregation of polar and nonpolar

r~sidues

is more clearly defined in the hexamer

than in any of the subunits: the surface is largely covered with polar side chains;
even the surface pockets and channels are lined with groups such as the B5
histidine, B9 serine, B13 glutamate, and the hydroxyl functions of both B-chain
tyrosine residues. The apolar residues exposed at the surface of the hexamerthe A14 tyrosines, B25 phenylalanines and A10 isoleucines-are utilized in
interhexamer contacts in the crystal and probably in solution, where hexamer
associations occur at relatively high hexamer concentration.

Interhexamer

contacts are formed between the A14 tyrosine and A15 glutamine residues and
between the A18 asparagine and B25 phenylalanine residues. Besides filling of
the large hexamer pockets by AS-All loops, two B5 histidine residues from
adjacent hexamers come into close contact (4S4). The importance of B29 lysine
to the association of hexamers is illustrated by rat insulin

n,

which possesses a

methionine at this position and which forms cubic instead of rhombo-hedral
crystals in the 2-Zn++ form (481).
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Assessment of insulin aggregate behavior in established assay systems is
precluded by the inability 1) to deliver solutions of lmown aggregate composition
to tissues {due to probable dissociation in serum) in in vivo systems and 2) to
obtain meaningful results in in vitro systems using the high concentrations of
insulin at which significant proportions of aggregates occur.

Thus, it is

necessary to infer the insulin-like activity of aggregates in bioassays and
immunoassays from lmowledge of the hormone's tertiary structure and from the
effects of substituent alterations.
Of the residues implicated in the dimerization face, B25 phenylalanine is
known to be involved in the receptor binding site and the B30 residue may affect
insulin immunoreactivity, while the A14 tyrosines, which make contact in dimerdimer

interactions,

alteration

are

important

of the A14 tyrosine

immunodeterminants. Since

chemical

leads to a 96% reduction in insulin

immunoreactivity {see Table 1), it is expected that the insulin-like activity of the
hexamer in immunoassays would be attenuated accordingly.

A more precise

estimate of aggregate activity in assay systems relative to monomeric insulin is
provided by studies involving FITC-insulin conjugates. Mono-FITC insulin, which
forms hexamers as well as native insulin, retains about 50% biologic activity
{mouse convulsion assay) and 24-56% immunoreactivity {immune hemolysis
inhibition); di-FITC insulin, which forms only monomers and dimers, possesses 4%
biologic activity and 3.3-31% immunoreactivity; tri-FITC insulin, which exists
only as monomers, exhibits no detectable biologic activity and 0.001-3.8%
immunoreactivity {136). Thus, net values are bioactivity

=8%, IRI =14-55% for

di-FITC insulin and bioactivity =0%, IRI =0.2-6.8% for tri-FITC insulin.
Furthermore, desoctapeptide {DOP; lacking B23-B30 residues, involved in
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the wleated sheet structure of the dimer) and guinea pig insulins do not form
aggregates; DOP insulin possesses 0-15% biologic activity and 0.08-11%
immunoreactivity relative to native monomeric bovine and porcine insulins,
while the corresponding values found for guinea pig insulin are 10% biologic
activity and 0.001% immunoreactivity (136,138, 18, 217). Also, insulin dimers do
not exhibit negative cooperativity, the site for which is situated in the receptorbinding region of the monomer (217). Thus, insulin aggregates should be virtually
undetectable by existing bioassays and immunoassays for insulin.

Certainly,

superhexameric aggregates are undetectable by these assays, since the A5
glutamines, A19 tyrosines, A21 asparagines, and B25 phenylalanines, residues
important to insulin biologic and immunologic activity that are exposed at the
hexamer surface, are covered by interhexameric contacts.

INSULIN PRECURSORS

Pro insulin
In 1965, Givol et al. (482) proposed the use of disulfide interchange

enzyme as a probe for the thermodynamically most stable form of proteins.
They based this proposition on their observation that treatment of oxidized
native bovine pancreatic ribonuclease and chymotrypsinogen A with the enzyme
and a thiol, such as s-mercaptoethanol ( s-ME), did not significantly alter the
activity of the proteins (the latter measured after conversion to a-chymotrypsin
with trypsin), while their tryptic digestion products, the three-chain "C-protein"
derivative of RNase and a-chymotrypsin, rapidly lost activity under the same
circumstances. The authors concluded that the primary structure of "stable"
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single-chain protein precursors dictates a tertiary structure in which

cy~teine

residues are properly apposed to form the disulfide bonds of their products.
ObServing that treatment of insulin with disulfide interchange enzyme and 13-ME
results in chain separation and loss of immunoreactivity, they postulated that the
hormone exists in a metastable state, which is the product of a "zymogen-like"
conversion of a stable single-chain precursor.
Within two years, Steiner and coworkers had reported the isolation of such
a precursor from tumors of human islets of Langerhans and normal isolated rat
islets (483,484). When slices of human islet cell adenoma were incubated with
3H-L-leucine or 3H-L-phenylalanine, the acid-ethanol extractable material
precipitated with ethanol-ether (see specific isolation procedures, below) yielded
3 radioactive fractions upon Sephadex G-50 chromatography with 1 M acetic
acid.

The first, designated peak a, eluted with a large protein peak at the

column exclusion volume. The third, peak c, eluted with a smaller protein peak
and was identified as insulin.

The second, "peak b", eluted at a position

corresponding to a protein of molecular weight 10,800 daltons and possessed
insulin immunoreactivity (determined as insulin-displacable anti-insulin globulin
binding).

Tryptic digestion of peak b material yielded a radioactive fraction

eluting with porcine insulin and another, lower molecular weight, radioactive
peak that was not seen following tryptic digestion of radiolabeled insulin.
Column chromatography of peak b after sulfitolysis (which dissociates insulin A
and B chains) revealed no generation of insulin chains or apparent change in
molecular weight.

Neither was insulin released from peak b material by

extremes of pH, high ionic strength, 50% acetic acid, nor 8M urea (483).
Incubation of tumor slices with 3H-L-leucine resulted in the appearance
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on G-50 chromatography only of radioactive peaks a and b after 40 minutes, with
the appearance and progressive increase in radioactive peak c after 80 minutes.
When isolated rat islets were pulsed with 3H-L-leucine for 40 minutes, about
'lO% of peak b radioactivity had shifted to peak c 140 minutes after a non-

radioactive leucine chase was begun, even in the presence of cyclohexamide, an
inhibitor of protein synthesis.

The investigators concluded that peak b

represents an insulin precursor that is converted to the hormone by a proteolytic
process in the

S~ell

with a half-life of about 1 hour, and termed the precursor

protein proinsulin (484,485).
The following year, Roth et al. (486) reported the discovery of a serum
component that possesses insulin immunoreactivity, but elutes ahead of normal
or "little" insulin on Sephadex G-50 columns. They found that this "big insulin"
accounted for as much as 50% of total insulin immunoreactivity in normal human
serum, in which the two species apparently are not easily interconvertible, since
rechromatography of each fraction did not yield significant amounts of the other
and addition of large quantities of pancreatic insulin to serum did not result in
the recovery of increased amounts of "big insulin".

These investigators

demonstrated that the pancreas was the source of ''big" as well as "little" insulin
by infusing a dog with glucose and collecting blood from the pancreatic vein and
the femoral artery.

At 10 minutes and 25 minutes after completion of the

glucose infusion, pancreatic venous plasma had a more than 50-fold greater IRI
concentration than did arterial plasma.

At both times the concentrations of

"little" and of "big" insulin were distinctly higher in the pancreatic effluent than
in the peripheral arterial plasma.
At about the same time, Steiner and coworkers demonstrated the
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presence of proinsulin in human serum and urine by G-50 chromatography and
RJAs for proinsulin and insulin (487). They observed that serum proinsulin, when
tmmunoassayed in serial dilutions, showed immunologic identity with a standard
of pancreatic human proinsulin and they provided evidence that the lower
molecular weight product of proteolytic proinsulin conversion, known as
connecting peptide (C-peptide), is secreted with insulin from the 13-cell in
equimolar amounts (485).

They found that, in a patient with an islet cell

adenoma, the molar fraction of proinsulin in acid ethanol-extractable material
reacting with anti-insulin serum was 52% for the tumor and 77% for fasting
serum; the proinsulin fraction in serum did not exceed 10% after removal of the
tumor (485). Berson and Yalow's group verified that high proportions of serum
"big insulin" are largely limited to persons with insulinomas when they reported
that, while "big insulin" comprised 24-55% serum IRI in such individuals, this
fraction accounted for less than 20% serum IRI in 32 subjects without tumors,
including obese normals, diabetics and myotonic dystrophy patients, and did not
exceed 10% in 32 of 59 serum samples collected from these persons under
diverse circumstances (488).
Finally, Roth and coworkers (489) demonstrated that "big insulin" is
indeed circulating proinsulin as follows: 1) when human "big insulin", isolated
from plasma by G-50 chromatography, was mixed with 1251-porcine proinsulin
and rechromatographed, the peaks of immunoreactivity and radioactivity were
coincident; 2) when plasma was extracted by a method used for the isolation of
insulin and proinsulin from pancreas, the location and relative proportions of
"big" and "little" insulins upon G-50 chromatography were the same as those
obtained by chromatography of whole plasma;

3) 90% of "big insulin" was
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converted to "little insulin" by treatment with 20-200
trypsinization of human "big insulin" mixed with

125

l.l

g trypsin;

4)

I~orcine proinsulin resulted

in >90% conversion of both to "little insulin"; and 5) guinea pig anti~orcine

proinsulin serum absorbed with porcine insulin bound both porcine proinsulin and
human "big insulin", but not porcine insulin and human "little insulin".
Steiner's recommended procedure for isolation of proinsulin from
insulinoma tumor tissue is based on Davoren's insulin extraction method (108).
About 170 mg tissue is homogenized with 2.2 ml acid ethanol (375 ml 95%
ethanol + 7.5 ml cone. HCl) + 0.8 ml water. After 6 hours at 4°C, the supernate
is decanted and 0.7 ml acid ethanol + 0.3 ml water is added to the precipitate.
After 6 hours at 4°C, the second supernate is combined with the first, which are
then clarified by centrifugation, adjusted to pH 8.3 with 6N NH 40H, allowed to
stand 15 minutes at 4°C, again clarified by centrifugation and adjusted to pH 5.3
with 4N HCl.

After addition of 0.025 ml 2M ammonium acetate per ml acid

ethanol extract, insulin and proinsulin are precipitated with 3 volumes absolute
ethanol + 5 volumes ethyl ether for 12 hours at 4°C. The suspension is then
centrifuged at 4°C; the precipitate is dried and dissolved in 1-2 ml 3M acetic
acid, followed by chromatography on a 1 x 50 em Bio-Gel P-30 column in the
same solvent (485, 490).
Islets of Langerhans are isolated from rat pancreas by digesting the
minced tissue with collagenase and are extracted by homogenization in acid
ethanol.

The supernate is adjusted to pH 8 with 6M NH 40H, clarified by

centrifugation and adjusted to pH 5.3 with 6M HCl; 2 drops 2M ammonium
acetate, pH 5.3, per ml extract are added, followed by 2 volumes ethanol + 4
volumes ethyl ether. The remainder of the isolation procedure is the same as
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that employed for tumor tissue (490).
Proinsulin and various two-chain intermediate forms are most readily
purified from commercial preparations of crystalline insulin with which they
eocrystallize during preparation of the insulin; precursors represent 2-6% of this
material, whereas they represent only about 0.0005% by weight of whole
pancreas (453, 490). A crude precursor fraction is obtained by chromatography
of the first crystals of bovine insulin on G-50 with 1M acetic acid or on P-30
with

3M

acetic

acid.

This

fraction

is

then

chromatographed

on

carboxymethylcellulose (CM-cellulose) with 0.01M sodium citrate, 7M urea, pH
5.5, yielding the two proinsulin intermediates des arg 31 ,arg 32 proinsulin and des
lys59 ,arg 60 proinsulin. Further elu}ion of the column with 0.2M NaCl in starting
buffer yields proinsulin and the insulin dimer, which are separated by DEAEcellulose chromatography utilizing a 400 ml linear gradient of o-o.2M NaCl in
0.02M Tris-HCl, 7M urea, pH 7.6 (490).
Chance (141) has isolated proinsulin and its intermediates from crystals of
porcine insulin by a single chromatographic procedure on a 5 x 140 em column of
DEAE-cellulose utilizing a 12-liter gradient of O-G.09M NaCl in 0.01M Tris-HCl,
0.001M EDTA, 7M urea, pH 8.1.

This procedure resulted in the isolation of

proinsulin, des lys 62 ,arg 63 proinsulin, proinsulin split between residues leu 54 and
ala55' desnonapeptide proinsulin (lacking residues 55-63), arginyl insulin (+
arg31), 'and diarginyl insulin (+ arg 31 ,arg 32 > (See discussion of proinsulin
structure, below).

Further purification of some of these fractions could be

achieved by a subsequent step of gel filtration. The two rat proinsulins have
been isolated from crystals of rat insulin using gel filtration, ion-exchange
chromatography and preparative gel electrophoresis at pH 4.4 (111, 491). Similar

166

techniques have also been applied to the isolation of small amounts of pro~nsulin
from the cod (492) and the angler fish (493). Aliquots of human serum (2-10 ml)
are diluted with 2 volumes water and extracted with 7.5 ml acid ethanol per ml
serum before purification and separation of IRI components as outlined for
insulinoma tissue (490).
The molecular weight of proinsulin has been found by gel filtration to be
8,000-9,000 daltons (486-487). Based on the amino acid composition of human
proinsulin (461), the molecular weight of this species is 9,430 daltons.
Aggregation with increasing concentration at pH 7, equilibrium constants of selfassociation at acid and neutral pH, and Zn++ -binding properties of proinsulin are
the

same

as

insulin

under

cprresponding

circumstances

(452).

The

physicochemical properties of proinsulin are summarized in Table V.
An important early indication that proinsulin is a single-chain precursor of
insulin was Steiner's demonstration of N-terminal phenylalanine in peak b
material (483). It may be seen from the primary structure of porcine proinsulin,
pictured in Figure 14, that the entire insulin B-chain makes up the N-terminal
portion of proinsulin, followed by a 29-amino acid C-peptide segment, and that
the entire insulin A-chain comprises the carboxy end of the molecule. The Cpeptide is connected to the insulin segments by two basic dipeptides that are
readily removed by proteases with tryptic specificity. C-peptide lacks aromatic
residues and cysteine, is largely composed of amino acids that can confer
additional solubility on the molecule, and exhibits a high degree of variability in
amino acid composition .among species (Fig. 15). More than half the C-peptide
residues are variant among human, bovine and porcine proinsulins and only 5
amino acids-which may be important to proper protein folding--are invariant
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FIGURE 14. AMINO ACID SEQUENCE OF PORCINE PROINSULIN.

(Reproduced, with permission from the American Diabetes Association, Inc.,
from Ref. 453. Copyright 1972 by the American Diabetes Association, Inc.)
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FIGURE 15. THE C-PEPTIDE IN INSULINS OF VARIOUS SPECIES. INVARIANT
RESIDUES ARE INDICATED BY BOLD TYPE, DELETIONS BY DASHES. ·
(Reproduced, with permission, from Ref. 104. Copyright 1975 by Ellis Horwood,
Ltd.)
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among the mammalian species studied thus far. The two basic

dipeptid~s

are

alsO invariant, reflecting the importance of enzymic cleavage by proteases with
tryptic specificity.
Evidence for the existence in the a-cell of additional enzymes with
carboxypeptidase B (CPB) and perhaps chymotrypsin specificities comes from
identification of bovine and porcine proinsulin intermediates isolated from
crystalline insulins (453).

Proinsulin intermediates lacking either dipeptide

(arg 31 -arg3 2 or lys 62 -arg 63 in porcine proinsulin) and monoarginine insulin (arg 31
attached to ala 30 of the B chain), as well as insulin itself, suggest the action of
enzymes with trypsin and CPB specificities. Diarginine insulin (+ arg3 1-arg32),
porcine split proinsulin (leu 54-ala 55 bond cleaved), and porcine desnonapeptide
proinsulin (lacks sequence 55-63) suggest the action of enzymes with trypsin,
chymotrypsin, and both trypsin and chymotrypsin specificities, respectively.
As mentioned previously, the fact that native insulin was recovered in
poor yield after reformation of reduced disulfide bonds served as evidence that
insulin is formed from a single-chain precursor protein in which the native
hormone exists as the thermodynamically most stable conformation. Soon after
its discovery, it was noted, in fact, that proinsulin reoxidizes in high yield after
complete reduction by mercaptoethanol in urea (454). Furthermore, CD studies
indicate that the conformation of insulin in proinsulin, as well as in split
proinsulin and desnonapeptide proinsulin, is the same as in free insulin (452).
Thus, it has been concluded that the main function of the C~eptide is to direct,
interact and hold the A and B chains in a conformation favorable for correct and
efficient pairing of cysteinyl residues (461).
The fact that both proinsulin and split proinsulin possess no more than
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one-third the biologic activity of desdipeptide proinsulin, desnonapeptide
proinsulin and mono- and diarginine insulins (in which the A1 glycine is exposed),
which exhibit nearly as great an activity as free insulin (Table V), serves as
additional evidence that the a-amino group of the A1 glycine is an important
part of the insulin active site (452). Cross-reaction of anti-insulin antibodies
with proinsulin is highly variable, with 25-75% immunoreactivity compared to
insulin being observed in early work (485, 488). When antibodies are generated
against the proinsulin or

C~eptide

of a given species, they exhibit little or no

cross-reactivity with proinsulins and

C~eptides

from other species. Antigenic

determinants have been implicated within the 33-54 segment, a requirement for
leu 54 has been demonstrated, and the probable major antigenic determinant has
been identified as the 41-54 sequence, which is an unusually hydrophobic region
and also one of considerable variability among species, explaining the lack of
cross-reactivity (461).

The increase in IRI with anti-insulin serum following

cleavage of the arg-A1 gly bond (Table V) also supports the contention that the
C-peptide covers important insulin immunodeterminants, especially the A19
tyrosine.

Proinsulin Precursors
In 1973, Yalow and Berson (494) reported the discovery of a high

molecular weight insulin precursor in plasma samples from an insulinoma
suspect.

When the plasma was chromatographed on G-50 with 0.02M veronal

buffer, pH 8.6, 45-100% of the IRI eluted in the exclusion volume. This material,
designated "big, big" insulin", behaved similarly to

y -globulin

in gel

chromatography and exhibited a sedimentation velocity between y -globulin and
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albumin in ultracentrifugation, indicating a molecular weight of 100,000-1.50,000
daltons. "Big, big" insulin has about one-half the mobility toward the anode of
porcine or crystalline human insulin on starch gel electrophoresis and exhibits
about one-third the mobility of crystalline human insulin on starch block
electrophoresis, indicating that it is more basic than insulin.

This protein

exhibited complete cross-t'eactivity with insulin for guinea pig anti-insulin
antibody binding sites and was more than 80% convertible to insulin by trypsin
treatment. These investigators found that "big, big insulin" comprised 0.7-1.0%
of the IRI extracted from human insulinoma and normal pancreatic tissue with
acid ethanol and subjected to G-50 chromatography under the same conditions as
the plasma samples.
Identification, isolation and study of the human insulin gene and its
messenger RNA (mRNA) product have revealed the true proinsulin precursor,
termed preproinsulin, to be proinsulin with an additional 24-amino acid Nterminal extension, which serves as a signal peptide to direct the molecule to the
secretory machinery of the f3 -cell (495).

The molecular weight of human

preproinsulin, based on its 110-amino acid sequence, is 11,981 daltons.
Therefore, "big, big insulin" cannot be a proinsulin precursor and most likely
represents an aggregate form of proinsulin, since Yalow and Berson carried out
their G-50 chromatography at pH 8.6 and they did not detect IRI where
proinsulin would be expected to elute (494).
The 330-nucleotide sequence for preproinsulin is completely contained
within the human insulin gene, but in a discontinuous fashion.

The mRNA

sequence consists of 465 nucleotides, the first 59 and last 76 of which are
untranslated, completely contained within a 1,431-nucleotide precursor (nuclear)
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RNA sequence, which represents the immediate transcription product of the
insulin gene. In the insulin gene, the mRNA sequence is interrupted after the
42nd nucleotide by the first of two intervening sequences, which consists of 179
nucleotides.

The second intervening sequence, comprising 787 nucleotides,

begins after the 246th mRNA nucleotide, which is the first nucleotide coding for
the va163 of preproinsulin.

The complete insulin gene consists of 1,726

nucleotides, the first 260 of which comprise a "cap site" and the last 35 of which
comprise a termination site, both untranscribed (495).

Insulin Biosynthesis
The present understanding ()f insulin synthesis in the pancreatic s-cell is
as follows:
1.

The insulin gene is transcribed into a precursor RNA that is clipped and

spliced in the nucleus to yield a messenger RNA (495, 496).
2.

The messenger RNA (mRNA) is translocated to the rough endoplasmic

reticulum (RER), which is contiguous with the nuclear membrane. There, the
central portion of the mRNA is translated by polyribosomes into preproinsulin
(495-497).
3. The amino-terminal "signal peptide" of preproinsulin enables the molecule to
be secreted into the cisternae of the RER and directed in an energy-requiring

step to the Golgi apparatus. The signal peptide is removed from preproinsulin
very soon after its synthesis; in the rat, conversion of preproinsulin to proinsulin
proceeds with a half time of about 1 minute (495-497).
4. By the time proinsulin is packaged into vescicles in the Golgi apparatus, the
molecule has folded into its proper conformation and disulfide bonds have been
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formed.

The vescicles, which contain immobilized on their inner membrane

surfaces proteases with the specificities of trypsin, carboxypeptidase B and
chymotrypsin, bud off from the Golgi apparatus (496, 497).

s.

As the vescicles traverse the cytoplasm, the proteases convert proinsulin to

insulin through split proinsulin and arginyl insulin intermediates. The newly
formed insulin condenses into hexameric crystals, receding from the edge of the
vescicles and terminating the enzymic reactions before the hormone can be
degraded to its desalanine and desoctapeptide forms (104, 496, 497).
6. At the S-cell periphery, mature vescicles, termed secretory granules, fuse
with the plasma membrane and release their contents-equimolar quantities of
insulin

and

C-peptide

and

so~e

unreacted

proinsulin-into

the

lumen

(emiocytosis), from whence they are transported into the systemic circulation
(104, 485, 498).

Insulin synthesis-from preproinsulin to mature secretory granulesrequires about one hour (497). An increase in the extracellular concentration of
glucose-the most important signal for insulin secretion from

S-cells-

stimulates this process at both translational and emiocytotic levels, independent
of cAMP (497 ,499,500).

Glucose stimulation of insulin release, but not

biosynthesis, is Ca++-dependent (497). Insulin secretion and biosynthesis can be
stimulated further in the presence of glucose through activation of the &-cell
adenylate cyclase system by glucagon and S-adrenergic agonists (497).
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"BOUND INSULIN"

The phenomenon of "atypical" insulin-like activity (ILA) was recognized
with the development of bioassays sufficiently sensitive to measure insulin in
serum or plasma.

Using both in vivo and in vitro assays, Beigelman and

coworkers detected ILA in f3.-globulin fractions prepared from human peripheral
venous serum by fractional precipitation and paper electrophoresis {501-504).
The ILA was measured by blood glucose decrement in alloxan-diabetic
hypophysectomized {ADH) mice and stimulation of glucose uptake in rat
epididymal fat pads. Randle and Taylor demonstrated anti-insulin serum {AIS)neutralizable ILA in these serum fractions by stimulation of glucose uptake and
glycogen synthesis in isolated rat diaphragm (505-507).

That the s-globulin

form of ILA may be a transport form of insulin was suggested by the observation
that in two samples of plasma from portal venous blood most of the ILA was in
the albumin- a 1 globulin fraction (116), an observation indicating that insulin
may be secreted in the free form by the pancreas and become incorporated
elsewhere into the 8-globulin fraction.
Beigelman et al. found that Cohn Fractions IT + lll and

m-o,

and the

Plasma Globulin Precipitate fraction (PGP) obtained by zinc precipitation from
blood plasma collected in acid-citrate-dextrose solution (ACD), possessed ILA
measured in vivo (ADH rats), but that identical plasma fractions obtained from
blood collected not in ACD, but through cationic exchange resin were devoid of
ILA (501,502). Antoniades and coworkers found that when human whole blood or
serum was passed through Dowex 50 x 8 or 50 x 2 or IRC 50 cation exchange
resins, while typical insulin was not retained by the resin, a considerable quantity
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of ILA was retained and eluted from the resin by acid (0.1N H2so 4, 0.1N HCl or
0•2M citrate, pH 2-3) or alkali (0.1 or l.ON NH 40H, pH 10.5-11) (247 ,508-510).
This ILA, which Antoniades designated "bound insulin" (BI), was measured by
induction of hypoglycemia in ADH rats (508, 509) and stimulation of 14co 2
production from glucose-1-14 c by rat epididymal adipose tissue (509, 511); BI
ILA in the fat pad was abolished by 20-40 mM reduced glutathione (511).
Furthermore, this ILA was found to stimulate incorporation of uniformly labeled
glucose carbon into muscle and adipose tissue glycogen and into fat of adipose
tissue in intact rats (512) and into fat and glycogen of isolated rat epididymal
adipose tissue (511).

BI was observed to migrate in electrophoresis with a

mobility similar to B-and y-globulins, to possess a molecular weight between
60,000 and 100,000 daltons by Sephadex gel chromatography, and to precipitate
with Cohn Fractions D + ID and

m-o

(compared with endogenous typical insulin

activity, which is found in Cohn Fractions D + ID, IV-1 and V) (511-513). Unlike
the B-globulin ILA described by Beigelman and Randle and Taylor, however, BI
is virtually undetectable by glucose uptake in the isolated rat diaphragm and is
unreactive with anti-insulin antibodies (247 ,509,512,514).
Antoniades, however, observed an increase of BI ILA in the rat diaphragm
assay after various treatments of the fraction.

Treatment with acid (0.2M

citrate, pH 2-3) or alkali (pH 9.8), an aqueous extract of rat adipose tissue, or
acid-ethanol produced a many-fold increase in BI ILA measured by this assay
(509,511).

The diaphragm ILA increment induced by pH extremes (with

subsequent neutralization) was especially pronounced

when

followed by

centrifugation, leading Antoniades to conclude that such treatment liberated
free insulin from an insulin-protein complex by rendering the cationic carrier

178

protein insoluble (509).

A maximum adipose tissue extract (ATE)-induced

increment in diaphragm assayable BI ILA was obtained after 30 minutes
preincubation of the BI fraction with ATE, which exerts no effect on the ILA
exhibited by crystalline insulin in the diaphragm assay (514).

The BI ILA

increment increased progressively with increasing ATE protein concentration,
attaining a maximum of about 1,000 \.J U/ml eluate at an ATE nitrogen content
of 18\.Jg/ml incubating medium (514). Further purification of ATE revealed that
the factor responsible for the ILA increment migrates in electrophoresis with
albumin and the a 1-globulins (514) and is heat stable, suggesting a small
molecule (512).
Examination of the soluble and insoluble products of resin eluates
subjected to pH extremes provided further evidence for an insulin-protein
complex. ILA remaining in the supernate of BI fractions treated with citrate, pH
2.0, migrated on paper electrophoresis at pH 7.6 as an anion, in the albumin/ a1globulin zone (as does typical insulin), and exhibited a molecular weight below
40,000 daltons by gel chromatography (509,512). the redissolved (O.lM acetate
buffer, pH 4.0) precipitate obtained from BI fractions adjusted to pH 9.8
migrated on paper electrophoresis, pH 7.4, anodally toy-globulins and stained
with ninhydrin, suggesting a very cationic protein with an isoelectric point near
10 (509).

The supernatant ILA was neutralized by anti-insulin serum (AIS),

indicating that this, indeed, represented free insulin (509).

No change in the

diaphragm-assayable ILA of BI incubated with rat adipose tissue and AIS less
than 2 hours was seen, but a significant decrease of ILA, which became greater
with incubation time, occurred after 2 hours (511). A significant decrease in ILA
of acid ethanol extracts of BI fractions was observed in the presence of AIS
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within 90 minutes (511). This finding should be contrasted with the potentiation
of Bl diaphragm-assayable ILA after treatment with acid ethanol.
Antoniades postulated conversion of "free" to "bound" insulin in the liver
(512), but was unable to demonstrate binding of exogenous radiolabeled insulin to
a cationic protein in vitro or in vivo. Human serum incubated directly with 1311insulin or obtained from nondiabetic subjects injected with 131 1-insulin showed
no significant loss of radioactivity after passage through cation exchange resin
(509).

He determined the mean concentration of BI (400 \.lU/ml) in fasting

nondiabetic humans to be about 10 times that of free insulin (512).

It is

noteworthy that insulin-antibody complexes were not absorbed by the cation
exchange resin (509).
Confirmation of Antoniades' observations came with the work of Shaw and
Shuey, who demonstrated an AIS-neutralizable ATE-induced 12-fold increase in
normal fasting human serum ILA, from 50 \.l U/ml to 600 ).JU/ml, measured by
both glucose uptake and glycogen synthesis in the rat diaphragm (390). They
obtained essentially the same results with a serum BI fraction eluted from
Dowex 50w-x8 with 0.02M NH 40H. Gundersen and Lin extended the concept of
bound insulin by demonstrating that heparin also causes increase of BI ILA in the
rat diaphragm to about that found with the fat pad assay (391). They found that
addition of AIS to Bl-heparin mixtures decreased diaphragm-assayable ILA 2495% and fat pad-assayable ILA 25-80%.

These investigators also showed a

striking increase of ILA with dilution (to 1:8) of normal and diabetic human
serum in both the diaphragm and fat pad. Heparin increased the ILA of dilute
serum 8-fold in the diaphragm, but not in the fat pad.
Several investigators pointed out apparent contradictions in the data of
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proponents of bound insulin, however. Berson and Yalow (515) noted that the
results of Antoniades and coworkers in three separate reports show that total
plasma insulin ("bound" plus "free") decreases strikingly after intravenous glucose
administration and that earlier observations by Valiance-Owen et al. (516)
demonstrated high insulin concentrations in plasma of diabetic subjects by the
rat diaphragm without ATE. Using rat diaphragm assays based on glucose uptake
and glycogen production, the latter 25 times more sensitive than Antoniades'
assay, Meade et al. (517) obtained ILA values for BI fractions intermediate
between what Antoniades observed with and without ATE and were unable to
increase the ILA by treatment with ATE, acid alcohol, alkali or heparin. These
investigators also found no ILA in, vivo (mouse hypoglycemia) for BI fractions,
whether prepared by themselves or obtained from Antoniades, they reported that
different batches of Dowex 50-xS or 50w-x8 resin did not always yield BI, and
they pointed out that dialysis tubing-if not properly prepared-could contribute
to ILA.

Anderson et al. (518) have extracted insulin from plasma under

conditions that presumably would dissociate BI and found with an in vivo assay
that the concentration of plasma insulin in the fasting dog is only 30 ).JU/ml.
Christopher et al. (519) demonstrated that the significant quantities of
diaphragm-assayable ILA that could not be increased by ATE, acid alcohol, alkali
or heparin found by others in BI fractions could be due to prolonged alkalinity of
eluates, which would lead to irreversible dissociation of BI. These investigators
first demonstrated a 4-fold increase in undialyzed human plasma ILA (measured
by glucose uptake in the rat diaphragm) by ATE (which exerted no effect on
crystalline insulin ILA) to a level about equal to dialyzed plasma ILA, which was
further increased 2.5-fold by ATE. Plasma BI fractions eluted from Dowex 50 x

181

8 resin with 0.1N NH 40H, however, exhibited high ILA that could not be
increased significantly by ATE. When the plasma was incubated 15 minutes at
pH 10, followed by neutralization, passage through the cation exchange resin and
alkaline elution, about 90% of the BI ILA shifted to the plasma-saline effluent
(not adsorbed), providing additional evidence that BI represents ILA bound to a
cationic substance.
By 1965, proof of BI awaited only two developments: 1) demonstration of
JRI by RIA following treatment of BI fractions in a way known to release "free"
insulin, the ILA of which had been reported to be AIS-suppressible; and

2)

demonstration of reversible binding of exogenous radiolabeled insulin to a serum
protein.

The latter development appeared to be achieved when several

investigators reported migration of radioactivity with

o. - and

e-globulins

following incubation of exogenous radiolabeled insulin with human serum. Using
immunoelectrophoresis and radioautography, Clausen et al. (520) demonstrated
binding of 125 1-insulin to a 2- and ~~macroglobulins. Mitchell (521) showed
that, while 131 1-insulin alone migrated just behind albumin on cation exchange
resin paper electrophoresis and with the e -/

y

-globulins after incubation with

AIS, the radioactivity was associated with the o.-/ S-globulins after incubation
of the radiolabeled hormone with normal human serum. Prout et al. (522) found
that 1311-insulin alone migrated ahead of albumin on agar electrophoresis, but in
both

agar- and

immunoelectrophoresis

followed

by

radioautography

the

radioactivity migrated with y-globulins after incubation of 1311-insulin with AIS
and with o. 1-globulins after incubation with normal human serum.
In several reports and reviews, however, Berson and Yalow dealt a serious

blow to the concept of bound insulin from three directions:
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1. Demonstration that association of radioactivity with serum protein fr:actions

following incubation of exogenous radiolabeled insulin with human serum
represents irreversible binding of "damaged" insulin to proteins and thus
constitutes an artifactual observation.
labeled

insulin~rotein

Berson and Yalow reported that the

species observed in the studies mentioned above fail three

primary criteria of physiologically significant

hormone~rotein

association: a)

reversibility of binding, indicated by release of free labeled insulin upon addition
of a large excess of unlabeled (cold) insulin; b) competitive inhibition of binding
with cold insulin; and c) demonstration of labeled insulin binding to protein in
vivo, following injection of the labeled hormone into an animal (515). Observing
that insulin may be damaged during the radiolabeling procedure and during
incubation with plasma, Berson and Yalow found that incubation-damaged
radiolabeled insulin binds to a-globulins and albumin in a non-saturable and
irreversible manner and that nearly all 131 I-insulin may be damaged if incubation
with plasma is sufficiently prolonged (515).

They showed that, when care is

taken to avoid artifactual results due to insulin damage, labeled insulin in buffer
or normal human plasma migrates just behind albumin on starch block
electrophoresis and

is

adsorbed

at

the

site of application on paper

electrophoresis (409). In addition, 131 1-insulin sediments in the ultracentrifuge
with the same velocity in the presence or absence of plasma (410).
2. Inability to enhance IRI by methods employed to release "free" insulin from
BI. Berson and Yalow (523) incubated fasting sera from 5 diabetic and 5 nondiabetic subjects with ATE according to the method of Antoniades and were
unable to find any increase in plasma insulin as measured by immunoassay.
Meade et al. (524) found that serum or pancreatic extract IRI is not changed by
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passage through a cation exchange column. Also, the cation resin eluate did not
yield any IRI, either before or after attempts to convert "bound" to "free"
insulin. Furthermore, Leonards (397) reported that AIS had little or no effect on
normal human serum ILA.
3.

Inconsistencies between the concept of bound insulin and established

observations.

Plasma

levels

of ILA

do

not

change

following

total

pancreatectomy (515} and are then increased after glucose administration,
despite symptoms of severe diabetes and complete absence of plasma IRI (398),
suggesting that BI ILA is of extrapancreatic origin. Total serum insulin activity
(TSIA, which is the diaphragm-assayable ILA found after treatment of plasma
with acid alcohol and dialysis, yielding an insoluble suspension in which the
diaphragm is incubated} exceeds 3 mU/ml plasma (525, 526}. Yet, Froesch et al.
(527} reported human serum concentrations of AIS-suppressible ILA (measured by
the rat fat pad assay} in the fasting state and after glucose almost identical to
those found by RIA. Calculations of normal daily insulin secretion rates on the
basis of these values and the kinetics of insulin metabolism yield estimates of
about 50

U/day, about equal to the insulin requirements of totally

depancreatized subjects (528, 529}. Berson and Yalow (528} also pointed out that
the physiologic properties on insulin, namely a biologic half-life of less than 40
minutes, which is consistent with the short-lived effects of exogenous insulin in
vivo and the rapid onset of diabetic symptoms after pancreatectomy, are
inconsistent with two protein-hormone models:

a) thyroxine, which is

transported by thyroxine-binding globulin in the blood. The biologic half-life of
thyroxine is about one week and the onset of the symptoms of hypothyroidism
occur weeks after thyroidectomy; and b) diabetics with severe insulin resistance
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due to large concentrations of serum anti-insulin antibodies may

requir~

very

large doses of exogenous insulin for control of an acute episode of ketosis,
following which, in the absence of any further insulin therapy, repeated insulin
reactions may occur for days as a result of slow dissociation of insulin-antibody
complexes. Finally, Sheps et al. (396) reported that some plasma ILA persists
after treatment of plasma with reduced glutathione.
Recently, however, Guenther (387) reported an increase in the IRI of BI
fractions following treatment with heparin. He also demonstrated an increase of
the diaphragm-assayable ILA of these fractions by biotin, implicating the
vitamin as the active factor in ATE. Since Guenther utilized gentler cationexchange methods for the isolation of BI than those employed previously by
Antoniades and others and since heparin had not been used in previous studies of
BI IRI, the entire question of the identity of BI has again been opened to dispute.

THE SYNALBUMIN INSULIN ANTAGONIST

An alternate explanation for the observations leading to the postulation of
bound insulin was advanced by Valiance-owen and coworkers based on the
existence in blood of a substance that antagonizes the effect of insulin on
diaphragm muscle. These investigators found significant insulin antagonism in
this system by albumin precipitated with trichloroacetic acid from the plasma of
nondiabetic and diabetic humans and normal cats (530-532). This antagonist,
which they termed the "synalbumin insulin antagonist" (SIA) (533), was noted at a
concentration of 1.2596 albumin derived from prediabetic and diabetic humans
and 3.5-5.596 albumin derived from normal humans and cats (530-532, 534), but
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not in 1.25% albumin from normal humans or in whole plasma from. obese,
untreated diabetic and normal humans (383, 516, 530, 534). The SIA was noted,
however, in the whole plasma of cats after pancreatectomy, leading ValianceOwen to conclude that normally SIA in whole plasma is completely masked by
the production of adequate amounts of insulin by the pancreas (535). Since 3.55.5% normal human plasma albumin completely inhibits the effect of 1,000

)..1

U

insulin/ml on the diaphragm (531), normal human plasma apparently contains
more than 1 mU insulin/ml, a conclusion consistent with the observation of
Gundersen and Lin (391) that 8-fold dilution of normal and untreated diabetic
sera yielded diaphragm-assayable ILA up to 780 and 2,100

lJ U/ml,

respectively.

Valiance-Owen and Lilley (532) reported that the albumin of two
adrenalectomized patients was free of SIA, but in one case the antagonist
appeared after treatment with cortisone. Valiance-Owen et al. also noted that
the SIA disappears from the albumin of diabetic and nondiabetic humans
following hypophysectomy (531), but Lowy et al. observed no change in SIA after
hypophysectomy or pituitary destruction by other means and demonstrated no
effect of albumin fractions on

fat~ad

assayable ILA (536).

Thus, the SIA

appears to be adrenal glucocorticoids, which are lmown to antagonize insulinstimulated glucose utilization by muscle (537) and which are transported in blood
by albumin and transcortin, an a-globulin (538).
The observation that SIA inhibits insulin action on muscle, but not on fat
led to development of the concept that a protein-bound form of insulin in serum
may be alternatively explained by the presence of SIA (539). When ValianceOwen and coworkers repeated Antoniades' experiment with serum, they found
diaphragm-assayable ILA in the 0.1M NH40H eluate from Dowex 50-x8 resin
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without the use of ATE.

Reasoning that this ILA may represent dissociated

"free" insulin, these investigators reapplied the neutralized eluate to the resin,
but the ILA was again retained by the resin and NH 40H elution once more
yielded an AIS-suppressible, ATE-independent diaphragm-assayable ILA. Since
preincubation of serum with AIS yielded no detectable ILA upon Dowex cation
exchange resin chromatography, even in the presence of ATE, there arose the
possibility that insulin itself may behave like a cation under the conditions of the
experiment. They found that insulin behaves like an anion, passing through the
resin, above pH 7.0, but behaves like a cation and is retained by the resin below
pH 6.6.

This was verified by the observation that crystalline insulin, when

submitted to electrophoresis, behaves like an anion above pH 6.8 and like a
cation below pH 6.6. Furthermore, 16% of exogenous insulin added to serum was
eluted from the resin with NH 40H by the method of Antoniades (539).
The SIA was also retained by Dowex cation exchange resin and eluted with
NH 40H.

The antagonist was inactivated by preincubation with diaphragm or

adipose tissue and with alcoholic extracts of adipose tissue (ATE) or muscle
(MTE). It was noted that subsequent to incubation with ATE or MTE SIA eluted
from the resin with NH 40H was inactivated. Following incubation of serum with
ATE or MTE, a significant elevation in glucose uptake by diaphragm muscle
above serum controls was observed (539). Interpretation of Antoniades' results in
terms of inactivation of SIA is contradicted, however, by persistence of serum
ILA following pancreatectomy (515).
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ATYPICAL INSULIN

Approaching the problem from a different direction, Samaan, Fraser and
coworkers concluded that a protein-bound form of insulin exists in the peripheral
circulation after observing that only 30% of fat pad-assayable ILA (measured by
conversion of 14 c-glucose to 14 co 2 or 14 c-fatty acids) in human peripheral
venous blood is AIS-neutralizable while about 90% of portal venous serum ILA
was neutralized (540, 541). These investigators pointed out that, although the
majority of peripheral serum fat pad-assayable ILA cannot be neutralized by a
quantity of AIS capable of neutralizing 300 mU typical insulin, this entity, which
they termed "atypical insulin" (AI)', increases the conversion of glucose to C0 2
and fatty acids by adipose tissue, is acid ethanol extractable (during which some
AI is converted to typical insulin), is abolished by 0.04 M cysteine, and is
eliminated--along with typical insulin-from the circulation of the rat by
injection of AIS, indicating that AI contains typical insulin (541, 542). Consistent
with an insulin-binding protein being produced in the liver, AI was found to be
low in liver disease, while typical insulin levels are normal or slightly elevated
(542). AI levels were found to be one-third normal in juvenile ketotic diabetics,

lowered in thin adult diabetics, and very high in obese adult diabetics (542).
Samaan et al. (543) concluded that BI and AI are not the same, however,
after observing that serum AI
decreases.

~ncreases

after glucose administration whereas BI

Other observations also indicated that AI may not contain typical

insulin. Although 90% of portal venous serum ILA is AIS neutralizable, total ILA
concentration at this site is 5 times that of peripheral circulation, meaning that
AI concentration is about the same in both. Likewise, infusion of 40-60 U insulin
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into dogs resulted in a 100-300% increase in AI levels, but the increase in .AI was
only 2-4% as great as the increase in typical insulin (385). Fraser and Samaan
reported that pancreatectomy of dogs leaves some, but a reduced level of serum
AI, along with diabetes mellitus of varying severity (542), while Leonards and
coworkers (397, 544) found that plasma AI persisted at least 16 days after
pancreatectomy of dogs. Also, there is little change in serum AI during glucose
tolerance tests (542). On the other hand, hypophysectomy of dogs resulted in a
40% reduction in serum ILA from the average preoperation value of 463 J.l U/ml
(545), indicating a pituitary involvement.

NONSUPPRESSffiLE INSULIN-LIKE ACTIVITY (NSILA)

By far the most extensive investigation of atypical serum ILA has been
carried out by a group of Swiss scientists, most notably E.R. Froesch, who
termed fat pad-assayable (net gas exchange and glucose uptake) serum ILA in the
presence of an excess of AIS "nonsuppressible insulin-like activity" (NSILA)
(527).

Only 7% (mean = 13 JJU/ml, range = 0-93 JJU/ml) of normal fasting

human serum ILA (mean = 180 JJU/ml, range = 68-587 JJ U/ml, n = 22) is AIS
suppressible (SILA) and presumably represents pancreatic IRI, since serum levels
of SILA compare well with RIA-assayable serum insulin and nuctuate with
varying physiologic and pathologic conditions as expected for typical insulin (527,
546).

Serum levels of NSILA don't change under physiologic or pathologic

conditions and the species doesn't disappear after pancreatectomy (although it
decreases considerably after alloxan induction of diabetes in rats), indicating
that NSILA does not mimic insulin's effects in vivo (527, 546). Human studies
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indicate that exogenous insulin is not converted to NSILA in vivo (527).
When acetone powders prepared from lyophilized human plasma or Cohn
fraction B, which lacks albumin and gamma globulins, were treated with acid
ethanol, it was found that 5-10% of NSILA was soluble and this species was thus
designated NSILA-8 (546-548).

The NSILA-8 was eluted from Sephadex G-75

with 5M acetic acid/0.15M NaCl in a sharp protein peak corresponding to
molecular weight 6,000-10,000 daltons. When NSILA-8 was chromatographed on
Sephadex G-100 in 0.1 M ammonium acetate, pH 7.2, it eluted in a broad peak,
corresponding to a protein of molecular weight 50,000-70,000 daltons.

When

rechromatographed on G-75 at neutral pH after treatment with 5M acetic
acid/0.15M NaCl, this material eluted as a protein of molecular weight 6,000,
indicating binding to a carrier protein rather than aggregation (547). NSILA-8
was later determined to be a heat-stable (80°C, 3 hours) single-chain polypeptide
of 7,500 daltons molecular weight that is 40-50% inactivated by glutathione, but
is not inactivated by rat liver (546, 547).
Acid ethanol-precipitable NSILA (NSILA-P), which accounts for more than
90% serum NSILA, was found to be a heat-labile (inactivated at 80°C in 15
minutes) protein of 100,000-150,000 daltons molecular weight that is not
convertible to NSILA-8 and is not dissociable by acid, urea or EDTA, but is more
than 90% inactivated by mercaptoethanol and urea (546, 547). While only 0-10%
NSILA-P was retained by Dowex 50 cation exchange resin, 27-80% of NSILA-8
was retained and two-thirds of the serum ILA eluted from Dowex 50 with 0.02M
NH 40H eluted from G-75 with 5M acetic acid-D.15M NaCl at the same column
volume as NSILA-8 (547), indicating that Bl may be NSILA-8.
NSILA-8 has been characterized more extensively than NSILA-P. In 1976,
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Rinderknecht and Humbel (549) reported the results of a systematic purification
and characterization of NSILA-S. Starting with a crude extract that contained
50-80 mU NSILA-8/g, they achieved about 150-fold purification with a yield of
85% by extraction with 0.5M acetic acid followed by G-75 chromatography in
0.5M acetic acid. Chromatography on G-50 with 1M acetic acid yielded at least
80% of starting NSILA-S with an average specific activity of 30 mU/mg. When
this material was subjected to sodium dodecyl sulfate polyacrylamide gel
electrophoresis (SDS-PAGE), 55% of total NSILA-S activity was recovered in a
single fluorescamine-positive band. This product, with a specific activity of 300
mU/mg, exhibited a molecular weight of 5,500-5,800 daltons by Bio-Gel A-5m
chromatography in 6M guanidine HCl, G-50 chromatography in 1M acetic acid,
and SDS-P AGE. No change in molecular weight was noted after reduction with
dithiothreitol. The isoelectric point of NSILA-8 was found to be 8.2 ± 0.4.
Ion-exchange chromatography of this material on SE-Sephadex C-25 with
a gradient of 0.05M pyridine-acetate, pH 2.5/2.0M pyridine-acetate, pH 5.0, at
55°C yielded two NSILA peaks. The less cationic protein was termed NSILA I
and the more cationic fraction, after further purification by gel electrophoresis
at pH 4.3, was termed NSILA II.

Both purified NSILAs possessed a specific

activity of about 400 mU/mg and together represented about 30% of starting
activity.

Both proteins lack histidine and tryptophane.

methionine.

NSILA II also lacks

Each form of NSILA-8 was found to contain 4 cysteines per

molecule, but no free sulfhydryl groups, indicating 2 intrachain disulfide bonds.
Amino acid analysis also indicated a molecular weight of 5,757 daltons for NSILA
I and 5,904 daltons for NSILA II. Biological activity of the polypeptides was fully
conserved after heating to 70°C at pH 7.6 for 15 minutes, exposure to 8M urea,
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6M guanidine HCI or 0.1% SDS, storage in 50% acetic acid at 4°C for several
weeks, or repeated freezing and thawing, but was abolished by oxidation· with
performic acid or reduction and alkylation with iodoacetate or ethyleneimine,
indicating that the disulfide bonds are necessary for the molecules' biological
activity.
Determination of the amino-terminal sequences (the first 31 residues of
52 for NISLA I and 53 for NSILA ll) of the two polypeptides revealed 73%
identity between them through residue 30 and 47% homology between NSILA I
and the human insulin B chain. The only B-chain invariant residue substituted in
NSILA-8 is tyr 16. Changes in conservatively variant insulin residues include the
B10 histidine and the B14 alanine, suggesting that NSILA-8 does not form
aggregates in the presence of zinc, and B5 histidine. The degree of similarity
(50%) between insulin B chains of man and coypu is the same as that between
coypu insulin B chain and NSILA n and the highest degree of sequence identity
(57%) is found between NSILA I and tuna fish insulin, indicating that NSILA-S
and insulin diverged after duplication of an ancestral gene early in vertebrate
evolution (549, 550).
Complete sequencing of NSILA I, which was found to contain 70 amino
acids, revealed two segments having nearly 50% (24/51) homology with the
porcine insulin A and B chains (5-25 :::B6-B26, 42-61 :::A1-A20) with a 12-residue
"connecting peptide" showing no homology with proinsulin and an extra 8 residues
at the carboxy terminus (551).

The arrangement of cystines in NSILA I is

identical to that of insulin and 17 of 19 invariant insulin residues are retained.
The homology of NSILA I to porcine insulin thus found is intermediate between
hagfish insulin and relaxin.

Insulin residues involved in dimerization are
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conserved or are conservatively substituted in NSILA I, but B10 histidine is
changed to glutamate 9 and 3 of 10 dimer-dimer contacts are significantly
changed, suggesting that NSILA I probably forms dimers but not hexamers.
The lack of NSILA immunoreactivity with AIS is explained by the fact
that the antibody-binding regions are much altered: B5 histidine corresponds to
threonine 4, A14 tyrosine corresponds to arginine 55, and A19 tyrosine,
corresponding to tyrosine 60, is probably covered by the C-peptide and the
carboxy extension.

Eight of eleven receptor residues are conserved or are

conservatively varied, but the A1 and A21 residues are not terminal. Alteration
of these residues has resulted in retention of no more than 2% insulin bioactivity
programs, Blundell et al. (551) were able
(see Table 1). Using computer graphic
.
to construct a three-dimensional model of NSILA I very similar to the tertiary
structure of insulin and possessing the same hydrophobic core.
NSILA-8 mimics most of insulin's effects on adipose tissue and muscle in
vitro and in vivo (552, 553). It stimulates glucose transport, C02 production and
lipogenesis while inhibiting lipolysis, glycogenolysis and epinephrine action,
including cyclic AMP release, in adipose tissue (527, 548, 554), and stimulates
glucose transport and glycogen synthesis in muscle (554). NSILA-8 exhibits 20%
of insulin activity in stimulating glucose transport in heart muscle (548), but the
highest nonsuppressible fat pad ILA found for this species is 470 mU/mg (555),
indicting that NSILA-8 possesses about 2% insulin activity in adipose tissue (548,
549).

This fact and the finding of normal levels of NSILA-8 in the sera of

diabetics suggest that this substance does not exert an important physiologic
insulin-like effect (527, 556, 557), although intravenous injection of NSILA-8 into
normal and adrenalectomized rats elicited hypoglycemic responses (558, 559).
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Other studies, however, suggest that the physiologic role of NSILA-8 is
that of a growth factor. This substance has been found to be a potent sulfation
factor in both chick and rat cartilage {560, 561), being 50-100 times more
effective than insulin in stimulating [ 35 s] sulfate, [ 3H) uridine and [ 3H]
or

[ 14 cl leucine incorporation into chick cartilage and activity of ornithine

decarboxylase {549, 561, 562). NSILA-S is also 20 times more potent than insulin
in promoting DNA synthesis, cell proliferation, glucose uptake and lactate
production in cultured chick embryo fibroblasts {527).

Thus, NSILA-S is

effective as a growth factor at concentrations of 0.1-10 lJU/ml, while exerting
insulin-like effects at concentrations greater than 10 J.J U/ml {557).
Poffenbarger {563) systematically characterized what he termed serum
nonsuppressible insulin-like protein {NSILP), which apparently corresponds to
NSILA-P.

He isolated a NSILA protein of molecular weight 90,000 daltons,

which under reducing conditions exhibited 2 SDS-P AGE bands corresponding to
molecular weights of 42,000 and 56,000 daltons. NSILP has a pi of 6.2, Stokes
radius of 42.7 A,

s2o,w=4.27

x 10-13 sec., carbohydrate content of 16%, and

partial specific volume of 0.724 ml/g. Amino acid analysis revealed a relatively
high proportion of glutamic acid {or glutamine), glycine, arginine and
tryptophan.

A NSILP

immunoassay indicated a normal human serum

concentration of 1.2 J.Jg/ml and anti-NSILP serum suppresses 70-80% total serum
ILA.
Reber and Liske {564) developed an RIA for NSILA-s that exhibited a
sensitivity of 150 pg/ml {0.07 J.J U/ml), an intraassay variation of 8.3% and an
interassay variation of 16.8%. They found a range of human plasma NSILA-s
concentrations of <0.15-25 ng/ml (11.8 J.J U/ml; mean = 4 ng/ml, or 1.9 J,JU/ml)
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for adults and <0.15-20 ng/ml (9.4 J..!U/ml) for children. These values are about
10-20% of those determined by bioassay (527, 546). RIA of acid-ethanol extracts

of human plasma, however, yielded a tenfold higher concentration of NSILA-8
(564), again suggesting the existence of a plasma carrier protein for this

substance. In contrast to humans, plasma NSILA-S in rats declines from about 20
ng/ml at 2 weeks of age to about 8 ng/ml at 4 weeks and then rises steadily to
about 60 ng/ml by 6 months (564). Displacement of 125 1-NSILA-8 from antibody
by goat, dog, rat and human plasma parallels the human NSILA-S standard doseresponse

cu~ve,

indicating that this compound is immunochemically very similar

in all these species and thus is highly conserved through mammalian evolution.
When Zapf et al. (556) attempted to measure human serum levels of
NSILA-S with a solubilized fibroblast receptor assay, instead of displacement of
radiolabeled NSILA-8, they found increased binding of label as the serum
concentration was raised, further suggesting binding of NSILA-8 by a serum
component.

These

investigators then systematically demonstrated and

characterized a specific NSILA-S carrier protein in human serum (557). Using
inhibition of adsorption of 125 1-NSILA-8 to albumin-coated charcoal as the
criterion for this binding, they demonstrated that a maximum of about 0.8 J.l U
exogenous NSILA-8 is bound by 1 ml serum at a concentration of 10-20 J..!U 125 1NSILA-8/ml. These observations and the RIA data indicate that about 90% of
human NSILA-8 is bound at physiologic concentrations of the substance, lending
further support to the contention that sufficient concentrations of NSILA-8 to
exert insulin-like effects do not exist in vivo. More than 90% of 1 25 1-NSILA-~
bound by 1:4 diluted human serum is displaced by 250 J..!U unlabeled NSILA-8/ml
and efficiency of displacement is directly proportional to the biologic activity of
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the unlabeled compound. Insulin, HGH and ACTH do not compete for the NSILAS binding site in serum. Chromatography of 1251-NSILA-S-serum on Sephade~ G200 at pH 7.5 revealed three peaks of radioactivity in the large molecular weight
region and a fourth one corresponding to low molecular weight unbound labeled
NSILA-S.

An excess of unlabeled NSILA-s during preincubation led to the

disappearance of the two major large molecular weight peaks and to a
concomitant increase of the peak eluting in the low molecular weight range.
Binding of NSILA-s is saturable and concentration dependent, with halfmaximal binding attained at 4-5

~

U exogenous NSILA-8/ml, and is time

dependent, with maximal binding attained after 24 hours, but is temperature
independent between 0 and 30°C. Scatchard plots indicate a single affinity of
association with a pH optimum of 7-8. The binding protein is not albumin, since
2% HSA binds less than 20% of the 1251-NSILA-s bound by 1:4 human serum, is
heat labile ( >98% inactivated at 100°C for 5 minutes), and exhibits a molecular
weight of about 70,000 daltons in Sephadex gel chromatography (548, 557).
NSILA-s activity in the insulin RRA using cultured human lymphocytes
and purified rat liver plasma membranes is the same as in the insulin bioassay,
.!·~·

NSILA-s exhibits 2% cross-reactivity with the insulin receptor {548-565).

Zapf et al. (556) demonstrated specific binding of 125 1-NSILA-s to cultured chick
embryo fibroblasts and developed an RRA for NSILA-s using solubilized
receptors prepared from the fibroblasts by Triton X-100 extraction. Binding of
NSILA-s to its receptor is time-, temperature-, and pH-dependent, and exhibits
saturation kinetics.

Linear Scatchard plots indicate a single binding affinity,

with a Ko of 8 x 10-10 M { :::2 ~ U/ml; Kassoc. =109 M-1>, which is about the
same NSILA-s concentration {1-2

~U/ml)

at which half-maximal stimulation of
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3H-thymidine incorporation into fibroblast DNA is achieved. A

similar!~

good

correlation between binding and the biologic activity of NSILA-8 was obtained
with adipocytes (556) and the perfused rat heart (566). There are 18,000-24,000
NSILA-8 binding sites per fibroblast cell and the pH optimum of binding is
between 7.5 and 8.0. Cross-reactivity of insulin with the NSILA-8 receptor is
0.001-1% and no displacement of 125 !-NSILA-S from fibroblasts by glucagon,

ACTH or HGH was noted.

SOMATOMEDINS

In 1957, Salmon and Daughaday (567) demonstrated that growth hormone

stimulates incorporation of labeled sulfate into the costal cargilage of
hypophysectomized rats via a secondary factor, measurable in serum, which they
termed "sulfation factor." Sulfation factor was shown to stimulate incorporation
of 14 c-1eucine into glucosaminoglycans (568), conversion of 14 c-uridine-proline
into collagen-hydroxyproline (569), incorporation of 3 H-uridine into RNA (568)
and incorporation of 3 H-thymidine into DNA (570) in rat cartilage and uptake
of a-aminoisobutyric acid, cycloleucine and metabolizable amino acids into
chick cartilage (571). The term somatomedin, indicative of serum factors that
mediate the effects of somatotropin, has been applied to substances exhibiting
the properties of sulfation factor (572) and is more generally defined as all
growth hormone-dependent factors that exert an anabolic insulin-like action on
their target tissues (573). Most bioassays of somatomedin measure incorporation
of radiolabeled sulfate into chondroitin sulfate of cartilage glucosaminoglycans
(574).

Daughaday et al. (575) found a linear relation between the uptake of
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labeled sulfate into costal cartilage of hypophysectomized rats and log of serum
concentration.

A more convenient assay, utilizing incorporation of labeled

sulfate into cartilaginous pelvic leaflets from 11- or

12~ay-old

chick embryos,

was developed by Hall (576, 577). Numerous bioassays for somatomedins have
also been developed based on incorporation of radiolabeled thymidine into DNA
(578-580).
Somatomedins have been found to be effective in the cartilage of many
vertebrates, including monkey, horse, calf, dog, pig, sheep, rat and frog (573,
581), but no such substances were found in the blood of the carp or atlantic
bluefish (582, 583).

somatomedins have also been found to stimulate

incorporation of 35so4= into polysaccharides of human fetal lung fibroblasts
(584) and of 3H-thymidine into DNA of human glial cells in culture (585). Rat
plasma somatomedins stimulate incorporation of radiolabeled leucine into
hypophysectomized rat diaphragm (586), indicating that these substances are also
effective on muscle. The somatotropin dependence of somatomedins is reflected
in findings of high serum levels of somatomedins in human acromegalies (575577, 587).

Total hypophysectomy in man was followed by falling levels of

somatomedin (575, 587) and the half-life of somatomedin in three such patients
was 9-18 hours (587). Low levels of somatomedin were found in pituitary dwarfs
(575, 588). In retarded growth induced by other hormonal imbalances such as
thyroid deficiency or cortisone administration normal somatomedin levels were
obtained (577).

Administration of HGH always caused a prompt rise of

somatomedin in pituitary dwarfs (588-591).

During long-term treatment of

pituitary dwarfs with HGH a correlation was seen between serum levels of
somatomedin and growth rate (592). Furthermore, an increase of somatomedin
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was found in normal humans at the time of puberty by Almqvist and Rune (593).
In newborns and children less than 4 years of age, the levels were lower than in

adults (575, 589, 593). Somatomedin-like activity in frog serum is decreased
following hypophysectomy and is restored to normal by administration of
somatotropin or triiodothyronine (581). Perfusion of rat liver and kidney slices
with growth hormone was accompanied by production of a somatomedin-like
factor in the medium (594-596), indicating that these organs are sources of the
substance.
Acid-ethanol extraction of human serum yielded a 20-40% recovery of
somatomedin activity purified 50- to 200-fold (577, 578). Further purification by
gel chromatography, ion-exchange chromatography, isoelectric focusing and
paper electrophoresis revealed that somatomedins migrate on electrophoresis
with

S~lobulins

(573, 577, 578).

Thus, 10-20% plasma somatomedins were

recovered from acid-ethanol extraction of Cohn Fraction IV. Sephadex G-75
chromatography with 1% formic acid containing 0.01 M 2-mercaptoethanol
yielded a single peak of activity corresponding to molecular weight 6,000-8,000
daltons and representing an overall purification of 20,000-50,000-fold (577).
Further purification of this material by charge, including paper electrophoresis,
Dowex 50 x 2 ion-exchange chromatography and isoelectric focusing yielded
three polypeptides of about the same molecular weight (7 ,000 daltons), but
differing in their physical and biologic properties.

A neutral (pi

= 7.1-7 .5)

polypeptide that stimulates sulfate incorporation into chick cartilage was
designated somatomedin A (SMA; 577, 585). This material was recovered from
human plasma in a yield of 2% and a maximum specific activity of 7,000 U/mg (1
unit SMA activity is equivalent to 200 J.l U porcine insulin; 597), representing an
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overall purification of 1-2 x 10 6-fold (577). An acidic (pi= 5.9-6.4) polypeptide
that promotes incorporation of thymidine into DNA by human glial cells was
termed somatomedin B (SMB; 585).

A basic (pi = 9-10) polypeptide that

stimulates sulfate and thymidine incorporation by rat cartilage was designated
somatomedin C (SMC; 598, 599).
In addition to its effect on chick cartilage, partly purified SMA was found

to exert a totally insulin-like effect on rat adipose tissue (600). During optimal
stimulation of rat adipocyte lipolysis by such lipolytic hormones as epinephrine,
norepinephrine, glucagon, ACTH, TSH, LH and parathyroid hormone SlVIA
potentiated glycerol release, but during unstimulated and slightly stimulated
lipolysis, SMA caused a dose-dependent depression of glycerol release. Whereas
the adenylate cyclase-stimulating lipolytic hormones increase the uptake of
labeled calcium by these cells, both S\1A and insulin cause an inhibition of
calcium retention. Thus, SMA, insulin and calcitonin exert a similar effect on
lipolysis as well as on uptake of glucose and calcium by rat adipocytes (600).
Partially purified human plasma SlVIA also stimulates transport of

a -

aminoisobutyric acid into muscle (573). In a study of both healthy children and
children with certain growth disturbances, a correlation was found between
serum SMA levels and dental maturity as well as body height growth (601). The
mean serum level of SMA in 28 normal children (7-11 yrs.) was found to be 0.92 ±
0.06 (SEM) U/ml, while those of 29 short and 9 tall children were 0.64 and 1.24
U/ml, respectively (601).

A specific RIA for SMB indicated a mean plasma

concentration of 9.8 ± 1.7

llg/ml for normal adult males, 6.6 ±0.5

l.1

g/ml for

17 adult males with diagnoses of chromophobe adenoma and growth hormone
deficiency, and 19.3 ± 2.3

JJg/ml for 22 adult males with clinical acromegaly

200
and proven hypersecretion of growth hormone (602).
Whereas purified SMB has no effect on adipose tissue, SMC has been
shown to exert an insulin-like effect.

Partially purified SMC stimulates

oxidation of 14 C-glucose to 14 co 2 in isolated fat cells, 1 unit of SMC being
equivalent to 30-50 J..IU insulin (573). SMC also inhibits glycerol release in vitro
in epinephrine-stimulated rat epididymal fat tissue. In this system 1 unit of SMC
is equivalent to 120 J..IU porcine insulin (603). SMC, as well as somatotropin,
stimulates hypothalmic somatostatin release, resulting in inhibition of pituitary
somatotropin excretion, and also inhibits stimulation of somatotropin release by
a delayed, direct mechanism that completes a negative feedback loop further
indicating that SMC is a mediator of somatotropin action (604). A 37% inhibition
of somatotropin release from cultured rat adenohypophyseal cells by a
pharmacologic dose (625 J..IU/ml) of insulin was also observed (604). Amphibia is
the most primitive class of vertebrates in which a SMC-like substance has been
detected, but displacement of 125 1-sMC from specific antibodies by frog serum
does not parallel displacement by normal human serum.

DNA synthesis and

mitosis in frog lens epithelium is abolished by hypophysectomy and is restored by
administration to the animals of SMC, which causes resumption of the cell cycle
in G0 phase and continuation through S phase. Somatotropin, frog prolactin and
thyrotropin, which enhance synthesis of SMC in mammalian liver (TSH via
thyroid hormones), stimulate mitogenesis in hypophysectomized frog lens
epithelium in vivo, but not in vitro. SMC also stimulates mitogenesis in vivo.
Likewise, somatotropin and triiodothyronine restore lens cell proliferation in
vivo, but not in vitro (581). Using a specific SMC RIA, Furlanetto et al. (582)
found that serum SMC levels were lowest at birth (0.38 ± 0.05 (SEM) U/ml) and
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rose dramatically during early childhood to reach 1.30 ± 0.16 U/ml by 4 years of
age.

The mean serum SMC concentration in 23 normal adults was 1.50± 0.10

U/ml (apprx. 150 ng/ml).

The levels were 6.28 ± 0.37 U/ml in 14 active

acromegalies and <0.2 U/ml in 19 hypopituitary children.
Experimental observations with SMA and SMC iterated above indicate
that somatomedins exert their anabolic effects by a mechanism that antagonizes
adenylate cyclase-activating hormones and, in fact, a partially purified
somatomedin preparation has been found to suppress the adenylate cyclase
activity of membrane fractions obtained from rat lymphocytes, adipocytes and
hepatocytes, and from chick embryo cartilage (605). A similar mechanism has
been postulated for insulin action (see Chapter ITI) and, indeed, extensive crossreaction of somatomedins, proportional to their ILA, has been reported. SMC
competes with 125 1-insulin for membrane binding sites on adipocytes and the
displacement curves obtained with the two hormones are parallel. The apparent
ratio of SMC to insulin of 50 J.IU insulin per unit of SMC is very similar to their
relative biologic activities.

Scatchard plots of 1251-insulin binding in the

presence of both insulin and SMC are compatible with simple competition for the
same receptor sites.

SMA also competes with 125 1-insulin for binding to

adipocytes and particulate adipocyte membrane preparations (606,607). SMC has
also been found to compete with insulin for binding to rat liver (606) and human
placental (598,608) membranes. SMA in doses above 1 J.lg/ml displaces 125 1insulin from placental membrane and 1 llg SMA is as potent as 1.25 ng insulin
(4.5 J.l U ILA/U SMA) in this respect (609), but SMB up to a concentration of 10

J.l g/ml has no effect in this system.
Furthermore, SMA and SMC have been shown to have specific binding
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sites on placental membrane (608-610). The specifically bound 125 1-sMA was
readily displaced by unlabeled SMA.

Insulin in high doses could also displace

oound 12 51-sMA, but was 100-1,000 times less potent than SMA in this respect
(610).

The Scatchard plots for insulin and S'IIJA in this system are biphasic,

indicating at least two types of binding sites.

The calculated apparent

association constant of the high-affinity sites is 3.8 x 10 8 M-1 for insulin and 2.7
x 10 7 M-l for SMA. The corresponding amounts of binding sites are 5.4 nmole
and 19 nmole per milligram of membrane protein, respectively (609).

A

placental membrane radioreceptor assay for SMA yieldedmean serum values of
0.57 and 3.2 U/ml for pituitary dwarfs and acromegalies, respectively, while

corresponding values of 0.41 and .1.61 U/ml were found using a bioassay (609).
Despite their definition based on selectivity of biologic activity, specific binding
of SMA to rat cartilage and of SMC to chick cartilage has been observed
(573,608). Displacement of 1251-sMC from human placental membranes by frog

serum also did not parallel displacement by human serum (581).
The biologic, membrane-binding, and physicochemical properties of SMA
and SMC are very similar to those of NSILA-8 (577 ,597 ,603). Hall and Uthne
(573,597) found that SMA and NSILA copurified from human plasma and, in fact,

the two are inseparable. NSILA-8 also stimulates incorporation of radiolabeled
sulfate into rat and chick cartilage and is regulated by somatotropin (560,573).
Serum NSILA levels are increased in acromegalies and decreased in pituitary
dwarfs (572). In addition, evidence for somatomedin carrier proteins in serum
has been obtained (573,585,598,602,611,612).

The lack of similarity between

SMB and other somatomedins is reflected by the fact that anti-8MB serum
doesn't react with NSILA-8 or SMA (613). Neither SMB nor SMC compete with
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NSILA-8 for binding to liver plasma membranes, but SMA is 10% as active as
NSILA-8 in competing for the NSILA-S receptor (614).

SERUM GROWTH FACTORS

Serum has been known to be a necessary component of cell and tissue
cultures since their inception at the beginning of this century (615). Nearly all
animal cells in culture require serum for proliferation, although transformed
cells (those that form tumors when injected into syngeneic animals) generally
have lower serum requirements in vitro than do their normal counterparts (616).
Serum has been shown to stimulate the rates of growth and DNA synthesis in
cultures of normal chicken, mouse and hamster cells (617-620). Griffiths (621)
found that 10% fetal bovine serum (PBS) and amino acids present in minimal
essential medium (MEM) cause protein and DNA synthesis and cell division in
confluent cultures of MRC-5 human diploid fibroblasts, which normally exhibit
decreased growth, protein, DNA and RNA synthesis, and amino acid uptake at
confiuency.

Addition of amino acids at this point has no effect on DNA

synthesis, but causes an increase in protein synthesis, while addition of serum
stimulates DNA synthesis and amino acid uptake by the cells, but not cell
division.

Thus, the synergism of the two additives results in cell division.

Stimulation of 3 H-thymidine incorporation into the DNA of human skin
fibroblasts was observed in the presence of 1.25% PBS, was half-maximal with
2.5% PBS, and was maximal with 5% PBS (555).
Plasma has been found to have little growth-promoting activity for
cultured cells compared to serum (622-625), although factors necessary for cell
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survival in vitro are present in both plasma and serum (616). Since cells. in vivo
are exposed to plasma except in wounds, where they are exposed to serum, it
may be concluded that plasma growth factors, such as NSILA-8, epidermal
growth factor (EGF) and the somatomedins, are important to systemic growth
requirements while serum growth factors, deriving from platelets and enzymic
conversion of plasma precursors during clotting may be important for wound
healing (616).
In introducing their 1959 report of the first defined medium supporting

growth of mammalian cells in culture at rates comparable to those obtained with
serum, Lieberman and Ove (626) outlined three major reasons for identifying the
growth factors of serum:

1) the desirability of better defined media for

biochemical and other studies, 2) the elucidation of growth requirements not
detectable in experiments with whole animals, and

3) the accumulation of a

baseline of knowledge for future investigation of comparative biochemistry and
nutrition on a cellular level.

Using a bicarbonate-buffered basal medium

composed of a mixture of amino acids, inorganic salts, glucose, reducing agents,
antibiotics and vitamins, these investigators were able to replace serum with
serum protein (flattening) factor isolated from serum, catalase, insulin and
versene

(disodium

ethylenediaminetetraacetate,

Na 2EDTA)

in

supporting

proliferation of the human epithelial cells appendix A1 and HeLa, the latter
derived from a carcinoma of the cervix. The medium did not support long-term
survival or cloning (propagation of single cells) of these cells, however, and, with
the exception of the basal medium and catalase at low inocula (20,000 cells per
flask), growth was not prevented by the omission of any single component
(including serum).

The serum protein factor was later found to be the
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globulin fetuin, a glycoprotein of molecular weight 45,000 daltons that

~robably

promotes cell proliferation by acting as a cationic bridge between the cells and
their glass or plastic suport (626-628).
It was not until the late 1960s, with the general availability of separation

methods permiting isolation of small quantities of active polypeptides from the
complex mixture of serum proteins and improvements in cell culture techniques
enabling investigators other than tissue culture specialists to study the effects of
serum factors on isolated cells in vitro, that serum growth factors such as
multiplication stimulating activity (MSA) were identified and the growthpromoting properties of plasma factors such as NSILA-8 and the somatomedins
were fully elucidated. Difficulties due to mitotic inhibitors (chalones) and toxic
factors in serum also had to be overcome (616). Prior to this time, only growth
factors such as nerve growth factor (NGF) and EGF, which are produced in
significant quantities by specific tissues and whose effects are demonstrable in
vivo, were discovered. Furthermore, as indicated by the studies of Lieberman
and Ove and others, survival factor and migration . factor activities are not
related to the stimulation of DNA synthesis and mitosis (629).
Since serum growth factors may appear to possess ILA in certain tissues
due to elicitation of a positive pleiotypic response, 1·~· stimulation of metabolic
parameters secondary to a primary induction of cell proliferation, major serum
growth factors affecting insulin target cells in culture will be reviewed in this
section.
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Nerve Growth Factor

In 1948, Bueker (630) reported the increased sensory innervation of a
mouse sarcoma implanted in the body wall of a chick embryo and soon afterward,
Levi-Montalcini and Hamburger (631) showed that the tumor also caused
hypertrophy of the sympathetic ganglia of the embryo, suggesting that the
sarcoma cells released a diffusible nerve growth factor into the circulation. In
1954, NGF was isolated from male mouse submaxillary glands, as a factor
capable of stimulating. the growth and differentiation of immature nerve cells
(632). Significant quantities of this factor have also been found in snake venoms
(633-635).

NGF is secreted in

.!!!.!:2.

by mouse neuroblastoma cells (636), 3T3

mouse fibroblasts (637), L"""Cells (virus-transformed 3T3) (637 ,638), rat glioma
cells (639), and chick embryo fibroblasts (640).

Synthesis of this factor is

stimulated by androgens (641).

In vivo, the mitogenic {!.e., processes preceeding and causing cell division,
primarily DNA synthesis) effect of NGF is restricted to the early part of
embryonic life (642).

In vitro, the factor is vital to survival of embryonic

sensory and sympathetic nerve cells.

When it is absent, most nerve cells

disintigrate; when it is present, nerve cells survive in excellent condition and
axons grow vigorously (643).

However, no mitogenic effect of NGF on nerve

cells or fibroblasts has been reported (616).

In the picogram range, NGF

enhances survival of embryonic sensory and sympathetic nerve cells in culture
(643). In the nanogram range, it stimulates neurite outgrowth (644), neurotubule
polymerization (644), anabolic metabolism (644,645), electrical excitability (646),
and acetylcholine sensitivity (646).

In the microgram range, it induces the
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regeneration of adrenergic fibers (647), stimulates an increase in cell-cell and
cell-substratum adhesiveness (648), inhibits the synthesis of mucopolysaccharides
in chondrocytes (649), and induces the enzyme systems involved in adrenergic
neurotransmitter synthesis (650). NGF elicits a positive pleiotypic response in

-

vitro that includes increased transport of glucose (651) and synthesis of RNA

(645,652}, lipids (653), proteins (652), and the specific enzymes of adrenergic

nervous

transmission,

especially

tyrosine

hydroxylase

and

dopamine

S -hydroxylase (650).
The high molecular weight NGF complex, the 7S species (M.W. 140,000),
consists of 3 subunits termed a, Sand y (654,655). The S subunit, in which the
biologic activity of NGF resides, consists of a dimer of two identical monomers
of molecular weight 13,259 daltons, containing 118 amino acids and 3 disulfide
bonds (655-658).

The

y

subunit of 7S NGF is an arginylesteropeptidase that

activates the S zymogen (molecular weight 22,000 daltons) by cleavage at a
specific arginine residue (659). A 16 percent homology between the amino acid
sequences of mouse NGF and human proinsulin suggest that both polypeptides
evolved from a common ancestral gene (616,660).

Epidermal Growth Factor (EGF)
In 1962, Cohen (661) reported the isolation from male mouse submaxillary

glands of a substance that promotes premature opening of eyes (7 days instead of
12-14 days) and eruption of incisors (6-7 days instead of 8-10 days) in newborn

mice. Also effective in newborn rats, this factor, which Cohen termed tooth-lid
factor, caused stunting of mouse growth (1/3-2/3 normal weight at 10 days) and
inhibition of hair growth (661). This epidermal growth factor (EGF) is present in
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mouse serum at a level of 1 ng/ml and stimulation of adrenergic receptors by
phenylephrine in normal adult mice leads to a marked increase in the serum
level, reaching 150 ng/ml in 1 hour (662). Levels of organ EGF may be controlled
by androgens (663).
Mouse EGF stimulates epithelial cell proliferation in a variety of organ
culture systems, from the cornea of chick embryo or human fetus (664,665) to
epithelial cells of mouse mammary glands and mammary carcinomas in organ
culture (666,667). It also stimulates keratinization and proliferation of mouse
epidermal tissue in vivo (668). Nanogram amounts of EGF are mitogenic in vitro
for epithelial cells of mouse mammary glands and mouse mammary carcinomas
(666), epidermal cells from chick embryo and human fetal cornea (664,665),
bovine corneal endothelial cells (669), human foreskin fibroblasts (670,671), 3T3
cells (672) and human glial cells (673), stimulating DNA, RNA and protein
synthesis (670,67 4), polyribosome formation and small molecule transport
(including

amino

acids, nucleotides and sugars) and

inducing ornithine

decarboxylase (616,675). Human EGF not only induces DNA synthesis in human
foreskin fibroblasts, but also increases the final cell density attained in the
presence of 196 or 1096 calf serum (676). Thus EGF, by itself,cannot completely
satisfy the serum requirement of mammalian cells in culture. EGF has also been
shown to stimulate cell migration in aggregates of chick embryo epidermal cells
(668) and the synthesis of prostaglandins in cultures of canine kidney cells (677),
but is not mitogenic for WI38 human lung fibroblasts (678), nor does it exhibit
ILA in adipocytes (652).
Cohen (661) originally purified EGF from homogenates of male mouse
submaxillary glands by centrifugation, streptomycin and 5696 ammonium sulfate
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precipitations, dialysis, carboxymethyl (CM)-cellulose and DEAE-cellulose ionexchange chromatography, Sephadex G-75 gel chromatography and Sephadex G25 gel filtration, achieving a 2096 yield and 150-fold purification. The product
was homogeneous in ultracentrifugation, paper chromatography and paper
electrophoresis, was heat-stable (l00°C for 30 mimutes), but was destroyed by
0.1 N sodium hydroxide at 100°C for 1 hour, 0.2 N hydrochloric acid at 100°C for
2 hours, chymotrypsin and bacterial proteinase.

It exhibited a sedimentation

coefficient of 1.25 S and a pi of 4.2. Amino acid analysis revealed the absence
of lysine and phenylalanine and a miminum molecular weight of about 15,000
daltons.

Taylor et al. (679,680) have isolated mouse EGF by the method of

Cohen (661) with additional gel filtration steps and have shown it to be a singlechain polypeptide of molecular weight 6,045 daltons, consisting of 53 amino acids
and 3 disulfide bonds, all of which are necessary for biologic activity. It exhibits
a pi of 4.6 and possesses no carbohydrate, lysine, phenylalanine or alanine. The
amino acid sequence of EGF reveals no homology with insulin (681,682). Human
urine EGF differs from mouse EGF in amino acid composition, a more neutral pi
and lower molecular weight (5,300-5,500 daltons) (676).
The mitogenic effect of EGF on human fibroblasts is inhibited by
dibutyryl cyclic AMP, theophylline and cholera toxin (674), suggesting that this
factor acts by reducing intracellular cyclic A"\fP levels. Specific EGF receptors
have been found on human, mouse, rat and chick cells (674). Human foreskin
fibroblasts can bind 10 5 EGF molecules per cell with a Kn of 2-4 x 10-10 M
(678). EGF receptors are lost after transformation of cells with murine or feline
sarcoma viruses, but not after transformation with the DNA tumor viruses
polyoma and SV40 (683). No other peptide hormones complete for EGF receptors
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(674); likewise, EGF does not compete for insulin or NSILA-8 receptors
(614,670). Mouse EGF has been shown to be associated with a high molecular
weight carrier protein in crude homogenates of submaxillary gland. This carrier
protein possesses arginyl esterase activity and may be responsible for the release
of active EGF from a higher molecular weight precursor since active EGF has a
c-terminal arginine (679,681).

Multiplication Stimulating Activity (MSA)
About 10 years ago, Temin suggested that, since growth factors in serum
must be produced by some cell in the body, and since all cells in an organism
possess the same genetic information, it might occur that cells could adapt to
serum-free culture by producing their own growth factors. This consideration
led Temin to investigate the components of a medium conditioned by the growth
of Coon rat liver cells, a cell line that does not require serum. He and his coworkers purified the growth-promoting activity in this conditioned medium,
which

stimulated

DNA synthesis

in

chick fibroblasts,

and

termed

it

multiplication stimulating activity (MSA) (629). Previously, Pierson and
Temin (684) had purified MSA from calf serum. These investigators found that
MSA stimulates chick embryo fibroblast (CEF) DNA synthesis and mitosis, as
well as cell proliferation.

The factor also stimulates uridine, glucose and

a - aminoisobutyrate (AlB) uptake (629). The stimulation of glucose uptake is

primary,

1·~·

it is not inhibited by actinomycin D or cycloheximide, but

stimulation of AlB uptake was inhibited by actinomycin D, indicating that MSAenhancement of amino acid transport is dependent on protein synthesis. They
found a definite correlation between stimulation of glucose uptake and DNA
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synthesis by MSA, but not by serum, suggesting that increased glucose uptake
does not necessarily cause DNA synthesis.

MSA had no effect on leucine or

phosphate uptake or cell migration or survival. This factor possesses sulfation
factor activity and NSILA, leading Smith and Temin (629) to conclude that MSA
belongs to a family of polypeptides, including insulin, NSILA-s and the
somatomedins, that exhibits ILA. MSA was also shown to support growth of and
exhibit mitogenic activity including stimulation of DNA synthesis (although to a
lesser extent than serum) in rat embryo, 3T3 and human fibroblasts (685-688).
Pierson and Temin (629) utilized Antoniades' method of BI isolation for
initial purification of MSA from calf serum.

Dowex SOw cation exchange

chromatography of the whole serum resulted in retention of 20-3096 total CEF
mitogenic activity by the resin.

This material was further purified by gel

filtration and polyacrylamide gel electrophoresis, yielding a fraction that was
6,000-8,000 times more active than whole calf serum in stimulating CEF
proliferation, but possessing only 0.596 insulin ILA. A molecular weight of 4,0005,000 daltons was determined for this preparation, which was stable to heat and
acid and sensitive to periodate, chymotrypsin and dithiothreitol. When Dulak and
Temin (685,689) purified MSA from Coon rat liver cell conditioned medium by
salt precipitation, ion-exchange chromatography, and gel filtration, they
obtained 4 differently charged polypeptides (pi

= 5.7-7 .1),

all exhibiting a

molecular weight of about 10,000 daltons.
Specific MSA receptors have been demonstrated in CEF and rat liver
membranes (687 ,690). Cell binding of MSA was inhibited by NSILA-s and S'!\fA.
Proinsulin and insulin inhibited MSA receptor binding in CEF and human
fibroblasts, while SMB, EGF, fibroblast growth factor (FGF) and NGF had no
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effect on MSA binding; SMC exhibited 1% cross-reactivity with MSA receptors
(690).

Cells established in culture from human fibrosarcomas were unable to

bind MSA, but human renal cell carcinomas, chondrosarcoma and glioblastomas
in culture retain the ability to bind MSA (691). MSA competes with insulin for
binding at rat liver cell membranes (629) and is as active as NSILA-8 in
competing for the NSILA-S receptor (614).

Fibroblast Growth Factor (FGF)
While isolating well-characterized hormones such as thyrotropin and
luteinizing hormone from pituitary glands, several investigators noted that partly
purified preparations exhibited growth-promoting and mitogenic effects in 3T3
cells, but highly purified hormones did not, suggesting that the pituitary gland
produces an active mitogen besides the familiar melange of hormones
(618,692,693). The first isolation and purification of FGF, from bovine pituitary
glands, was reported by Gospodarowicz in 1975 (694). A growth factor has also
been purified from bovine brain which is physically and biologically similar to
pituitary FGF (695}.
FGF is a potent mitogen for cells derived from the embryonic mesoderm,
including mouse and human fibroblasts, chondrocytes, adrenal cells, vascular
endothelial cells, bovine myoblasts, primate smooth muscle, glial cells, cornea
endothelial cells and amniotic cells (616,669,695-704}, but not for ectodermal
(e.g_., epidermal and adenohypophyseal} or endodermal (e.g., liver and pancreas)
cells (669), nor for WI38 fibroblasts (698), avian fibroblasts (including CEF} and
myoblasts (701}, and SV40 and polyoma-transformed cells (705).
Initiation of DNA synthesis in resting sparse cultures of 3T3 cells can be
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obtained at concentrations of FGF as low as 10 pg/ml, and a plateau has been
obServed at 1 ng/ml in 3T3 cells maintained quiescent in the presence of
glucocorticoids (695).

However, the effect of FGF alone on the initiation of

DNA synthesis is 30% that of serum, and a combination of FGF and
glucocorticoids is required to replace serum. FGF and glucocorticoids not only
initiate DNA synthesis in 3T3 cells, but also induce cell division in both sparse
and confluent cultures (697). In density-inhibited cultures, FGF alone or FGF
plus glucocorticoids provokes a morphological transformation that makes the
cells appear virus-transformed (706). Upon removal of FGF, the cells revert to
their normal morphology.
Human foreskin fibroblasts respond to nanogram concentrations of FGF
(698). However, the effect of FGF on these cells differs from that observed with
3T3 cells in two respects: 1) glucocorticoids have no effect or are inhibitory,
and 2) the mitogenic effect of FGF is dependent on the serum concentrations in
which the cells are maintained.

In low serum ( <0.6%), FGF has little or no

effect. In high serum (>2.5%), it has a strong mitogenic effect, additive over the
effect of serum, and it reduces the doubling time of the human foreskin
fibroblasts from 48 to 24 hours, indicating that the division of early passage
fibroblasts is not controlled by the same system of steroids and macromolecules
as is the division of 3T3 cells.
In susceptible cells, FGF stimulates transport of sugars, nucleotides and

amino acids, polyribosome formation, and synthesis of messenger RNA, transfer
RNA and proteins as well as DNA (707), but the factor does not possess ILA
(616), nor does it compete for NSILA-8 receptors on liver plasma membranes
(614).
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FGF purified from bovine pituitary glands by acid and ammonium sulfate
precipitation, dialysis, and ion-exchange and gel chromatography exhibits a pi of
9.5 and a molecular weight of 13,400 daltons (694,700). The factor does not
inhibit adenylate cyclase, indicating that decreased intracellular levels of cAMP
do not mediate its effects, but it may stimulate guanylate cyclase activity in
3T3 cell plasma membranes (708).

Other Growth Factors
Ross et al. (624) demonstrated that addition of medium in which platelets
had been incubated with thrombin renders plasma as effective as serum in
supporting growth of pigtail macaque arterial smooth muscle cells. Kohler and
Lipton (623) found that addition of platelet extract to 3T3 cells maintained in
low concentrations of plasma induces a resumption of growth similar to that
observed with serum.

Gospodarowicz et al. (625) confirmed these results and

showed that FGF and glucocorticoids could substitute for the platelet extract,
suggesting that FGF could be similar to the platelet factor. Paul (709) showed
that 3T3 DNA synthesis and cell division in response to FGF, insulin and
dexamethasone requires the presence of two serum factors, a
survival factor and a

SOO,OOO~alton

158,000~alton

serum growth factor. SV-40-transformed

3T3, the growth of which is also serum dependent, require the serum factors but
not the hormones for mitogenesis.
Katsuda et al. (710) found that most serum mitogenic activity for Yoshida
ascites tumor cells was associated with an a-globulin and the albumin fraction.
Holmes and Wolfe (711) isolated a -globulin- and albumin -containing serum
protein fractions with growth-1>romoting activities for HeLa and Chang
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endothelial cells.

Healy and Parker (712) found that serum growth-promoting

activity for mouse embryo fibroblasts was associated with an a 2-macroglobulin
and an a1-acid glycoprotein.

The role of a 2-macroglobulin appears to be

protective, since it could be replaced by nonprotein polymers. In later studies,
these investigators isolated a serum fraction composed of three components that
could reduce (at 250 IJg/ml) the doubling time of mouse embryo fibroblasts from
4 days to 1 day (628). Holmes has prepared an

a~lobulin

from human serum

that can stimulate (at concentrations as low as 0.4 1-1 g/ml) the proliferation of
HeLa, conjunctiva and human heart cells, an effect that cannot be duplicated by
insulin (713 ).
Holley and Kiernan (714) purified a serum growth-promoting activity for
3T3 cells from B~lobulins by gel chromatography at low pH.

This fraction,

which stimulated 3T3 division at 11Jg/ml, exhibited a molecular weight of about
20,000 daltons and required one or more other serum factors to elicit an effect
comparable to that of serum.

Hoffmann et al. (715) isolated from FBS two

proteins, termed 81 and s2,that together optimally stimulated the growth of
embryonic rat fibroblasts. s 1 was found to be a complex of insulin and an a 2macroglobulin, both of which are necessary for growth stimulation. s 2 exhibits a
molecular weight of 26,000 daltons and a pi of 4.9, and does not cross-react
immunologically with 81.
Houck and Cheng (716) purfied a serum sialoglycoprotein mitogenic for
WI38 fibroblasts. It has a molecular weight of 120,000 daltons and a pi of 5.25.4; besides sialic acid, it contains hexose and its activity is destroyed by both
trypsin and neuraminidase. The factor comprises 0.5% of total serum protein
and 50 IJg/ml is as effective as 10% FBS in supporting WI38 proliferation. Since
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other serum growth factors such as MSA, EGF and FGF are roughly one-tenth
the molecular weight and active at one thousandth the concentration, this
species may represent a complex between a smaller active molecule and its
carrier protein, a possibility supported by the fact that activity is partially lost
during ion-exchange chromatography and high-current electrophoresis.

JLA, Revisited
When Antoniades et

.!!!·

(717) re-examined serum substances retained by

Dowex 50w x 8 cation exchange resin (BI) for growth-promoting activity in vitro,
they found that the ability of human serum to cause 3T3 division almost
completely resides in Bl.

This fraction induces DNA synthesis and mitosis in

confiuent 3T3 cells, but does not promote cell survival and does not possess
Insulin immunoreactivity. The mitogenic activity is heat stable (100°C, 20 min.),
but was 75% abolished by trypsin or chymotrypsin and completely abolished by
mercaptoethanol. The BI ILA eluted from Sephadex G-100 in a molecular weight
range of >100,000 to about 30,000 daltons, while mitogenic activity was found
at 10,000-35,000 daltons. Isoelectric focusing revealed at least two mitogens,
one co-eluting with ILA (pi

= 7.3-9.4)

that exhibited a pi of 8.6-8.8 and a

molecular weight of about 30,000 daltons and the other free of ILA, with a pi of
9.6-9.9 and a molecular weight of 13,000 daltons. About 8 ng protein (equivalent
to 8 ml serum) from the latter fraction was sufficient to induce DNA synthesis in
8796 of 3T3 cells in a confiuent monolayer and cell division, and to cause the
cells to assume a random orientation characteristic of transformation. Thus, the
latter mitogen may be FGF while the ILA fractions probably contained NSILA-8
and somatomedins.
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As previously mentioned, sulfation factor activity of NSILA-8 at
concentrations found in blood and the somatotropin dependence of these
concentrations indicate that the physiologic role of NSILA-8 is that of a growth
factor.

This substance also displays significant growth-promoting activity in

Morell and Froesch (554) found a 1.5- to 4-fold increase in DNA synthesis
-vitro.
by CEF 8 hours after addition of 10-100
U (21-213 ng) NSILA-S/ml.
\.1

Furthermore, 10-100

\.1 U

NSILA-8/ml caused a twofold increase in CEF glucose

uptake and lactate production 21 hours after addition, and a twofold increase in
cell number after 4 days in the presence of 300 \.lU NSILA-S/ml was noted, but
NSILA-S was far less potent than FBS in this respect. Rinderknecht and Humbel
(549) observed a linear response of thymidine incorporation into CEF DNA in the
presence of 0.75-25 ng NSILA I or ll/ml with a maximal 4-fold stimulation
attained at 250 ng/ml.

Half-maximal stimulation occurred at 1.6 nM (9.3

ng/ml). Stimulation of CEF ornithine decarboxylase activity by NSILA-S has also
been demonstrated (718).
Rechler et al. (555) showed that for human fibroblasts NSILA-8 increases
the fraction of cell nuclei incorporating thymidine and stimulates thymidine
uptake as well as incorporation into DNA. Stimulation of DNA synthesis was
detected at 50 ng NSILA-8/ml, half-maximal stimulation occurred at 150 ng/ml,
and a maximal 5.4-fold stimulation of DNA synthesis was attained at 500 ng/ml
whereas 5% FBS induced a maximal 50-fold increase in DNA synthesis.
Destruction of disulfide bonds by reduction and aminoethylation abolished the
ability of NSILA-8 to stimulate DNA synthesis.

Combined additon to human

fibroblast cultures of maximally effective concentrations of insulin and NSILA-S
did not result in additive stimulation, suggesting that insulin and NSILA-8 act at
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a common point while serum induces DNA synthesis by a different mechanism.
In view of its growth-promoting properties and its striking homology with

insulin, Rinderknecht and Humbel (550) proposed a new designation for NSILA-5:
insulin-like growth factor (IGF) and termed NSILA I and U IGF I and U. During
purification and characterization of MSA, it became apparent that this factor
possesses physicochemical properties very similar to NSILA (684), and
Poffenbarger (563) found that an antiserum raised against NSILP also reacts with
MSA.
Salmon and Hosse (719) found that partially purified somatomedins
prepared from calf serum stimulate the growth of HeLa cells in a defined
medium deprived of serum.
concentration of 23

JJg

When this preparation was present in a

protein/ml, cell proliferation after 3 days was twice that

of control cultures. SMB stimulates initiation of DNA synthesis in cultured glial
cells at a concentration of 15 J..1 g/ml, whereas 45 ng/ml is sufficient to induce a
30% increase in lung fibroblast proliferation (720). SMB also stimulates DNA
synthesis in fibroblasts (573). However, Heldin et al. (721) have found that the
mitogenic effect of SMB on cultured human glial cells is neutralized by rabbit
anti-EGF IgG and that their preparation of SMB competes with 125 I-EGF for
binding to these cells, 10 J..1g SMB containing the equivalent of about 2 ng EGF,
indicating that SMB mitogenesis may be due to contaminating EGF. SMC is
mitogenic for cultured human fibroblasts and fetal rat hepatocytes, with a 3- to
4-fold stimulation of DNA synthesis by the latter cells in the presence of 0.01-1
J..1gSMC/ml being observed (598,722).

Thus, NSILA-5, SMA, SMC, MSA and

perhaps NGF may belong to a family of closely'1"elated IGFs.
Curiously, the oldest known growth-potentiating factor in vitro is
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insulin. Within three years after Banting and Best isolated the hormone, Gey and
Thalhimer reported an insulin-induced enhancement of CEF growth and glucose
uptake in tissue culture (723). Subsequent studies demonstrated that these are
consistent effects of the hormone on cultured fibroblasts, but pharmacologic
doses (>0.8 mU/ml) of insulin were always required to elicit an increment in cell
proliferation.

However, several investigators reported an insulin-induced

potentiation of fibroblast growth, but not glucose uptake, in the presence of 82096 serum (724-726).
Lieberman and Ove (626) found a fourfold stimulation of Appendix A1 and
HeLa proliferation in culture by 40 mU insulin/mi. The same effect was obtained
with 5-times recrystallized insulin and was abolished by treatment of insulin with
cysteine, indicating that it was due to the hormone rather than a contaminant.
No increment in the rate of glucose uptake by A1 cells during log'1>hase growth
in the presence of 130 J..l U-130 mU insulin/ml was seen, but 40 mU/ml caused a
6796 increase of this rate in confluent cultures. Temin showed that insulin (> 8 ng
or 200 J,JU/ml) .can stimulate thymidine incorporation into CEF DNA to

one~ixth

the maximum achieved with serum, but the hormone is 250,000 times less potent
than serum in this regard (727).

He also demonstrated that both serum and

insulin elicit their mitogenic effects by inducing cells to move out of G1 phase.
Griffiths (621) found that 1 mU insulin/ml causes protein synthesis and
cell division as well as DNA synthesis in confluent MRC-5 human diploid
fibroblasts .and also potentiates the effects of serum. He postulated that the
hormone's mitogenic effect may be due to its stimulation of amino acid uptake
and protein synthesis.

De Asua et al. (331) showed that 8 J..l g insulin/ml with

serum could induce baby hamster kidney (BHK) cells to reach higher final
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densities than with serum alone, while Clarke et al. (619) showed that 10 f.lg
insulin/ml potentiates the effect of serum on BHK DNA synthesis.

In 1973,

Morell and Froesch (554) reported a 3- to 4-fold stimulation of CEF DNA
synthesis by 10-100 mU insulin/ml as well as a 33-167% stimulation of glucose
uptake and a 30-150% stimulation of lactate production in these cells by 1-100
mU insulin/mI.

These investigators observed a 1.5-fold increase in CEF

proliferation after 4 days with 300 mU insulin/ml, half that obtained with 5%
FBS, but could demonstrate no effect of physiologic insulin concentrations (<1
mU/ml) on CEF and Wl38. Nor could they find any insulin effect on fibroblast
growth and glucose consumption in the presence of as little as 5% FBS, contrary
to previous studies.
Leffert (722) showed a 3- to 6-fold stimulation of DNA synthesis in
cultured fetal rat hepatocytes by 10 ng (250 f.! U)-10 f.lg insulin/ml, but 10% FBS
caused a 4.5-fold greater stimulation of DNA synthesis than 10 f.lg insulin/mi.
Rechler et al. (555) reported that stimulation of DNA synthesis in human
fibroblasts could be detected with 20 ng insulin/ml, half-maximal stimulation
occurred at 0.4 f.lg/ml and a maximal 2.5-fold stimulation was obtained with 20 g
insulin/mi. Insulin also increased the fraction of cells incorporating thymidine
and thymidine uptake. A 40% stimulation of DNA synthesis in human foreskin
fibroblasts was observed by Hollenberg and Cuatrecasas at insulin concentrations
as low as 40 ng/ml (222).
The finding that pharmacologic doses of insulin exhibit sulfation factor
activity in rat cartilage (560) supports the contention that pharmacologic doses
of insulin exert growth-potentiating effects on cells and pharmacologic
concentrations of IGFs exhibit ILA due to cross4'eaction with each other's
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receptors (728) and that insulin and the IGFs derive from a single ancestral gene
via duplication and divergence early in vertebrate evolution.
In summary, serum ILA, or "atypical insulin," apparently is due to IGFs

whose role in vivo is that of growth-promoting agents. However, the results of
Guenther (387), who found heparin-induced IRI in BI fractions and heparin and
biotin enhancement of BI ILA in the rat diaphragm assay, revive the possibility
of a serum insulin-binding protein important to systemic, insulin-dependent
metabolic homeostasis.

Futhermore, demonstration of serum binding proteins

for IGFs dispels the notion that polypeptide hormone binding proteins cannot
exist and makes a serum insulin-binding protein a plausible expectation. The
methods employed by Zapf ~ al. (557) to elucidate the NSILA-8 binding protein
of serum should be applied to this question using heparin and biotin as possible
potentiators of complex dissociation. These agents should also be utilized in a
systematic study of serum fractions with an in vitro bioassay capable of
discriminating the effects of physiologic concentrations of insulin from those of
growth factors, the kind of assay that proved vital to the elucidation of serum
growth factors: mammalian cells in culture.

TABLE V.

PROPERTIES OF CERTAIN COMPOUNDS EXHIBITING !LA AND OF GROWTH FACTORS

Compound

Mol. Wt.
(kd)

Electr.
Mobility
or (pi)

Typical Insulin

5-7.5

albumin-

Sol. in
acidethanol

s

Biol. Act.
(% TI)

100

(% TI)

RRA

(% TI)

IRI

Reference

100

100

102,104,115
116

136,138,182,
464

ctl

Insulin Aggreg.
Dimer

10-12.3

0-15

1.1-1.9

0-11

Hexamer

35.1-36

<15

<1.9

<11

143,464

>Hexamer

72
200-300

0

0

143,464

45

182,452,460
461,486,487
489,490

45

452,461

61

461

0

Insulin Precurs.
Pro insulin

Split Proins.

(leu ~-a~a;
bond 5 pl1.t 5

Desdipeptide
Proinsulin
(lysRt-arg63
abse )

8-9

s

2.5-18

3-20

58-100

20-28

t-:1
t-:1
t-..~

TABLE V. (CONTINUED)
Compound

Mol. Wt.
(kd)

Electr.
Mobility
or (pi)

Sol. in Biol. Act.
acid(% TI)
ethanol

RRA

(% TI)

IRI

Reference

(io TI)

Desnonapeptide
Pro insulin
(sequence 5563 absent)

60-90

61

452,461

Diarginine
Insulin
(+arg31-arg32)

60-90

80

452,461

Mono arginine
Insulin (+arg31)

60-90

67

461

"Bound Insulin"

60-100

8-y

I

8-lBa
100

0

390,391,501504,511-514

oc

NSILA
(8.2)

s

NSILA-S

7.5

NSILA-S/
carrier

50-70

s

NSILA I

5.8

NSILA II

5.9

s
s

2

2

548,549,555,
565
547

1.6

~49

1.6

549

N
N

w

TABLE V. (CONTINUED)
Compound

Mol. Wt.
(kd)

NSILA-P

100-150

NSILP
Somatomedins

90
6-8

SMA

7

SMB

5

SMC

7

Electr.
Mobility
or (pi)

Sol. in Biol. Act.
(% TI)
acidethanol

RRA

(% TI)

IRI

(% TI)

I

546,547
563

(6.2)

a
(7.1-7.5)
Cl

(5.9-6.4)
(9-10)

Reference

s
s

573,577,578
5.6

s
s

0.8-1.4

0.1

573,577,597,
599,609,612

<0.01

585,602,609
729

1.4

3.4

0

573,598,599,
606-608,612
603

Growth Factors
Nerve Growth
Factor (NGF)
Epidermal
Growth Factor
(EGF)

13.3

(9.3)

6.0

(4.6)

656
0

0

614,670,679,
680
N
N

~

TABLE V. (CONTINUED)
Compound

Mol. Wt.
(kd)

Multiplication
Stimulating
Activity (11SA)
Fibroblast
Growth
Factor (FGF)
WI38 Growth
Factor

10

13.4

120

Electr.
Mobility
or (pi)
(5.7-7.1)

(9.5)

Sol. in Biol. Act.
acid(% TI)
ethanol
0.5

0

(5.2-5.4)

a.

diaphragm assay

b.

fat pad assay; diaphragm assay + ATE or heparin

c.

by definition

RRA
('7o TI)

IRI

Reference

('7o TI)

0

629,684,685,
689
616,694,700

716

CHAPTER VI

MATERIALS AND METHODS

DEXTRAN-CHARCOAL INSULIN RIA

The method is a modification of that described by Herbert et al. (423),
as follows:

Barbital-acetate buffer, pH 7.4, consists of 1.471 grams sodium barbital, 0.971
grams sodium acetate, 7.65 grams sodium chloride, and 50 ml 0.1 N hydrochloric acid per liter aqueous solution.

Albumin buffer is prepared by adding 7 ml 5% human serum albumin ("Albumisol", Merck, Sharp and Dohme, West Point, Pa.) to 93 ml barbital-acetate
buffer to a final albumin concentration of 3.5 mg/ml (0.35%).

Dextran-coated charcoal suspension consists of 2.5 grams Norit A charcoal
(Matheson, Coleman and Bell, Norwood, Ohio) and 0.25 grams Dextran T-70
(Pharmacia Fine Chemicals, Piscataway, N.J.) per 100 ml barbital-acetate
buffer.
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Antiserum
Guinea pig anti-porcine insulin serum was a gift from Dr. Peter Wright,
was diluted 1:1,000 with albumin buffer, divided into aliquots, and stored at 65°C. One milliliter of this solution is mixed with 199 ml albumin buffer to
make a working antiserum dilution of 1:200,000.

One-tenth ml of working

antiserum is added to each assay tube for a final antiserum dilution of
1:1,600,000.

Insulin standard is prepared by dissolving 0.58 units human insulin (lot 25810648-27, obtained from Dr. Mary K. Root, Eli Lilly and Co., Indianapolis, lnd)
in 5.8 ml 0.01 N HCl.

This 100 mU/ml solution is diluted 1,000-fold with

albumin buffer to provide a 100 lJU/ml stock solution that is stored at -20°C.
This standard is diluted with albumin buffer to produce 5, 10, 15, 20, 30, and 40
lJ U/ml standards.

1251-msu
. li n
1251-bovine insulin

was purchased from

Amersham/Searle Corp.,

Arlington Heights, Til., in quantities of 5 microCuries ( ~Ci)/0.1

~

g in 5 ml

albumin buffer. The contents of one vial are mixed with 195 ml albumin buffer
to make a stock label of 0.5 ng 1251-insulin/ml with an activity of approximately 8, 800 dpm/0.1 ml.

The final incubation volume in each tube is 0.8 ml; 0.1 ml standard or
sample (undiluted, 1:5 or 1:20 dilution of serum) is mixed with 0.1 ml 1:200,000
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antiserum solution. Neither component is added to nonspecific binding (NS8)
tubes for standards and 0.1 ml of an appropriate pooled serum dilution alone is
used for NS8 tubes for samples; 0.1 ml antiserum alone is used for the zerostandard. The volume of each tube is brought to 0. 7 ml with albumin buffer.
After a 2-day incubation at 4°C, 0.1 ml 1251-insulin solution is added to each
tube and incubation is continued at 4°C for another 2 days.

Four-tenths ml

dextran-charcoal suspension is then added to each assay tube, which is vortexed
and centrifuged at 500 x g for 10 minutes.

The supernate is decanted into

another 12 x 75 mm culture tube and both are counted in an LK8 80000 gamma
ray spectrophotometer for one minute each.

Data Reduction
Percent 1251-insulin bound to antibody (not adsorbed to charcoal) in
each sample is calculated as

CPM sample spnt.- CPM NS8
%8=

X

100;

(CPM sample spnt. + ppt.)- CPM NS8
%8 0 =%B standard or sample /%8 zero standard.
The insulin concentration of samples was determined from a linearized doseresponse curve prepared by plotting %8 0 of standards relative to their insulin
concentrations on logit-log graph paper. Sample %8 and insulin concentration
0

in

lJ U/ml

were calculated from supernate and precipitate CPM using a Wang

desk computer program into which was entered the parameters of 50%
intercept, y-intercept, and slope from the manual plot.
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The insulin RIA described above was employed routinely during 19741975 for clinical determination of serum insulin levels for the Foster G. McGaw
Hospital, Maywood, Illinois.

Addition of Heparin to Insulin Standards
Twenty or 200 mg sodium heparin (Nutritional Biochemicals, Cleveland,
Ohio) was dissolved in 10 ml barbital-acetate buffer to produce 2 mg/ml and 20
mg/ml solutions, respectively.

Equal volumes of these solutions and insulin

standards were mixed and incubated 3 hours at 25°C; 0.2 ml solution was added
to assay tubes instead of 0.1 ml standard for a final heparin concentration of
0.25 or 2.5 mg/ml.

DOUBLE-ANTIBODY INSUUN RIA

The assay is a modification of the method of Morgan and Lazarow (435).

Reagents
1.

Albumin buffer: 0.35% bovine serum albumin (BSA) (Sigma Chern. Co.,
St. Louis, Mo.) in barbital-acetate buffer, pH 7.4.

2.

EDTA: 0.1 M Na EDTA (Mallincrodt, Inc., Paris, Ky.).
2

3.

Standards: 5, 10, 15, 20, 30, and 40

J.l U/ml

human insulin standard

(Burroughs Wellcome, Research Triangle Park, N.C.) in albumin buffer.
4.

Controls and unknowns: human plasma or serum samples undiluted or
diluted appropriately with albumin buffer.
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s.

Anti-insulin serum (AIS): 1:50,000 AIS (Burroughs Wellcome) in albumin
buffer.

6.

Trace: 0.5 ng/ml 1251-bovine insulin (New England Nuclear, Boston,
Mass.) in albumin buffer, after purification through 25 ml Sephadex G50.

7.

Second antibody: 1:8 anti-guinea pig serum (Burroughs Well com e) in
albumin buffer.

8.

Carrier protein: 1:200 guinea pig serum (Gibco, Grand Island, N.Y.) in
albumin buffer.

The reagents are mixed in 12 x 75 ml glass culture tubes and treated
according to the protocol outlined in Table VI.

Precipitates (antibody-bound

radioactivity) were counted in a Picker Pace-1 automatic gamma ray spectrophotometer (Picker Corp., Highland Heights, Ohio).

Data Reduction
%B

=

CPM sample - CPM NSB
CPM total count - CPM NSB

x 100.

Logit-log standard curves were prepared as described for the dextran-charcoal
assay. Insulin concentrations of samples were also calculated using a Wang desk
computer program.

231
TABLE VI.
DOUBLE-ANTIBODY INSULIN RADIOIMMUNOASSAY PROTOCOL

Sample

Albumin

Standard Unknown or EDTA
buffer
control

. li n
AIS 1251-msu

ml added
Total
count

0.9

0

0

0

0

0.1

NSB

0.8

0

0

0.1

0

0.1

Bo

0.7

0

0

0.1

0.1

0.1

Stds.

0.6

0.1

0

0.1

0.1

0.1

Unknowns

0.6

0

0.1

0.1

0.1

0.1

& Control

Incubate 72 hr. at 4°C.
Add 0.1 ml 1:200 guinea pig serum + 0.1 ml 1:8 anti-G PS to each tube, except
Total Counts.

Incubate 48 hr. at 4° C.

Centifuge at 2,000 x g 20 min., 4° C.; aspirate supernate; wash 1X with
barbital-acetate buffer; count precipitates (except Total Counts).
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CATION-EXCHANGE CHROMATOGRAPHY OF HUMAN PLASMA

The method is that described by Guenther (387). Ten grams Sephadex
c-50 (carboxymethyl-Sephadex, Pharmacia) was allowed to swell in 900 ml
0.005 M ammonium carbonate buffer, pH 7.8, overnight at room temperature.
Two units of outdated citrate-phosphate-dextrose (CPD) plasma from
separate donors, obtained from the Foster G. McGaw Hospital blood bank, were
pooled and centrifuged at 1,500 x g for 20 minutes, 4°C. The 450 ml recovered
was mixed with the gel after aspiration of the supernatant buffer and stirred
for 3 hours at 4°C. The mixture was poured over a double layer of cheesecloth
in a Buchner funnel to which was applied mild suction. The residue was kept
constantly covered with a wash solution of cold deionized water until the
filtrate was clear.
A 2.5 x 100 em glass column (Bio Rad Laboratories, Richmond, Ca.) was
packed with the gel (column and accessory equipment were kept in a cold room
at 4°C) and 0.005 M (NH ) co , pH 7.8, was run through the column until a
42 3
steady baseline (as monitored by an LKB Uvicord m, LKB Instruments, Inc.,
Rockville, Md, and recorded on an LKB Biocal recorder Type 6520-5) was
obtained
A one-liter salt gradient of 0.005 to 1.5 M potassium chloride was
applied to the column using a two-chamber plexiglass gradient mixer and
dispenser, specially constructed by the Experimental Medical Shop, University
of Missouri, the flow was maintained at 30 ml per hour with an LKB 10200
Perpex peristaltic pump, and 5 ml fractions were collected with a Buchler
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Fracto Mette 200 automatic fraction collector (Buchler Instruments, Inc., Fort
Lee, N.J.). The column was further eluted with 1.5 M KCl for 24 hours.
The gradient was traced by determining the osmolality of selected
fractions using a model 68-3L Advanced osmometer (Advanced Instruments,
Inc., Needham Heights, Mass.). Fractions exhibiting ultraviolet absorption at
280 nm (A

> were pooled. The protein content of each major fraction was
280
estimated from A280 using E~"81 ~ = 1.0 and 2 ml of each were reserved for
determination of ffii with and without heparin using the dextran-charcoal RIA.

Fractions were adjusted to pH 7.3

0.1 with 0.01 or 1.0 N acetic acid or 0.001

or 0.01 N potassium hydroxide, were then lyophilized, and were stored dessicated at -20°C. Fractions exceeding 140 ml volume were concentrated through
UM 10 membranes (molecular weight cutoff

= 10,000

daltons; Amicon Corp.,

Danvers, Mass.) in an ultrafiltration cell (Amicon) to 50 ml and those exceeding
a salt concentration of 0.3 M were diluted to 0.005 M by repeated addition of
water and

~oncentration

through UM 10 membranes before lyophilization.

For the RIA, lyophilized fractions were dissolved or suspended in water
at a protein concentration of 2.5-10 mg/ml and a salt concentration of 0.050.31 M. Heparin was added to pooled fractions at a concentration of about 40
JJ g/mg

protein and to reconstituted fractions at a concentration of 100

(1Q-40

JJ

lJ g/ml

g/mg protein), which were then incubated at 33°C for 30 minutes and

assayed relative to standards containing a comparable amount of heparin.
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IMMUNOREACTIVE ENDOGENOUS INSULIN DETERMINATION AND EXOGENOUS
INSULIN RECOVERY FROM VARIOUS SERUM AND PLASMA SAMPLES

N- pooled normal serum

serum:

SS (stripped serum) -pooled serum treated with Amberlite IRA 400
(anion exchanger; J.T. Baker Chern. Co., Phillipsburg, N.J.) 24 hr. at
4°C.
Plasma:

P- citrated plasma from a single donor (outdated)
SP (stripped plasma) - citrated plasma from two donors, treated
with Amberlite rnA 400 24 hr. at 4°C.

Recoveries: 69 or 104 1-1 U of human insulin standard was added to 1.0 ml of
each of the above samples.

Significance of comparisons was determined by

Student's t test (730).
Heparin:

11 mg sodium heparin (Sigma) was dissolved in 1.1 ml deionized
water.

Ten 1-11 was added to 1.0 ml each of N, SS, P, SP, and

recoveries.
Biotin:

8 mg of D-biotin (Sigma) was dissolved in 8 ml hot saline. Ten 1-11 (10
1-1 g) was added to 1.0 ml each of N, SS, P, SP, and recoveries.

For replicate samples, 10 mg D-biotin was dissolved in 0.1 N NaOH
dropwise.

The alkaline solution was brought to 10 ml with barbital-acetate

buffer, pH 7.4, for a 1 mg/ml solution. Ten 1-11 (10 llg) was added to each sample
immediately before incubation. Separate standard curves for control, heparin
and biotin additions were included. All assay tubes were incubated 30 minutes
at 37°C before assay with the dextran-charcoal RIA.
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SEPHADEX CHROMATOGRAPHY OF UNTREATED AND TREATED HUMAN SERUM
AND PLASMA SAMPLES CONTAINING EXOGENOUS RADIOLABELED
AND UNLABELLED INSULIN

Initial Chromatography
1251-insulin (10

).l

Ci) was purchased from New England Nuclear Corp.

and was twice purified on a 25 ml Sephadex G-50 disposable column.

The

purified product was divided into three equal parts, which were lyophilized and
stored at -20°C for no more than one week before use. A serum pool of 30 ml
was prepared from three normal donors and stored at -20°C in three aliquots of
9.9 ml each before use. Biotin solutions were prepared as in the recovery study
immediately before use.

A 2.6 x 90 em (477 ml) Sephadex G-200 column was

prepared and equilibrated with barbital - acetate buffer.

The column was

calibrated with a mixture of 25 mg blue dextran (Pharmacia), 40 mg catalase (2
ml Boehringer crystalline suspension, no.

15674, Boehringer Mannheim Bio-

chemicals, Indianapolis, Ind.), 53 mg hexokinase (Nutritional Biochemicals), 75
mg bovine serum albumin (BSA, Sigma Fraction V), and 23 mg chymotrypsinogen
A (Worthington Biochemicals, Freehold, N.J.) in 8 ml barbital-acetate buffer.
All elutions were with barbital-acetate buffer at 4°C using an LKB 12000
Varioperpex ·peristaltic pump set at 1.5 x 10 counterclockwise (flow
ml/hr.), an LKB Uvicord

n

= 17-21

UV monitor set for 280 nm, and an LKB 6520-3

recorder, recording at 20 mm/hr.
For the test runs, a serum aliquot was thawed in a 37°C water bath
while a lyophilized 1251-insulin aliquot was reconstituted with 0.3 ml deionized,
distilled water.

The serum was added to the labeled insulin and mixed. The
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following was added immediately: control, nothing; biotin, 0.1 ml (100

~g)

biotin

solution. After mixing, 0.1 ml was removed for counting and the remainder
applied to the column.

The eluate was monitored as before and two-ml

fractions were collected with an LKB fraction collector.

Fractions were

counted for radioactivity in a Searle 1185 automatic gamma-ray spectrophotometer for 2 minutes each. Fractions of protein and/or radioactive peaks were
pooled, sterilized by filtration, and stored at 4°C prior to lyophilization, after
which they were stored dessicated at -20°C. Radioactive fractions were each
reconstituted with 20 ml distilled water and dialyzed against 100 volumes of
barbital-acetate buffer, pH 7.4 (3 changes in 24 hrs.). Fractions designated A
(A ) were dialyzed through Fisher cellulose (M.W. 12,000 cutoff) and B (B 1)
1
fractions were dialyzed through Spectrapor membrane (M. W. 3,500 cutoff).
Dialysis retentates were lyophilized and stored at -20°C.

Rechromatoghraphy of Pooled A + B Fractions
Another 475 ml Sephadex G-200 column was prepared and calibrated as
before. All A and a fractions were reconstituted to their respective dialysis
1
1
retentate volumes and pooled. The pool (108 ml) was concentrated to 15 ml
through Amicon UM 2 membranes and was centrifuged at 8,000 RPM for 10
minutes. The supernate was applied to the column and fractions collected as
before. A 105 ml (2.5 x 21 em) G-200 column was prepared and calibrated.

Rechromatography of the A Fraction
2
Pooled fraction A (A ) from rechromatography was concentrated to 15
2
ml through UM 2 membranes and lyophilized. Two-thirds of the lyophilizate

237
was reconstituted and applied to the small column; two-ml fractions were
collected The pooled A3 fraction was concentrated, lyophilized, reconstituted,
and incubated with 1,000 J.l U bovine insulin before chromatography on the small
column (A 3-I).

Chromatography of Stripped Plasma (SP)
CPO (citrate-phosphate-dextrose) plasma from a single normal donor
was obtained from the Foster G. McGaw Hospital blood bank after preparation
of packed red cells, maintained continuously at 4°C.

Fifty ml plasma was

stirred with 25 grams Amberlite IRA-400 at 4°C overnight, after which the
resin-plasma suspension was centrifuged at 1, 700 x g 20 minutes at 4°C. The
supernate was dialyzed through cellulose (cutoff M. W. 12,000) vs. normal saline
(3 changes of 200 volumes in 2 days) at 4°C.
Radioiodinated insulin (1251-insulin) was obtained from New England
Nuclear Corp.

(NEX-104, lot 135-264).

The contents of one vial were

reconstituted with 0.31 ml distilled, deionized water (to 50

J.l Ci/ml

+ 0.050 ml

5% bovine serum albumin (BSA, in 0.01 M phosphate-buffered saline, PBS) and
applied to a column of Sephadex G-50 fine, bed volume 25 ml. One-ml fractions
were collected and assayed for 1-125 activity in a Picker Pace-1 auto gamma
counter, 0.1 min. each. After addition of 0.070 ml 5% BSA to each, insulin peak
tubes were pooled and lyophilized
Approximately 0.5 1JCi of this purified 1251-insulin was reconstituted
with 0.3 ml water, mixed with 9 ml ion-depleted plasma, incubated 30 minutes
at 37°C, and chromatographed on 477 ml Sephadex G-200 as previously
described. In addition, 0.2 ml 5% BSA was added to each peak B tube before
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pooling and lyophilization.

The procedure was repeated with the addition of

2.25 mU unlabeled bovine insulin to the incubation mixture (SP-1).

Chromatography of Long-Incubated Stripped Plasma (L)
1251-insulin (Lot 135-278) was obtained from New England Nuclear
corp.; 14.5 J..!Ci was reconstituted with 0.3 ml distilled, deionized water + 0.1
ml 3.5% BSA in 0.01 M phosphate-buffered saline (PBS). The resultant solution
was applied to a 25 ml column of Sephadex G-50 fine and eluted with barbitalacetate buffer, pH 7.4. Each 1 ml fraction, collected in a 12 x 75 mm Falcon
polystyrene tube, was counted 0.1 min. in a Picker Pace-1 auto gamma counter.
Fractions from the second radioactive peak were pooled; 2.5
for the double-antibody RIA and the remaining 3.1

J..!

J..! Ci

was diluted

Ci (in 6.1 ml) was dialyzed

through Spectrapor 3 tubing vs. 3 changes of 1 liter 1/10 normal saline (0.085%)
at 4°C. The retentate was lyophilized and reconstituted with 1 ml water.
Normal CPD plasma from a single donor (0-neg.; #29-00236), kept at
4°C continually after collection, was obtained from the Foster G. McGaw
Hospital blood bank; 50 ml of this plasma was stirred with 25 grams Amberlite
IRA-400 anion exchange resin at 4°C overnight and then was centrifuged at
2,000 x g at 4°C.

Twenty ml of the supernate was dialyzed through Fisher

cellulose tubing vs. 3 changes of 4 liters normal saline at 4°C. Ten ml of the
retentate was mixed with the reconstituted purified 1251-insulin, the mixture
was sealed in a vial and kept at 4°C 5 days.

Following this incubation the

mixture (2.5 J..! Ci) was applied to a 475 ml column of Sephadex G-200. Chromatography and collection of eluted fractions was carried out as for SP.
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f_!'eparation of Rabbit Anti-HSA (human serum albumin)
A New Zealand white rabbit (approx. 3 kg) was immunized with multiple
subcutaneous injections of 1 mg HSA in complete Freund's adjuvant three times
at weekly intervals.

One week after the last challenge, the rabbit was

exsanguinated by heart puncture.
The efficacy and specificity of the serum vs. HSA was tested with
precipitin ring tests, immunodiffusion, and hemagglutination using HSA conjugated to sheep red blood cells with chromic chloride (731).

The serum was

found to have an excellent titer against HSA (0.5-1.0 mg antibody/ml) and no
detectable reactivity with bovine serum albumin (BSA).

Immunodiffusion
Chromatography fractions were tested for HSA using the Ouchterlony
double diffusion technique (732).

A hexagonal array of six small wells

surrounding a larger center well is cut out of a highly purified agar plate using a
planchet. Antiserum is put into the center well and the samples to be tested
into the peripheral wells. If a sample contains the antigen to which the antiserum reacts, a precipitin band forms between that well and the center well
within 24 hours of incubation at room temperature. The plate is then washed in
normal saline twice in 48 hours and distilled water twice in 24 hours, allowed to
dry 24 hours, stained with Naphthalene Black 30 minutes, and washed several
times with acetic acid/methanol/water 1:7:2.8. The bands stain dark blue. For
serum chromatography and rechromatography, 10 mg of each lyophilized
fraction was dissolved in 1 ml water for testing. Unlyophilized fractions were
used directly.
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Amounts of radioactive'· peak C and A and protein peak

n lyophilizates

from the three CPO plasma/125 I-insulin columns (control, cold insulin ~dded,
and 5-day incubation) containing 10 mg protein each were reconstituted with 1
ml water.

The resultant solutions or suspensions were dialyzed through

Spectrapor 3 tubing vs. 3 changes of 200 volumes normal saline at 4°C. The
retentates (C-fractions were first centrifuged to remove insoluble material)
were then tested without dilution (1% protein) and at 0.1% protein dilutions for
BSA, HSA, and human IgG vs. the appropriate antisera by the Ouchterlony
double diffusion technique.

Rabbit anti-HSA, anti-BSA, and anti-human IgG

sera were obtained from Miles Laboratories, Inc., Elkhart, Ind.

Protein Determinations
Protein in each fraction was assayed using the method of Lowry (733).
Dissolved lyophilized fractions were assayed at a concentration of 0.5 mg/ml;
partially soluble lyophilized fractions were incubated with 0.1 ml 1 N NaOH/ml
at room temperature overnight and then diluted twenty-fold for assay; unlyophilized fractions were assayed directly or, if they represented a large
absorbance peak at 280 nm, were first diluted tenfold.

Total protein was

calculated on the basis of totallyophilizate recovered or total fraction volume.

Dextran/Charcoal Analysis of Radioactive Fractions
Each group consisted of three 12 x 75 mm plastic culture tubes:
1.

0.1 ml trace + 0.9 ml albumin buffer.

2.

0.1 ml trace + 0.1 ml 1:10,000 guinea pig anti-insulin serum (AIS) + 0.8
ml albumin buffer.
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3.

0.1 ml trace+ 0.1 ml AIS + 0.1 ml human insulin standard (0.1 mU) + 0.7
ml albumin buffer.

4.

0.1 ml trace + 0.9 ml albumin buffer in 8 M urea.

5.

0.1 ml trace + 0.1 ml AIS + 0.8 ml albumin buffer in 8 M urea.
The above tubes were incubated 2 days at 4°C.
For the following three groups, 78 mg (25 mg protein) of 5-day
incubation A-fraction (AL) lyophilizate was reconstituted with 1-2 ml
water for each group of three tubes and dialyzed through Spectrapor 3
tubing vs. 3 changes of 200 volumes barbital-acetate buffer at 4°C 2
days. The retentate was diluted to 3 ml (group 6) or 2. 7 ml (groups 7
and 8).

6.

AL alone (1.0 ml).

7.

0.9 ml AL + 0.1 ml insulin standard (0.1 mU).

8.

0.9 ml AL + 0.1 ml 1:10,000 AIS.
Groups 7 and 8 were further incubated 2 days at 4°C.

9.

78 mg AL lyophilizate was reconstituted with 2 ml water and dialyzed
through Spectrapor 3 tubing vs. 500 ml barbital-acetate buffer in 8 M
urea at 4°C (3 changes in 2 days). The retentate was diluted to 3.0 ml
with barbital-acetate buffer in 8 M urea and 1.0 ml was put in each of
three tubes.
To each of the 27 tubes was then added 0.5 ml of a cold dextran-

charcoal suspension (0.25g Dextran T-70 + 2.5g Norit A/100 ml barbital-acetate
buffer). The contents of each tube were agitated and then centrifuged at 2,000
RPM 10 minutes at 4°C.

The supernates were decanted into 12 x 75 mm
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culture tubes. Both supernatant ("bound") and precipitate ("free") tubes were
assayed for 1-125 activity in the Picker Pace-1 auto gamma counter.

_g>S Polyacrylamide Disc Gel Electrophoresis
1.

The calibration mixture consisted of 4 mg each bovine insulin, chymotrypsinogen A, BSA, catalase, and 8 mg glucose oxidase dissolved in 10
ml barbital-acetate buffer, pH 7.4.

2.

Six mg (2.1 mg protein) long incubation A-peak (AL) was reconstituted
in 0.4 ml deionized water + 0.6 ml barbital-acetate buffer (B/ A).

3.

Solutions were dialyzed vs. 500 ml 2.5% sodium dodecyl sulfate (SDS) in
0.01 M sodium phosphate buffer, pH 7.2, 3 hours at 25°C.

4.

Dialysis was continued in 500 ml 0.1% SDS in 0.01 M sodium phosphate
buffer, pH 7.2, with 1.6 M urea and 0.05% dithiothreitol 17 hours at
25°C.

5.

Gels consisted of the following:
A 1%'SDS
1
1 M sodium phosphate buffer, pH 7.2
deionized water
A acrylamide
2
bis-acrylamide
water
B Ammonium persulfate
2
TEMED
water

40 ml
40 ml
to 180 ml
40g
1.04g
to 180 ml
90 mg
0.05 ml
10 ml
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For 12 gels, 22.5 ml A1 + 22.5 ml A2 + 5 ml B2 are mixed, duaerated 30
seconds to 1 minute, 2.5 ml poured into each glass tube, overlayed with
water, and allowed to stand until solidified, about 30 minutes.

Gels

measured approximately 10 em length x 0. 7 em diameter.
6.

0.1 ml of each solution was applied to duplicate gels.

7.

Gels were electrophoresed (15-20 v, 2-3 rna/gel) in 0.1% SDS in 0.1 M
phosphate buffer 16 hours, until a bromphenol blue dye marker was 0.5
em from the end of the gel.

8.

Gels were removed from tubes with a stream of ice water and
transferred to a fixative solution consisting of methanol/glacial acetic
acid/water 45:10:45.

9.

The gels were agitated 5 days at 25°C with 12 changes of fixative, until
all residue was removed.

10.

Gels were stained with 1% fast green in fixative 2 hours at 25°C,
washed once with tap water, and agitated in 3 changes of fixative 1-1.5
days.

11.

The gels were destained 5-6 days in 2 changes of fixative and stored in
fixative at 25°C.

Affinity Chromatography
1.

Four. grams CNBr-activated Sepharose 4B (Sigma Chern. Co.) were
swollen in 20 ml 0.001 M HCl in a scintered glass funnel 15 minutes and
then washed with 800 ml 0.001 M HCl.

2.

The gel was then washed and resuspended to 28 ml with 0.1 M
bicarbonate buffer, 0.5 M NaCl, pH 8.65.
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3.

The gel was divided into two equal portions; to one portion was added
50 mg BSA in 1.5 ml bicarbonate buffer, the same concentration of HSA
to the other.

4.

The suspensions were rocked at 4°C overnight and then washed with
bicarbonate buffer.

5.

Each gel was resuspended in 7 ml 1 M ethanolamine, pH 8.0, and rocked
2 hours at 25°C.

6.

The gels each were washed alternately 5 times with 0.1 M acetate
buffer, 0.5 M NaCl, pH 4.0, and 0.1 M borate buffer, 0.5 M NaCl, pH
8.45, followed by 0.01 M PBS, pH 7.4.

7.

The gels were resuspended to 7 ml each and stored in 0.01 M PBS with
0.1% sodium azide before being poured into two glass columns.

8.

Fourteen ml rabbit anti-BSA (Miles lot no. R148, Miles Laboratories,
Inc., Elkhart, Ind.) was passed through the HSA-Sepharose column to
remove cross-reacting antibodies; the retained antibodies were eluted
with glycine-HCI buffer, pH 3.0, and the eluate was immediately
neutralized with 0.1 N NaOH.

9.

The first eluate (hereafter called the eluate) was then passed through
the BSA-Sepharose column.

10.

The neutralized eluted retentate (hereafter called the retentate) was
pooled with a second retentate obtained by passing the eluate through
the column again, the pool was concentrated to 10 ml through a PM 10
membrane, and dialyzed through cellulose tubing vs. 2 liters 1/10
normal saline at 4°C with 3 changes in 2 days.
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u.

Rabbit anti-HSA (9.5 ml; Miles lot no. RHA 2) was passed through the
HSA column and two pooled retentates were processed as was the antiBSA.

12.

Pure anti-BSA and anti-HSA were lyophilized after dialysis and reconstituted in 1 ml bicarbonate buffer each.

13.

The anti-BSA (5.8 mg) and anti-HSA (7 .6 mg) solutions were added to
respective gel suspensions and the proteins coupled to CNBr-activated
Sephorose 4B as described above.

14.

312.5 mg (100 mg protein) AL was dissolved in 20.7 ml water; 5 ml was
assayed for 1-125 activity in a Picker Pace-1 auto gamma ray spectrophotometer in a plastic centrifuge tube.

15.

The AL solution was passed through the anti-BSA column until no
protein was eluted with glycine-HCl, six times.

16.

The pooled anti-BSA retentates were concentrated to 8.0 ml through a
PM 10 membrane; the resultant retentate, filtrate, and membrane were
assayed for radioactivity (membrane activity was added to retentate
activity).

17.

The final anti-BSA eluate was passed through the anti-HSA column
twice and the pooled retentates concentrated to 7.2 ml through a PM 10
membrane.

18.

The final eluate was concentrated to 9.0 ml through a PM 10 membrane
and the resultant filtrate concentrated to 8.4 ml through a UM 2
membrane. All fractions were assayed for radioactivity as for the antiBSA retenta te.
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19.

Immunochemical identification of fractions was made using the Ouchterlony double diffusion technique and protein was determined using the
method of Lowry.

Dextran-Charcoal Binding Study
Immunoreactive insulin content of the UM 2 retentate was ascertained
alone, with AIS, and with AIS + unlabeled insulin using dextran-coated charcoal
as described above.

MAINTENANCE OF HUMAN CELLS IN CULTURE

Culture media, L-glutamine, trypsin and antibiotics (unless otherwise
indicated) were purchased from Grand Island Biological Co. (Gibco), Grand
Island, N.Y.

Hy-Clone fetal bovine serum (FBS) was purchased from Sterile

Systems, Inc., Logan, Utah (incubated at 56°C for 60 minutes to inactivate
complement before use), and disposable polystyrene culture flasks were obtained from Corning Glass Works, Elmira, N.Y.

WI38 Fetal Lung Fibroblasts
WI38 cells in the 15th passage level were obtained in frozen ampuoles
from the American Type Culture Collection, Rockville, Md.

After thawing

rapidly in a 37°C water bath and centrifugation in warmed Eagle's Basal
Medium with Earle's salts (BME) containing 10% FBS and 2 rnM L-glutarnine
(BME CM), the cells (in 5 rnl BME CM) were placed in a T-250 culture flash and
incubated at 37°C in an atmosphere of 5% C0 /95% air in a Hotpack
2

co 2
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incubator (Hotpack Corp., Philadelphia, Pa.).

Confluent monolayers were

subcultivated in BME CM using 0.25% trypsin or 0.125% trypsin/0.01%
Na EDTA. Antibiotics (100 U penicillin-100 \.Jg streptomycin/ml or 100 \.J g
2
gentamicin/ml) were added after the 20th passage level. The cells were used up
to the 30th passage level (54 generations).

SK-HEP-1 Hepatoma Cells
Samples of this cell line were generous gifts from Dr.

J~rgen

Fogh at

the Sloan-Kettering Institute for Cancer Research, Rye, N.Y. Two samples of
SK-HEP-1 growing in glass culture tubes were transferred to a 37°C incubator
in an atmosphere of 5% C0 2/95% air. The tube mouths were covered with
sterile gauze to enable gas equilibration. Within one week, the cells were
removed from the tubes by treatment with 0.25% trypsin (Gibco) and transferred to T-250 culture flasks, which were kept in the C0 incubator. When cells
2
attained confluency, they were subcultivated into other T flasks by trypsinization as before. SK-HEP-1 was cultivated in MEM alpha medium with 15% FBS
and 100 U penicillin/ml-100 \.Jg streptomycin/mi.

Other Cell Lines
LT2 squamous-cell vulvar carcinoma cells were established in continual
culture and characterized a8 described (734).

AU471 ovarian carcinoma cells

were obtained in frozen ampuoles from W.A. Nelson-Rees, Naval Biosciences
Laboratory, Oakland, Ca., and BeWo choriocarcinoma cells were obtained from
R.A.

Pattillo, Medical College of Wisconsin, Milwaukee. All three cell lines

were maintained in RPMI-1640 medium with 15% FBS (CM).
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REPLICATE CULTURE TECHNIQUES

Cells maintained in adherent culture in 75 cm 2 plastic culture flasks
(Corning) were washed with 10 ml Dulbecco's phosphate-buffered saline (PBS)
without Ca ++ and Mg++ and detached with 2-10 ml trypsin/EDT A for 1-15
minutes at 37°C. The reaction was stopped by addition of at least an equal
volume of complete maintenance medium (containing FBS) and the cell suspension was centrifuged at 400 x g for 10 minutes at room temperature. The cells
were resuspended in 5 ml PBS; to 0.1 ml of this suspension was added an equal
volume of 0.4% trypan blue in normal saline and number of viable cells (those
excluding dye) was determined using a hemacytometer and a light microscope
(American Optical Scientific Instruments, Buffalo, N.Y.)
The cells were centrifuged once more and resuspended in maintenance
medium to a concentration of 1 x 10 6 cells/mi. This suspension was further
diluted with maintenance medium with or without varying concentrations of
human (Wellcome) or bovine (Sigma) insulin to a concentration of 5 x 10 3 (WI38,
SK-HEP-1, AU471, and BeWo) or 1 x 10 4 (LT2) cells/mi. One-ml aliquots were
distributed among the center 8 wells of 24-well (2 em 2 area/well) polystyrene
cluster plates (Costar, Cambridge, Mass.) using a Manostat (Manostat Corp.,
New York, N.Y.) dispenser.

Proliferation of cells in the peripheral wells of

these cluster plates had been found to be inconsistent and thus these wells were
each filled with 2 ml sterile distilled water. Periodically, the medium from 2-8
replicate wells was removed, centrifuged and assayed for glucose in a Beckman
glucose analyzer (Beckman Instruments, Inc., Fullerton, Ca.).

Aliquots were

frozen for double-antibody insulin RIA. The cells in these wells were retrieved
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with 1 ml trypsin/EDT A. After centrifugation, cells were resuspended in 0.1 ml
PBS + 0.1 ml trypan blue and counted as described above.
Log-phase growth rates (doubling time, tD) were determined from the
linear portion (established by least-squares regression analysis) of plots of log
viable cell number (N) vs. time. Significance of difference in growth rates with
2

and without insulin was determined from t =(be- bi);/sb

2
+ sb. ' where be =

c

slope of control, bi = slope with insulin and

~ is

1

the standard error of the slope

(730). For cells in lag phase (before log phase) and stationary phase (in medium
lacking serum or at confluence), rate of glucose uptake, r, was determined as
u/Nt, where u is glucose uptake in mg, N is average number of viable cells in
millions, and t is time in days. Fo.r cells in log phase, r = u/N t, where N is the
g

c

g

geometric mean of viable cell number (in millions) = antilog {(log initial cell
number +log final cell number)/2}.
In addition, insulin effects on WI38 cells were examined using three
replicate monolayer systems: 1) initial lag phase cultures. Five thousand single
cells in one ml BME CM with or without various amounts of insulin were seeded
in each well.

At various times thereafter the supernates were assayed for

glucose, then frozen for insulin RIA, and the cells were harvested for counting
with trysin/EDTA; 2) log phase cultures. Twenty thousand cells were seeded in
each well. Two days later, medium was replaced with one ml BME CM with or
without various amounts of insulin.

Supernates and cells were harvested at

various times thereafter; 3) confluent cultures.
were seeded in each well.

One hundred thousand cells

Two days later, medium was replaced with or

without various amounts of insulin.

Supernates and cells were harvested at

various times thereafter. All operations until the final harvest were carried
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out with sterile equipment and reagents, using sterile techniques in a laminar
flow hood (Germfree Laboratories, Miami, Fla.).
Efficiency oi plating (EOP) was determined by seeding duplicate Costar
cluster wells with 100, 200, 500 and 1,000 cells in 1 ml each. After 24 hours in
the co incubator, the medium was removed, the cells were washed with PBS,
2
and the cells were fixed in 95% ethanol and stained with Giemsa 5 minutes
each. The cells in each well were counted on an inverted microscope (Olympus
Corp. of America, New Hyde Park, N.Y.).

CULTURED FIBROBLAST INSUUN BIOASSAY

The assay is a modification of the method of Morell and Froesch (615).
One-ml aliquots of 2 x 10 4 viable WI38 cells in BME CM were distributed among
the center 8 wells of Costar cluster dishes.

After 1 day, the medium was

aspirated, the cells were washed with 1 ml PBS/well, and 1 ml stationary
medium (0.35% BSA in BME) was added to each well. After 2 days, medium was
aspirated, cells washed and test samples in 1 ml stationary medium (aliquots
reserved for glucose assay) were added to each well. After 4 days, medium was
removed for glucose assay and cells were harvested for counting as described
above.
The parameters of the assay are:

I=

u/N.

v=

number viable cells in test well/number viable cells in control well
(stationary medium alone).
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R=

rt/rc, whre rc =control rand rt =sampler= u/Ngt if Nt> Nc or ~/Nt if
Nt ~ Nc.

U=

ut/uc.

ILA, determined from a plot of U vs. insulin concentration.
Specific ILA = ILAs' determined from a plot of R vs. insulin concentration.

0.301 (t -38 hrs.)
log (N/N

0

)

FBS equivalent = (22 hrs./tD) x 0.1 ml.

EFFECT OF AIS ON INSULIN-TREATED CULTURES

Wellcome human insulin standard was reconstituted with stationary
medium to a concentration of 100

~

U/ml. To 2 ml of this solution was added

0.2 ml 1:5,000 normal guinea pig serum (Gibco) or 0.2 ml 1:5,000 guinea pig
anti-insulin serum (Wellcome).
through 0.2

~m

The solution were sterilized by filtration

Swinny filters (Gelman Sciences, Inc., Ann Arbor, Mich.),

incubated at 37°C for 30 minutes and then were added to WI38 cells in replicate
wells prepared for bioassay as described above.

CHARACTERIZATION OF CELL-SURFACE INSULIN RECEPTORS

Tracer Determination of Cell-Surface Insulin Binding
Radioiodinated (1251) insulin (New England Nuclear) was purified as
described for Sephadex chromatography of plasma and serum.
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One-ml aliquots of SK-HEP-1 cells in 0.5% BSA/MEM spinne.· culture
medium (MEM-SC) brought to 300 mg glucose/dl with 20% dextrose/MEM-SC
solution at concentrations of 5 x 10 5 - 10 6 viable cells/ml were distributed
among 12 x 75 mm polystyrene culture tubes. To each tube was added 1.33 lJ U
or 13.3 lJ U 1251-insulin and the tubes were shaken in a 37°C water bath before
removal at 5 min., 30 min., and 5 hrs. The tubes were centrifuged at 300 x g 10
minutes and the pellets washed once with PBS. Pellets were assayed for 1-125
activity in a Picker Pace-1 auto gamma ray spectrophotometer.
The same quantities of 1251-insulin were added in 1 ml aliquots of 0.5%
BSA/MEM-alpha or CM to adherent SK-HEP-1 or LT2 cells (3.5-5.0 x 10 4 viable
cells) in Costar cluster wells. After 30 minutes and 5 hours, superna tes and a 1ml PBS wash were pooled and assayed for activity as above.
Cells from adherent cultures of SK-HEP-1 and LT2 were also removed
with trypsin, washed with PBS, and treated with 1251-insulin as described for
suspension cultures.
Binding of 1251-insulin to Wl38 cells in suspension was studied by using
cells harvested with trypsin/EDT A and washed twice with PBS, pH 7.4. Four
million cells were resuspended in 0.6 ml 5% BSA/PBS; an equal number of cells
were resuspended in the same buffer containing 1 U bovine insulin/ml to
ascertain non-specific binding of 1251-insulin.

Aliquots of 0.05 ml cell

suspension were t>laced in polystyrene culture tubes; 0.05 ml of various
concentrations of 1251-insulin were then added to each tube, followed by
incubation at 25°C for 2.5 hours with occasional shaking. Four ml PBS was then
added to each tube, the contents were mixed, and the tubes were centrifuged at
300 x g 10 minutes. The supernates were decanted and the precipitates assayed
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for I-125 activity 20 minutes each in a Searle 1185 auto gamma ray spectrophotometer.

Net percent 1251-insulin bound to cells was determined as (CPM

without cold insulin - CPM with cold insulin)/(total CPM - CPM with cold
insulin).

Immunocytochemical Determination of Cell-Surface Insulin Binding
Anti-insulin peroxidase/anti-peroxidase (PAP) staining of SK-HEP-1,
LT2, Wl38 and BeWo cells was performed by a modification of the method of
· Sternberger (735) as follows:
1.

Cells dispersed from adherent culture with trypsin/EDTA were resuspended in 1 mU or 10 mU bovine insulin in 0.5% BSA/PBS or MEM-SC at
a concentration of 10 6' cells/ml and incubated 5 minutes at 37°C.

2.

The cells were washed once in PBS and resuspended in 0.1 ml FBS. Four
smears were made on standard glass microscope slides.

Subsequent

treatments were carried out by placing 3 drops of solution on an area in
the center of the slide, demarcated by an ink circle.

Slides were

washed in a Coplin jar.
3.

0. 75% gelatin in 0.01 M PBS, pH 7.6, 30 min. 25°C. Blot.

4.

1:2,000 guinea pig anti-insulin serum (Wellcome) in 0.1% gelatin/PBS 46
hrs. 4°C, 2 hrs. 25°C. Wash 3 times in 0.1% gelatin 5 min. each. Blot.

5.

1:8 rabbit anti-guinea pig serum (Wellcome)/0.1% gelatin 30 min. 25°C.
Wash 3 times (5 min.) in PBS. Blot.

6.

Two slides 1:10 goat anti-rabbit serum (Polysciences, Inc., Warrington,
Pa.)/0.1% gelatin 30 min. 25°C, two slides 1:10 normal goat serum
(controls); 3 x 5 min. PBS wash. Blot.
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1.

1:50 rabbit PAP (Polysciences)/0.1% gelatin 30 min. 25° C; 3 x 5 min.
PBS wash. Blot.

s.

0.05% diaminobenzidine tetrahydrochloride (Sigma) in 0.0196 hydrogen
peroxide/PBS 8 min. 25°C; 3 x 2 min. water wash. Blot.

9.

One control and one test slide were counterstained with 0.196 toluidine
blue in 0.1 M acetate buffer, pH 4.2, 5 min.; 3 sec. rinse.

BULK FRACTIONATION OF HUMAN SERUM

Normal human serum in 500 ml bottles was purchased from Gibco,
filtered through 0.2 lJm Nalgene units (Nalge Co., Rochester, N.Y.) and stored
at 4°C; 488 ml of this serum was concentrated to 142 ml through Amicon PM 10
(M. W.

cutoff 10,000 daltons) membranes in a stirred cell under positive

nitrogen pressure at 4°C. The filtrate was then concentrated to 52 ml through
UM 2 (M.W. cutoff 2,000 daltons) membranes.

One-half of each retentate

(PM10r1, 3.44x cone., and UM2r1, 6.60x cone.) was lyophilized. The remaining
PM 10 retentate was diluted to 502 ml with water and was reconcentrated
through a PM 10 membrane to 84.5 ml {PM 10r2, 2.89x cone., 5.94x desalted);
the remaining UM 2 retentate was diluted to 300 ml with water and was
reconcentrated through a UM 2 membrane to 24.5 ml (UM2r2, 7.OOx cone.,
12.24x desalted). These retentates and both UM 2 filtrates {UM2fl and UM2f2)
were lyophilized
For bioassay, various quantities of lyophilized fractions were reconstituted with stationary medium alone or containing 100 lJ g heparin/ml or 10 lJg
D-biotin/ml to produce a 10% increase in medium tonicity and were then
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sterilized by filtration. In addition, the PM10r1 fraction was assayed by further
10-fold and 100-fold dilutions with corresponding stationary media.

Various

quantities of lyophilized fractions were also reconstituted with normal saline or
albumin buffer for Lowry protein assay and double-antibody insulin RIA,
respectively.

Treatment of the PM 10 Retentate
C (control). 64.8 mg PM10r2 was dissolved in 10 ml normal saline and
incubated at 37°C for 30 minutes. The solution was then transferred to an ice
bath and concentrated 10-fold through a PM 10 membrane. Both the retentate
(CR) and filtrate (CF) were dialyzed in Spectrapor 3 tubing against 2 liters of
1/10 normal saline with 2 changes in 48 hours at 4°C. The dialysis retentates
were each divided into 3 equal parts and lyophilized for bioassay as described
above.
Equal amounts (64.8 mg) of PM10r2 were treated as above (C) with the
following differences:
H.

The fraction was dissolved in a solution of 100

~g

heparin/ml

normal saline.
~g

B.

The fraction was dissolved in a solution of 10

biotin/ml normal

U.

The fraction was dissolved in 2 ml normal saline, to which was

saline.

then added 4.805 g urea in 8 ml normal saline (final urea concentration
AE.

=8 M).

259 mg PM10r2 was dissolved in 2.48 ml 0.1 N ammonium acetate,

pH 7.2, and transferred to an ice bath; 7.44 ml 96% cold ethanol was added and
mixed vigorously, followed by addition of 0.15 ml concentrated hydrochloric
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acid and remixing. The suspension was then incubated at 4°C for 30 minutes
and centrifuged at 12,000 x g for 30 minutes at 4°C. The supernate was then
treated like the control, commencing with the concentration step, and the
precipitate (AEP) was resuspended in 2 ml normal saline and treated like the
control, commencing with the dialysis step.

Gel Chromatography of the PM 10 Retentate
A 2.6 x 70 em (bed volume 371 ml) Sephacryl s-200 superfine (Pharmacia) column was prepared according to the manufacturer's instructions (736)
and was equilibrated with 0.01 M sodium phosphate buffer, pH 7.4, at a flow
rate of 26 ml/hour for 24 hours at 4°C. The column was calibrated with the
following standards:

Standard

Amount (mg) Molecular Weight(kd)
20

2,000

glucose oxidase

100

186

3.

BSA

100

67

4.

chymotrypsinogen A

50

25

5.

myoglobin

50

16.9

1.

Blue Dextran

2.

The standards were dissolved in 7.5 ml phosphate buffer and the solution
was clarified by centrifugation and filtration before application to the column,
which was then eluted with phosphate buffer at a flow rate of 23 ml/hr. The
effluent was monitored for ultraviolet absorbence at 280 nm.
Three grams PM10r1 were reconstituted with 10 ml deionized, distilled
water, clarified by filtration, applied to the column and eluted as described for
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the calibration; 2-ml fractions were collected.

Twenty-four major fractions

were prepared by pooling the contents of 5-49 collection tubes; 6 tubes were
pooled for each of the 20 fractions (2-21) commencing with the first protein
peak.

One ml from each fraction was reserved for Lowry protein assay and

RIA.

Fractions were then lyophilized and one-third of each fraction was

reconstituted for bioassay.

Dextran-Charcoal Analysis of Chromatography Fractions
One-tenth ml of each aliquot reserved from the Sephacryl fractions was
mixed with 0.1 ml 1251-insulin + 0.6 ml albumin buffer (NSB

=0.1 ml trace + 0. 7

ml albumin buffer) and incubated for 3 days at 4°C; 0.4 ml dextran-charcoal
suspension was then added to each tube, which was further treated as described
for dextran-charcoal analysis of radioactive fractions.

Acid Treatment of Serum and Serum Fractions
One ml serum or reconstituted fraction was mixed with 9 ml 0.05 M
glycine-HCl, pH 2.8, adjusted to pH 3.0 with concentrated HCl, and concentrated tenfold through PM 10 membranes. Filtrates were neutralized with an
equal volume of 0.05 M PBS, pH 7.4, and adjusted to pH 7.4 with 1 N sodium
hydroxide.

Retentates were dialyzed against 200 volumes 0.001 N HCl in

normal saline, followed by PBS. Both retentates and filtrates were assayed for
IRI and dextran-charcoal adsorption. In the latter assay, 0.6 ml 8 M urea in
albumin buffer or 1 mU bovine insulin in 0.6 ml albumin buffer was also added
to 0.1 ml sample + 0.1 ml trace.
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NSILA-S Screen
Fractions (46.3 mg fraction 9, 58.3 mg fraction 12) were each dissolved in
0.15 M acetic acid in 0.15 M sodium chloride. Each solution was concentrated
tenfold through PM 10 membranes. All fractions were dialyzed against 4 liters
0.01 M phosphate buffer, pH 7.4, in Spectrapor 3 tubing.

Each fraction was

then divided into 3 equal parts and lyophilized for bioassay.

Comparative RIA
Double-antibody insulin RIA of selected fractions was carried out with
1251-labeled and unlabeled porcine insulin (Pharmacia), as well as with 1251bovine insulin and human insulin standard.

GEL CHROMATOGRAPHY OF HUMAN SERUM ACETONE POWDER

The lyophilizate from 200 ml human serum (Gibco) was suspended in 500
ml acetone (-20°C) and stirred for 1 hour at 4°C. The suspension was filtered
through 2 layers of Whatman no. 42 paper in a Buchner funnel and the residue
was washed 4 times with 500 ml acetone (-20°C) and dried per ~ for 25
minutes at room temperature and in vacuo for 45 minutes at room temperature
(547, 737). Three grams of acetone powder were homogenized with 10 ml 0.01
M phosphate buffer, pH 7.4, in a 30-ml syringe.

Undissolved residue was

removed and the clarified solution was applied to a 2.6 x 71.5 em (380 ml bed
volume) Sephacryl 8-200 column and eluted with 0.01 M phosphate buffer, pH
7.4, at a flow rate of 25 ml/hr. Two-ml fractions were collected and pooled to
produce 24 major fractions as described above.
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STATISTICAL METHODS

Means (R), standard deviations (SD), coefficients of variation (CV(%)

=

[soH~ x 100) and standard errors of the means (SEM) for RIA quality control and

standard curve parameters and recovery data, dextran-charcoal analysis of
affinity chromatography fractions, and cell number, glucose uptake and rates of
glucose uptake were determined by standard variance analysis (730). Significance of differences between means was determined by both paired and
unpaired Student t-tests.
Semi-log growth curve and glucose analyzer response parameters were
determined by least-squares linear regression analysis (730).

Significance of

differences between log-phase proliferation slopes was tested as described for
"replicate culture techniques."

Normal populations were established for the

bioassay parameters U and \) by determining these parameters for each control
well relative to the average glucose uptake and cell number, respectively, of
two control wells per plate. The normal range was determined from the mean
of

I control parameters -11.:!:. standard deviation x t-statistic of 95%

confidence

limit for control population degrees of freedom. Thus, any test-well parameter
falling outside this normal range exhibited a minimum significance (high or low)
of P<0.05.
values.

Specific ILA significance was determined relative to control r-

CHAPTER Vll

RESULTS

DEXTRAN-CHARCOAL INSULIN RIA

A typical parabolic dose-response curve for this assay, obtained by plotting
percent 125 I-insulin bound to antibody (%B) relative to concentration of
unlabeled insulin added, is reproduced in Figure 16. Plots of logit (%B 0 ) relative
to log (unlabeled insulin] (Fig. 17) were linear between 5 lJU/ml and 15-20lJ U/ml.
Based on the 90% intercepts of logit-log plots for the 9 dextran-charcoal RIAs
utilized in the research described herein, this assay exhibits a minimum
sensitivity of 2.1 lJ U/ml (0.21 lJ U or 8.4 pg insulin in the assay tube).

The

interassay variance of curve parameters (slope and 50% intercept) was less than
10% (Table Vll).
Nonspecific binding (NSB) of 125 I-insulin in albumin buffer ranged from 614% and in undiluted serum (diluted 8-fold in the assay tube) from 6-38%. Where
NSB exceeded 20%, data were obtained from dilute sera, if possible. B0 ranged
from 38% to 50% in these assays. Interassay variance of serum controls was
approximately 10% (Table VU) and intraassay variance of a normal serum pool
run 12 times in one assay was 9.5% (Table XI). Recovery of 69 lJU exogenous
insulin/ml from this pooled serum using this RIA was virtually 100% (Table X).
The mean insulin concentration of 17 normal fasting human sera
determined using the dextran-charcoal RIA was 6.2% 4.9 (S.D.) lJ U/ml, yielding a
260
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FIGURE 16.

DEXTRAN-CHARCOAL INSULIN RIA: STANDARD CURVE.

ordinate: Free insulin is adsorbed by dextran-coated
charcoal, while antibody-bound insulin is not.
Therefore, %

12 5I-insulin

bound to antibody,

%B = CPM in the supernate - CPM nonspec. bound*
Total CPM - CPM nonspecifically bound
X 100,
Abscissa: Concentration of unlabeled insulin added to
the assay tube.

Since 0.1 ml standard is add-

ed to each tube, the range of absolute quantity
of unlabeled insulin in the assay tubes is

o.s-3.0

*

~u.

CPM in supernate in the absence of antibody or standard.
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FIGURE 17.

DEXTRAN-CHARCOAL INSULIN RIA STANDARD CURVE:

LOGIT-LOG TRANSFORM.
ordinate: (left) %B 0 = percent of CPM specifically bound
to antibody in the absence of unlabeled insulin.
(right) logit (%B ) = ln
o

%Bo

~to~o~--%-B-

Abscissa: log 1 o (insulin concentration)
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TABLE VII.

DEXTRAN-CHARCOAL INSULIN RIA: INTERASSAY
VARIANCE
Logit-Log Parameters
Slope

Number

50% Intercept
( f! U/ml)

9

9

-2.43

13.4

Standard
Deviation

0.21

0.9

Coefficient
of Variation (%)

8.8

7.0

Mean

Serum Controls
(f!U/ml)
Normal
Pool
Number
Mean
Standard
Deviation
Coefficient of
Variation (%)

8

High Serum
6

42.2

116

4.3

10

10.1

8.9
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gs% confidence range of 0-16.6 lJU/ml, close to the observed range of .0-15.4

lJllml. This RIA also yielded values for the Phadebus Reference Serum within the
range found by the Phadebus insulin radioimmunoassay and for sera provided by
the College of American Pathologists within the range found by other
laboratories

using

their

own radioimmunoassays,

and

showed

expected

nuctuations in human insulin levels in response to a glucose load or tolbutamide
administration in both normal individuals and maturity-onset diabetics.

EFFECT OF HEPARIN ON THE DEXTRAN-CHARCOAL INSULIN RIA

Heparin was found to inhibit binding of 1251-insulin to antibody at
concentrations above 100 J.lg/ml in the assay tube. Although dose-response curves
were parallel, 0.25 mg heparin/ml depressed %B 19% and 2.5 mg heparin/ml
depressed %B 45%.

DOUBLE - ANTffiODY INSULIN RIA

Assay Characteristics
The range of variability of triplicate standards in the dose response curve
(Fig. 18) indicates a useful range for this assay of 1-30 lJU/ml with a resolution
of 1 lJU/ml at 5 lJU/ml to 2 lJU/ml at 30 lJU/ml. The 90% intercept on the loglogit curve (Fig. 19), which is linear between 5 and 40 lJ U/ml, indicates a
sensitivity of 3.6 lJU/ml. NSB for both buffer and sera was consistently less than
496.

Therefore, samples and standards were not corrected for NSB in this

assay. B0 varied between 50 and 72%.
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FIGURE 18.

DOUBLE-ANTIBODY INSULIN RIA: STANDARD CURVE.

•

Insulin standards in albumin buffer

0

Serum D.N.-CPD plasma

•

Serum D.N.-CPD plasma, diluted 10-fold with
albumin buffer

•

Serum D.N.-CPD plasma, diluted 20-fold with
albumin buffer

Insulin concentration of D.N. serum was determined by
assay of serum diluted with albumin buffer.
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FIGURE 19.

DOUBLE-ANTIBODY INSULIN RIA STANDARD CURVE:

LOGIT-LOG TRANSFORM.
Range of insulin standards = 5-40

~U/ml.

Insulin quantity in assay tube is one-tenth of insulin
standard concentration.

270

-

0

N
I

I

M
I

li'D01.

0
0

0

z

_.

::;,
Cl)

z

0

11'1

o-

0

o-

0

co

0

.0

0

11'1

0

"f

0

M

0

N

lN3::>~:t3d

271

When a patient sample showing a high concentration of insulin (D.N ., 496
Jl)/ml) was serially diluted with CPD plasma low in insulin, displacement of
radiolabeled insulin was nearly superimposible on the standard curve (Fig. 18)
over several dilutions. Recovery of exogenous human insulin standard added to
CPD plasma was essentially 100% from about 10

\.l

U/ml to 300

\.l

U/ml (Table

VID). High assay values at low concentrations indicate an actual sensitivity and
resolution of about 4

\.1 U/ml.

Quality Control
Intraassay variation was determined by assaying 15 replicates of three
human serum and plasma samples, ranging from about 7 to 500 U insulin/ml, in
one assay.

Coefficients of variation for samples exceeded 10% only at low

insulin concentrations (Table IX). Interassay variation of curve parameters was
less than 15%, but exceeded 15% for serum controls.

The 23% CV for N1

underscores the inaccuracy of the assay for insulin levels less than 10

\.1

U/ml.

Patient Samples
Fifty patient samples, including four oral glucose tolerance tests, showing
normal glucose levels were obtained from Dr. Marion Brooks. The distribution of
insulin concentrations determined for 27 fasting samples among these is skewed
to the right with a median of 4.5 lJU/ml. Although the arithmetic mean is 8.8
11U/ml, treatment of the population as a normal distribution yields a 95%
confidence range of 0-19.4 \.1 U/ml (or approximately 0-20 \.1 U/ml), rather close
to the observed range of 2.3-18.2 lJU/ml.
Insulin concentrations assayed for the glucose tolerance tests show
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TABLE VIII.

RECOVERY OF

H~~

INSULIN STANDARD ADDED

TO CPD PLASMA BY DOUBLE-ANTIBODY RIA
Insulin Added

Percent Recovered

±

(~U/ml)

Standard
Deviation

303

107

10.6

129

130

19.7

80.8

106

2.5

35.8

105

16.8

20.8

100

20.7

6.3

163

11.2

2.8

236

94.8

CPD = citrate-phosphate-dextrose
Each recovery determination is based on triplicate samples.
Percent recovered =

Total ~U/ml - plasma ~U/ml
Insulin added (~U/ml)

x 1 00 ·
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TABLE IX.

DOUBLE-ANTIBODY INSULIN RIA QUALITY CONTROL.
Number

Mean

Std. Dev.

Coeff. Var.
(percent)

Intraassay
Variation
Nl

15

N1 o
(~U/m1)

15

124

10

8.1

D.N.

15

496

29

5.8

(~U/m1)

(~U/m1)

7.38

0.90

12.2

Inter assay
Variation
Slope

22

-2.59

0.31

12.0

50% intercept (~U/ml)

22

27.5

2.5

9.1

Nl

20

6.4

1.5

23.4

N1 o

19

(~U/ml)

(~U/ml)

121

22

18.2
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TABLE X.

SERUM AND PLASMA IRI AND RECOVERY OF EXOGENOUS
INSULIN BY RIA: AVERAGE OF TRIPLICATE DETERMINATIONS
IMMUNOREACTIVE INSULIN

(~U/ml)

(Recoveries)
Sample

No Additions

+ 100

~g/ml

heparin

+ 10 ~g/ml
biotin

N

51.1

44.6

38.6

p

0.3

0.3

1.5

ss

13.8

12.4

10.2

SP

4.4

4.4

6.7

+ 69
N

~U/ml

120 (99.9%)

114 (100.6%)

96.6 (84.1%)

p

72.3 (104.3%)

65.1 (93.9%)

58.9 (83.2%)

ss

85.6 (104.1%)

70.0 (83.5%)

63.1 (76.7%)

SP

73.3 (99.9%)

68.1 (92.3%)

54.4 (69.1%)
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TABLE XI.

SERUM AND PLASMA IRI AND RECOVEI\.Y OF EXOGENOUS
INSULIN BY RIA: STATISTICAL ANALYSIS
UNTREATED SAMPLES

Sample

% Recovery

IRI

(no.
JJU/ml
replicates) ±S.D. (S.E.M.)

N (12)

42.2±4.0 (1. 2)

(12)

0.1±0.3 (0.1)

p

SP (12)

3.0±0.7 (0.2)

ss (12)

21.2±5.1 (1.5)

N 100 (12)
p

132 ±17

±S.D. (S.E.M.)
+ 104 JJU

Comparison
with % Recovery of N

(4.7) 86.5±16.3 (4.5)

100 (12)

74.3±7.2 (2 .1) 71.3 ±6.9 (2. 0)

significantly
lower
(P<O.Ol)

ss 100 (12)

93.2±7.6 (2.2) 69.2 ±7.3 (2.1)

significantly
lower
(P<0.005)

SP 100 (12)

79.9±8.9 (2.6) 73.9 ±8.6 (2.5)

significantly
lower
(P<O. 05)

+ 10 lJg/ML BIOTIN
Sam:ele

IRI

% Recover~
+99.8 lJU

N (12)

41.7
±3.9
(1.1)

Comparison Comp. with
with IRI of % Recovery
untreated
of N
sam:eles
no sign.
diff.
(P>O. 5)

Comp.
with
% Rec
Untr.
Sm:els
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TABLE XI.
Sample

(CONTINUED)
IRI

% Recovery

+ 99.8 JJU

p (12)

0

Comparison Comp. with
with IRI of % Recovery
untreated
of N
samples

Comp.
with
% Rec.
Untr.
Smpls.

no sign.
diff.
(P>0.2)

SP (12)

2.2
±0.3
(0.1)

sign.
lower
(P<0.005)

ss (12)

15.4
±2.1
(0.6)

sign.
lower
(P<0.005)

N 100
(12)

71.± 8
113
±8
(2.4)
(2. 4)

p 100
(12)

66.5 66.6±10.0
±10.0 (2.9)
(2.9)

no sign.
diff.
(P>0.20)

no sign.
diff.
(P>O .1)

SP 100
(12)

75.2 73.1±8.6
±5.9
(2.5)
(1.7)

no sign.
diff.
(P>O. 4)

no sign.
diff.
(P>0.5)

ss 100

82.1 62.9±11.6
±11.6 (3.3)
(3.3)

no sign.
diff.
(P>O. 05)

no sign.
diff.
(P>O.l)

(12)

sign.
lower
(P<O.Ol)
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expected fluctuations and a comparison of insulin values of the 50 samples from
this assay and from Dr. Brooks' clinical endocrinology laboratory (dextrancharcoal RIA) by the t-test for paired data shows no significant difference (t

=

0.207; p >0.5).

CATION-EXCHANGE CHROMATOGRAPHY OF HUMAN PLAS\IIA

Chromatography of 450 ml CPD plasma on Sephadex C-50 was undertaken
in order to determine the reproducibility of Guenther's observed heparinpotentiation of IRI in cationic serum fractions. About 10 1-1 U IRI/ml plasma was
adsorbed by the cation exchanger and 4396 of this IRI was eluted in the most
cationic fraction (Fraction Xll), but heparin did not enhance IRI in this fraction
or overall (Fig. 20). Heparin increased IRI 0.2- to 3-fold in Fractions I, VIT, X
and XI, but heparin-induced IRI in no case exceeded 1
significant

heparin-potentiation

of

IRI

was

found

1-1

in

U/ml plasma.
any

No

lyophilized,

reconstituted fraction. The fact that 4.8 mg protein/ml plasma was recovered
from the gel suggests that most of the IgG was not eluted.

ENDOGENOUS IRI AND EXOGENOUS INSULIN RECOVERY FROM SERUM
AND PLASMA

Since it was possible that insulin could be dissociated from a putative
binding protein in CPD plasma and thus not be adsorbed by the cation exchanger,
IRI in various serum and plasma samples was determined.

Furthermore,

reversible binding of insulin to a protein should be capable of detection by RIA as
anomalous recovery of exogenous insulin from serum and plasma.
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FIGURE 20.

•--•

SEPHADEX C-50 CHROMATOGRAPHY OF HUMAN PLASMA.

Effluent osmolality

Open bars: Protein
Black bars: IRI without heparin
Hatched bars: IRI with heparin
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Serum and plasma were also treated with an anion exchange resin
(Amberlite IRA 400; "stripped" serum, SS, and "stripped" plasma, SP). If free
insulin-binding protein exists in serum or plasma or anion stripping generates
free binding protein, then recovery of IRI from such samples should be low. If
heparin or biotin dissociates insulin from a binding protein, an enhancement of
IRI should be observed.
It is evident from Table X that heparin caused no significant change in the

IRI of any sample studied; 10 JJg D-biotin/ml caused slight increases of IRI in
plasma and stripped plasma and a decrease of IRI in normal serum. However,
appreciably low recoveries of IRI were seen in heparin-treated stripped serum
and all biotin-treated samples, but recoveries from untreated samples were
complete. Statistical analysis of IRI in replicate untreated and biotin-treated
samples (Table XI) revealed that recovery of exogenous insulin from CPD
plasma, stripped serum and stripped plasma was significantly lower than from
normal serum, representing a loss of approximately 30 JJ U added insulin/ml
sample. Biotin treatment caused a small but significant decrement of IRI in
stripped serum and plasma and reduced recovery of IRI from normal serum to
that seen in other samples, but did not further reduce recoveries from plasma,
stripped serum or stripped plasma.

GEL CHROMATOGRAPHY OF RADIOLABELED INSULIN IN HUMAN SERUM
AND PLASMA

Since diminished recovery of exogenous IRI could also be caused by
enhancement of serum or plasma proteolytic activity, a systematic examination
of human serum and plasma for an insulin-binding protein using the methodology
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employed by Zapf et al. (557) to elucidate the NSILA-8-binding protein was
undertaken.
Purification of 1251-insulin + 5% BSA using Sephadex G-50 resulted in
elution of no more than 17% radioactivity in the albumin fraction and 5% in the
iodide fraction.

G-200 calibration curves, depicted in Figure 21, indicate that

significant differences in the elution behavior of proteins can occur with
different columns.
Despite differences in protein elution patterns of serum and plasma, the
qualitative profile of 1251-insulin elution is very consistent (Fig. 22). About 90%
of the radioactivity (peak B) eluted at volumes consistent with globular proteins
of molecular weight 26,500-39,000 daltons (Tables

xn,

XIV, XV), indicative of

tetramer-hexamer aggregation. This possibility is supported by elution of the
final serum protein peak (V) appreciably after peak B, which eluted at a position
between BSA and chymotrypsinogen A, while plasma peak B eluted coincident
with the final protein peak (IV), at the position of chymotrypsinogen A. Less
than 5% of the radioactivity (peak A) eluted coincident with protein peak

m,

corresponding to molecular weight 117,000-158,000 daltons. Less than 1% of the
radioactivity (peak C) in plasma eluted at the exclusion volume (M.W. >360,000
daltons). 1-125 activity nonspecifically associated with eluted protein. accounted
for little more than 6% of recovered activity.
Approximately 90% of Fraction B radioactivity was lost between elution
from the first column to dialysis and another 90% of that activity was lost by
completion of dialysis. Losses are attributed to adherence of labeled insulin to
glass.

Essentially no Fraction A activity was lost, however, from elution to

dialysis and approximately 75% was recovered after dialysis; thus, high
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FIGURE 21.

ve /Vo =

SEPHADEX G-200 CALIBRATION CURVES.

Elution volume (ml)/Exclusion volume (elution
volume of blue dextran)
2.6 x 90 em columns:

•

Initial chromatography

•

Rechromatography of A1 + B1

•

Chromatography of stripped plasma and long incubated stripped plasma
2.5 x 21 em column:

0--o

Chromatography of A2 and A3 -I

Standards:

a. catalase
b. glucose oxidase
c. hexokinase
d. BSA
e. chymotrypsin A
f. ribonuclease A
g. insulin

Molecular Weight (daltons)

0
<

•...

~

IV

0

w
0
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FIGURE 22. SEPHADEX G-200 CHROMATOGRAPHY OF EXOGENOUS
125 r-INSULIN IN HUMAN SERUM AND PLASMA.

Open peaks: protein, designated by roman numerals.
Shaded peaks: radioactivity, designated by letters.

BD

blue dextran

cat

catalase

GO

glucose oxidase

hex

hexokinase

BSA

bovine serum albumin

chnA

chymotrypsinogen A

ve

elution volume (ml)
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TABLE XII.

SEPHADEX G-200 CHROMATOGRAPHY OF 125 I-INSULIN
IN NORMAL HUMAN SERUM

Fraction

ve (ml)

Ve /V o

Molecular Weight
(daltons)

CONTROL:
>360,000

I

162

1.0

II

222

1. 370

232,000

III

314

1.938

115,000

IV

500

3.086

28,000

v

555

3.426

18,200

A

312

1.926

117,000

B

456

2.814

39,000

I

135

1.0

II

190

1.407

220,000

III

260

1.925

117,000

IV

420

3.111

27,000

v

455

3.370

19,800

A

270

2.000

106,000

B

390

2.888

35,500

BIOTIN:
>360,000
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TABLE XIII.
Fraction

RECHROMATOGRAPHY OF G-200 ELUTION FRACTIONS
ve (ml)

Ve/Vo

Molecular Weight
(daltons)

A+ B Pool:
I (Ilia)

142

0.861

>360,000

II (IIIb)

210

1.273

350,000

III (IIIc)

300

1. 818

82,000

IV

432

2.618

<20,000

A

306

1. 855

74,000

B

422

2.558

<20,000

I

63

1.848

62,000

II

106

3.109

<20,000

A

59

1.730

80,000

68

1.994

47,500

II

109

3.196

20,000

A

67

1.965

49,500

A

Control (A2):

Insulin (A 3 -I):
I
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TABLE XIV.

SEPHADEX G-2JO CHROMATOGRAPHY OF 125 I-INSULIN
IN STRIPPED PLASMA (SP)
PROTEIN PEAKS

Fraction

ve (ml) Ve/Vo Molecular Protein (mg)
Weight

Control
I

162

1

>360,000

II

222

1. 370

365,000

100

III

298

1.840

149,000

257

IV

444

2.741

26,000

I

161

1

II

220

III
IV

17.9

+ Cold

!nsuiin
>360,000

34.7

1.366

370,000

91.8

294

1. 826

151,000

440

2.733

26,500

235

RADIOACTIVE PEAKS
Fraction

Ve (ml)

Ve/Vo

M.W.

Percent Insulin
Recover. equiv.
( JJU)
Act.

Control
A

292

1.802

158,000

1.3

B

440

2.716

27,500

89.9

c

166

1.025

>360, 000

0.3

2.5
177
0.5
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TABLE XIV.

(CONTINUED)

Fraction

ve

(ml)

Ve /Vo

M.W.

Percent Insulin
Recover. equiv.
Act.
(f.LU)

+ Cold

!nsulin
A

294

1. 826

151,000

1.5

B

432

2.683

29,000

91.1

c

166

1.031 >360,000

0.2

3.0
188
0.5
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TABLE XV.

SEPHADEX G-200 CHROMATOGRAPHY OF CPD PLASMA/

125I-INSULIN AFTER FIVE DAYS INCUBATION AT 4°

c

PROTEIN PEAKS
Fraction

ve (ml)

Ve/Vo

Molecular Weight
(daltons)

Protein (mg)

I

159

1

II

217

1.365

365,000

138

III

297

1. 868

140,000

336

IV

446

2.805

22,800

>360,000

63.3

RADlOACTIVE PEAKS
Fraction

ve (ml)

Ve/Vo

M.W.

Percent
recov.
act.

Insulin
equiv.
( lJ U)
11.1

A

294

1.849

147,000

1.7

B

434

2.730

26,500

91.6

c

162

1.019

>360,000

0.3

604
2.2
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molecular weight-associated 1-125 activity is stable to dialysis.

The elution

profile (Fig. 22) resulting from G-200 chromatography of CPO plasm.a/1251insulin after a 5-day incubation at 4°C shows the effect of proteolysis during the
extended incubation as an enlarged protein peak IV. Yet, the profile of
radioactivity remains essentially the same as found for 125 1-insulin in stripped
plasma after 30 minutes incubation.
The 1251-insulin/stripped plasma (SP) G-200 B-fraction, which contained
approximately 3596 BSA (added after chromatography to prevent losses of
radiolabeled insulin by adherence to glass or dialysis tubing) when applied to a
50-ml G-50 column, yielded elution of nearly half the activity around the
exclusion volume, indicating association of 1251-peptides with BSA. Decreased
ability of this "damaged" labeled insulin to bind to AIS is demonstrated by
incubation of elution fractions with AIS in the absence of unlabeled insulin (B 0 )
in the RIA (Fig. 23).

Material eluted in the second peak showed a B0

characteristic of purified 1251-insulin (trace).

No downfield 1251- peak was

found.
Displacement of this second peak activity and trace by increasing
concentrations of unlabeled insulin was parallel in linear RIA dose-response
curves (Fig. 24).

Dose-response behavior of second peak material was nearly

identical to that of trace in logit-log plots, including values for 5096 B0 xintercept and slope. Thus, despite elution of B-peak activity from G-200 in a
supramonomeric position, rechromatography of this fraction yielded material
immunochemically identical to 1251-insulin.
Rechromatography of pooled serum A + B peaks and the A peak (Table XID)
resulted in a shift of both peaks and their coeluting protein peaks to lower
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FIGURE 23.

SEPHADEX G-50 CHROMATOGRAPHY OF FRACTION B

(L-B).

The final peak of radioactivity (B-peak) eluting
from a Sephadex G-200 column after application of a plasma/
125!-insulin mixture incubated for 5 days at 4° C was
rechromatographed on a Sephadex G-50 column.
Double-antibody radioimmunoassay:

% NSB = % total radioactivity in "bound" fraction
(guinea pig serum-antiguinea pig serum precipitate) in
the absence of anti-insulin serum (AIS) and unlabeled
insulin.
B0 = % radioactivity specifically bound to AIS
in the absence of unlabeled insulin:
in bound fraction - NSB CPM
% B = CPM Total
CPM - NSB CPM
Ve

= elution

volume (ml)
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FIGURE 24.

DOUBLE-ANTIBODY RADIOIMMUNOASSAY OF FRACTION B.

Solid line:

125 I-insulin

Broken line: Fraction B (L-B)
Bars: Range of triplicates

The second peak of radioactivity eluting from the
Sephadex G-50 column was examined in the RIA for ability
of unlabeled insulin to displace radioactivity from AIS.
Actual quantity of unlabeled insulin in the assay
tube was one-tenth the concentration added (abscissa).
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molecular weights (B <20,000, A= 74,000-80,000 daltons). Treatment of 125Iinsulin added to the serum A-peak (A 3-I), to serum or to plasma with· biotin
(Table Xll) or excess unlabeled insulin (Tables xm and XIV) resulted in no change
in the elution pattern of radioactivity compared to controls and no shift of Apeak

radioactivity

to

positions

consistent

with

free

insulin,

although

chromatography of A3-I continued the trend of elution of both radioactivity and
protein at higher elution volumes with successive rechromatography.

DEXTRAN-COATED CHARCOAL ANALYSIS OF FRACTION A

The data

in Table XVI indicates that antibody-antigen reactions,

represented by AIS-125 I-insulin, are a good model for study of reversible protein
associations using dextran-coated charcoal. Only 896 of 125 I-insulin activity was
not adsorbed to dextran-coated charcoal, while nearly 8496 activity was
transferred to this supernatant "bound" fraction in the presence of 1:10,000
AIS. Antibody binding of labeled insulin activity is nearly completely reversed
by 0.1 m U unlabeled insulin, indicating competition for antibody binding sites by
an immunochemically identical substance. Adsorption of more than 9096 labeled
insulin to dextran-coated charcoal is unaffected by 8 M urea, but half the
antibody-bound insulin is dissociated under these conditions.
No dissociation of Fraction A activity is produced by these criteria by
excess unlabeled insulin or 8 M urea, but a small fraction of "unbound" activity
may have been transferred to the "bound" fraction by excess AIS.
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TABLE XVI.

ASSESSMENT OF PROTEIN-BOUND I-125 ACTIVITY
USING DEXTRAN-COATED CHARCOAL

Preparation

"Bound"
Fraction
(spnt.)
(±

CPM
Eercent

"Free"
Fraction
(ppt.)

Percent "Bound"
(± percent
deviation*)

dev.*~

125I-insulin

393
(4.2)

4,517
(1.4)

8.0
(5.0)

125I-insulin
+ AIS

4,064
(2.1)

787
(5 .1)

83.8
(0.7)

125I-insulin
+ AIS +
cold ins.

797
(5.1)

4,073
(2.9)

16.4
(6.7)

125I-insulin
in 8 M urea

432
(7.2)

4~,

4 74
(1.4)

8.8
(8.0)

2,912
(1.9)

41.4
(2.4)

674
(21. 8)

471
(9.1)

58.8
(6.1)

A + cold
insulin

735
(1. 2)

369
(2.9)

66.6
(0.8)

A + AIS

763
(7.0)

275
(9. 0)

73.5
(1.4)

697
(19.8)

383
(18.5)

64.5
(2. 0)

125I-insulin + 2,054
AIS in 8M urea (4.1)
Fraction A
(5 day inc.)

A in 8M urea

*

percent deviation

=

determination of greatest
cliff. from mean - mean
mean

Triplicate determinations
cold insulin = 100

~U

unlabeled human insulin

x 100
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IDENTITY OF HIGH MOLECULAR WEIGHT RADIOACTIVE FRACTIONS

Immunochemical Analysis of Serum Proteins
Ouchterlony immunodiffusion of 125 1-insulin-serum G-200 fractions against
specific antisera revealed that strong HSA reactivity resides in Fraction A.
Protein found in Fraction B is due almost entirely to BSA added to stabilize
insulin. Immunodiffusion of

125

1-insulin-plasma (SP and L) fractions (Table XVll)

demonstrated that maximum concentrations of HSA and BSA (added to stabilize
tracer) were both found to reside in A-fractions (protein peak ill) and most of the
human IgG was found in protein peak

n, with lesser amounts in radioactive peaks

A and C.

SDS Polyacrylamide Disc Gel Electrophoresis of A-Fraction
Rf values for SDS-PAGE bands were determined from band migration/dye
migration from both the stained gels (Fig. 25) and densitometer scans of the
gels.

A calibration curve (Fig. 26) was constructed by plotting the Rf of the

calibration bands vs. log M. W. An unexpected sixth band was assigned to the
60,000 dalton subunit of catalase.
The apparently homogeneous G-200 protein peak m (A-peak) was found to
consist of more than seven distinct proteins, ranging in molecular weight from
70,000 (probably albumin) to 240,000 daltons (Table XVID). A-peak albumin was
estimated to be 9.596 AL protein from the area under the densitometer scan
peaks. Thus, albumin comprised slightly more than 7 mg of the 75 mg recovered
protein and 4.4 mg HSA remained after subtraction of the 2.74 mg total BSA
retentate recovered.
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TABLE XVII.

IMMUNOREACTIVE PROTEIN CONTENT OF CPD PLASMA/

l25I-INSULIN SEPHADEX G-200 CHROMATOGRAPHY FRACTIONS
Fraction

vs. anti-BSA

vs. anti-HSA

vs. antihuman IgG

Control

+

c
II

+++

+++

A

++++

++++

++++

Insulin

c

++

±

II

+++

+++

++++

A

++++

++++

++

Five day
incubation

c

++

+

II

+++

+++

++++

A

++++

++++

+

Results of Ouchterlony immunodiffusion analysis.

Scoring

is based on intensity of band and proximity to antibody
well, which reflects relative concentration of antigen.

300

FIGURE 25.

SDS POLYACRYLAMIDE DISC GEL ELECTROPHORESIS

OF A-FRACTION.
A-fraction was obtained by Sephadex G-200 chromatography
of stripped plasma +

12

5I-insulin incubated for 5 days

at 4° C.

Gels were stained with 1% fast green and fixed in methanol/
acetic acid/water (45:10:45).
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FIGURE 26.

SDS POLYACRYLAMIDE DISC GEL ELECTROPHORESIS

CALIBRATION CURVE.
Rf determined from:

e gels
• densitometer scans
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TABLE XVIII.

RESULTS OF SDS POLYACRYLAMIDE DISC GEL
ELECTROPHORESIS
Band

Rf

M.W.
(daltons)

1 (catalase)

0.039

240,000

2 (glue. ox.)

0.173

187,000

3 (BSA)

0.418

67,000

4 (catalase
subunit)

0.471

60,000

5 (chn A)

0.562

25,000

6 (insulin)

0.717

5,500

1

0.030

243,000

2

0.078

223,000

3

0.191

172,000

4

0.273

125,000

5

0.315

106,000

6

0.369

85,800

7

0.414

71,700

Calibration

Sample
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_!ffinity Chromatography of the the A-Fraction
A fraction of 41.2% activity nonspecifically bound to protein was assigned
from extrapolation of G-200 interpeak radioactivity. Thus, NSB Rctivity for a
given AL protein fraction was calculated as AL NSB activity (CPM) x percent
total recovered AL protein in the fraction.

The results of affinity

chromatography and ultrafiltration, summarized in Table XIX, show that about
five-sixths of the activity in AL was associated with BSA and HSA.

The

remaining activity exhibited a molecular weight less than 10,000 daltons and thus
may correspond to the 20-27% radioactivity lost during dialysis of other AFraction preparations.
The 4% A-fraction radioactivity exhibiting a molecular weight between
2,000 and 10,000 daltons may correspond to the apparent 796 IRI found for AL in
previous dextran-charcoal binding studies, but this material did not behave like
IRI in dextran-charcoal analysis (Table XX).

EFFECT OF INSULIN ON PROLIFERATION AND GLUCOSE UPTAKE BY
CELLS IN CULTURE

WI38 fibroblasts exhibit strictly monolayer growth, elongated morphology
and parallel orientation in confiuent adherent cell culture (Fig. 27a).

Cell

number determined for WI38 in 4 replicate wells exhibited a variance less than
1596 when in excess of 2,500 cells per well. WI38 fibroblasts in passage 15-20
plate with an efficiency of 4596. After an initial lag phase of about 18 hours,
5,000 cells in a 2 cm 2 cluster well enter log phase growth with a generation time
of about 22 hours, until they attain confiuency at about 10 5 cells (Figs. 28 and
29). The hepatoma line SK-HEP-1, with an efficiency of plating (EOP) of 3696,
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TABLE XIX.

PARTITION OF A-FRACTION ACTIVITY THROUGH
AFFINITY CHROMATOGRAPHY

Species

mg protein

% recov.

CPM*

protein

% recov. Proj.
act.

NSB
act.
(CPM)

BSA

2.74

3.6

1,699

31.3

HSA

4.40

5.9

1,186

21.9

132

90.5

1,935

35.7

2,024

126

2.3

359

6.6

Other
Protein

68.1

2,00010,000
M.W.

1

<2,000
M.W.

0

*

as of Feb. 7, 1977

0

80.5

% Apeak
act.
50.7
33.0
0
3.9

0

11.3
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TABLE XX.

DEXTRAN-CHARCOAL ADSORPTION OF 2,000 - 10,000
DALTON MOLECULAR WEIGHT A - FRACTION

Preparation

Percent "Bound" ± S.D. (n = 4)

UM-2 Retentate

43.8 ± 4.5

UM-2 Retentate

45.9 ± 4.1

UM-2 Retentate

40.4 ± 2.7

+ 1:400,000 AIS
+ 1:400,000 AIS
+ 40 \..lU insulin
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FIGURE 27.

WI38 FIBROBLASTS.

a. Adherent cell culture; 300X magnification.
b. Detached cell, peroxidase-antiperoxidase stain for
insulin; 350X magnification.
c. and d. Adherent cell culture in the presence of 6.9 mg
human serum acetone powder Fraction 4/ml stationary
medium; 300X magnification.
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FIGURE 28.

INSULIN EFFECTS ON WI38 CELL PROLIFERATION

AND GLUCOSE UPTAKE IN BME WITH 10% FBS.

e

BME CM, mean of 4 determinations

£

100

•

10 mU bovine insulin, average of duplicates

~U

human insulin, average of duplicates

Solid lines: cell number
Dashed lines: medium glucose
Bars: standard deviation
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FIGURE 29.

INSULIN EFFECT ON WI38 CELL PROLIFERATION:

SEMI-LOG PLOT.
Data of Figure 28.

•

BME CM, time = 19.5-145.5 hours; n = 24, r = 0.990,
t 0 = 22.4 hours, t = 32.7, P<O.OOl.
human insulin, time = 3.5-167 hours; n = 16,

£

100

•

r = 0.101, t 0 = 665 hours, t = 0.381, P>O.l.
10 mU bovine insulin, time = 3.5-167 hours; n = 16,

~U

r = 0.966, t 0 = 31.9 hours, t = 13.9, P<O.OOl.
bars: standard deviation
n

= number of points

r = correlation coefficient
t 0 = doubling time
t

=

Student's t-statistic (significance of slope difference
from zero

P = probability that slope = 0

5.0

0 4.0
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•
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exhibited a log-phase tn of 26 hours, while the more differentiated squamouscell carcinoma cell line, LT2, exhibited a 2996 EOP and a tn of about 61 hours
(Table XXI).

LT2 cells also attain confiuence, while the less differentiated

malignant cell lines SK-HEP-1, AU471 and BeWo did not attain confiuence within
10 days.
Figure 30 indicates that the Beckman Glucose Analyzer exhibits a high
degree of accuracy and reproducibility. Glucose consumption by WI38 fibroblasts
increased proportionately with cell growth (Fig. 28) at an overall rate of -7.7
mg/10 6 cells/day (Table XXI) and slowed markedly to -o.9 mg/1o 6·day at
confluence.

However, when 12,500 WI38 cells were plated in each well, log-

phase r was -4.00 mg/1o 6·day, although the tn, 21.1 hours, was very similar to
that found when 5,000 cells were plated per well. Furthermore, when glucose
uptake was measured after 6.2 x 104 cells were allowed to attain confluence
over a period of two days, the rate of glucose consumption was found to be only
slightly below log phase uptake: -3.2 mg/10 6 cells/day. Log-phase r for other
cell lines ranged from -3.5 to -8.6 mg/1o 6·day (Table XXI).
In the presence of 10 mU bovine insulin, WI38 cells entered log phase with
a significantly lower generation time of about 32 hours and, in the presence of
100

~U

human insulin, these cells remained in lag phase, exhibiting no growth

during a 7-day interval (Figs. 28 and 29).

Glucose consumption by WI38

fibroblasts in the presence of 10 mU bovine insulin (r

= -8.1

mg/10 6·day) is not

significantly different from that of control cultures, but a 5096 increment in r (11.7 mg/to 6·day) was seen with 100 ~U human insulin (Table XXI). Insulin added
to these cells during log-phase growth had no apparent effect on growth rate, but
glucose consumption rate followed the same pattern: no significant effect of 10

TABLE XXI.

INSULIN EFFECTS ON CELL PROLIFERATION AND GLUCOSE UPTAKE BY
SEVERAL CELL LINES
Oiff. from
zero-sloEe
p
t

CM vs. insulin sloEe
p
t

26.0
30.0
28.7

14.7 <0.001
10.3 <0.001
5.67 <0.02

0.16 >0.1
0.55 >0.1

3.52
3.88
4.28

CM
100 llu h.i.
1 mU b. i.

22.4
665
31.9

32.7 <0.001
0.38 >0.1
13.9 <0.001

10.8 <0.001
5.77 <0.001

7.69
11.7
8.14

AU471

CM
100 llu h.i.

19.9
34.5

21.3 <0.001
9.8 <0.001

5.58 <0.001

4.93
8.91

BeWo

CM
100 llu h.i.

27.8
81.5

14.9 <0.001
5.18<0.001

6.98 <0.001

8.59
52.5
,

LT2

CM
100 llu b.i.
10 mU b.i.

60.8
48.7
518

10.9 <0.001
2.86 <0.05
0.63 >0.1

0.56 >0.1
4.26 <0.001

6.49
15.2
7.73

Cell
Line

Medium/
Additive

SK-HEP-1

CM
1 mU b.i.
100 mU b.i.

WI38

to
(hrs.)

CM = complete medium (t;/ith FBS)
b.i.

= bovine

insulin

h.i. = human insulin

-r

(mg/l06~day)

t 0 = doubling time
r = rate of glucose uptake
(-mg glucose/106 cells/day)
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FIGURE 30.

e and •

BECKMAN GLUCOSE ANALYZER RESPONSE.
Separate assays

r

= 0.9998

y

= 0.987x- 1.77

•
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mU bovine insulin (-4.6 mg/1o 6·day) and about 5096 increment with 100 'IJU human
msulin (-5.8 mg/10 6·day).

Cell number was also unaffected by insulin added

after cell confluence, while r was unaffected by 10 mU bovine insulin (-2.6
mg/10 6·day) and 100

ll U

human insulin caused a 2596 increase in r (to -4.2

mg/10 6·day). An insulin-induced repression of cell proliferation and stimulation
of glucose uptake rate was also observed for LT2, AU471 and BeWo, but not for
SK-HEP-1 (Table XXI).

CELL INSULIN RECEPTORS AND DEGRADATION

After incubation with 1 mU bovine insulin/ml and washing, Wl38 cells
showed strong positive staining with anti-insulin/peroxidase-antiperoxidase (Fig.
27b). Although a mean specific 1251-insulin binding of 0.90 t 0.5196 was found,
no progressive change in this binding was seen in the range 0.95-19.0 ll U 1251insulin. A specific association of about 0.2 'IJU (8 pg) insulin with 3.33 x 10 5 cells
indicates a minimum of 2,400 insulin binding sites per cell for Wl38 fibroblasts.
A consistent activity of 1-596 associated with suspended, adherent, and
trypsinized SK-HEP-1 cells in quantities of 5 x 104-10 6 after 5 minutes-5 hours
incubation with 1.33 'IJU and 13.3 ll U 1251-insulin indicates less than 200 insulin
receptors per cell. Likewise, 0-296 activity was found associated with about 5 x
10 4 adherent or 106 trypsinized LT2 cells, indicating less than 120 insulin
receptors per cell.
Immunocytochemical staining with PAP, able to detect less than 100
molecules antigen/cell, was plainly negative for SK-HEP-1 cells, despite heavy
background staining, and definitely positive for LT2 cells, with a lighter
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background, as well as for AU471 and BeWo.
RIA of replicate WI38 culture supernates revealed that insulin degradation
occurred in cultures, resulting in 50% of the initial insulin concentration
remaining after 22-48 hours in initial, log phase, and confluent cultures. The
rate of insulin degradation decreased as medium insulin concentration decreased,
with about 25% IRI remaining after 72 hours of log-phase growth. Bovine insulin
RIA of supernates from SK-HEP-1 adherent cell cultures in the presence of 1 mU
bovine insulin/ml showed no loss of immunoreactive insulin from the medium.

WI38 ASSAYS FOR INSULIN IN THE PRESENCE OF SERU\1

Short-form assays utilizing confluent cultures of WI38 (Table XXD) yielded
a glucose uptake rate of 3.21 mg/10 6·day, which was still about half that for logphase cultures. Initial growth cultures reflect both glucose uptake and growth.
Indices in all short-form assays were significantly increased in the presence of
physiologic concentrations of human insulin.
The rate of glucose consumption in confluent cultures was seen to increase
progressively in an apparent dose-response relationship in the presence of 10100 J.lU human insulin, returning to control levels at higher insulin concentrations
( ~1 mU). The same kind of dose-response increase in mg glucose consumed/10 6
viable cells (but less pronounced) and a decrease in cell number was seen for
cells seeded in the presence of 10-100 l-!U insulin. No progressive changes were
seen when 10 J.lU-100 mU insulin was added to log-phase cultures. The variance
of these parameters relative to their mean changes in these assays was too
great, however, to enable their use as bioassays for insulin.

TABLE XXII.

EFFECTS OF INSULIN ON WI38 FIBROBLASTS IN THE PRESENCE OF SERUM
tD
(hr.)

-r
I 6
(mg/lo 6 ·d) (mg/10 )
±SD (n)

t unpaired

3.44

Confluence
BME CM

3.21±0.64
(27)

100 llu hu. insulin

4.14±0.88
(9)

BME CM

21.1

6.28±1.86
(11)

100 llu hu. insulin

21.1

7.17±1.86
(5)
2.32

Initial Growth

100 llu hu. insulin

22.4
00

2.00±6.81
(6)
.15.2±12.2
(6)

p

<0.005

9.29

Log Phase

BME CM

t paired

<0.001

<0.05
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CULTURED FffiROBLAST ASSAY FOR INSULIN

Figure 31 illustrates that the stationary medium (SM,0.35% BSA in BME)
described by Morell and Froesch (615) does, indeed, cause Wl38 fibroblasts to
enter stationary phase 10 hours after complete medium (CM, BME with 10% FBS)
is replaced with SM. These cells

re~nter

log phase 38 hours after SM is replaced

with CM (based on a log-phase t 0 of 21.1 hours).

Therefore, 38 hours were

subsequently subtracted from the time of SM culture when calculating the
proliferation rates of cells in the presence of serum fractions. Cell number was
unaffected by 100

~U

human insulin after 3 days.

This quantity of insulin,

however, caused a significant 65% increase in glucose uptake by these cells
relative to controls and this insulin-induced increment in r was completely
reversed by 0.1 ml 1:5,000 AIS (Table

xxm). The mean r of -3.56 mg/10 6

cells"day for 182 determinations, with a standard deviation of 1.20 mg/10 6·day
and a two-tailed t-statistic of 1.98 at P

= 0.05

(730) yields a 95% confidence

range for control culture r of -1.18 to- 5.94 mg/10 6·day. The normal ranges for
U (n

=86, i =0.044, SD =0.051) andv(n =86, f =0.11, SD =0.084) were found to

be 0.85-1.15 and 0.72-1.28, respectively. Thus, assay parameters falling outside
these ranges are high or low at a minimum significance level of P

< 0.05.

Both assay parameters, U and R, show a progressive, dose-response
increase with increasing insulin concentration (Fig. 32).

The U-response is

curvilinear and is linearized by logit transformation, permitting extrapolation
beyond 100

~U/ml.

This parameter represents total ILA since it is independent of

cell number and therefore includes the pleiotypic increment in glucose uptake
due to the proliferative effects of growth factors. The R-response is directly
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FIGURE 31. EFFECT OF STATIONARY MEDIUM, WITH AND WITHOUT
INSULIN, ON WI38 CELL PROLIFERATION.
CM:

Complete medium, BME with 10% FBS.

SM:

Stationary medium, BME with 0.35% BSA.

.

~

A

SM

•

100

~U

human insulin in SM
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TABLE XXIII.

EFFECT OF INSULIN ON GLUCOSE UPTAKE BY
STATIONARY-PHASE WI38 CELLS

cv

n

Mean r
(-mg/
10 6 • d)

S.D.

182

3.56

1.20

33.7

0.09

SM +
100 ll u
human
insulin

10

5.87

1.13

19.3

0.36

6.23 <0.001

SM +
100 ll u
human
insulin
+ AIS

5

3.26

0.73

22.4

0.33

0.88 >0.10

Medium

SH

(%)

S.E.M.

Comparison
with Control
p
t
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FIGURE 32.

CULTURED FIBROBLAST BIOASSAY FOR INSULIN:

STANDARD CURVES.
a. Total ILA
U

= glucose ultake (mg)
control g ucose uptake (mg)

b. Specific ILA
R = rate of
contro

Abscissa:

Insulin concentration in assay well.
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linear and represents specific ILA since it is corrected for increase in cell
number, measuring insulin-like effects on r.

Thus, this assay is capable of

delineating the effects of growth factors and insulin, and was chosen as the in

--

vitro bioassay for the systematic study of serum fractions.

BULK FRACTIONATION OF HUMAN SERUM

At least 99% of both serum proteins and IRI was retained by the 10,000dalton M. W.-cutoff membrane (Table XXIV A). A nearly 60-fold enhancement of
IRI was seen in the PM10r1 fraction compared to the PM10r2 fraction. Serum
ILA was about 180 lJU/ml (Table

~XIVB)

and ILAs agreed well with this value.

Human serum potentiation of Wl38 proliferation was 13% of FBS. The enhanced
IRI of PM10r1 was reflected in the ILA and ILAs values for this fraction. A 10fold dilution of PM10r1 yielded an ILA value that agreed well with the IRI. A
large enhancement of growth potentiation was also seen in this fraction. The
ILAs of J;>M10r2 agreed well with IRI, while about two-thirds of serum ILA was
recovered in this fraction, which possessed more growth-potentiating capacity
than whole serum. Less than 2% of recovered serum ILA or ILAs was found in
UM2 retentates and filtrates. No heparin or biotin enhancement of ILA, ILAs, or
growth potentiation was seen in serum. Heparin enhancement of PM10r1 (100x)
ILA, PM10r2, Ul\1:2fl and UM2f2 ILAs and PM10r1 (100x) growth potentiation and
biotin enhancement of UM2f1 growth potentiation was also noted.

Treatment of the PM10 Retentate
Re-concentration of PM10r2 through a PM 10 membrane resulted in nearly

TABLE XXIVA.
Fraction

Human Serum

BULK FRACTIONATION OF HUMAN SERUM: IRI
Vol.
(ml)

mg residue

488

Total
Protein
(mg)

Serum
Equiv.
(ml)

31,134

488

17.4

JJU/ml

IRI
JJU/mg
Protein
0.27

PMlOrl

71.0

18,255

17,160

244

6,591

PM10r2

84.5

17,514

16,638

244

98.2

0.50

UM2rl

26.0

413

54

172

9.3

UM2r2

24.5

101

45

172

27.3

Total
%
Total
JJU
8,491

100

467,933 5,511
8,294

97.7

4.5

241

2.8

3.4

1.9

84

1.0

UM2fl

291

2,406

48

291

0

0

0

0

UM2f2

275

228

6.8

24

0

0

0

0

TABLE XXIVB.
Fraction

Human
Serum

BULK FRACTIONATION OF HUMAN SERUM: BIOASSAY

Treatment

v

r
(-mg/10 6 'd)

~U/ml

ILA
Total ~U/ml
mU serum

FBS
!LAs
tD
~U/ml Total ~U/ml (hrs. )equiv.
mU
serum
(ml/ml
serum)

177
179
234

208
88
140

101
43
68

208
88
140

423 1,735
748
1&2
424 1,738

0
0
0

0
0
0

0
0
0

36.0 1. 78
43.7 1.46
31.5 2.03

14,411'~( 1,023 4,195 3,500
25,496* 1,810 7,419 2,000
15, 825'~( 1,124 4,606
0

249
142
0

1,018
582
0

125
5.13
65.4 9.80
87.9 7.28

9.7
21
4.9

40
85
20

102
0.22
194
0.11
78.8 0.28

0
0
0

0
0
0

90.7 0.04
116
0.03
95.3 0.03

3.4
1.9
4.0

20
11
23

Control
Heparin
Biotin

1. 26
1.31*
1. 33'~(

5.49
5.13
5.33

177*
179')\'

PMlOrl
(lOx)

Control
Heparin
Biotin

2.82*
2.35*
3.28*

3.71
3.36
3.46

5, 963-;\'
2, 570'~(
5,974')\'

(lOOx)

Control
Heparin
Biotin

1.38*
1.85*
1.58*

4.67
4.52
4.46

PM10r2

Control
Heparin
Biotin

1. 44')\'
1. 21
1.60*

4.69
5.10
4.78

3701(

UM2rl

Control
Heparin
Biotin

1. Sl·k
1. J8"1'c
1. 48')\-

UM2r2

Control
Heparin
Biotin

0.25*
0.40*
0.23*

234'~(

86
87
114

535')'(

27
31
45

112
128
185

115
245
58

3.20
3.31
2.85

81
78
0

2.1
2.0
0

12
12
0

0
0
0

10. 3')'c'
7. 531c
11.4')\-

0
0
0

0
0
0

139
78
163

322'~(

0
0
0

173
148
140

00
00
00

0.13
0.15
0.16

0
0
0
~

t-:1
CJ:)

TABLE XXIVB. (CONTINUED)
Fraction

UM2fl

UM2f2

*

Treatment

v

r
(-mg/10 6 'd)

~U/ml

ILA
Total ~U/ml
mU serum

Control
Heparin
Biotin

1.03
0.89
1.33*

4.32
4.95
3.48

0
0
0

0
0
0

0
0
0

Control
Heparin
Biotin

0.27*
0.20*
0.27*

6.14*
8. 74""~'(
7.26*

0
0
0

0
0
0

0
0
0

Significantly different from control population.

!LAs
tD
FBS
(hrs.
)equiv.
~U/ml Total ~U/ml
mU serum
(ml/ml
serum)
0
93
0
3.4
8.9
5.8

0
27
0
0.9
2.4
1.6

0 1,253
93
0
130
00

39
102
66

(See legend to Fig. 34.)

00
00
00

0.02
0
0.18
0
0
0
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50% of IRI passing through the membrane, but less than 5% of IRI passed through
the membrane after treatment of this fraction with heparin, biotin or urea

(Table XXV A). Inability of these agents to enhance passage of insulin through
PMlO membranes was reflected in ILA (Table XXVB), but ILAs was found in
heparin, biotin and urea filtrates. Growth potentiation followed the pattern of
ILA.

Heparin enhanced ILA in the heparin filtrate and the acid-ethanol

precipitate, ILAs in the control retentate, biotin retentate and filtrate, and urea
filtrate and growth potentiation in the heparin filtrate. Biotin enhanced ILA in
the control, heparin and biotin filtrates and the acid-ethanol precipitate, ILAs in
the urea filtrate and growth potentiation in the heparin filtrate and acid-ethanol
precipitate.

Gel Chromatography of the P'ilO Retentate
All of the PMlOrl IRI applied to the Sephacryl S-200 column was recovered
in the eluate and more than 90% of the recovered IRI eluted as protein less than
M.W. 12,000 daltons (calibration curve, Fig. 33) with a peak at about 6,500
daltons (Table XXVIA).

A minor IRI peak also occurred in Fraction 4,

corresponding to about 240,000 daltons, possibly coincident with a peak of
growth potentiation since v was increasing in Fraction 2. However, ILA data of
Fractions 3-8 were obliterated due to toxicity of these fractions for WI38 cells,
resulting in loss of all cells in Fractions 3-5 (Table XXVm, Fig. 34).
ILAs is not depicted in Fig. 34 wherever v is significantly lower than the
control population (resulting in spurious elevation of ILAs, which is dependent
upon cell number), but major ILA and ILAs peaks occur at Fraction 10 (M.W.
37 ,000), coincident with a minor IRI peak.

ILA peaks at Fractions 12 (M. W.
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TABLE XXVA.
Sample

Vol.
(ml)

TREATMENT OF PM10r2: IRI
Serum
equiv.
(ml)

~U/ml

IRI
Total

~u

% Recovered

CR

1.3

0.90

10.4

13.5

43.8

CF

10.5

0.80

0.9

9.9

32.1

HR

1.1

0.90

5.7

6.3

20.5

HF

10.9

0.82

0

0

0

BR

1.1

0.90

18.0

19.8

64.3

BF

10.9

0.82

0.1

0.9

2.9

UR

1.5

0.90

5.4

8.1

26.3

UF

10.5

0.79

0

0

0

AEP

5.1

3.6

0

0

0

c = control
H = heparin
B = biotin

u=

8 M urea

AEP = acid ethanol precipitate
R = PM 10 membrane (M.W. cutoff = 10,000) retentate

F = PM 10 filtrate

TABLE XXVB.TREATMENT OF PM10r2: BIOASSAY
Sample

\)

r
(mg/10 6 'd)

CR
1. 77* 3. 55
heparin 1. 20 3.81
biotin 2.29* 2.97
CF
0.99
heparin 1.03
biotin 1.09

4.30
3.85
4.32

HR
2.24* 4.08
heparin 2.17* 3.67
biotin 2.29* 3.77
HF
0.95 5.37
heparin 1.93* 4. 70
biotin 1. 25 4.77
BR
1.38* 4.72
heparin 1.09 5.37
biotin 1.63* 4.58
BF
0.87
heparin 0.80
biotin 1.00

5.19
5.65
4. 74

UR
1.55* 4.79
heparin 1. 68'l'C' 4. 28
biotin 2.06* 4.02

JJU/ml

301*
194*
228
0
0
6.3
132*
74
97*
0
7.2
2.6
124*
94*
152*
0
0
2.9
84*
64';'C'
75*

ILA
Total JJU

ILA

Tota~ JJU

FBS
equiv.
(hrs.) (ml/ml
serum)
tD

JJU/ml
serum

llU/ml

391
252
297

434
280
330

0
59
0

0
77
0

0
86
0

0
0
66

0
0
83

0
0
0

0
0
0

0
0
0

145
81
107

161
90
119

0
0
0

0
0
0

0
0
0

47.4 0.46
49.3 0.45
46.1 0.48

0
78
28

0
95
34

18
4.5
0

22
5.5
0

0
61.6 0.39
182
0.13

137
103
167

152
115
186

0
23
0

0
25
0

126
0.17
470
0.05
82.9 0.27

0
0
31

0
0
38

23
95
0

27
115
0

126
95
112

140
11
125

32
0
0

35
0
0

1.7
0.4
0
0
20
0
2.1
8.7
0
21
0
0

llU/ml
serum

66.9 0.33
210
0.11
46.1 0.48
00

1,292
443

0
0.02
0.06

00

00
00
00

0
0
0

92.1 0.24
77.8 0.28
55.9 0.39

w
w
w

TABLE XXVB. (CONTINUED)
Sample

\)

UF
0.88
heparin 0.82
biotin 0.77

r
(mg/l06'd)

5.03
5.57
5.82

1.30* 4.63
heparin 1.32* 5.01
biotin 1.91* 3.19

AEP

*

J,JU/ml

5.2
3.2
0
21
55
56

ILA
Total J.JU

J.JU/ml J.JU/ml
serum

55
34
0

69
43
0

109
282
287

30
78
80

ILA
Tot a~ J,JU J.JU/ml
serum

7.7 81
18
189
243
23

103
239
308

0
0
0

0
0
0

Significantly different from control population.

0
0
0

FBS
equiv.
(hrs.) (ml/ml
serum)
tD

00
00
00

0
0
0

177
0.12
168
0.13
71.9 0.31

(See legend to Fig. 34.)
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FIGURE 33.

ve /Vo =

SEPHACRYL S-200 CALIBRATION CURVE.

elution vol. (ml)/exclusion vol. (ml)
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TABLE XXVIA.
Fraction

GEL CHROMATOGRAPHY OF PMlOrl: IRI

M.W. (kd)

Total
Protein
(mg)

IRI
Total ll U/ml
%
serum total
llu

Dextran/
Charcoal
% bound

1

>250

0

22

0.6

0.03

0

2

>250

12.2

120

3.0

0.2

1.0

3

>250

170

918

23

1.2

4.6

4

210->250

218

943

24

1.2

6.0

5

137-210

211

689

17

0.9

5.6

6

98-137

169

685

17

0.9

5.0

7

72-98

156

449

11

0.6

4.0

8

54-72

145

401

10

0.5

1.9

9

42-54

152

314

7.9

0.4

2.5

10

33-42

180

336

8.4

0.4

1.8

11

26-33

192

271

6.8

0.4

0.4

12

21-26

196

486

12

0.6

0.9

13

17.5-21

182

528

13

0.7

1.6

14

14.6-17.5

163

595

15

0.8

1.0

15

12.2-14.6

155

818

20

1.1

1.1

16

10.5-12.2

96.7

1,704 43

2.2

0.2

17

9.0-10.5

52.1

3,652 91

4.8

0

18

7.8-9.0

36.2

8,748 219

11.4

0

19

6.8-7.8

32.5

19,296 482

25.2

0

20

6.1-6.8

26.0

25,904 648

33.8

0.7

21

5.5-6.1

17.8

21,484 537

28.0

0
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TABLE XXVIA. (CONTINUED)
IRI
Total J.IU/ml
%
j.lu serum total

M.W. (kd)

Total
Protein
(mg)

22

5.0-5.5

7.8

11,970 299

15.6

0

23

<5

2.5

5,480 137

7.1

0

24

<5

4.6

1,000

1.3

0.6

Fraction

Total

25

106,813 2,670 139
2,577
(91.4%)

Dextran/
Charcoal
% bound

TABLE XXVIB.

GEL CHROMATOGRAPHY OF PMlOrl: BIOASSAY

Fraction Serum
equiv.
assayed
(ml)

\)

ILA
r
(mg/10 6 ·d) Total ~U/ml
serum
~u

'7o total

ILA 5
FBS
% total
tD
Total ~U/ml
equiv.
serum (hrs.) (ml/ml
~u
serum)

1
neparin
biotin

1.4

1. 71*
1.36*
1.38*

3.46
3.69
3.46

987* 25
1,079-;'( 27
816* 20

1.4
3.6
1.2

636
795
564

16
20
14

63.8 0.02
111
0.01
106
0.01

1.4
1.0
0.7

2
neparin
biotin

1.3

1.77*
1.59*
2.19*

3.13
3.09
2.44

523'>''" 13
387* 10
296
7

0.8
1.3
0.4

0
0
0

0
0
0

59.9 0.03
73.8 0.02
43.6 0.04

1.6
1.6
1.9

3

1.4

TOXIC

4

1.3

TOXIC

5

1.2

TOXIC

6
neparin
biotin

1.2

7
neparin
biotin

1.2

8
neparin
biotin

1.2

0.27*
0.51*
0.47*

8.62*
4. 79
5.82

0
0
0

0
0
0

0
0
0

5,712
1,572
2,687

143
39
67

0.26*
0.26*
0.37*

7.36*
6.43*
5.26

0
0
0

0
0
0

0
0
0

6,175
4,973
3,429

154
124
86

0.44*
0.69"""
0.54*

5.75
4.34
5.70

0.3
1.7
0.8

4,670
2,673
4,620

117
67
116

185
5
501'''" 13
539"''" 13

00
00
00

00
00
00

00
00
00

0
0
0

0
0
0

0
0
0

0
0
0

0
0
0

0
0
0

(.o.)
(.o.)

<0

TABLE XXVIB.

(CONTINUED)

Fraction Serum
equiv.
assayed
(ml)

\)

!LA
r
(mg/10 6 'd) Total llU/ml
serum
llu

t
FBS
!LAs
% total
equiv.
% total Total llU/ml 0
serum (hrs.) (ml/ml
llu
serum)
22
14
3

9
lieparin
biotin

1.2

1.04
1. 24
1.65*

4.64
4.29
3.86

801*
937*

20
20
23

1.2
2.7
1.3

10
neparin
biotin

1.2

4.22
0.97
1.50* 3.02
0.16* 19.5*

1,850*
1,254*
463*

46
31
12

2.7 2,311 58
4.1
658 16
0.7 23,032 576

11
heparin
biotin

1.3

0.96
0.67*
1.09

2.83
4.35
2.40

618*
683"(
604*

15
17
15

0.9
2.3
0.9

1,144
3,492
473

29
87
12

12
heparin
biotin

1.2

1.13
0.96
1.01

2.66
3.04
2.98

794*
766*
1,004*

20
19
25

1.1
2.6
1.4

883
1,504
1,406

22
38
35

13
neparin
biotin

1.2

0.74
0.78
1.06

4.38
3.86
3.41

427*
321*
581*

11
8
15

0.6
1.0
0.8

1,950
1,300
748

49
33
19

681

0
0
0
0
0.003 0.1

14
neparin
biotin

1.3

1.05
1. 25
1.13

3.83
3.45
3.89

532*
339*
505*

13
8
13

0.7
1.1
0.7

561
240
448

14
6
11

814
178
325

0.002 0.1
0.01 0.7
0.005 0.3

BOO"(

875
545
132

1,089
0.002 0.1
198
0.009 0.6
85.2 0.02 1.0
00

105
00

00
00

397
280
00

3,439
00
00

0
0.02
0

0
1.1
0

0
0
0
0
0.004 0.2
0.006 0.4
0
0
0.001 0.03

w

""'

0

TABLE XXVIB.
Fraction

(CONTINUED)

Serum
equiv.
assayed
(ml)

\/

ILA
r
(mg/l0 6 •d) Total ~U/ml
serum
~u

ILAs

% total Total
~u

~U/ml

serum (hrs.)

0.85
1.14
1.00

4.39
3.15
3.43

531*
405*
461*

13
10
12

0.8
1.4
0.7

1,618
219
472

40
5
12

0.85
0.91
1.04

3.79
3.32
2.99

444*
296
340*

11
7
9

0.6
1.0
0.5

1,311
776
242

33
19
6

0.93
0.59*
1.09

3.60
4.82
2.79

389*
100
271

10
2
7

0.6
0.3
0.4

704
2,066
0

18
52
0

1.32*
0.59*
1.04

3.35
5.14
3.54

434*
121
260

11
3
7

0.6
0.4
0.4

237
1,904
487

6
48
12

1.5

1.26
1.02
1.35*

3.86
3.95
3.41

507*
348*
292*

13
9
7

0.7
1.2
0.4

352
420
190

9
11
5

1.5

0.03* 29.6
0.63* 5.49
0.08* 35.1

0
275*
0

0
7
0

25,558
0
0.9 2,470
30,745
0

639
62
769

15
neparin
biotin

1.2

16
neparin
biotin

1.2

17
neparin
biotin

1.3

18
neparin
biotin

1.4

19
neparin
biotin
20
neparin
biotin

t0

FBS
%
equiv. total
(ml/ml
serum)
0
0.006
0

0
0.4
0

0
0
0.002

0
0
0.1

0
0
0.004

0
0
0.2

1,088

0.01
0
0.001

0.6
0
0.07

185
2,156
142

0.008
0.001
0.01

0.5
0.05
0.5

0
0
0

0
0
0

00

303
00

00
00

940
co
00

428
154
co

co
co
co

c.,
~

1-'

TABLE XXVIB.
Fraction

(CONTINUED)

Serum
equiv.
assayed
(ml)

\)

!LA
r
6
(mg/10 'd) Total ~U/ml '7o total
serum
~u

I LAs
Total ~U/ml
serum
~u

1.06
1.35*
0.95

4.39
2.96
3.88

358*
205
279*

9
5
7

0.5
0.7
0.4

781
0
390

20
0
10

2.1

0.92
1.25
1.16

3.09
2.30
2.44

183
133
183

5
3
5

0.3
0.4
0.3

166
0
0

4
0
0

23
neparin
biotin

1.6

0.80
0.90
0.59*

2.73
2.35
3.72

109
79
182

3
2
5

0.2
0.3
0.3

538
225
1,700

13
6
43

24

1.7

21
neparin
biotin

1.8

22
neparin
biotin

Total
heparin
biotin
*

tD
(hrs.)

FBS
%
equiv. total
(ml/ml
serum

607
118
00

00

159
238
00
00
00

0.002
0.01
0

0.1
0.7
0

0
0.007
0.005

0
0.5
0.2

0
0
0

0
0
0

0.08
0.09
0.10

4.5
6.3
5.1

TOXIC
9,671
8,093
8,013

242
202
200

13.9
25.0
11.5

Significantly different from control population.

(See legend to Fig. 34.)

343

FIGURE 34.

SEPHACRYL S-200 CHROMATOGRAPHY OF PMlOrl.

Bioassay: Solid bars =no treatment
Open bars = heparin (100
Hatched bars = biotin (10

~g/ml)
~g/ml)

b.d. = blue dextran
g.o.

= glucose

oxidase

BSA = bovine serum albumin
Mb = myoglobin
IRI = immunoreactive insulin (measured by RIA)
= cell number/control cell number
!LA s = specific insulin-like activity

* Significantly higher than control population.
A 95% confidence-limit control range was determined
by assigning each control culture a U-value based on
the average glucose uptake of two control cultures
per plate.
= 0.85-1.15.

Range

= l±(mean of IU-11+ {t 0 • 05 x S.D.})

Therefore, cultures of U>l.l5 were

judged to be higher than the control population at
a minimum significance level of P<0.05.
t

Toxic

*

Control range (determined like !LA control range)
= 0.72-1.28.

g.o.
b.d.

••

BSA

•

Mb

•

---

_}t

.,.. • c.

<

..J
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24,000), 14 (M. W. 16,000) and 19 (M.W. 7 ,000), and 1LAs peaks at Fractions 13
(M.W. 19,000), 15 (M.W. 13,000), 21 (M.W. 6,000) and 23 (M.W.<5,000) were ·also
observed. A peak of growth potentiation occurred at Fraction 18 (M.W. 8,000).
Heparin-induced increase of 1LAs occurred in Fraction 12. Biotin-enhancement
of both 1LA and ILAs was also seen in this fraction.

Enhancement of cell

proliferation by heparin occurred in Fraction 10 and by biotin in Fractions 2
(M.W. >250,000) and 9 (M.W. 48,000). Fractions 20 (M.W. 6,500) and 24 (M W<
5,000) were also toxic for W138 fibroblasts.

Heparin caused inhibition of 1LA,

1LAs and v in several fractions. Both heparin and biotin significantly decreased
1LA and 1LAs in Fraction 10, and biotin also decreased v in this fraction.
Because cytotoxicity of high molecular weight fractions could have been
caused by lipidic material such as low-density lipoproteins and chylomicrons
(738,739), bioassay was carried out on an acetone powder of Fraction 4. Loss of
toxicity with a peak of 1LA due to a growth-potentiating effect was noted in the
treated fraction (Table XXVll).

Dextran-Charcoal Analysis of Fractions
Since appearance of large quantities of monomeric 1R1 in PM10r1 is
consistent with dissociation of the hormone from a serum binding protein,
dextran-charcoal analysis of S-200 chromatography fractions was undertaken to
detect appreciable binding of 1251-insulin by a liberated binding protein.

A

maximum net binding of 696 was found in Fraction 4 (Table XXVIA).
Reversibility of this binding was tested by dextran-charcoal analysis of acidtreated human serum, PM10r2 and PM10r1 S-200 Fraction 5 PM-10 retentates.
Although these fractions exhibited about 2096 net binding of 1251-insulin, no

TABLE XXVII.
Fraction

TREATMENT OF PMlOrl CHROMATOGRAPHY FRACTIONS

Serum
equiv.
assayed
(ml)

\}

r
ILA
(mg/ 106 ·d) Total lJ U/ml % total
serum
vU

ILA 8
Total uU/ml
serum
uU

4 AP
heparin
biotin

1.3

2.00*
1.82*
1.71*

2.59
2.64
2.66

766*
740*
654*

19
18
16

1.1
2.5
0.9

90
90
30

2
2
1

9 HOAcR
heparin
biotin

1.2

1.18
1.17
1. 21

3.58
3.56
3.20

230
202
111

6
5
3

0.3
0.7
0.2

0
0
0

0
0
0

9HOAcF
heparin
biotin

1.1

1.43*
1.12
0.87

4.22
3.79
6.02*

273
108
30'1

7
3
8

0.4
0.4
0.4

0
203
756

0
5
20

12HOAcR
heparin
biotin

1.2

0.67*
0.91
0.98

4.33
3.44
3.13

192
248
235

5
6
6

0.3
0.8
0.3

1,481
461
82

37
12
2

12HOAcF
heparin
biotin

1.1

1.11
1.14
0.87

4.68
4.59
5.58

288
309
298

7
8
7

0.4
1.0
0.4

128
0
624

3
0
15

')'c

Significantly different from control population.

A:P

acetone powder

tn
(hrs.)

FBS
%
equiv. total
(ml/ml
serum)

57.8
66.9
74.6

0.03
0.02
0.02

1.6
1.7
1.1

212
223
184

0.009
0.008
0.01

0.5
0.6
0.5

98.0
309

0.02
0.007
0

1.2
0.4
0

0
0
0

0
0
0

0.005
0.007
0

0.3
0.5
0

00

00
00
00

380
303
00

(See legend to Fig. 34.)

R PM 10 retentate

w

~

0')

HOAc

acetic acid

F

PH 10 filtrate
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decrease in this binding was observed after treatment of fractions with 6M urea
or 1 mU insulin despite apparent enhancement of monomeric IRI by acid
treatment (Table XXVlli).

NSILA~

Screen

Acid treatment of PM10r1 S-200 Fraction 9 resulted in appearance of
significant growth-potentiating activity in the PM 10 filtrate.

Heparin and

biotin did not enhance the activity of the filtrate. A biotin-enhanced !LAs was
also seen in acid-treated Fractions 9 and 12 (Table XXVD).

Comparative RIA
Appearance of large amounts of IRI in PM10r1 is also consistent with
contamination by exogenous insulin, especially since porcine insulin was being
purified by another investigator in the same laboratory. One possible mode of
contamination could have been through common use of lyophilization flasks. Use
of porcine trace and standards in the insulin RIA was undertaken in order to
discriminate

dose-response

behavior

of

human

and

porcine

insulins.

Unfortunately, no significant difference in displacement of porcine trace by
human and porcine standards was found, so that this question could not be
answered.

GEL CHROMATOGRAPHY OF HUMAN SERUM ACETONE POWDER

In order to examine characteristics of the important exclusion region of

chromatographed serum, S-200 chromatography was carried out on human serum
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TABLE XXVIII.
Fraction

Vol.
(ml)

ACID TREATMENT OF SERUM AND SERUM FRACTIONS

~u

IRI
% IRI
recov.

% total
recov.

Dextran-Charcoal
Treatmt. % bound

Human
Serum
Retentate

1.2

18.8 108

33.0

Filtrate

20.1

38.2 220

67.0

19.9

24.7

None
6 M urea
Insulin

20.3
26.0
30.2

None
6 M urea
Insulin

21.7
25.8
29.6

None
6 M urea
Insulin

20.3
46.3
26.8

PM10r2
Retentate

1.2

Filtrate

20.2

57.8

60.6 176

75.3

PMlOrl
Fraction 5
Retentate

1.0

131

69.0

64.5

Filtrate

19.0

72.2

38.0

35.5
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acetone powder, the results of which are summarized in Tables XXIXA and Band
FigUre 35.
All of the IRI applied to the S-200 column was recovered in the eluate, but
more than half of this material eluted at positions corresponding to molecular
weights greater than 18,000 daltons. IRI peaks were seen at Fractions 3 (M. W.
240,000), 7 (M.W. 57,000), 11 (M.W. 21,000), 16 (M.W. 8,000) and 20 (M.W.
5,000). The expectation that acetone would extract toxic lipids from serum was
realized since toxicity was completely eliminated from the exclusion fractions,
verifying a pleiotypic ILA peak, probably at Fraction 3. Unfortunately, bioassay
of untreated and biotin-treated Fraction 3 was unable to be completed because
of microbial contamination.
A peak of growth potentiation was seen in Fraction 7 (coincident with an
IRI peak), followed by an ILA peak at Fraction 8 (M. W. 43,000) and an ILAs peak
at Fraction 9 (M.W. 33,000). Another peak of growth potentiation occurred at
Fraction 10 (M. W. 26,000), followed by an ILA peak at Fraction 11 and an ILAs
peak at Fraction 12 (M.W. 17,000). An ILA peak coincident with a v peak and
heparin- and biotin-inhibited ILAs occurred at Fraction 15 (M. W. 10,000).
Extensive cytotoxicity was seen below M.W. 9,000, from Fraction 16. ILA peaks
were also observed at Fractions 5 (M.W. 110,000) and 13 (M.W. 14,000), and ILAs
peaks at Fractions 1 (M.W. >250,000) and 13.
Heparin stimulation of cell proliferation and ILA was noted in Fraction 1
and of ILAs in Fractions 5, 7, and 10. The compound also appeared to exert a
sparing effect on loss of cells in Fractions 12 and 14. Biotin stimulated cell
proliferation in Fraction 1, ILA in Fractions 5-7 and 9, and ILAs in Fractions 5,
7, and 10. Heparin inhibited ILA in the serum acetone powder and Fractions 2
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·rABLE XXIXA.

GEL CHROMATOGRAPHY OF HUMAN SERUM ACETONE
POWDER: IRI

Fraction

M.W. (kd)

Total
Protein
(mg)
2,032

AP
1

>250

2

>250

0.08
32.8

Total llu
631
0

IRI
llU/ml
serum
17.0

% Total
100

0

0

20.4

0.5

3.2

3

190->250

125

78.0

2.1

12.4

4

130-190

126

44.4

1.2

7.0

5

92-130

122

39.6

1.1

6.3

6

65-92

132

24.0

0.6

3.8

7

49-65

152

61.2

1.6

9.7

8

37.5-49

157

46.8

1.3

7.4

9

28.5-37.5

146

2.4

0.1

0.4

10

23-28.5

140

0

0

0

11

18.7-23

154

16.8

0.5

2.7

12

14.9-18.7

158

0

0

0

13

12.5-14.9

150

0

0

0

14

10.7-12.5

143

0

0

0

15

8.9-10.7

146

0

0

0

16

7.6-8.9

125

10.8

0.3

1.7

17

6.8-7.6

109

9.6

0.3

1.5

18

5.9-6.8

73.2

48.0

1.3

7.6

19

5.2-5.9

32.8

63.6

1.7

10.1
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TABLE XXIXA.
Fraction

20

(CONTINUED)

M.W. (kd)

<5-5.2

Total
Protein
(mg)

IRI

Total lJU

lJU/ml
serum

% Total

13.4

82.8

2.2

13.1

21

<5

3.7

75.6

2.0

12.0

22

<5

3.1

21.6

0.6

3.4

23

<5

2.1

14.4

0.4

2.3

24

<5

14.1

14.6

0.4

2.3

Total

2,261
(111%
recoy.)

675

18.2
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TABLE XXIXB.
Fraction

GEL CHROMATOGRAPHY OF HUMAN SERUM ACETONE POWDER: BIOASSAY

Serum
equiv.
assayed
(ml)

\)

r
ILA
(mg/l06•d) Total llU/ml
serum
llu

FBS
%
equiv. total
(ml/ml
serum)

104
0
0

0
1.7
0

620
0
0

17
0
0

115
126

0
0.02
0.02

0
5.4
4.6

13
8
0

3.0
1.9
0

197
77
110

5
2
3

106
151

0.01
0.009
0

3.3
2.3
0

661*

18

7.4

144

4

0.02

5.1

4.54
4.25
4.13

222*
132
156

6
4
4

1.4
1.5
1.8

31
0
0

1
0
0

120
194
120

0.01
0.006
0.01

2.8
1.7
2.5

1.13
0.90
1.00

3.82
4.52
4.26

380*
302*
434*

10
8
12

2.4
3.4
5.0

344
833
644

9
22
17

330

0.004
0
0

1.1
0
0

0.71*
0.90
0.82

5.42
4.91
5.63

229*
374*
463*

6
10
12

1.4
4.2
5.4

1,287
946
1,430

35
25
39

0
0
0

0
0

1.96*
1.98*
2.09*

4.14
3.66
3.46

1
'fieparin
biotin

0.9

0.90
1.41*
1.37*

4. 75
3.88
3.63

0
266
0

0
7
0

2
'fieparin
biotin

1.7

1.45*
1.30*
0.31*

3.52
3.58
3.65

482*
310*
0

3
neparin

1.5

1.62*

4.24

4
'fieparin
biotin

1.8

1.38*
1.22
1.38*

5
'fieparin
biotin

1.7

6
'fieparin
biotin

1.7

neparin
biotin

I LAs
tD
Total llU/ml
serum (hrs.)
llu

3,875
0
0

0.1

AP

% total

15,939* 430
8, 955·k 241
8,638 233

100
100
100

58.7
57.9
53.6
00

00

73.7

00
00

00
00
00

0.37
0.38
0.41

1.00
100
100

0

...,
(11
('.,)

TABLE XXIXB.
Fraction

(CONTINUED)

v
Serum
equiv.
assayed
(ml)

r
(mg/10 6 ·d)

ILA
Total

~U/rnl

~u

serum

% total

!LAs
tD
Total ~U/ml
serum (hrs.)
~u

FBS
equiv.
(ml/ml
serum)

%
total

7
neparin
biotin

1.6

1.72*
1.33*
1.25

3.80
4.34
4. 70

414*
433*
514*

11
12
14

2.6
4.8
6.0

0
214
440

0
6
12

74.4
142
181

0.02
0.01
0.008

5.1
2.6
1.9

8
neparin
biotin

1.6

1.23
1.17
1.17

4.29
3.42
3.84

581*
242
339*

16
7
9

3.6
2.7
3.9

531
150
219

14
4
6

172
226
226

0.008
0.006
0.006

2.2
1.6
1.5

9
neparin
biotin

1.6

0.86
0.88
1.15

5.14
5.27
4.40

225
280*
317*

6
8
9

1.4
3.1
3.7

580
673
151

16
18
4

0
0
0.005

0
0
1.2

10
neparin
biotin

1.6

1.32*
1.12
0.96

3.62
4.13
4.43

363*
438*
374*

10
12
10

2.3
4.9
4.3

124
407
610

3
11
16

0.01
0.004
0

2.6
1.0
0

11
neparin
biotin

1.5

0.43* 12.02*
0.65* 7.52*
0. 45"~\" 9.98*

446
224
220

12
6
6

2.8
2.5
2.5

4,929 133
2,111 57
3,660 99

0
0
0

0
0
0

12
heparin
biotin

1.5

0.58* 12.38*
0.82
7.78*
0.54* 10.99*

237
369*
298"('

6
10
8

1.5
4.1
3.4

3,273
1,074
2,606

0
0
0

0
0
0

88
29
70

()0
()0

276
139
340
00

()0
()0
()0

00
00
()0

(..)

C/1
(..)

TABLE XXIXB.
Fraction

(CONTINUED)

Serwn \1
equiv.
assayed
(ml)

13
heparin
biotin

1.5

14
heparin
biotin

1.5

15
heparin
biotin

0.64*
0.69*
0.81

r
ILA
(mg/10 6 ·d) Total ~0/ml
serum
~u

% total

ILA 5
tD
Total ~U/ml
serum (hrs.)
~u

9.98*
9.58*
8.28*

417*
292*
323*

11
8
9

2.6
3.3
3.7

2,681
2,472
1,771

72
67
48

0.67* 12.05*
1.17
7.71*
0.72 11.58*

291*
342*
256*

8
9
7

1.8
3.8
3.0

1,887
191
1,658

51
5
45

268

1.4

1.23
1.05
1.35*

632*
582*
645*

17
16
18

4.0
6.5
7.6

1,126
676
411

30
18
11

203
861
140

16
heparin
biotin

1.5

0.40* 11.58*
0.46* 10.31*
0.57* 8.61*

0
84
76

0
2
2

0
0.9
0.9

3,138
2,513
1. 650

85
68
44

17
heparin
biotin

1.4

0.06* 33.30*
0.09* 19.71*
0.11* 15.81*

0
0
0

0
0
0

0
0
0

16,039
8,299
6,088

432
224
164

18
heparin
biotin

1.5

0.02* 0*
0.05* 10.66*
0.05* 1.85

0
0
0

0
0
0

0
0
0

0
4,209
0

0
113
0

9.83*
8.72*
8.07*

00
00
00

00

00

00
00
00

00
00

00

00
00
00

FBS
%
equiv. total
(ml/ml
serum)
0
0
0

0
0
0

0
0.006
0

0
1.5
0

0.008
0.002
0.01

2.1
0.5
2.7

0
0
0

0
0
0

0
0
0

0
0
0

0
0
0

0
0
0
w
c.n

·~

TABLE XXIXB.
Fraction

(CONTINUED)

Serum
equiv.
assayed
(ml)

19
neparin
biotin

1.5

20
neparin
biotin

1.4

21
neparin
biotin

1.0

22
neparin
biotin

1.2

23
neparin
biotin

1.8

24

1.3

\)

ILA
r
(mg/106 ·d) Total ~U/ml
serum
~u

% total

!LAs
tD
Total ~U/ml
serum (hrs.)
~u

0.27* 13.29*
0.08* 7.60*
0.07* 2.16

0
0
0

0
0
0

0
0
0

0.06* 8.52*
0.01* 70.99*
0. 004* 0,'<'

0
0
0

0
0
0

0
0
0

3,296
89
48,481 1,307
0
0

0.02* 25.72*
0.01* 98.77*
0.07* 12.52*

0
0
0

0
0
0

0
0
0

12,210 329
58,127 1,567
4,089 110

0.04* 15.09*
0.01* 0*
0.04* 1. 77

0
0
0

0
0
0

0
0
0

9,440
0
0

254
0
0

0.08* 13.30*
0.02* 80.22*
0,'<'
0,'<'

0
0
0

0
0
0

0
0
0

3,507
32,487
0

95
876
0

TOXIC

4,990
1,688
0

134
46
0

00
00
00

00
00
00

00
00
00

00
00
00

00
00
00

FBS
%
equiv. total
(ml/ml
serum)
0
0
0

0
0
0

0
0
0

0
0
0

0
0
0

0
0
0

0
0
0

0
0
0

0
0
0

0
0
0

Fraction

Serum
equiv.
assayed
(ml)

\}

r
!LA
(mg/l0 6 'd) Total llU/ml
serum
llU

4,919
5,331
4,415

Total
heparin
biotin
2

*

1.9
1.0
0.2

0.70*
2.91*
1.66*

0.85*
5.90
5.02

133
144
119

0
0
88,06S"k 2,374
65,099* 1,755

% total

I LAs
tD
Total llU/ml
\.IU
serum (hrs.)

FBS
equiv.
(ml/ml
serum)

io
total

0.07
0.08
0.06

18.9
21.8
14.4

0
0.06
0.15

0
17.3
41.0

30.8
59.6
51.1
0
552
408

Significantly different from control population.

0
4,371
15,386

0
118
415

"'

36.4
76.7

(See legend to Fig. 34.)
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FIGURE 35.

SEPHACRYL S-200 CHROMATOGRAPHY OF HUMAN

SERUM ACETONE POWDER.
See legend to Figure 34.
t

Lost due to microbial contamination.
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(M.W. >250,000), 4 (M.W. 160,000), 5, 8, 11 and 13, and n..As in the

ac~tone

powder and Fractions 1, 2, 4, 6 (M. W. 79,000), 8 and 15. Biotin inhibited cell
proliferation in Fraction 2, ILA in 11, 13 and 14 (M.W. 12,000), and ILAs in the
acetone powder and Fractions 1,2,4, 8, 9 and 15.

SUMMARY OF RESULTS PERTINENT TO SPECIFIC OBJECTIVES

Cation-exchange chromatography with Sephadex C-50 was carried out on
human plasma as described by Guenther. Although about 5 \JU IRI/ml plasma was
found in the most cationic fraction eluted from the column, significant
quantities of heparin-induced IRI were not found in any fraction, nor did heparin
increase IRI in normal human serum and plasma. Thus, heparin was not used in
subsequent experiments designed to elucidate a serum insulin-binding protein.
Sephadex G-200 gel chromatography of 125 I-insulin (6.2-70\.l U/ml) added to
normal human serum and plasma revealed that less than 5% of radioactivity was
associated with a protein fraction that included albumin. This pattern was not
changed by treatment of the mixture with biotin (10 g/ml) or a ten-fold excess
of unlabeled insulin, or prolonged incubation (5 days, 4°C) of the 125 I-insulinplasma solution.

High molecular weight radioactivity was unaffected by

rechromatography with or without excess unlabeled insulin (1 mU). Dextrancoated charcoal analysis of the high molecular weight I-125 activity revealed
that radioactivity was not dissociated by a thirty-fold excess of unlabeled insulin
or 8 M urea. Affinity chromatography of this material showed that more than
80% of radioactivity was associated with albumin and about 10% exhibited a
molecular weight of less than 2,000 daltons.
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In order to determine the nature of serum ILA, human cell lines were
examined for their ability to serve as the basis for an in vitro bioassay capable of
discriminating specific ILA and the pleiotypic effects of growth factors. I found
that Wl38 human fetal lung fibroblasts possess

cell~urface

insulin receptors.

Physiologic concentrations of insulin added to replicate culture wells in medium
containing 10% fetal bovine serum caused a significant increase in the rate of
glucose uptake by these cells and inhibited traversal of the cells from lag phase
to log phase. Both of these effects were found to be dose-dependent. The three
of four malignant human cell lines that were found to possess insulin receptors
also showed significant increases in glucose uptake rate and inhibition of cell
proliferation in response to various concentrations of insulin. The one cell line
negative for insulin receptors showed neither insulin response.
A cultured fibroblast bioassay for insulin was developed by maintaining
Wl38 cells in stationary phase in serum-free medium in multiple-well plastic
cluster dishes for 4 days at 37°C, after which cells were counted in a
hemacytometer and medium glucose was measured with a Beckman Glucose
Analyzer. Insulin or other preparation to be tested was added to medium before
addition to cells

prev~ously

plated in wells.

physiologic concentrations (25-100

~U/ml)

Cell number was not affected by

of insulin after 4 days.

Total ILA

measurements were based on the curvilinear increase of the parameter U
(glucose uptake/control glucose uptake) with increasing insulin concentration,
while measurements of specific ILA were based on the linear increase of the
parameter R (rate of glucose uptake/control rate of glucose uptake) with
increasing insulin concentration.

Stimulation of cell proliferation was

determined from the parameter v(cell number/control cell number).

361

Concentration of normal human serum by ultrafiltration through a M.W. 10
kd cutoff membrane (PM 10) apparently caused the liberation of large amounts
of IRI in the retentate (100 times the serum level). Less than 5% of serum IRI
passed through the membrane, even in the presence of 8 M urea, but acid
treatment caused two-thirds of serum IRI to pass through the membrane. Values
obtained for both total ILA and specific ILA were similar to IRI in this fraction,
but in serum these values were ten times the IRI. Less than 1% of serum ILA
and three-fourths specific ILA passed through the membrane after treatment of
a retentate fraction with 8 M urea.
On Sephacryl S-200 gel chromatography of a serum PM 10 retentate
fraction, about 90% of the IRI apparently generated during serum concentration
eluted at a position corresponding to proteins of M. W. <10 kd, but significant
quantities of IRI eluted in discrete peaks at higher molecular weights. Dextrancoated charcoal analysis of elution fractions indicated a maximum serum insulin
binding capacity of 4 J.J U/ml. Dextran-coated charcoal analysis also revealed no
reversible binding of 1251-insulin to acid-treated human serum and high
molecular weight serum fractions.
Gel chromatography of a human serum acetone powder revealed that most
serum ILA eluted at about 250 kd M. W., with virtually all of the serum's capacity
to stimulate cell proliferation.

Both biotin and heparin enhanced as well as

decreased total ILA, specific ILA and cell number in various fractions. About
half of serum IRI eluted at positions corresponding to proteins of M.W. >18 kd.
Although only 0.5 J.J U IRI/ml serum was found at the column exclusion volume
(Fraction 2), with large quantities of dilution-enhanced cell proliferation
stimulation activity, dilution of this fraction also greatly enhanced specific ILA,
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which attained a maximum of about 400 \JU/ml serum at an equivalent of 0.2 ml
serum/ml, representing about 2096 of the total ILA in the fraction.

CHAPTER Vlll

DISCUSSION

IS THERE A SERUM INSULIN-BINDING PROTEIN?

By 1965, two major lines of evidence supported the existence of an
insulin-binding protein in human serum: 1) AIS-suppressible ATE"'1>otentiated ILA
in serum and BI fractions (390,511) and 2) apparent association of radiolabeled
insulin with human serum

a - Y globulins (520-522).

However, Berson and

Yalow and others were unable to enhance IRI of human serum and BI fractions by
treatment that potentiated ILA measured by bioassays (523, 524). Furthermore,
Berson and Yalow demonstrated that apparent association of radiolabeled insulin
with globulins was, in fact, irreversible binding of damaged tracer to serum
proteins, especially albumin (515). These investigators also refuted the existence
of a serum insulin-binding protein on theoretical grounds, pointing out that the
known effects of hormone-binding proteins are inconsistent with insulin decay
kinetics in vivo and that insulin-binding antibodies in diabetics are highly
disruptive of

insulin~ependent

carbohydrate homeostasis (528).

On the other hand, insulin-like growth factors (IGFs), such as NSILA-8
(IGFs I and ll) and the somatomedins, which show extensive homology with insulin
and presumably derive from a common ancestral gene, have recently been shown
to have serum binding proteins (557, 573, 585, 598, 602, 611, 612). Thus, an
insulin-binding protein is a plausible expectation. Finally, Guenther's
363
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demonstration of heparin-induced IRI in BI fractions {387) both confirmed
Gundersen and Lin's observations with a rat diaphragm assay {391) and provided
direct evidence for a human serum insulin-binding protein.
In the present study, Sephadex C-50 chromatography of human plasma

using Guenther's protocol resulted in elution of 10

J.l

U IRI/ml plasma retained

on the cation exchanger, about half the IRI that Guenther found in the untreated
BI fraction. About 43% of this IRI was eluted in the most cationic fraction, but
the same quantity of heparin employed by Guenther did not significantly increase
the IRI in this or any other fraction. Nevertheless, this experiment confirms the
presence of cationic IRI in human plasma. The presence of an insulin-binding
protein in human serum and plasma was also supported by loss of approximately
30% exogenous insulin added to CPD plasma and both plasma and serum after
treatment with an anion-exchange resin {to remove insulin), measured by the
dextran-charcoal RIA. However, these results could also be explained by
potentiation of degradative enzyme activity. Again, heparin did not enhance IRI
in any serum or plasma sample.

Systematic examination of the 1251-insulin

binding capacity of human serum and plasma using gel chromatography and
dextran-coated charcoal as employed by Zapf et al. {557) to elucidate the
NSILA-6 serum binding protein revealed that less than 5% of the 1-125 activity
was associated with material in the molecular weight range 50,000-160,000
daltons.

This material was stable to dialysis and rechromatography and was

apparently unaffected by treatment with biotin or large quantities of unlabeled
insulin, suggesting irreversible binding of radiolabeled material.
Dextran-charcoal analysis of this high molecular weight radioactivity
revealed no liberation of free 1-125 activity by unlabeled insulin or 8 M urea,

365

confirming the irreversibility of the association. Subsequent dextran-charcoal
analysis of Sephacryl S-200 fractions of a serum PM 10 retentate in which a
large quantity of monomeric IRI was apparently liberated again revealed a
maximum 6% binding of 1251-insulin that could not be reversed by unlabeled
insulin or 6 M urea. If the insulin had been dissociated from a serum carrier
protein during ultrafiltration, one or more high molecular weight fractions would
be expected to exhibit a large reversible binding capacity for 125 1-insulin.
Immunodiffusion analysis and SDS polyacrylamide gel electrophoresis
revealed that the high molecular weight radioactivity (peak A) consistently
eluted with the major fraction of albumin. Affinity chromatography of A-peak
material in fact showed that five-sixths of the 1-125 activity was bound to
albumin and that about 10% activity exhibited a molecular weight of less than
2,000 daltons, confirming Berson and Yalow's contention that apparent
association of radiolabeled insulin with serum components represents irreversible
binding of damaged tracer to proteins, particularly albumin. Thus, it must be
concluded that no physiologically significant insulin-binding protein exists in
normal human serum or plasma.

WHAT IS ILA?

The reason that findings of atypical IRI were judged to be the most
pertinent evidence for a serum insulin-binding protein despite extensive findings
of atypical ILA measured by various bioassays relates to the subsequent
discovery of numerous substances that mimic insulin's effects in bioassays, but
possess structures and physiologic roles that differ from those of the hormone.
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The extent of the discrepancy between typical insulin and atypical ILA is
suggested by the fact that more than 90% of serum ILA is not suppressible by
AIS (527, 546).
Much, if not all, of this NSILA is due to the effects of serum and plasma
growth factors, several of which exhibit "specific" ILA (e.g_., stimulation of
glucose

uptake

concentrations.

and

lipid

and

glycogen

synthesis)

at

supraphysiologic

These IGFs include NSILA-8 (IGFs I and ll), which comprises

about 10% of total serum NSILA, the somatomedins and MSA (546, 547, 550,
629). Poffenbarger (563) also showed that an antiserum raised against NSILP,
which accounts for 70-80% human serum NSILA, reacts with MSA. In addition,
non-IGF growth factors, such as FG:f' and EGF, may exert a pleiotypic effect on
cells that could produce ILA in certain bioassays. For instance, BI may contain
FGF as well as IGFs (717).
Clearly, a bioassay capable of discriminating specific ILA and growth
potentiation would be a very useful tool in dissecting the nature of serum ILA.
In this

study, a cultured fibroblast bioassay apparently exhibiting this

discrimination and a double-antibody RIA for insulin were used to characterize
human serum fractionated according to molecular size.
The WI38 fetal lung fibroblast line is the only one of five human cell lines
studied that was derived from a nonmalignant source.

WI38 cells exhibit a

diploid karyotype (740) and have a finite lifetime of 50 ±10 population doublings
(741). The doubling time (tn> of 30 hours reported by Houck and Cheng (716) is
similar to the 22-hour tn found in this study. Although these cells were used up
to 54 generations, the consistency of tn and rate of glucose uptake (r) indicates
that they had not become senescent. Of the five cell lines studied, SK-HEP-1
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was the only one that was negative for insulin receptors by both 1251-insulin
adsorption and PAP immunocytochemical staining. This cell line was also the
only one that showed no significant increase of r in the presence of insulin.
Although the initial study of WI38 human fetal lung fibroblast growth in
the presence of serum indicated a decrease of r at confluence, subsequent
studies of this cell line demonstrated that r remains relatively constant at -3 to
-4 mg/10 6·day in log-phase, stationary and confluent cultures. Thus, the rate of

glucose uptake appears to be independent of cell number and medium glucose
concentration, contrary to other reports (554, 724-726), suggesting a facilitated
or active glucose transport mechanism. The rate of glucose uptake exhibited by
the other cell lines studied indicates that r is apparently independent of rate of
cell proliferation and malignant transformation.
Suprisingly, despite extensive documentation of insulin as a growth
potentiator in pharmacologic doses, the hormone was found to inhibit
proliferation of cultured cells positive for insulin receptors in this study when
added at the time of plating in concentrations of 10

J.J

U/ml-10 mU/ml. Only

SK-HEP-1 proliferation was apparently unaffected by insulin, suggesting that
this effect, as well as stimulation of glucose uptake, is mediated through insulin
receptors and thus is insulin-specific, rather than being due to an insulin
contaminant. This contention is supported by the fact that these effects are
elicited by both human and bovine insulin preparations and is confirmed for
enhancement of r by reversal in the fibroblast bioassay by AIS. The absence of
toxic contaminants in insulin preparations is further indicated by the normal
appearence of insulin-inhibited cells, which did not exhibit excessive granulation
or floating debris, and the lack of insulin effect on cell number when the
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hormone was added during log phase, confluence or stationary phase. Therefore,
the concentration-dependent insulin jnhibition of cell proliferation appears to
involve a hormone mechanism specific for lag-phase cells, in which cells are
prevented from exiting lag phase or the subsequent log-phase cell cycle is
somehow prolonged.
A possible mechanism is suggested by Shapiro and Lam's observation that
intracellular Ca++ concentrations increase as human fibroblasts age in culture
(742).

Cultured fibroblast senescence is characterized by cessation of cell

division (741, 743) and several investigators have provided evidence that insulin
increases intracellular Ca++ concentrations (see Chapter ID). Teng et al. (7 44)
have found that 16 mU insulin/ml shortens Gr1>hase and extends the S-and G2phase of CEF in culture, while Koontz and Iwahashi (745) showed that physiologic
concentrations of insulin (5 x 10-ll M) cause rat hepatoma cells to exit G1phase.

Thus, it is unlikely that lag-phase is G1-phase.

Inhibition of cell

proliferation by insulin is also consistent with the hormone's physiologic role,
which is to encourage energy storage through synthesis of macromolecules.
Use of cultured Wl38 human fetal lung fibroblasts for an insulin bioassay
is well-suited to examination of the nature and effect of human serum ILA on
normal human cells since this cell line is diploid and well-characterized.
Artifacts that could be encountered using malignant or non-human cells are
exemplified by the evident loss of insulin receptors by SK-HEP-1 hepatoma cells,
production of a growth factor (MSA) by Coon rat liver cells, rendering them
serum-independent (629), and the fact that insulin is a much more potent
mitogen for avian fibroblasts than for mammalian fibroblasts (616).
In this study, a significant, specific (AIS-reversible), consistent, dose-
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dependent insulin-induced increase in rate of glucose uptake by cultured WI38
fibroblasts is well documented.

In addition, the use of stationary medium

according to the method of Morell and Froesch (615) enables discrimination
between specific ILA (!LAs) and the pleiotypic effects of growth factors. The
insulin

dose~ependent

increase in the parameter U (glucose uptake/glucose

uptake of control) is appropriate for measurement of total ILA since it is
independent of cell number and does not discriminate between increments of U
due to the stimulation of cell proliferation and those due to increase of r. !LAs is
best measured by determination of the parameter R (r/control r), which also
increases with increasing insulin concentration.

However, because this

parameter is dependent upon cell number, factors that cause loss of cells can
yield artifactual enhancement of !LAs.

Therefore, !LAs values were ignored

where v (cell number/control cell number) fell below the control population
( <

0.71). The validity of these assay parameters is indicated by the fact that

both the ILA (177

~U/ml)

and ILAs(208

~ U/ml)

found for normal human

serum are very close to the mean fat-pad assayable serum ILA (180 \.l U/ml)
reported by Froesch et al. (527).
Similar quantities of ILA were recovered in the total of Sephacryl S-200
chromatography fractions (each assayed in 1-2 ml serum equivalents) from a
human serum PM 10 retentate (PM10r1, M.W.

>10,000, ILA recovered =242

\.lU/ml serum) and from a human serum acetone powder (133

~ U/ml

serum).

However, total ILA recovered from the PM10r1 fractions represents only 14% of
the 1,735

~U

ILA/ml serum found when PM10r1 was assayed at a 0.035 ml

serum equivalent, a value similar to ILA concentrations obtained by Gundersen
and Lin (391) for dilute human sera using the fat pad assay.

No ILAs was
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detected in the tenfold diluted PM10r1 preparation, suggesting the dilutionenhanced ILA is due to attenuation of inhibitors of one of more serum growth
factors.

This possibility is supported by dilution enhancement of PM10r1

stimulation of Wl38 cell proliferation, to 5 and 40 times the rate expected with
equivalent amounts of FBS and human serum, respectively, based on cell
proliferation rates in the presence of 10% concentrations of these sera.
Furthermore, numerous S-200 fractions caused decreases in cell number relative
to controls and several exhibited frank toxicity, evidenced by disintigration of
cells. The possibility that high molecular weight lipidic material constitutes an
important class of growth factor inhibitors is supported by abolition of toxicity
in exclusion fl"actions by extraction qf fractions or serum with acetone, enabling
measurement of cell growth stimulation by these fractions.
About 5% recovered PM10r1 ILA eluted at 6,800-7,800 daltons, where
free NSILA-8 would be expected. Only 5% recovered serum acetone powder ILA
eluted around 70,000 daltons, where NSILA-8 associated with its carrier protein
should be found. However, nearly 20% ILA, coincident with an ILAs peak, eluted
from both columns between 30,000 and 50,000 daltons. Zapf et al. (557) reported
that considerable amounts of serum NSILA-8-binding activity was also detected
at molecular weight 30,000-40,000 daltons, indicating that the binding protein
may be present in serum partly as oligomers. The results of this study support
the contention that a 35,000-dalton protein represents the primary NSILA-8
-binding component of human serum. About 10% ILA eluted from both columns
between 12,500 and 17,500 daltons, suggesting a NSILA-8 dimer.

All these

putative NSILA-8 fractions contained concomitant ILAs and did not stimulate
significant cell proliferation.

The ability of the cultured fibroblast assay to
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detect serum protein-bound NSILA-8 is supported by passage of about one-third
PM10r2 ILA through a PM 10 membrane after treatment of the fraction with 8 M
urea.

The acetone powder ILA peak at about 10,000 daltons may be due to

MSA. This assay, however, would not be expected to detect EGF or FGF.
About 20% of acetone powder ILA eluted at the column exclusion volume
with a peak of cell proliferation potentiation.
concentration-dependent, however.

This activity is very

When Fraction 2 was assayed at a 1.9-ml

serum equivalent, complete suppression of both ILA and cell growth potentiation
was seen, but both these parameters increased markedly as the fraction was
diluted, until at 0.2 ml serum equivalent it exhibited 1,755\.l U ILA/ml and 41%
total acetone powder growth potentiation.

In addition, 1.5-1.8 ml serum

equivalent of Fractions 3 and 4 caused WI38 fibroblasts to form multilayered foci
in which the cells grew in a random orientation, satisfying a morphologic
criterion of malignant transformation (746).

Thus, a serum growth factor of

approximately 240,000 daltons molecular weight not only accounts for the entire
potentiation of WI38 cell proliferation by human serum, but also is the apparent
cause of serum

dilution~otentiated

ILA.

The dilution enhancement of ILA

and v may be due to attenuation of an inhibitory substance or a concentration
optimum of factor-receptor interaction.

This growth factor may be an

aggregate form of NSILA-P or the WI38 growth factor, or an as-yet
uncharacterized growth factor. However, only 8% of acetone powder ILA, with
concomitant ILAs and without growth stimulation, eluted between 92,000 and
130,000 daltons, where NSILA-P and WI38 growth factor would be expected, but
a major peak of cell proliferation, containing 8% ILA and no ILAs, eluted at half
the molecular weight, 49,000-65,000 daltons.
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On the other hand, the exclusion-volume cell proliferation stimulating
activity may represent aggregate forms of transforming growth factors (TGFs)
and platelet-derived growth factors (PDGFs) bound to serum carrier proteins.
However, only a

biotin~otentiated

peak of cell proliferation was found in a

PM10rl S-200 fraction corresponding to molecular weight ::.:37,000 daltons,
within the range of 30-40 kd reported for PDGF (747), and no stimulation of cell
proliferation was found in the molecular weight range 10-20 kd, where TGFs
would be expected to elute (7 48).

IS THERE OCCULT INSULIN?

Although the results of this study indicate that serum ILA could be due
totally to IGFs and other growth factors, there also remains evidence for the
existence of an occult form of insulin in human blood. Like Guenther, I found a
significant amount of IRI (about 4
fractions.

~U/ml

plasma) in highly cationic plasma

Furthermore, more than half the IRI in a serum acetone powder

eluted from Sephacryl S-200 at positions corresponding to proteins in excess of
18,000 daltons molecular weight.
If occult insulin cannot be due to an as-yet uncharacterized specific
serum insulin-binding protein, then it most likely is due to the one known insulinbinding protein: insulin.

Elution of serum IRI peaks from Sephacryl roughly

corresponds to what would be expected for the dimer, tetramer, hexamer, dihexamer and hexa-hexamer and, in fact, the ILA ascribed to IGFs could also be
due to insulin.

Since insulin aggregates, especially the hexamer and

polyhexamers, are expected to exhibit only a small fraction of monomeric IRI,
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this high molecular weight serum IRI could represent a much greater absolute
amount of insulin -as much as 2 mU/ml or more, which was apparently
"liberated" in PMlOrl.

However, this phenomenon could not be reproduced

(although the circumstances of the reproduction were not identical to the
original conditions) and comparable quantities of IRI were not found in PM10r2
and UM2r2, the fractions resulting from dilution and reconcentration of one-half
PMlOrl.

Unfortunately, the possibility that this IRI was an artifact due to

contamination of the fraction with porcine insulin was unable to be tested since
the RIAs employed were unable to distinguish between human and porcine
insulins. The existence of insulin aggregates in human serum is also supported by
a 2- to 3-fold enhancement of IRI and passage of two-thirds to three-fourths of
this IRI through a PM 10 membrane after treatment of human serum or PM10r2
with acid, whereas

s;

1% untreated serum or PM10r2 IRI passes through the

membrane.
A specific ILA of 415 lJU/ml serum was found at a 0.2 ml serum
equivalent of acetone powder S-200 Fraction 2, which exhibited an IRI of only
0.5 lJU/ml serum.

The ILAs in the assay well at this dilution thus was about

80 lJ U, nearly the optimum insulin concentration for this assay.

This result,

therefore, indicates that this fraction actually contains about 1,000 times more
insulin than the IRI (consistent with insulin aggregates, which would be expected
to exhibit only a small fraction of the IRI of monomeric insulin) and that
circulating insulin aggregates may account for 20-25% total serum ILA.
The exceedingly small proportion of aggregates found in neutral aqueous
insulin solutions at physiologic concentrations of the hormone (and of Zn++) and
calculations based on equilibrium association constants determined for insulin
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aggregates has led to the general conclusion that significant quantities of insulin
aggregates cannot exist in systemic circulation. However, these studies involved
measurement of insulin association at equilibrium after crystalline insulin was
dissolved at acid pH. In vivo, crystalline insulin is released into the circulation
at pH 7.4. Therefore, a more appropriate model of insulin aggregates in vivo
would be measurement of crystalline insulin dissociation in dilute neutral
solution. An example of such an experiment is measurement of the appearance
with time of monomeric IRI in a stirred suspension of 80 ].J g crystalline zincporcine insulin in one liter 596 BSA/pH 7.4 PBS at 37°C.
The possibility that the equilibrium association constants observed for the
formation of insulin aggregates results from rates of dissociation far slower than
relatively slow association rates, to the extent that insulin aggregate
dissociation in vivo is far from equilibrium is supported by examination of insulin
aggregate characteristics iterated in Chapter V.

Whereas hydrogen bond

formation between amino acid substituents cannot be expected to contribute to
subunit association (and, in fact, should add an unfavorable fiG increment since
organic nitrogen and oxygen form stronger hydrogen bonds with water than with
each other (749)), the 4 hydrogen bonds per dimer and 6 additional hydrogen
bonds per hexamer contribute a
of these aggregates (749).

t~G

of about +2.4 kcal/mole each to dissociation

The net

t~G

of about +0.75 kcal/mole required to

break amino acid-water hydrogen bonds and form internal hydrogen bonds during
subunit association is reversed upon dissociation. Likewise, the ll G involved in
displacement of water coordinated to Zn ++ by coordination of amino acid
substituents to Zn++ during formation of the Zn++ tetra mer and hexamer is
reversed during dissociation of these species.
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Therefore, the -

!::.

G underlying the positive equilibrium association

constants observed for insulin aggregation is probably due primarily to transfer
of apolar amino acid side chains from water to an apolar environment. However,
if the 12 apolar side chains that appear to make contacts in the dimer and the 42
additional apolar side chains that have been implicated in the hydrophobic
interactions of hexamer formation were completely buried, yielding a t:. G of
about -2.5 kcal/mole each (750, 751), the resultant equilibrium association
constants would be much higher than those observed, suggesting that these side
chains are not completely buried. This contention is supported by the fact that
the A14 tyrosines and B25 phenylalanines are exposed at the surface of the
hexamer (464).
Nevertheless, amino acid-water hydrogen bonds and Zn++ - water
coordinate bonds must first be broken before hydrophobic interactions can occur
during subunit association, while not only internal hydrogen and coordinate bonds
must be broken, but energy must also be expended to transfer apolar side chains
to water before the -

t:.G of water-bonding can be realized during aggregate

dissociation, indicating that the rate of dissociation must be much slower than
the rate of association. Studies of insulin aggregation in neutral solution have
indicated that the 2-Zn++ hexamer is essentially completely dissociated at
concentrations below 10-7 M (472). Therefore, if hexamers exist in the systemic
circulation at a concentration of 10-9 M, they are less than 5% dissociated. In
other words, if significant quantities of insulin aggregates exist in the systemic
circulation-and the results of this study indicate that they do-it can only be
due to an extremely low rate of dissociation, much lower than the rate of
systemic degradation of monomeric insulin so that insulin aggregate dissociation
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is extremely limiting. Furthermore, since examination of the primary structure
of insulin reveals that the hormone possesses a net charge of -1 per monomer at
neutral pH, cationic IRI could represent

>

2 Zn++ tetramers and hexamers.

The disruption of glucose homeostasis by insulin-binding proteins
postulated by Berson and Yalow would not apply to insulin aggregates because of
a fundamental difference between the nature of competitive protein binding,
such as that which occurs with antibodies, carriers and receptors, and insulin
aggregation. The former would be expected to involve high-avidity interactions,
i,e. a very rapid association and a relatively rapid dissociation, enabling

displacement by additional ligand or dilution, while the latter apparently involves
a very slow dissociation and a relatively slow association. This supposition is
supported by the fact that 8 M urea caused no generation of monomeric IRI in
PM10r2, while acid treatment of this fraction resulted in passage of 75% IRI
through a PM 10 membrane.

Provided the systemic

insulin degradative

mechanism remains intact, monomeric insulin provided by aggregate dissociation
will be destroyed nearly as quickly as it is generated.
What, then, is the purpose of circulating insulin aggregates?

One

possibility is that it is the harmless consequence of an elegant mechanism of
acute secretion of a hormone that causes the rapid utilization of nutrients, like
the proinsulin coincidentally secreted with insulin. The other possibility is that
circulating insulin aggregates serve a physiologic function. One possible function
is suggested by insulin enhancement of glucose transport across the blood-brain
barrier (752). An acute requirement for glucose by the central nervous system
may arise during a prolonged fast, when serum insulin and glucose levels are
basal.

Although nervous stimulation of pancreatic insulin release has been
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demonstrated, the physiologic role of this phenomenon is unclear (753).
Certainly, neural induction of pancreatic insulin secretion during a prolonged
fast would appear to be both wasteful and dangerous, since most of the serum
glucose would be absorbed by peripheral tissues and a severe hypoglycemia would
ensue before a glucagon-induced release of glucose by the liver could occur. If
brain capillary endothelium, for instance, possessed an inducible enzyme system
capable of dissociating insulin aggregates in situ however, insulin-stimulated

---

glucose uptake would occur where needed and serum glucose levels would fall
slowly enough to enable compensation by liver glucose release. In addition, a
precedent for enzyme-mediated dissociation of macromolecular aggregates
stabilized by hydrogen bonds and hydrophobic interactions exists within the most
ancient forms of life: DNA polymerases.
Besides the in vitro study of crystalline insulin dissociation mentioned
above, the following experiments would be helpful in ascertaining the existence
and role of circulating insulin aggregates.
1.

The existence of insulin aggregates in blood should be verified by

further purification of gel chromatography fractions containing high molecular
weight serum IRI, using ion-exchange chromatography; purified IRI should then
be subjected to gel chromatography after acid treatment to determine whether
monomeric IRI is generated.
2. The hypothesis that insulin aggregates dissociate slowly in vivo should
be tested by monitoring blood IRI and glucose in fasted animals infused with
specific inhibitors of the insulinases, such as antibodies raised against the
enzymes and biologically inactive insulin analogs
insulin).

~.,A-

and B-chains and DOP-
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3.

The existence of an insulin aggregate dissociating enzyme should be

ascertained by testing for generation of monomeric IRI in human serum during
prolonged incubation after concentration and in the presence of tissue
homogenates, especially of brain.

THE EFFECTS OF HEPARIN AND BIOTIN ON SERUM ILA

Heparin did not enhance the IRI of human serum or plasma, even after
treatment with an anion-exchange resin, and it did not cause significant decrease
in recovery of IRI from serum or plasma. Neither did it significantly affect the
IRI of plasma cation exchange fractions and it did not cause IRI to be passed
through a PM 10 membrane, indicating that heparin does not potentiate
dissociation of insulin aggregates or a putative hormone-protein

compl~

Heparin also did not increase serum ILA or ILAs and did not appear to dissociate
NSILA-8 from its carrier protein, since, where it increased ILA
PM10r1), it did not increase ILAs.

~.,

in dilute

On the other hand, several instances of

heparin enhancement of ILAs without increase of ILA are probably artifactual.
The possibility that heparin enhances serum ILA by potentiating the effects of
one or more growth factors is supported by heparin-stimulated WI38 cell
proliferation with PM10r1, PM10r2, PM10r1 S-200 Fraction 10 (M.W. 33-42 kd),
and human serum acetone powder S-200 Fraction 1 (M.W. >240 kd). Generally,
it is expected that heparin, as a polyanion, will potentiate anionic effecters by
complexing cationic inhibitors and will inhibit cationic effecters.

Therefore,

heparin would be expected to potentiate the effects of NSILP, SMB, MSA and
WI38 growth factor, and to inhibit NSILA-8 and SMC. The expected effects on
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ILA and/or cell proliferation were seen in fractions corresponding to free NSILAS and NSILA-8 bound to a carrier protein of about 30 kd M. W., NSILP and SMC,
but not in fractions where SMB, MSA or WI38 growth factor would be expected
to elute.
Biotin appeared to cause a significant decrease in the recovery of IRI
from serum. However, S-200 chromatography of exogenous radiolabeled insulin
in human serum after treatment with biotin showed no difference in magnitude
or position of eluted radioactive and protein peaks relative to the control,
indicating that biotin causes neither dissociation of an insulin-protein complex
nor enhancement of serum proteolysis. Biotin also did not significantly stimulate
cell proliferation or ILA of human. serum or bulk serum fractions, but did
increase these parameters in specific serum S-200 fractions. The possibility that
biotin enhancement of ILA in serum fractions is due to a synergistic potentiation
of growth factor effects by the substance is supported by a report that biotin
stimulates guanylate cyclase activity in rat tissues (754). The resultant increase
in intracellular concentrations of cG MP is known to stimulate cell proliferation
in many systems (296). In this study, however, biotin alone did not affect the
RIA and neither heparin nor biotin alone affected the fibroblast bioassay.
Finally, there remains the question of heparin-induced IRI. I found that
heparin interferes with the RIA, causing a partial dissociation of antigenantibody complexes that would result in false increments of IRI, but not at the
concentration employed by Guenther. Neither did Guenther find any effect of
this amount (100 J.Jg/ml) of heparin on his RIA (387). For his study, however,
Guenther employed a pool of patient sera prepared by the Foster G. McGaw
Hospital Clinical Chemistry Laboratory, reasoning that this pool ''should thus
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represent a good cross-section of sera". There is also an excellent possibility
that this pool included sera from diabetics whose blood often contains hirge
quantities of exogenous insulin complexed by anti-insulin antibodies (409).
Although high-affinity guinea pig anti-insulin antibodies are unaffected by 100
J.lftleparin/ml, relatively low affinity human anti-insulin antibodies (449) may be
partially dissociated from antigen by this concentration of heparin, yielding
'

concentrations of free insulin that could produce the increments of IRI observed
by Guenther.
In conclusion, the results of this study indicate that there is no serum

insulin-binding protein, that most ( :.: 75%) of the serum ILA observed using in
vitro bioassays is due to the effects of growth factors, ·and that significant
quantities of circulating insulin aggregates may exist in vivo and play a
physiologic role in carbohydrate homeostasis.

SUMMARY

With the advent of in vitro bioassays for insulin, human blood components

---

that mimic the effects of insulin in these assays, yet do not possess the
physicochemical properties of insulin were discovered.

Specifically, serum

substances retained by cation-exchange resins were found to enhance glucose
uptake and utilization by rat diaphragms and epididymal fat pads, but did not
react with anti-insulin antibodies. This atypical insulin-like activity (ILA) led to
speculation that a fraction of circulating insulin is complexed to a specific
carrier protein.

In 1974, H. Guenther (Loyola University, Chicago, Ph.D.

Dissertation) lent support to this contention by demonstrating that insulin
concentrations measured by radioimmunoassay (RIA; immunoreactive insulin,
IRI) in cationic human serum fractions were increased e>y t.E-parin, a polyanion,
and that ILA measured by in vitro bioassays in these fractions was increased by
heparin and biotin. The present study was undertaken to test the reproducibility
of these results and to ascertain more specifically the nature of atypical ILA in
human serum and plasma using a cultured fibroblast bioassay capable of
discriminating specific ILA and the pleiotypic effects of growth factors.
Four hundred fifty milliliters normal human plasma was mixed with ten
grams Sephadex C-50 cation exchanger after hydration of the gel, which was
then transferred to a 2.5 x 100 em column and eluted with a 0.005-1.5 M
potassium chloride gradient. Although about 5 J.l U IRI/ml plasma was found in
the most cationic fraction eluting from this column, heparin did not significantly
affect the IRI of this or any other fraction. Heparin also did not increase the IRI
381
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of normal human serum or plasma, or bulk serum fractions prepared by
ultrafiltration, nor did it significantly decrease the recovery of exogenous IRI
from serum or plasma.
A systematic examination of the ability of human serum and plasma
components to bind exogenous radiolabeled insulin specifically and reversibly,
using Sephadex G-200 gel chromatography and dextran-coated charcoal, revealed
that less than 5% of the 1-125 activity eluted with albumin (A-peak) and less than
1% radioactivity eluted at the column exclusion volume (C-peak, molecular
weight >360,000 daltons), while about 90% of the added radioactivity eluted at
positions corresponding to molecular weights less than 40,000 daltons (B-peak,
M.W. <40 kd) and was immunochemically identical to free 1251-insulin. The size
and relative positions of the high molecular weight radioactive peaks were
unaffected by rechromatography, biotin or 1-2.25 mU unlabeled insulin.

A

thirtyfold excess of unlabeled insulin and 8 M urea also failed to liberate free
insulin from A-peak material, as determined by dextran-charcoal adsorption of 1125 activity. Affinity chromatography of A-peak material through columns of
anti-albumin antibodies covalently coupled to Sepharose 4B revealed that 84% of
A-peak radioactivity was bound to albumin and an additional 11% radioactivity
exhibited a molecular weight of less than 2,000 daltons, confirming Berson and
Yalow's contention that exogenous radiolabeled insulin apparently associated
with serum components represents "damaged" label irreversibly bound to serum
proteins, particularly albumin, and that a physiologically significant insulinbinding protein does not exist in human serum.
Cultured human fibroblasts maintained in stationary phase in the absence
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of serum were found to offer a means for discriminating the effects of growth
factors from specific ILA since the rate of glucose uptake by these cells is
significantly stimulated by insulin in a dose-dependent manner. The use of 1-ml
cultures in multi-well plates affords a convenience of replicate determinations
hitherto lacking in in vitro bioassays.

Use of this bioassay to examine human

serum fractionated by molecular size revealed that virtually all of the capacity
of human serum to stimulate cell proliferation and about 95% potential serum
ILA reside in one or more serum components of M. W. :: 240 kd.

Most of the

remaining ILA was consistent with well-characterized insulin-like growth
factors.

Half of serum IRI eluted at M. W. >18 kd, suggesting that appreciable

amounts of insulin aggregates exist in the peripheral circulation. Both biotin and
heparin enhanced ILA in certain serum fractions concomitant with potentiation
of cell proliferation, but without stimulation of glucose uptake rate, indicating
that previously reported increase of ILA by these agents is due to potentiation of
serum growth factors.
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